

# Department of Clinical Investigation

*Annual Research Progress Report*



Fiscal Year **1993**  
Madigan Army Medical Center  
Tacoma, Washington

# REPORT DOCUMENTATION PAGE

Form Approved

OMB NO 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 30 Sep 93 3. REPORT TYPE AND DATES COVERED Annual 1 Oct 92 - 30 Sep 93

4. TITLE AND SUBTITLE 5. FUNDING NUMBERS

Annual Research Progress Report  
Department of Clinical Investigation

6. AUTHOR(S)

Nancy J. Whitten, Editor

PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Department of Clinical Investigation  
Madigan Army Medical Center  
Tacoma, WA 98431-5000

7. PERFORMING ORGANIZATION REPORT NUMBER

8. SPONSORING MONITORING AGENCY NAME(S) AND ADDRESS(ES)

Clinical Investigation Regulatory Office  
U.S. Army Medical Center and School  
Fort Sam Houston, Texas 78234-6125

9. SPONSORING MONITORING AGENCY REPORT NUMBER

10. DISTRIBUTION STATEMENT (See Instructions for Guidance)

11. DISTRIBUTION STATEMENT (See Instructions for Guidance)

Unlimited

12. DISTRIBUTION CODE

13. ABSTRACT (See Instructions for Guidance)

This report covers all research protocols that were administratively or technically supported by the Department of Clinical Investigation, Madigan Army Medical Center, during FY 93. Included in the individual reports are title, investigators, funding, objective, technical approach, and progress for FY 93. Also included in the report are personnel rosters for the Department, funding information, and presentations and publications emanating from Madigan Army Medical Center during this period.

14. SUBJECT TERMS

Research protocols, investigators, objectives, technical approach, progress, funding

15. NUMBER OF PAGES

516

16. SECURITY CLASSIFICATION OF REPORT

Unclassified

17. SECURITY CLASSIFICATION OF ABSTRACT

Unclassified

18. SECURITY CLASSIFICATION OF ABSTRACT

Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT

UL

**ANNUAL PROGRESS REPORT**

30 SEPTEMBER 1993

DEPARTMENT OF CLINICAL INVESTIGATION  
MADIGAN ARMY MEDICAL CENTER  
TACOMA, WASHINGTON 98431-5000

THE FINDINGS IN THIS REPORT ARE NOT TO BE  
CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE  
ARMY POSITION UNLESS SO DESIGNATED BY OTHER  
AUTHORIZED DOCUMENTS.

DESTROY THIS REPORT WHEN NO LONG NEEDED.  
DO NOT RETURN IT TO THE ORIGINATOR.

APPROVED FOR PUBLIC RELEASE  
DISTRIBUTION UNLIMITED

## TABLE OF CONTENTS

Introduction .....	1
Acknowledgements .....	1
Foreword .....	2
Unit Summary .....	3
Committee Members .....	7
Bryon L. Steger Research Award .....	10
Wergeland Research Award .....	11
Publications .....	12
Presentations .....	19
Index To Protocols .....	29
Protocols...	
Active Duty Student Detachment, HSC .....	51
Behavioral Sciences Division, clinical psychology .....	54
Department of Clinical Investigation .....	56
Department of Dentistry .....	71
Department of Emergency Medicine .....	78
Department of Family Practice .....	90
I Corp Surgeon, Fort Lewis, WA .....	100
Department of Medicine, Allergy/Immunology Service .....	102
Department of Medicine, Critical Care Medicine .....	104
Department of Medicine, Cardiology Service .....	107
Department of Medicine, Endocrinology Service .....	113
Department of Medicine, Hematology/Oncology Service .....	137
Department of Medicine, Infectious Disease Service .....	152
Department of Medicine, Internal Medicine Service .....	156
Department of Medicine, Neurology Service .....	161
Department of Medicine, Pulmonary Service .....	166
Department of Medicine, Rheumatology Service .....	176
Department of Nursing .....	180
Department of Obstetrics/Gynecology .....	199
Preventive Medicine Service .....	220
Department of Pathology, Blood Bank .....	225
Department of Pediatrics .....	227
Department of Radiology .....	250
Department of Surgery, Anesthesia Service .....	273
Department of Surgery, ENT Service .....	284
Department of Surgery, General Surgery Service .....	289
Department of Surgery, Ophthalmology Service .....	296
Department of Surgery, Orthopedic Surgery Service .....	302
Department of Surgery, Plastic Surgery Service .....	307
Department of Surgery, Urology Service .....	309
Fort Ord MEDDAC .....	314
Fort Wainwright, AK .....	318
Letterman MEDDAC .....	320
U.S. Department of Agriculture .....	322
Walter Reed Army Medical Center .....	324



## TABLE OF CONTENTS (CONT'D)

Cancer Group Protocols...	
Gynecology Oncology Group .....	326
National Cancer Institute .....	384
National Surgical Adjuvant Breast & Bowel Project.....	386
Pediatric Oncology Group.....	390
Puget Sound Oncology Consortium .....	397
Southwest Oncology Group .....	400
University of Washington Neuro-Oncology Group.....	494
Index .....	498
Distribution.....	516

# ANNUAL RESEARCH PROGRESS REPORT

FISCAL YEAR 1993

DEPARTMENT OF CLINICAL INVESTIGATION  
MADIGAN ARMY MEDICAL CENTER  
TACOMA, WASHINGTON 98431-5000

## INTRODUCTION

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals" as prepared by the Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Institutes of Health, and Title 9, Subchapter A, Parts I, II, and III of the Code of Federal Regulations. The investigators adhered to Title 21, Part 50 of the Code of Federal Regulations and the recommendations from the Declaration of Helsinki in the performance of investigations involving human subjects.

## ACKNOWLEDGEMENTS

I would like to take this opportunity to thank Nancy Whitten and Troy Patience for the effort which is obvious in the compilation, preparation, and editing of this publication.

## FOREWORD

FY 93 was eventful for the Department of Clinical Investigation as well as for MAMC, which moved into its new state-of-the-art facility. DCI essentially tripled the size of its bench space with this move, as well as adding two new ultra-modern surgical suites and supporting animal use facilities. In spite of the considerable time and effort expended in preparing for and making the move, the number of new protocols increased and total protocols supported remained essentially unchanged.

Personnel changes included the much-appreciated addition of CPT Keith Martin, who lent his expertise to the expanding molecular biology thrust of the department. DCI-sponsored "Introduction to Research" courses were given to three departments during the year. MAMC continued its success in bringing extramural funding to the institution. MAMC nurses were recipients of grants from nursing research funds and MAMC investigators garnered two of the six grants awarded from the FY 93 MRDC breast cancer appropriation.

I wish to acknowledge the continued commitment to excellence by all DCI personnel during this period of time, as well as the vital support of BG Leslie Burger, Commander, and COLs Michael Weir and Al Buck, who served as DCCS during this period.

## UNIT SUMMARY

### 1. Objective

To provide the facilities and environment to stimulate an interest in clinical and basic investigations within Madigan Army Medical Center.

### 2. Technical Approach

<u>Description</u>	<u>MANPOWER</u> <u>Rank</u>	<u>MOS</u>
Chief, Clinical Investigation MOORE, Dan C., M.D., COL, MC	06	60P9A
C, Clinical Studies Service JONES, Robert E., M.D., COL, MC	06	61C9A
C, Surg & Animal Care Svc POWELL, Douglas, D.V.M., MAJ, VC (Aug 91 - Aug 93)	04	64C9B
C, Surg & Animal Care Svc CALDWELL, Stephen, D.V.M., CPT, VC (Sep 93 - )	03	64A00
C, Microbiology Svc STEWART, Robert S., Ph.D., MAJ, MS	04	68A9B
C, Bioresearch Svc MARTIN, Keith, Ph.D., CPT, MS	03	68C8Z
NCOIC HANDY, Kevin , SSG (Mar 90 - Dec 92)	E6	92B3M4
NCOIC ROBERTS, Teresa, SFC	E7	91T30R
Vet Animal Spec HEATH, George, SGT (Aug 89 - Aug 93)	E5	91T20
Vet Animal Spec SPAHN, Shelley, SGT (Feb 89 - Dec 92)	E5	91T20
Vet Animal Spec FULK, Terry, CPL	E4	91T20
Vet Animal Spec CARREIRO, Frank, SPC	E4	91T20
Lab Tech CARTAGENA, Edward, SPC	E4	92B
Lab Tech HERNANDEZ, Carlos, SGT	E5	92B

<u>Description</u>	<u>Rank</u>	<u>MOS</u>
C, Biochemistry Svc MOORE, Katherine Hines, Ph.D	GS12	0601
Med Tech MATEJ, Louis A., B.S., M.T.	GS9	0644
Med Tech WRIGHT, James R., B.A., M.T.	GS9	0644
Med Tech STYNER, M. J., B.S., M.T.	GS9	0644
Med Tech THOMSON-ARCHER, Kelly, B.S., M.T.	GS9	0644
Statistician Medical PATIENCE, Troy H., B.S.	GS9	0301
Edit Asst/Steno WHITTEN, Nancy J., B.A. (Mar 93 - )	GS7	1087
Sec/Steno HOUGH, Eugenia R.	GS6	0318
Maintenance Worker KAEO, Curtis	WG7	4749
Med Tech CRISS-TILLOTSON, Mary "Tilly"* (Dec 92 - )	GS9	0644

\* Breast Grant Hire.

Funding FY 93

MEDCASE Equipment	\$ 96,561.00
Capital Equipment	50,620.00
Civilian Salaries	280,366.40
Military Salaries	
Consumable Supplies	134,160.00
Contractual Services	6,817.25
TDY - departmental	7,598.00
TDY - presentations	<u>27,638.89</u>
	\$596,163.54

EXTRAMURAL FUNDING:

Federal sources:

USAMRDC	\$146,077
NCI	119,900
Other	508,793

Non-federal sources:

FACT	152,034
HMJ	<u>5,081</u>
	\$931,703

### 3. Progress

During FY 93 there were 394 active protocols that received administrative and/or technical support during the year. Of these, 268 are presently on-going; 6 are in a suspended status, 88 were completed; and 32 were terminated. The principal investigator distribution was as follows: 306 staff protocols, 42 resident protocols, 35 fellow protocols, 2 intern protocols, and 9 other category protocols.

There were 117 publications and there were 120 presentations at regional, national, or international meetings.

### 4. Fellowship/Residency Program Support

Fellowship/Residency programs supported by DCI: 26  
43 protocols involving 75 residents  
123 protocols involving 30 fellows

### 5. Other training programs supported by DCI:

Training protocols: (1) Department of Surgery: 3  
(2) Department of Emergency Medicine: 2  
(3) Department of Pediatrics: 1  
(4) Department of OB/GYN: 1  
(5) Department of Clinical Investigation: 1

### 6. Other protocols supported:

43 protocols held by MAMC staff members  
161 group oncology protocols  
2 Intern protocols  
1 Fort Wainwright, AK protocol  
1 Letterman MEDDAC protocol  
1 USDA protocol  
1 I-corps protocol  
2 Fort Ord protocols  
2 Active duty student protocols  
1 Walter Reed Army Medical Center protocol

## COMMITTEE MEMBERS

Commander

Madigan Army Medical Center  
BG Leslie M. Burger, M.D., MC

### Clinical Investigation Committee

Chairman

Chief, Clinical Investigation  
COL Dan C. Moore, M.D., MC

Chief or delegated representative of:

Department of Clinical Investigation  
Department of Pediatrics  
Department of OB/GYN  
Department of Family Practice  
Department of Emergency Medicine  
Department of Nursing  
Department of Medicine  
Department of Surgery  
Department of Pathology  
Department of Radiology  
Pharmacy Service  
Clinical Psychology Service  
Clinical Studies Service, DCI  
Microbiology Service, DCI  
Biochemistry Service, DCI  
Bioresearch Service, DCI  
Lab Animal and Surgery Service, DCI  
Medical Statistician, DCI



## COMMITTEE MEMBERS (CONT'D)

### Human Use Committee

Chairman

Deputy Commander of Clinical Services  
COL Alfred S. Buck, M.D., MC

Chief or delegated representative of:

Department of Clinical Investigation  
Department of Nursing  
Department of Radiology  
Department of Ministry and Pastoral Care  
Pharmacy Service  
Social Work Service  
Public Affairs Office  
Center Judge Advocate  
Non-institutional member

COMMITTEE MEMBERS (CONT'D)

Animal Use Committee

Chairman

\*Deputy Commander of Clinical Services  
COL Alfred S. Buck, M.D., MC

Chief or delegated representative of:

Department of Clinical Investigation  
Lab Animal & Surgery Service  
Department of Nursing  
Public Affairs Office  
Veterinary Services  
Non-institutional member

### BRYON L. STEGER RESEARCH AWARD

This award is given to residents, submissions are judged on their scientific merit, relevance, objectivity of evaluation, interpretation of results, and the potential importance of the subject of the research.

Recipient of this award for 1993:

*Comparison of Induction and Recovery From Propofol-Nitrous Oxide Versus Methohexital-Isoflurane-Nitrous Oxide Anesthesia in Ambulatory Oral Surgery Patients* by LTC Robert J. Wygonski, DC.

Other nominees were:

*Twelve Hour Urine Collections in Comparison to Twenty-Four Hour Urine Collections in Patients with Preeclampsia* by CPT Wilma I. Larson, MC.

*A Comparison of Sinus X-rays with Computed Tomography in Acute Sinusitis* by MAJ Thomas F. Burke, MC.

## WERGELAND RESEARCH AWARD

This award is given to fellows, submissions are judged on their scientific merit, relevance, objectivity of evaluation, interpretation of results, and the potential importance of the subject of the research.

Recipient of this award for 1993:

*The Dual-Perfusion Cotyledon Model: Is a Control Needed?* by MAJ Timothy J. Boley, MC.

Other nominees were:

*Lead Levels and Their Relationship to Attention Deficit Hyperactivity Disorder and Developmental Delay* by CPT Cynthia Kahn, MC.

*Do Not Resuscitate: Do Not Provide Care?* by CPT Lynn Keenan, MC.

*Activation of the PTC Oncogene: A Predictor of Aggressive Behavior in Papillary Thyroid Cancer* by CPT R. Michael Tuttle, MC

*The Association of Empathy and Specialty Choice In A Sample of Army Interns* by CDR William R. Kiser, MC

*Estimation of 24 Hour Urinary Nitrogen Excretion From Four and Six Hour Urine Collections in Critically Ill Patients Receiving Nutritional Support* by CPT Lynn Keenan, MC.

# PUBLICATIONS

## FISCAL YEAR 93

### DEPARTMENT OF CLINICAL INVESTIGATION

---

Gerena L, Bass GT, Kyle DE, Oduola AMJ, Milhous WK, Martin RK	Fluoxetine Hydrochloride Enhances in vitro Susceptibility to Chloroquine in Resistant Plasmodium falciparum. Antimicrob Agents & Chemother 36(12): 2761-2765, 1992.
Stewart RS, Phillips RH, Patience TH	PCR Technology in the Clinical Microbiology Laboratory: Thermal Cycler Idiosyncracies. J Mil Med Lab Science 22(3): 114-119, 1993.

### DEPARTMENT OF DENTISTRY

---

Engibous PJ, Kittle PE, Jones HL, Vance BJ	Latex Allergy in Patients With Spinabifida. Pediatric Dentistry 15(5): 364-466, 1993.
Goho CD	Chemoradiation Therapy: Effect on Dental Development. Pediatric Dentistry 15(1): 6-12, 1993.
Goho CD, Aaron GR	Enhancement of Antimicrobial Properties of Cavity Varnish: A Preliminary Report. J Prosthetic Dentistry 68: 623-25, 1992.
Guzman CM, Aaron Gr	Spondylometaphyseal Dysplasia (Kozlowski Type): Case Report. Pediatric Dentistry 15(1): 49-52, 1993.
Meadors LW, Jones HL	Fused Primary Incisors with Succedaneous Supernumerary in the Area of a Cleft Lip: Case Report. Pediatric Dentistry 14(6): 397-99, 1992.
Polk AM	Impaction and Malformation of a Maxillary Central Incisor: Sequelae of Trauma. Jour Dentistry for Children: 29-32, 1993.
Weber CR, Wygonski RJ, Griffin JM, Boyd BD	Undiagnosed Shrapnel of the Tongue. Military Medicine 158(6): 4427-28, 1993.

### DEPARTMENT OF EMERGENCY MEDICINE

---

Guertler AT	Usefulness of a Diagnostic Test. Annals of Emergency Medicine 21(12): 1516-1517, 1992.
Lillegard WA, Kruse R	Musculoskeletal Problems in Children, IN: Family Medicine, Principles and Practice, 4th ED, Chapter 16, Springer-Verlag Publishers, 1993.

### DEPARTMENT OF FAMILY PRACTICE

---

Forred WA, Brunader REA, Mork TJ, Kugler JP	An Educational Report: The Mechanics of Geriatric Assessment in a Military Community-Based Family Practice Residency. Military Medicine 157(11): 586-590, 1992.
Jerant AF, Arline AD	Babesiosis in California. Western J Med 158(6): 622-625, 1993.
Kiser WR	A Hospital Ethics Committee at War: The Hospital Ship Mercy Experience During Operation Desert Shield and Operation Desert Storm. Cambridge Quart Hlth Care Eth 4: 389-92, 1992.
Kraemer WJ, Dziados JE, et al	Effects of Different Heavy Resistance Exercise Protocols on Plasma B-Endorphin Concentratons. J Appl Physiol 74(1): 450-459, 1993.
Kraemer WU, Fleck SJ, Daizdos JE, et al	Changes in Hormonal Concentrations After Different Heavy Resistance Protocols in Women. J Appl Physiol 75(2): 594-4604, 1993.
Kugler JP	Cardiovascular Problems; IN: Handbook of Sports Medicine. A Symptom Oriented Approach, Lillegard WA and Rucker KS (eds); Andover Medical Publishers, Boston, MA, Chapter 22, 1993.

Kugler JP, Yeash J	The Impact of Sociodemographic, Health Care System, and Family Function Variables on Prenatal Care Utilization in a Military Setting. <i>Journal of Family Practice</i> 37(2): 143-47, 1993.
Lillegard WAW, Rucker KS	Handbook of Sport Medicine; A symptom Oriented Approach. Andover Medical Publishers, Boston, MA, 1993.
Norbeck JC, Ritchey MR, Bloom DA	Labial Fusion Causing Upper Urinary Tract Obstruction. <i>Urology</i> 42(2): 209-211, 1993.
Nusbaum MRH, Kiser WR, Ellis DD, Runkle GP, Kugler JP	Vitamin B(12) Deficiency. <i>Journal of Family Practice</i> 36(4): 373, 1993.
Runkle GP, Ellis DD, Nusbaum MRH	Psychosocial Support During High Risk Pregnancy. <i>New England Journal of Medicine</i> 328(12): 887, 1993.
Schirner WA	Exercise Induced Bronchospasm; IN: Handbook of Sports Medicine, A Symptom Oriented Approach; Lillegard WA and Rucker KS (eds); Andover Medical Publishers, Boston, MA, Chapter 17, 1993.
Stankus SJ, Johnson NT	Prophylthiouracil-Induced Hypersensitivity Vasculitis Presenting as Respiratory Failure. <i>Chest</i> 102(5): 1595-96, 1992.
Whittaker PE	Quality Assurance Successes: The Highest Quality Sick Call System in the Army. <i>AMEDD Journal</i> , Jul/Aug 1993
Whittaker PE, et al	The Computer-Aided PRP/Nuclear Surety Program. <i>AMEDD Journal</i> , Jun/Jul 1993.
Yetter JF	Cleft Lip and Cleft Palate. <i>American Family Physician</i> 46(4): 1211-1218, 1992.

## DEPARTMENT OF MEDICINE

Bell BK, Mazzaferri EL	Familial Adenomatous Polyposis (Gardners Syndrome) and Thyroid Carcinoma - A Case Report and Review of the Literature. <i>Digestive Diseases and Science</i> 38(1): 185-90, 1993.
Cragun WH, Grover B, Dunn T	Acute Respiratory Failure Associated with a Motor Vehicle Accident (Roentgenogram of the Month). <i>Chest</i> 102(5): 1581-1582, 1992.
Douglas DM, Brown JS	Intermittent Throat Tightness in a 37 Year Old Woman. <i>Annals of Allergy</i> 71(2): 100-102, 1993.
Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Seimberg SM, Arbuck SG, Beveridge RA	Phase II Study of Fluorouracil, Leucovorin, and Interferon Alfa-2a in Metastatic Colorectal Cancer. <i>J of Clinical Oncology</i> 11: 1737-1745, 1993.
Hnatink O, Pike J, Stoltzfus D, Lane W	Value of Bedside Plating of Semiquantitative Cultures for Diagnosis of Central Venous Catheter-Related Infections in ICU Patients. <i>Chest</i> 103: 896-99, 1993.
Hobbs CJ, Plymate SR, Rosen C, Adler RA	Testosterone Administration Increases Insulin-like Growth Factor-I Levels in Normal Men. <i>J Clin Endocrinol Metab</i> 77: 776-779, 1993.
Jones RE	The Diabetic Athlete. IN: Handbook of Sports Medicine, A Symptom Oriented Approach; Lillegard WA and Rucker KS (eds); Andover Medical Publishers. Boston, MA: 231-261, 1993.
Jullin JC	Localizing Right Septal Accessory Pathways Using the Maximally Pre-excited QRS Complex. <i>Circulation (Suppl)</i> 86(4): , 1992.
Kern JD, Torrington K	The Utility of Fiberoptic Bronchoscopy in the Evaluation of Solitary Pulmonary Nodules. <i>Chest</i> 104: 1021-1024, 1993.
Krivda s, Sorensen G, Finder K	Dermatologic Problems in the Athlete. IN: Handbook of Sports Medicine. A Symptom Oriented Approach. Lillegard WA and Rucker Ks (eds); Andover Medical Publishers. Boston, MA: 259-66, 1993.

## PUBLICATIONS - MAMC - FY 93

- LeMar H, Georgitis WJ      Effect of Cold Remedies on Metabolic Control of Non-insulin Dependent Diabetes Mellitus. *Diabetes Care* 16: 426-428, 1993.
- Lyons MF, Tsuchida AM      Foreign Bodies of the Gastrointestinal Tract. *Med Clinics of North America* 77(5): 1101-1114, 1993.
- MacKenzie MR, Wold H, George C., Gandara D, Ray G, Schiff S, Shields J, Davidson H      Consolidation Hemibody Radiotherapy Following Induction Combination Chemotherapy in High-Tumor Burden Multiple Myeloma. *Journal of Clinical Oncology* 10(11): 1769-1774, 1992.
- May EF, Ling GSF, Geyer CA, Jabbari B      Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism. *Neurology* 43(4): 836-38, 1993.
- Peele M, et al      TSH Beta Subunit Gene Expression in Human Lymphocytes. *Amer J Medical Science* 305: 1-7, 1993.
- Prewitt K, Laird J, cambier P, Wortham D      Late Coronary Aneurysm Formation After Directional Atherectomy. *American Heart Journal* 125: 249-251, 1993.
- Rone JK, Dons RF, Reed HL      The Effect of Endurance Training on Serum Triiodothyronine Kinetics in Man: Physical Conditioning Marked by Enhanced Thyroid Hormone Metabolism. *Clinical Endocrinology* 37(4): 325-330, 1992.
- Roth BJ, Cragun WH      The Serum Effusion Albumin Gradient in the Evaluation of Pleural Effusions - Reply. *Chest* 103(5): 1634-35, 1993.
- Roth BJ, Irvine TW, Liening DA, Duncan NO, Cragun WH      Acute Respiratory Compromise Resulting From Tracheal Mucous Impaction Secondary to a Transtracheal Oxygen Catheter. *Chest* 101: 1465-66, 1992.
- Staduhar KC, Laird JR, Rogan KM, Wortham DC      Coronary Arterial Ectasia - Increased Prevalence in Patients with Abdominal Aortic Aneurysm As Compared to Occlusive Artherosclerotic Peripheral Vascular Disease. *American Heart Journal* 125(1): 86-92, 1993.
- Tengllin RC      Hematologic Abnormalities. IN: *Handbook of Sports Medicine: A Symptom Oriented Approach*. Lillegard WA and Rucker KS (eds); Andover Medical Publishers. Boston, MA, 1993.

## DEPARTMENT OF NURSING

- Birgenheier PS      Parent and Children, War and Separation. *Pediatric Nursing* 19(5): 24-28, 1993.
- Bubien RS, Knotts SM, McLaughlin S, George P      What You Need to Know About Radiofrequency Ablation. *Amer Journal of Nursing*, July: 30-36, 1993.
- Loan LA      Spotlight Article - Does Routine Nursing Care Complicate the Physiological Status of the Premature Neonate With Respiratory Distress Syndrome. *Heart and Lung* 22(1): 89-92, 1993.
- Turner BS      Pediatric Variations of Nursing Interventions IN Whaley and Wong's *Essential of Pediatric Nursing*; D. Wong (Ed); Mosby Publishers, St Louis, pp 689-97, 1993.
- Turner BS      The Child With Respiratory Dysfunction IN Whaley and Wong's *Essential of Pediatric Nursing*; D. Wong (Ed), Mosby Publishers, St Louis, pp 710-755, 1993.
- Weaver J, Ow C, Walker D, Degenhardt E      A Questionnaire for Patients' Evaluations of Their Physicians' Humanistic Behaviors. *J General Internal Medicine* 3: 135-139, 1993.
- Williams D      Paperless Nursing Documentation. *ANC Quarterly Newsletter*, Marc, 1993.

**DEPARTMENT OF OBSTETRICS/GYNECOLOGY**


---

Adams MM, Read JA, Rawlings JS, Harlass FB, Sarno AP, Rhodes PH	Preterm Delivery Among Black and White Enlisted Women in the United States Army. <i>Obstetrics and Gynecology</i> 81(1): 65-71, 1993.
Kopelman JN	Antepartum Diagnosis of Arthrogryposis Associated with Trisomy-18. <i>Military Medicine</i> 158(7): 498-99, 1993.
Potter ME, Spencer S, Soong SJ, Hatch KD	The Influence of Staging Laparotomy for Cervical Cancer on Patterns of Recurrence and Survival. <i>Intl J Gynecological Cancer</i> 3(3): 169-74, 1993.
Yancey MK, Harlass FE, Benson W, Brady WK	The Perioperative Morbidity of Scheduled Cesarean Hysterectomy. <i>Obstetrics and Gynecology</i> 81(2): 206-10, 1993.

**PREVENTIVE MEDICINE SERVICE**


---

Hellman SL, Gram MC	The Resurgence of Tuberculosis. <i>Amer Assoc Occ Health Nurs J</i> 41(2): 67-72, 1993.
Rubertone MV, DeFraites RF, Krauss MR, Brandt CA	An Outbreak of Hepatitis A During a Military Field Training Exercise. <i>Military Medicine</i> 158(1): 37-41, 1993.
Strohm PF, Opheim GS	Mission-Oriented Risk Assessment. <i>J American Society Engineers</i> 38(6): 38-43, 1993.

**DEPARTMENT OF PATHOLOGY, BLOOD BANK**


---

Brissette M, Dhru RD	Hodgkin's Disease Presenting as Spontaneous Splenic Rupture. <i>Arch Path Lab Medicine</i> 116(10): 1077-1079, 1992.
----------------------	--

**DEPARTMENT OF PEDIATRICS**


---

Bass JW, Steele RW, Wittler RR, Weisse ME, Bell V, Heissner AH, Brien JH, Krober MS	Antimicrobial Treatment of Occult Bacteremia - A Multicenter Cooperative Study. <i>Pediatric Infectious Dis J</i> 12(6): 466-73, 1993.
Hinson RM, Schofield TD, French J, Stevenson JG, Stewart D, Kinney JB	Occult Kawasaki Syndrome With Giant Coronary Artery Aneurysms. <i>Western Journal of Medicine</i> 158(2): 188-191, 1993.
Rawlings JS, Smith FR, Garcia J	Expected Duration of Hospital Stay of Low Birth Weight Infants - Graphic Depiction in Relation to Birth Weight and Gestational Age. <i>Journal of Pediatrics</i> 123(2): 307-309, 1993.
Stafford EM	Pelvic Examination - An Essential Skill. <i>Pediatrics</i> 91(3): 682, 1993.
Waecker NJ, Ascjer DP, Robb ML, Moriarty R, Krober M, Rickman WJ, Butzin CA, Fischer GW	Age-Adjusted CD4+ Lymphocyte Parameters in Healthy Children at Risk for Infection With the Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> 17(1): 23-125, 1993.

**DEPARTMENT OF RADIOLOGY**


---

Bauman JM	Pseudodislocation of the Glenohumeral Joint Diagnosed by Bone Scintigraphy. <i>Clinical Nuclear Medicine</i> 18(2): 147-48, 1993.
Bauman JM	Carotid Occlusion Assessed by 99m-Tc HMPAO SPECT. <i>Imaging Insights Nuc Software</i> 1: 1-3, 1993.
Bender GN, Dodai DD, Briggs LM	Colonic Pseudo-obstruction - Decompression with A Tricomponent Coaxial System Under Fluoroscopic Guidance. <i>Radiology</i> 188(2): 395-98, 1993.
Choi HS, Kim Y, Smith DV, Bender GN	PACS and Its Hospital-wide Implementation: A Case Study at the Madigan Army Medical Center. <i>J Korean Radiol Soc</i> 29: 573-583, 1993.



## PUBLICATIONS - MAMC - FY 93

- Ebersole D, Heironimus J, Tony MO, Billingsley JL Comparison of Exercise and Adenosine Tc-99m-Sestimibi Myocardial Myocardial Scintigraphy for Diagnosis of Coronary Artery Disease in Patients with Left Bundle Branch Block. *American Journal of Cardiology* 71: 450-453, 1993.
- Ho VB, Fitz CR, Chuang SH, Geyer CA Bilateral Basal Ganglia Lesions - Pediatric Differential Considerations. *Radiographics* 13(2): 269-92, 1993.
- Ho VB, Fitz CR, Yoder CC, Geyer CA Resolving MR Features in Osmotic Myelinolysis (Central Pontine and Extrapontine Myelinolysis). *Amer Journal of Neuroradiology* 14(1): 163-67, 1993.
- Ho VB, Smirniotopoulos JG, Murphy FM, Rushing EJ Radiologic-Pathologic Correlation: Hemangioblastoma. *Amer Journal of Neuroradiology* 13: 1343-1352, 1993.
- Koo B, Becker LR, Chuang S, Merante F, Robinson BH, MacGregor D, Tein I, Ho VB Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like Episodes (MELAS): Clinical, Radiological, Pathological, and Genetic Observations. *Annals of Neurology* 34: 25-32, 1993.
- Peller PJ, Ho VB, Kransdorf MJ Extraosseous TC-99M MDP Uptake - A Patho-Physiological Approach. *Radiographics* 13(4): 715-34, 1993.
- Schofield TD, Youngberg RA Chest Radiograph Interpretation and Lung Cancer Experience At Madigan Army Medical Center. *Military Medicine* 158(5): 297-99, 1993.
- Smith DV, Smith S, Sauls F, Cawthon MA, Telepak RJ Design Strategy and Implementatin of the Medical Diagnostic Image Support System at Two Large Military Medical Centers. *SPIE Proceedings on Med Imagng* 1654: 148-157, 1992.

## DEPARTMENT OF SURGERY

- Burgess FW, Anderson DM, Colonna D, Sborov MJ, Cavanaugh DG Ipsilateral Shoulder Pain Following Thoracic Surgery. *Anesthesiology* 78(2): 365-68, 1993.
- Burgess FW, Plyman ML, Helman JD The Ideal Epidural Bupivacaine Concentration for Postoperative Analgesia. *Anesthesiology* 79: A796, 1993.
- Cameron SE Acute Compartment Syndrome of the Triceps - A Case Report. *Acta Orthopaedica Scandinavica* 64(1): 107-08, 1993.
- Cameron SE, Hanscom DA Rapid Development of a Spinal Synovial Cyst - A Case-Report. *Spine* 17(12): 1528-1530, 1992.
- Carpenter CT, Lester EL Skeletal Age Determination in Young Children: Analysis of Three Regions of the Hand/Wrist Film. *J Pediatric Orthopaedics* 13(1): 76-79, 1993.
- Cavanaugh DG, Barry MJ, Knight JA, Dearman RM Diagnosis of Superior Sulcus Tumors - A Further Use of the Thoracoscope. *Military Medicine* 158(8): 577-578, 1993.
- Chandler DW, Grantham DW Auditory Spatial Resolution in the Horizontal Plane As A Function of Reference Angle: Microstructure of the Azimuth Function.. *J of teh Acoustical Society* 93(4): 2350-2351, 1993.
- Chen JB Cuboid Stress Fracture, A Case Report. *J American Podiatric Med Assoc* 83(3): 153-55, 1993.
- Frey MAB, Mader TH, Bagian JP, Charles JB, Meehan RT Cerebral Blood Velocity and Other Cardiovascular Responses to 2 days of Head Down Tilt. *Journal of Applied Physiology* 74(1): 319-25, 1993.
- Grace TS, Sunshein K, Jones R, Harkless L Metatarsus Proximus and Digital Divergence: Its Association With Intermetatarsal Neuromas. *J The Amer Podiatric Med Assoc* 83(7): 406-11, 1993.
- Kruse RW, St Louis J, Fallace J Orthopedic Manifestations of Hyperlipoproteinemia - An Unusual Case of Knee Pain. *Military Medicine* 158(8): 576-577, 1993.

- Loop SM, Rozanski TA, Ostenson RC Human Primary Prostate Tumor Cell Line, ALVA-31 - A New Model for Studying the Hormonal Regulation of Prostate Tumor Cell Growth. *Prostate* 22(2): 93-108, 1993.
- Mader TH, Gibson CR, Caputo M, Hunter N, Taylor G, Charles J, Meehan RT Intraocular Pressure and Retinal Vascular Changes During Transient Exposure to Microgravity. *American Journal of Ophthalmol* 115(3): 347-350, 1993.
- Mader TH, Stulting RD Viral Keratitis. *Infect Dis Clin North America* 6(4): 831-49, 1992.
- Mader TH, Yuan R, Lynn MJ, Stulting RD, Wilson LA, Waring GO Changes in Keratometric Astigmatism After Suture Removal More Than One Year After Penetrating Keratoplasty. *Ophthalmology* 100(1): 119-27, 1993.
- Mooney MJ, Nyreen MR, Hall RA, Carter PL Hepatic Adenoma Presenting as a Right Lower Quadrant Mass. *The American Surgeon* 59(4): 229-32, 1993.
- Panje WR, Morris MR Reconstruction of the Oral Cavity and Oropharynx; IN *Local Skin Flaps and Free Skin Grafts In Head and Neck Reconstruction*. Mosby Yearbook, St Louis, MO, pp 348-262, 1992.
- Panje WR, Morris MR Oral Cavity and Oropharyngeal Reconstruction; IN *Otolaryngology-Head and Neck Surgery*. Mosby Yearbook, St Louis, MO, 2nd Ed, pp 1479-1498, 1992.
- Parmley VC, Stonecipher KG, Rowsey JJ Peters Anomaly - A Review of 26 Penetrating Keratoplasties in Infants. *Ophthalmic Surgery* 24(1): 31-35, 1993.
- Perkins JA, Morris MR Treatment of Acute Frontal Sinusitis - A Survey of Current Therapeutic Practices Among Members of the Northwest Academy of Otolaryngology. *American Journal of Rhinology* 7(2): 67-70, 1993.
- Perkins JA, Smith S, Lyons M Bowel Obstruction From Retained Inner Bumper Following Removal of Gastrostomy Tube - A Case Report. *Military Medicine* 158(2): 120-21, 1993.
- Place R, Velanovich V, Carter P Fine-Needle Aspiration in the Clinical Management of Mammary Masses. *Surgery Gynecology & Obstet* 177(1): 7-11, 1993.
- Roberts JD, Chen TY, Kawai N, Wain J, Dupuy P, Shimouchi A, Block K, Polaner DM Inhaled Nitric Oxide Reverses Pulmonary Vasoconstriction in the Hypoxic and Acidotic Newborn Lamb. *Circulation Research* 72: 246-254, 1993.
- Roberts JD, Polaner DM, Lang P, Zapol WM Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn. *Lancet* 340: 818-819, 1992.
- Souliere CR, Kileny PR, Zwolan TA, Kemink JL Tinnitus Suppression Following Cochlear Implantation: A Multifactorial Analysis. *Archives of Otolaryngology* 118: 1291-1297, 1992.
- Thrasher JB, Kreder KJ, Peterson NE, Donatucci CF Lidocaine as Topical Anesthesia for Bladder Mappings and Cold-Cup Biopsies. *The Journal of Urology* 150: 335-36, 1993.
- Travis MT, Cosio MQ A Retrospective Review of Orthopedic Patients Returning From Operations Desert Shield and Desert Storm To An Army Medical Center. *Military Medicine* 158(5): 348-51, 1993.
- Vaccaro JA, Davis R, Hansberry K Replacement of Nephrostomy Tube Using Ureteroscopes. *Journal of Urology* 149(2): 334, 1993.
- Varga JH, Wolf TC, Jensen HG, Parmley VC, Rowsey JJ Combined Treatment of Acanthamoeba Keratitis With Propamidine, Neomycin, and Polyhexamethylene Biguanide. *Amer Journal of Ophthalmology* 115(4): 466-70, 1993.
- Velanovich V Causality Concepts in Surgery. *Theoretical Surgery* 7(4): 197-200, 1992.
- Velanovich V, Kaufmann C Two Pitfalls of Laparoscopic Balloon Cholangiography - Recognition and Correction. *American Surgeon* 59(5): 290-92, 1993

## **PUBLICATIONS - MAMC - FY 93**

- Velanovich V, Tapper D      Decision Analysis in Children With Blunt Splenic Trauma - The Effects of Observation, Splenorrhaphy, or Splenectomy on Quality Adjusted Life Expectancy. *Journal of Pediatric Surgery* 28(2): 179-85, 1993.
- Waterhouse W,      Inflammatory Orbital Tumor as an Ocular Sign of a Battered Child.  
Enzenauer RW,      *American J Ophthalmology* 114(4): 510-12, 1992.  
Parmley VC
- White LJ, Mader TH      Refractive Changes With Increasing Altitude After Radial Keratotomy. *Amer Journal of Ophthalmology* 115(6): 821-23, 1993.
- Wilkinson SV, Jones RO,      Austin Bunionectomy: Postoperative MRI Evaluation for Avascular  
Sisk LE, Sunshien KF,      Necrosis. *The Journal of Foot Surgery* 31(5): 469-477, 1992.  
VanManen JW

## **DEPARTMENT OF RADIOLOGY**

- Dixon ZR, Burri BJ,      Dietary Vitamin A, Retinol-Binding Protein (RBP), and Relative Dose  
Neidlinger TR      Response (RDR) as Measures of Vitamin A Status. *FASEB J* 6: A4200, 1992.

## **U.S. DEPARTMENT OF AGRICULTURE**

- Burri BJ, Neidlinger TR,      Methods for Assessing Vitamin A Status in Healthy Adults. *FASEB J*  
Dixon ZR      6:A4904, 1992.

## PRESENTATIONS

### FISCAL YEAR 93

#### DEPARTMENT OF CLINICAL INVESTIGATION

Moore DC	Body Image and Eating Behavior in Adolescents.	33rd Annual Meeting of the American College of Nutrition, San Diego, CA, October 92.
Moore DC	Natural History of Compensated Hypothyroidism Due to Hashimoto's Thyroiditis in Childhood.	NW Pediatric Endocrine Society, Fall Meeting, Seattle, WA, October 92.
Stewart RS	Storage of Human Papillomavirus DNA at Ultralow Temperatures Results in Reduced Polymerase Chain Reaction Amplification.	American Society for Microbiology, 93rd Annual Meeting, Atlanta, GA, May 93.
Stewart RS, Phillips RH	PCR Technology in the Clinical Microbiology Laboratory: Thermal Cycler Idiosyncracies.	Society of Armed Forces Medical Laboratory Scientists, Washington, DC, February 93.
Styner MJ, Moore KH, Matej LA, Archer KT, Plymate SR	Identification of Insulin-Like Growth Factor Binding Proteins in Prostate Cancer Cell Lines.	The Endocrine Society, Las Vegas, NV, June 93.

#### DEPARTMENT OF EMERGENCY MEDICINE

Burke TF, Buertler AT, Timmons J	A Comparison of Sinus X-rays With Computed Tomography in Acute Sinusitis.	Society for Academic Emergency Medicine, San Francisco, CA, May 93.
Guertler AT	A Prospective Study of Benzocaine-Induced Methemoglobinemia in Humans.	Society for Academic Emergency Medicine, San Francisco, CA, May 93.

#### DEPARTMENT OF FAMILY PRACTICE

Ellis DD	Syncope.	7th MEDCOM Primary Care Conference, Willinger, Germany, October 92.
Ellis DD	ACLS Update.	7th MEDCOM Primary Care Conference, Willingenr, Germany, October 92.
Ellis DD	ADHD.	7th MEDCOM Primary Care Conference, Willingen, Germany, October 92.
Ellis DD	Health Screening.	7th MEDCOM Primary Care Conference, Willingen, Germany, October 92.
Ellis DD	Lightening Injuries.	7th MEDCOM Primary Care Conference, Willingen, Germany, October 92.
Grajcar MS	The Physiologic Toll of the Medical Internship.	Uniformed Services Academy of Family Practice Conference, Corpus Christi, TX, April 93.
Lillegard WA	Back Injuries.	American Academy of Family Physicians Annual Meeting, San Diego, CA, October 92.

## PRESENTATIONS - MAMC - FY 93

Lillegard WA	Elbow, Wrist, and Hand Injuries.	American Academy of Family Physicians Annual Meeting, San Diego, CA, October 92.
Lillegard WA	Should Injuries.	American Academy of Family Physicians Annual Meeting, San Diego, CA, October 92.
Porter SB, Blount BW	Pseudotumor of Infancy and Congenital Muscular Torticollis: A Case Report and Primary Care Perspective.	Uniformed Services Academy of Family Physicians Conference, Corpus Christi, TX, March 93.

## DEPARTMENT OF MEDICINE

---

Altemus D, Keeling J	Unusual Tattoo Reaction..	Academy of Dermatology Meeting, San Francisco, CA, December 92.
Altemus D, McCalmont T	Eosinophilic Folliculitis: The History Spectrum.	American Academy of Dermatology Meeting, San Francisco, CA, December 92.
Cadiz JL, Slieter SJ	Flow Cytometric Assessment of Progressive Platelet Activation in Stored Apheresis Platelets.	Army Chapter of the American College of Physicians, San Francisco, CA, October 92.
Cambier PA	Transcatheter Revascularization of Dysfunctional Dialysis Access: Results and Longterm Follow-up.	Army Chapter, American College of Physicians, San Francisco, CA, November 92.
Chapin BL	Corneal arcus: Its Relationship to Cholesterol Level and Cardiovascular Disease - A Meta Analysis.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Cragun WH, Keenan LM	Do Not Resuscitate: Do Not Provide Care?.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Ellis RB, Tuttle RM, Gomez RR	Polymerase Chain Reaction Amplification of B-2 Microglobulin Messenger RNA from Paraffin Embedded Breast Tissue.	Army Regional Meeting of the American College of Physicians, San Francisco, CA, November 92.
Georgitis W, Lemar H, McDermott M	Goitrogenic Effect of Tetraglycine Hydroperiodide Water Purification Tablets.	Army Chapteler of the American College of Physicians, San Francisco, CA, November 92.
Gibson CA, Jones RE, Bunner DL, Lance J, Moon M, Reed HL	Submaximal Cycloergometry to Determine Changing Metabolic Parameters Following 131-I Therapy for Thyrotoxicosis.	The Endocrine Society, Las Vegas, NV, June 93.
Gibson CA, Reed HL, Jones RE	Use of Basal Thyrotropin (TSH) Concentration to Predict Peak TSH Response to Thyrotropin Releasing Hormone.	U.S. Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Jhiang SM, Caruso DR, Tuttle RM, Gomez RR, Peele ME, Mazzaferri EL	Detection of the PTC Chimeric Transcripts in Human Paraffin-Embedded and Frozen Thyroid Tumors.	The Endocrine Society, Las Vegas, NV, June 93.
Jones DL, Jeffers DJ	Physician Generated Practice Guidelines in Reducing Drug Costs - A Prospective Interventional Study.	Society of General Internal Medicine, 16th Annual Meeting, Arlington, VA, April 93.

# PRESENTATIONS - MAMC - FY 93

Keenan LM, Charney PJ, Tuttle M, Snyder RH, Sado A	Estimation of Twenty Four Hour Urinary Nitrogen Excretion from Four and Six Hour Urine Collections in Critically Ill Patients Receiving Nutritional Support.	American College of Chest Physicians, 58th Ann International Scientific Assembly, Chicago, USA, October 92.
Keenan LM, Ficke RF, Walsh ES, Young- McCaughan SB, Kirk LC, Mueller JP, Cragun WH	Do Not Resuscitate: Do Not Provide Care?	Army ACP Meeting, San Francisco, CA, October 92.
Keenan LM, Ricke RFWalsh ES, Walsh ESYoung- McCuag, Young- McCaughan S, Kirk LC, Mueller JP, Cragun WH	Do Not Resuscitate: Do Not Provide Care?	American College of Chest Physicians International Meeting, October 92.
Landry FJ, Kroenke K, Lucas C, Reeder J	Increasing the Use of Advance Directives in Outpatients: A Randomized Trial of a Patient Seminar Versus Written Information.	Society of General Internal Medicine, 16th Annual Meeting, Arlington, VA, April 93.
LeMar HJ, Georgitis WJ, McDermott MT	Thyroid Adaptation To Use of Tetraglycine Hydroperiodide Water Purification Tablet.	The Endocrine Society, Las Vegas, NV, June 93.
Lyons MF, Gage TP, Tsuchida AM, Schlepp GE, Pearce WA, Peller TP, Walter MH	The Use of Savary Dilatators in the Management of Colorectal Strictures.	American Society for Gastrointestinal Endoscopy, Boston, MA, May 93.
Lyons MF, Tsuchida AM, Kim GJ, Schlepp GE, Pearce WA	Colonoscopy Is Not Warranted in Young People Who have Heme Positive Stool By Digital Examination.	American College of Gastroenterology, 57th Annual Scientific Meeting, Miami Beach, FL, October 92.
Lyons MF, Tsuchida AM, Schlepp GE, Pearce WA, Peller TP	Barrett's Esophagus Is Associated With Colon Cancer Compared To Gastroesophageal Reflux With Stricture.	American Gastrointestinal Association/Amer Assoc Study of Liver Diseases, Boston, MA, May 93.
Pearce WA, Guertler AT, Tsuchida AM, Lyons MF, Peller TP	Prospective Evaluation of Benzocaine- Induced Methemoglobinemia In Humans.	American Society for Gastrointestinal Endoscopy, Boston, MA, May 93.
Pearce WA, Peller TP, Tsuchida AM, Lyons MF	Endoscopic Diagnosis and Treatment of Complications of Vertical Banded Gastrostomy.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Peele ME	Detection of PTC Oncogene Expression in Fine Needle Thyroid Nodule Aspirates by Reverse PCR.	1992 Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Peller TP, Lyons MF, Tsuchida AM, Pearce WA, Schlepp GE, Lee SP	The "Budding" Appendiceal Polyp: A Potentially Overlooked But Treatable Lesion.	American Society for Gastrointestinal Endoscopy, Boston, MA, May 93.
Pike JD	Development of Respiratory Therapy Consultant Position In A Military Medical Center - A Pilot Study.	Army Chapter of the American College of Physicians, San Francisco, CA, October 92.

## PRESENTATIONS - MAMC - FY 93

Pike JD, Phillips Y, Argyros G	The Use of Bronchodilators by Metered Dose Inhaler Prior to Bronchoscopy.	American College of Chest Physicians, 58th Annual Scientific Assembly, Chicago, IL, October 92.
Sado AS	Use of Indirect Calorimetry in the ICU.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Thompson JW, Irvine T, Grathwohl K, Roth B	Misuse of Metered Dose Inhalers in Hospitalized Patients.	ACP Washington Regional Meeting, December 92.
Tuttle RM, Gomez RR, Peele ME	Polymerase Chain Reaction Amplification of beta-2-microglobulin Messenger RNA From Paraffin Embedded Thyroid Tissue.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.
Tuttle RM, Kowalski KR, Smith D, Moore KH, Reed HL	Changes in the Relationship of Circulating Sex Hormone to Sex Hormone Binding Globulin Associated With Winter Military Operations: A Possible Marker of Early Energy Deficits.	The Endocrine Society, Las Vegas, NV, June 93.
Tuttle RM, Peele ME	Thyroid Specimens Obtained by Fine Needle Aspiration of the Thyroid Can serve as Substrate for the Polymerase Chain Reaction.	Army Chapter of the American College of Physicians, San Francisco, CA, November 92.

## DEPARTMENT OF NURSING

---

Birgenheier P	The Physiologic Effects of Positioning Premature Infants in Car Seats.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Campanaro J	Legal Issues for Emergency Nursing.	Tri-Services Conference for Emergency Medicine and Nursing, May 93.
Harwood SJ	Piglet Tracheal Epithelial Regeneration After Suctioning.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Leander D	Interpreting the Language of Neonates.	Pacific Northwest Neonatal Nurses Association Conference, Seattle, WA, March 93.
Loan L	Neonatal Implications of Ventilator Inspired Gas Temperatures.	Western Society of Nursing Research Annual Research Conference, May 93.
Loan L	Endotracheal Suctioning in Neonates.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Loan LA	Neonatal Implications of Ventilator Inspired Gas Temperatures.	Pacific Northwest Neonatal Nurses Association Conference, Seattle, WA, March 93.
McCarthy M	Autonomic, Behavioral, and Self-Reported Assessment of Pain in a Selected Emergency Department Population Before and After Parenteral Analgesia.	Emergency Nurses Scientific Assembly, September 93.
Renaud M	Nursing Case Management.	ANC Advanced Practice Care Conference, Denver, CO, March 93.

## PRESENTATIONS - MAMC - FY 93

Renaud M	Hyperbilirubinemia: One Thousand Points of Light.	Pacific Northwest Neonatal Nurses Association Conference, Seattle, WA, March 93.
Renaud M	The Effects of A Modified Care Environment on the Growth and Development of High Risk Infants.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Turner BS	Jump Starting A Research Project.	Second Annual Nursing Research Conference, Durham, NC, December 92.
Turner BS	Team Approach to Research.	Second Annual Nursing Research Conference, Durham, NC, December 92.
Webb SB	Physiologic Responses to Exogenous Surfactant.	Washington State Nurses Association, Spokane, WA, August 93.
Williams D	Implications and Evaluation of Clinical Information Systems.	American Nurses Association International Conference, Rome, Italy, January 93.
Wilson S	Weaning: The Transition of the Preterm Infant to an Open Crib.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Yackel EE	A View on Nurses Smoking and Its Influence on Patient Health Practices.	Washington State Nurses Association Annual Meeting, Spokane, WA, June 93.
Young-McCaughan SB	Sexual Functioning in Women with Breast Cancer Comparing Women Treated with Systemic Adjuvant Therapy to Women Treated Without Pharmacological Manipulation.	Annual Meeting of AMSUS

## NUTRITION CARE DIVISION

---

Grediagin A	The Effect of Exercise Intensity on Body Composition Change in Untrained Moderately Overfat Women.	Sport and Cardiovascular Nutrition Meeting, San Diego, CA, April 93.
-------------	--	--

---

## DEPARTMENT OF OBSTETRICS/GYNECOLOGY

---

Armstrong AY	Hyperactivation in Cryopreserved Spermatozoa: Effects of Progesterone and Various Membrane-Active Agents.	Armed Forces District of the American College of Obstetricians/Gynecologists, Norfolk, VA, November 92.
Larsen WI, Brady WK, Kopelman JN	Twelve Hour Urine Collections in Comparison to Twenty Four Hour Urine Collections in Patients with Preeclampsia.	Armed Forces District of the American College of Obstetricians/Gynecologists, Norfolk, VA, November 92.
Macedonia CR, Rasband W	Three Dimensional Imaging of the Fetal Head Using A Continuous Running Acquisition Process.	American Institute of Ultrasound and Medicine, HI, March 93.
Markenson GR	The Effects of Estradiol and Progesterone on Vasoactive Substances in the Dually Perfused Cotyledon Model	Armed Forces District of the American College of Obstetricians/Gynecologists, Norfolk, VA, November 92.
Yanko CA, Kopelman JN, Read JA	Quantitative Evaluation of Blood Loss in Parturients With and Without Clinical Chorioamnionitis.	Western Society for Clinical Research, February 93.

---



## PRESENTATIONS - MAMC - FY 93

### DEPARTMENT OF PATHOLOGY, BLOOD BANK

Hodges GF, Lenhardt TM, Cotelingam JD	Bone Marrow Involvement in Large Cell Lymphoma - Prognostic Significance of Discordant Disease.	Canadian/American Association of Pathologists, New Orleans, LA, March 93.
---	---	---

### DEPARTMENT OF PEDIATRICS

Carter ER	Use of the Interrupter Technique in Assessing Airways Obstruction.	Regional Cystic Fibrosis Conference, Seattle, WA, May 93.
Carter ER	Use of Heliox in Obstructive Airways Disease.	Annual Meeting of the Washington Thoracic Society, January 93.
Carter ER, Stecenko A, Pollock B, Jaeger M	Update on Theophylline Use in Pediatric Asthma.	Pediatric Respiratory Disorder Conference, March 93.
Guevara JP, Clark J, Keplar B, Athya B	Prevalence of Cardiac Abnormalities in Children With SLE.	Uniformed Services Pediatric Society, San Antonio, TX, March 93.
Rawlings JS, Read JA	Effectiveness of Spontaneous Labor in Relation to the Hour of Onset.	Uniformed Services Pediatric Society, San Antonio, TX, March 93.
Vahn CA, Stephan MJ, Culbertson G	The Association of Mullerian Aplasia With the Oculoauriculovertebral (OAV) Spectrum.	David W. Smith International Conference on Morphogenesis and Malformations, Tremblant, Canada, August 93.

### DEPARTMENT OF RADIOLOGY

Bauman J, Budd S, Katts N, et al	A Conceptual Plan to Link A Nuclear Medicine Department to the Medical Diagnostic Imaging Support System (MDIS) PACS Configuration.	Society of Photo-Optical and Instrumentation Engineers, Newport Beach, CA, February 93.
Ho VB	Bone Scintigraphy in Sports Medicine.	Radiological Society of North America, 78th Annual Scientific Assembly, Chicago, IL, November 92.
Ho VB	Pineal Region Masses: Differential Diagnosis.	Radiological Society of North America, 78th Annual Meeting, Chicago, IL, December 92.
Ho VB	Scintigraphic Artifacts: A Systematic Approach.	Radiological Society of North America, 78th Annual Meeting, Chicago, IL, November 92.
Ho VB, Chuang HS, Rovira MJ, Koo B	Juvenile Huntington Disease: CT and MR Features.	American Society of Neuroradiology, Vancouver, Canada, May 93.
Ho VB, Smirniotopoulos JG	Pineal Region Masses: Differential Diagnosis.	American Society of Neuroradiology, Vancouver, Canada, May 93.
Ho VB, Smirniotopoulos JG	Pineal Region Masses: Differential Diagnosis.	Radiology Society of North America Annual Meeting, Chicago, IL, November 92.
Kransdorf MJ, Buetow PC, Meyer CA	Soft Tissue Tumors in the First Year of Life: A Review of 587 Cases..	American Roentgen Ray Society, 93rd Annual Meeting, San Francisco, CA, April 93.

## PRESENTATIONS - MAMC - FY 93

Leckie RG, Goerringer F, Smith DV, Smith S, Choi HS, Bender G, Haynor DR, Kim Y	An Early Evaluation of MDIS Workstations at the Madigan Army Medical Center.	Society of Photo-Optical and Instrumentation Engineers, Newport Beach, CA, February 93.
Leckie RG, Smith CS, Smith DV, Donnelly J, Cawthon MA, Weiser J, Willis CE, Goeringer F	The Medical Diagnostic Imaging Support (MDIS) System: A Large PACS and Teleradiology Project.	7th International Symposium and Exhibition for Computer Assisted Radiology, Berlin, Germany, June 93.
Leckie RG, Smith DV, Smith S, Cawthon MA, Weiser J, Donnelly J, Goeringer F	Computed Radiography: Successes and Concerns After Implementation of a Completely Digital Imaging System at a Large Medical Center.	American Roentgen Ray Society, 93rd Annual Meeting, San Francisco, CA, April 93.
Parker JES, Pestaner JC, Meyer CA, Babu SS	Nipple to Lesion Distance Discrepancy on Craniocaudal and Mediolateral Oblique Views.	American Roentgen Ray Society, San Francisco, CA, April 93.
Peller PJ, Ho VB	Scintigraphic Artifacts: A Systemic Approach.	Radiology Society of North America, Chicago, IL, November 92.
Rovira MJ, Ho VB	MRI and MRV of the Posterior Fossa Dural Sinuses: Normal Anatomy and Variants.	American Society of Neuroradiology, Vancouver, Canada, May 93.
Smith DV, Cawthon MA, Leckie RG, Mun SK	Medical Diagnostic Imaging Support (MDIS) System Implementation at Madigan Army Medical Center as a Model for Installing a Large Scale Picture Archiving and Communications System.	Third PACS-RIS School, Washington, DC, April 93.
Smith DV, Mun SK	Specifications and Future Directions for Large Scale Picture Archiving and Communications Systems (PACS).	Third PACS-RIS School Proceedings, Washington, DC, April 93.
Smith S, Leckie RG, Smith DV, Donnelly J, Cawthon MA, Sauls F, Romlein J, Willis CE	MDIS: A Large PACS and Teleradiology Project for the Military - An Overview of the First Year of Operation.	American Roentgen Ray Society, 93rd Annual Meeting, San Francisco, CA, April 93.

## DEPARTMENT OF SURGERY

Anderson EE, Perez LM, Amling CL, Thrasher JB, Newman GE, Joyner RE	Palliative Urinary Diversion for Ureteral Obstruction As A Consequence of Metastatic Prostate Cancer.	American Urological Association, 88th Annual Meeting, San Antonio, TX, May 93.
Burgess FW	Anticoagulant Effect of Magnesium Sulphate as Measured by Thromboelastography.	Eighteenth Annual Meeting of the American Society of Regional Anesthesia, Seattle, WA, May 93.
Burgess FW, Colonna D, Anderson DM, Sborov MJ	Postoperative Referred Pain Following Thoracotomy.	American Society of Anesthesiologists, October 92.
Burgess FW, Snodgrass G, Helman JD, Sborov MJ	Combined Epidural/General Anesthesia and the Hemodynamic Response to Hemorrhage.	American Society of Anesthesiologists, October 92.

## PRESENTATIONS - MAMC - FY 93

Carpenter CT, Cosio MQ	The Role of Arthrography in Ulnar Collateral Ligament Injuries of the Thumb.	American Orthopaedic Association Meeting, Seattle, WA, March-93.
Carter PL	Experience with Biliopancreatic Diversion in Reoperative Bariatric Surgery.	American College of Surgeons, October 92.
Chandler DW, Grantahm DW	Auditory Spatial Resolution in the Horizontal Plane As a Function of Reference Angle: Microstructure of the Azimuth Function.	Acoustical Society of America, Norfolk, VA, April 93.
Chandler DW, Souliere CR, Edmond CV	Effects of Blast Overpressure on the Ear: A Case Study.	American Academy of Audiology, Phoenix, AZ, April 93.
Cox H, Jones RO, Sunshein KF	Direct Extension Osteomyelitis Secondary To Onychocryptosis: A Review of Literature and 3 Case Reports.	American College of Foot and Ankle Surgeons, San Diego, CA, February 93.
Gee BT, Parmley VC, Fannin LA, Mader TH, Truxal AR, Varga JA, Kannen KA, Hansen CN	Safety of Intraocular Administration of E5 Gram-Negative Endotoxin Monoclonal Antibody in Rabbit Eyes.	Association for Research in Vision and Ophthalmology, Saratoga, FL, May 93.
Gingrich JR, Thrasher JB, Paulson DF	Radical Nephrectomy for Renal Cell Carcinoma: A Contemporary Review of Presentation, Complications, and Outcome of 356 Cases.	American Urological Association, 88th Annual Meeting, San Antonio, TX, May 93.
Grace TS, Jones RO, Sunshein KF, Harkless LB	Metatarsus Proximus and Digital Divergence: Its Association with Intermetatarsal Neuroma.	American College of Foot and Ankle Surgeons, San Diego, CA, February 93.
Knight RW, Hansberry KL, Bagg MD	Impotence Following Transurethral Resection of the Prostate (TURP). <i>First place for a resident paper.</i>	Kimbrough Urologic Seminar, November 92.
Mader TH, Aragonas, Fox, Stein	Ocular Injuries of Operation Desert Shield/Desert Storm.	American Academy of Ophthalmology, Dallas, TX, November 92.
Mancuso JJ	Epidural Analgesia in an Army Medical Center: Impact on Cesarean and Instrumental Vaginal Deliveries.	Society for Obstetric Anesthesia and Perinatology. 25th Annual Meeting, Indian Wells, CA, May 93.
Neary MT, Jones RO, Sunshein K, VanManen W, Youngberg R	Avascular Necrosis of the First Metatarsal Head Following Austin Osteotomy: A Follow-Up Study.	American College of Foot and Ankle Surgeons, San Diego, CA, February 93.
Neary MT, Jones RO, Sunshein K, VanManen W, Youngberg R	Avascular Necrosis of the First Metatarsal head Following Austin Osteotomy: A Follow-up Study..	American College of Foot and Ankle Surgeons Annual Meeting, San Diego, CA, February 93.
Ng JD	Comparison of Three Corneal Trephines for Penetrating Keratoplasties to Treat Large Central Corneal Perforations	"Keratoplasty Surgery in the Military" National Meeting, Washington, DC.
Perez LM, Thrasher JB, Robertson JE, Paulson DF	Is Radical Prostatectomy Appropriate in Elderly Men?	American Urological Association, 88th Annual Meeting, San Antonio, TX, May 93.

# PRESENTATIONS - MAMC - FY 93

Reno JP	Individual Preparedness As A Measure of Effectiveness of Hearing Conservation Programs.	Military Audiology Meeting, Norfolk, VA, 0.
St Pierre P, Staheli LT, Green NE, Smith JB	Femoral Neck Stress Fractures in Children and Adolescents.	American Orthopaedic Association, Seattle, WA, March 93.
Stonecipher KG, Jensen HG, Parmley VC, Rosey JJ	Culture and Sensitivities of the Eyelid and Conjunctiva Associated with Anterior Segment Infections - A Microbiological Analysis of 1083 Lid and Conjunctival Cultures.	Association for Research in Vision and Ophthalmology, Saratoga, FL, May 93.
Sunshein KF, Wilkinson SV, Jones RO, Sisk LD, VanManen JW	Evaluation of the Rate of Avascular Necrosis Formation Following Austin Bunionectomy.	American College of Foot and Ankle Surgeons, San Diego, CA, February 93.



## INDEX TO PROTOCOLS

O = Ongoing      T = Terminated  
C = Completed      S = Suspended

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Active Duty Students</b>			51
Creel CA #93/126	O	The Effect of Body Position on Ventricular Arrhythmias in the Coronary Artery Disease Patient in the CCU	52
Ribera JE #93/011	C	Sensitivity of Transiently-Evoked Otoacoustic Emissions in Monitoring Adult Cis-platin Patients	53
<b>Behavioral Sciences Division, Clinical Psychology</b>			54
Lambie MG #93/025	O	Sexual Harassment: Attitudes and Actions	55
<b>Department of Clinical Investigation</b>			56
Moore DC #87/100	O	Thyroid Size in Children and Adolescents	57
Moore DC #90/091	O	A Phase III Open Protocol for a Multicenter Study for the Treatment of Central Precocious Puberty with D-Trp(6)-Des-Gly(10)-N-ethylamide-LHRH, A Long-Acting Analog of Luteinizing Hormone Releasing....	58
Moore DC #91/092	O	Characterization of LH Isoforms in Treated and Untreated Precocious Puberty	59
Moore DC #92/048	O	Treatment use of Oxandrin (Oxandrolone) in Boys with Constitutional Delay of Growth and Puberty	60
Moore DC #91/060	C	Thyroid Volume in Adolescents as Determined by Ultrasound	61
Moore KH #92/058	O	Is Sex Hormone Binding Globulin Locally Produced in Breast Cancer Tissue?	62
Moore KH #91/043	C	Sex Hormone Binding Globulin (SHBG): Carbohydrate Function and Characterization	63
Moore KH #90/109	C	Characterization of Equine Inhibin: Sequence Analysis and Carbohydrate Composition	65
Powell DA #92/005	O	Veterinary Support Personnel and Investigator Training in Animal Care Procedures (Swine, Goat, Rabbit, Ferret, Rat, Mouse)	66
Stewart RS #92/074	O	Microbiological Analysis of Male NGU Specimens by Polymerase Chain Reaction: A Retrospective Study	67
Stewart RS #92/075	O	Precise Tissue Distribution of DNA and Hormone Receptors in Breast Biopsies as Clinical Prognosticators: A Retrospective Study	68
Stewart RS #92/073	O	Molecular Microbiology Assay Development	69
Styner MJ #92/034	O	Insulin-Like Growth Factor Binding Proteins in Prostate Carcinoma Cell-Lines	70
<b>Department of Dentistry</b>			71
Dorsett CR #91/059	C	The Influence of Prophylactic Administration of Intravenous Ondansetron on Post Operative Nausea and Vomiting and Length of Stay in the Post Anesthesia Care Unit	72
Engibous PJ #92/062	C	Postoperative Complications in Operating Room Dentistry for Children	73

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Kittle PE #90/068	C	Parental Recall of Informed Consent for General Anesthesia Dental Procedures	74
Kittle PE #92/098	C	Waste Anesthetic GAS (WAG) Exposure of Pediatric Dentists During Operating Room Dental Procedures	75
Page MG #92/063	C	Common Behavior Management Techniques Used in Pediatric Dentistry: Why Parents Accept or Object to Them	76
Wygonski RJ #91/061	C	Comparison of Induction and Recovery From Propofol-Nitrous Oxide versus Methohexital-Isoflurane-Nitrous Oxide Anesthesia in Ambulatory Oral Surgery Patients	77

## **Department of Emergency Medicine** 78

Brantner RD #92/100	O	The Randomized Use of Helium-Oxygen Mixture for the Administration of Bronchodilator Therapy in the Treatment of Bronchial Asthma	79
Brantner RD #93/120	O	The Randomized Use of Helium-Oxygen Mixture for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. A Blinded Trial	80
Burke TF #93/051	O	The Use of Intravenous Morphine for Early Pain Relief in Patients With Acute Abdominal Pain	81
Nold JM #92/039	O	Treatment of Corneal Abrasions: Is Eye Patching Necessary?	82
Noonburg GE #92/043	C	Utility of Sinus Tenderness as a Diagnostic Sign in Sinusitis	83
Peterson MW #93/019	C	The Effect of Calcium Administration on Albuterol's Ability to Lower Serum K <sup>+</sup> in a Hyperkalemic Swine Model	84
Rice MM #82/025	O	Emergency Room Procedure Training	85
Rice MM #90/016	O	Pediatric Intubation Training Utilizing the Ferret Model	86
Wedmore IS #93/169	O	The Relationship of Intraocular Pressure and Symptoms of Acute Mountain Sickness at Moderate Altitude	87
White DC #90/078	C	Oral Versus Intravenous Steroid: A Prospective Study in Acute Asthma	88
White DC #92/097	T	Pediatric Pain Assessment Survey	89

## **Department of Family Practice** 90

Ellis DD #93/076	O	Comparison of Family Practice (FP) In-Training Exam Scores Between Residents Who Have Done A General Medical Officer Tour of Duty After A FP Internship & Residents....Continuous 3 Year FP Residency	91
Harrington BC #93/013	O	Exercise Blood Pressure and Heart Rate Response in Pregnancy As A Predictor of Preeclampsia	92
Kiser WR #93/077	C	The Effect of Internship on Empathy	93
Kiser WR #92/083	T	The Effect of Internship on Moral Reasoning	94
Lewis EL #91/058	C	An Analysis of Selected Elements of Family Function and Related Variable in Adolescent Pregnancy	95

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Lovins DE #92/084	O	Back Pain in Aviators: A Descriptive Study of the Type of Care Received/Sought and Implications for Flight Status - Part Two	96
Nusbaum MR #93/093	C	The Prevalence of Sexual Concerns in a Population of Women Who Have Sought Routine Gynecological Care & What Barriers Exist for the Discussion of Sexual Concerns With Physicians/Health Care Providers	97
Johnson J #92/085	T	Diagnoses Which Stimulate Physician Initiated Discussions About Advance Directives: A Survey of Practicing Physicians	98
Runkle GP #93/123	O	Vasectomy Reversal: A Heuristic Investigation of the Experience	99
<b>I Corp Surgeon, Fort Lewis, WA</b>			100
Urich WM #93/047	O	Implementation of a Voluntary Fitness Program and Pilot Project and the Consequent Evaluation of Physical Fitness Levels of Pregnant Soldiers Before, During and After Pregnancy to Substantiate ....	101
<b>Department of Medicine, Allergy/Immunology Service</b>			102
Brown JS #89/055	T	Multicenter Clinical Evaluation of Penicillin Skin Testing	103
<b>Department of Medicine, Critical Care Medicine</b>			104
Sado AS #93/159	O	Randomized Trial of E5 Antiendotoxin Monoclonal Antibody in Patients With Severe Sepsis	105
Sheehan KM #93/131	O	Pilot Study - Thromboelastograph Assessment of Suspected Acute M.I./Unstable Angina Patients Pre- and Post- I.V. Magnesium Administration	106
<b>Department of Medicine, Cardiology Service</b>			107
Cambier PA #93/074	O	Transcatheter Closure of the Patent Ductus Arteriosus Using a Retrievable Coil Occlusion System in the Newborn Lamb Model	108
Clagett CL #93/151	O	Cardiac Safety of Sexual Intercourse Following Myocardial Infarction As Assessed by High Resolution Holter Monitoring	109
Mascette AM #93/018	O	Cardiac Dimensions in Female Athletes	110
Paris JA #93/103	O	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of RheothRx Injection (Polaxamer 188) in Patients with Suspected Acute Myocardial Infarction	111
Rave MA #93/027	O	Comparison of Intravenous Adenosine With Exercise in Thallium-201 SPECT in Patients With Left Bundle Branch Block	112
<b>Department of Medicine, Endocrinology Service</b>			113
Bunner DL #92/020	C	Evaluation of the Efficacy and Safety of Glimepiride versus Glyburide in Subjects with Noninsulin-Dependent Diabetes Mellitus (NIDDM)	114
Chapin BL #93/101	O	Androgen Effects on Glucose Metabolism in Men	115
Chapin BL #93/102	O	Evaluation of Calcium Metabolism After Biliopancreatic Bypass Surgery	116
Jones RE #92/069	O	Phospholipid Composition of Human Epididymal and Ejaculated Spermatozoa	117



<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Jones RE #87/023	O	Investigations into the Mechanisms of Phospholipid Synthesis in Human Spermatozoa	118
Jones RE #90/038	O	Detailed Studies Into Membrane Lipid Synthesis in Human Sperm	119
Jones RE #83/081	O	Studies on Fatty Acid Activation in Spermatozoa: Kinetics and Localization	120
Jones RE #88/026	O	Neutral and Polar Lipid Synthesis in Human Spermatozoa: A Correlation with Morphology and Function	121
Jones RE #88/070	C	Characterization of Serovar-Specific Ureaplasma Antigens by Analysis with Monoclonal Antibodies	122
Lemar HJ #92/068	O	The Time Course for Metabolic Responses to Thyroid Hormone: Specific Contributions of Muscle Efficiency and Resting Oxygen Utilization	123
Peele ME #91/097	C	The Use of Thyroid Tissue Obtained by Fine Needle Aspiration (FNA) as Substrate for Polymerase Chain Reaction (PCR) Amplification of Thyroglobulin and the Papillary Thyroid Cancer (PTC) Oncogene	124
Tuttle RM #91/081	O	The Effect of Thyroid Hormone Suppression on Thyroid Nodules Found to be Indeterminate by Fine Needle Aspiration	126
Tuttle RM #93/127	O	Oncogene Activation in Neoplastic Thyroid Tissue Occurring After Exposure To A Nuclear Blast: The Marshall Island Experience	127
Tuttle RM #91/080	O	A Prospective Evaluation of Gonadal Damage in Thyroid Cancer Patients Treated with Radioactive Iodine	129
Tuttle RM #93/033	C	Papillary Thyroid Cancer Oncogene: Prevalence, Specificity, and Clinical Significance	130
<b>Department of Medicine, Gastroenterology Service</b>			132
Lyons MF #90/098	C	Does Laparoscopy Add to the Diagnosis of Nonfocal Liver Disease?	133
Lyons MF #91/051	T	A Long-Term Screening Project for the Prevention of Adenocarcinoma of the Esophagus in Patients with Barrett's Esophagus, Intestinal Metaplasia of the Stomach and Partial Gastrectomy for Peptic .....	134
Lyons MF #93/004	T	A Multicenter, Randomized, Double-Blind, Placebo Controlled, Evaluation of Healing & Relapse Rate Following Oral GR122311X Compared With GR885202X, Ranitidine & Placebo in Patients With Duodenal Ulcer	135
Tsuchida AM #93/005	T	A Multicenter, Randomized, Double Blind, Placebo Controlled Evaluation of Healing & Relapse Rates Following Oral GR122311X Compared With GR88502X, Ranitidine & Placebo in Patients with Benign...	136
<b>Department of Medicine, Hematology/Oncology Service</b>			137
Bertram KA #93/100	O	A Long Term Safety Evaluation of Kapanol and MS Contin in Patients With Moderate to Severe Cancer Pain	138
Bertram KA #93/099	O	A Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy and Safety of Kapanol to MS Contin in the Management of Patients With Moderate to Severe Cancer Pain	139
Bertram KA #92/009	O	Fluconazole Versus Amphotericin B as Empiric Therapy in Febrile, Neutropenic Patients. University of Washington	140

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Bertram KA #93/001	O	The Role of Bone Marrow Micrometastases in Breast Cancer. A Two-Year Study funded by the U.S. Army Medical Research and Development Command	141
Bertram KA #93/130	O	Interaction of Breast Cancer and Bone Marrow Cells in Long-Term Culture: Effects on Cell Growth, Growth Factor, and Cytokine Production	142
Davidson H #92/103	O	Dolasetron Mesylate Protocol MCPR 0031: A Double Blind, Randomized, Parallel Study of the Antiemetic Effectiveness of IV Dolasetron Mesylate vs IV Zofran in Patients Receiving Cisplatin Chemotherapy	143
Ellis RB #92/072	O	Prognostic Significance of Oncogene Amplification and Expression in Human Breast Cancer	144
Ellis RB #92/070	O	Comparison of TLC D-99 Doxorubicin Liposome Injection versus Doxorubicin Injection in Metastatic Breast Cancer	145
Hu JSD #93/121	O	Clinical Significance of Lymphoid Aggregates in Bone Marrow	146
Robson ME #93/031	C	A Multicenter Clinical Study Using A Technetium-Labelled Monoclonal Antibody for Imaging Patients With Small Cell Lung Cancer	147
Robson ME #93/133	T	A Multicenter Clinical Study to Compare Imaging of Non-Small Cell Lung Cancer With A Technetium-Labelled Monoclonal Antibody Produced by Two Different Manufacturers	148
Robson ME #93/105	O	A Pilot Study of Granulocyte Colony-Stimulating Factor (G-CSF, Filgrastim) in the Empiric Treatment of Febrile Neutropenia Due to Myelosuppressive Chemotherapy	149
Sowray PC #90/082	T	A Pilot Study of Carboplatin and Daily Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer	150
Sowray PC #90/007	T	Treatment of Thrombocytopenia, Hemolytic Anemia, or Neutropenia with Ascorbic Acid	151
<b>Department of Medicine, Infectious Disease Service</b>			152
Cooper RH #93/021	T	A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of the Use of Weekly Azithromycin as Prophylaxis Against the Development of Mycobacterium avium Complex Disease in HIV Infected...	153
Cooper RH #91/099	C	Azithromycin in the Treatment of Nongonococcal Urethritis: A Multicenter Double-Blind, Double-Dummy Study Employing Doxycycline as A Comparative Agent	154
Cooper RH #93/158	O	Study of Pyelonephritis in Women	155
<b>Department of Medicine, Internal Medicine Service</b>			156
Grathwohl KWA #93/057	O	Swan Ganz Catheters' Sepsis: Prospective Randomized Study of Replacement of Swan Ganz Catheters	157
Jeffers DJ #93/035	C	Deletion From the MAMC Formulary of Nifedipine XL, Patient Effects and Side Effects	158
Jeffers DJ #89/062	T	Determination of the Sensitivity and Specificity of Light Reflection Rheography for the Diagnosis of Deep Venous Thrombosis in the Lower Extremity	159
Rohrer MK #93/163	O	Utility of the Physical Examination to Assess Extracellular Volume Status	160

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Department of Medicine, Neurology Service</b>			161
Bernier RM #92/066	O	A Prospective Study of Headache in Pregnancy	162
Clayton WL #93/080	O	A Randomized Double-Blind, Cross-Over, Placebo-Controlled Clinical Trial of D-alpha-Tocopheryl Acetate (Vitamin E) as Add-On Therapy for Epilepsy in Adults	163
Clayton WL #92/050	O	Effects of Valproic Acid on Semen Parameters in Male Epileptics	164
McCarty JP #92/094	C	Effects of Carnitine on Measures of Cognition, Mood, and Sleep in Adolescents with Epilepsy Treated with Valproate	165
<b>Department of Medicine, Pulmonary Service</b>			166
Murray TR #93/162	O	Exercise Capacity Following Radiation Therapy in Patients With Stages II and III Non-small Cell Lung Cancer	167
Pina JS #93/104	O	Does Sampling of the Lung With the Guidance of High Resolution CT Scan Improve the Utility of Bronchoalveolar Lavage or Transbronchial Biopsy	168
Roth BJ #92/059	O	Bleomycin vs. Minocycline in a Randomized Double Blind Prospective Trial of Intrapleural Therapy for Recurrent Malignant Pleural Effusions	169
Roth BJ #90/099	O	Comparison of the Serum Effusion Albumin Gradient to Traditional Criteria for Transudates in Patients with Pleural Effusions Secondary to Congestive Heart Failure	170
Roth BJ #91/015	O	Controlled Trial of Positive Pressure Ventilation via Nasal Mask in Patients with Severe Chronic Air Flow Obstruction and Chronic Respiratory Failure	171
Roth BJ #89/043	O	The Effects of Testosterone Replacement in Hypogonadal, Malnourished Patients with Chronic Obstructive Pulmonary Disease (COPD)	172
Roth BJ #92/024	O	Resectable Bronchogenic Carcinoma: Value of Routine Contrast - Enhanced Cranial MRI in Preoperative Staging	173
Winter MG #93/034	C	Validation of Infrasonics Adult Star Respiratory Mechanics Package	174
Zacher LL #93/084	O	Comparison of a High Resolution Computed Tomography Technique and Fiberoptic Bronchoscopy in the Evaluation of Hemoptysis	175
<b>Department of Medicine, Rheumatology Service</b>			176
Irvin TL #93/168	O	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Oral GR122311X Compared with Ranitidine and GR88502X for the Gastric or Duodenal Ulcers in Patients with Osteoarthritis ... Ulcers	177
Irvin TL #92/019	C	The Efficacy and Safety of Misoprostol for the Prevention of NSAID-Induced GI Complications	178
Riordan KK #91/083	T	Iontophoresis Therapy for Bursitis and Tendinitis	179
<b>Department of Nursing</b>			180
Birgenheier PS #93/116	O	Effects of Military Parents' Separation on Children	181
Carr MA #93/118	O	Crisis Intervention With Critical Care Families	182

<b>PI and No.</b>	<b>Status</b>	<b>Title</b>	<b>Page</b>
Harwood SJ #90/072	C	Piglet Tracheal Epithelial Injury and Regeneration Following Endotracheal Suctioning	183
Hellman S #92/082	C	Evaluation of Aftacare Videotaped Programs on Diabetes, Cancer & Heart Disease for Patient Education as an Intervention in Secondary Prevention of Complications Associated with These Chronic Diseases	184
Leander DJ #93/117	O	Exogenous Surfactant Therapy in Premature Infants	185
Loan LA #93/157	O	Temperature and Capillary Blood Flow Velocity Stability During Nursing Care Procedures in Premature Neonates: A Pilot Study	186
Loan LA #89/028	O	The Effect of Two Levels of Hyperoxygenation Given via a Manual Resuscitation Bag and Ventilator During Endotracheal Suctioning of Premature Infants	187
Mygrant BI #93/003	O	A Double Blind, Placebo Controlled Study on the Effect of a Lactobacillus Preparation on the Incidence of Tube-Feeding Related Diarrhea in ICU Patients	188
Neill GF #93/058	C	Children's Hospital EMLA Efficacy Research (CHEER) Trial	189
Rea RE #93/125	O	Clinical Information System: Impact on Nursing	190
Renaud MT #93/115	O	Neonatal Outcomes in a Modified NICU Environment	191
Renaud MT #92/102	C	The Effects of a Modified Care Environment on the Growth and Development of High Risk Infants	192
Turner BS #91/034	T	Impact of Continuous vs Intermittent Negative Pressure on Tracheal Trauma and Regeneration	193
Webb SB #92/086	C	Physiologic Responses to Exogenous Surfactant	194
Webb SB #93/094	C	Incidence of Patent Ductus Arteriosus in Premature Infants Receiving Exogenous Surfactant Therapy	195
Young-McCaughan SB #93/012	C	Sexual Functioning in Women with Breast Cancer Comparing Women Treated with Systemic Adjuvant Therapy to Women Treated Without Pharmacological Manipulation	196
Young-McCaughan SB #93/106	O	Family Home Visitation Program: The Nurse as Coach	198
<b>Department of Obstetrics/Gynecology</b>			199
Armstrong AY #92/010	O	Predictors of Response to Ovulation Induction with Clomiphene Citrate in the Overweight Patient	200
Armstrong AY #92/093	O	Hyperactivation in Cryopreserved Spermatozoa: Effects of Progesterone and Various Membrane-Active Agents	201
Boley TJ #92/021	C	Amniotic Fluid Index: A Comparison Between Real Time Ultrasound and Color Flow Doppler Ultrasound in its Determination	202
Boley TJ #92/071	C	The Establishment of the Doubly Perfused, Placental Cotyledon Model for the In Vitro Investigation of the Umbilical-Placental Circulation	203
Bullis WJ #93/156	O	The Use of Sertraline in Patients With Chronic Pelvic Pain	204

<b>PI and No.</b>	<b>Status</b>	<b>Title</b>	<b>Page</b>
Foos CC #93/043	O	A Crossover Evaluation of Alterations in Glucose Intolerance in Pregnancies Treated With Oral B Mimetic Tocolytic Agents	205
Foos CC #92/041	O	Correlation of Vaginal Ultrasonographic Findings with Pathology in GYN Surgical Patients	206
Harrison DH #93/002	O	Changes in Cervical Mucus Following Loop Electrosurgical Excision Procedure (LEEP) for Treatment of Cervical Dysplasia	207
Kopelman JN #93/017	C	Components of Prenatal Care and Low Birthweight	208
Kopelman JN #92/101	O	Neurodevelopmental Follow-Up of Infants of Mothers Who Seroconvert to HSV During Pregnancy	209
Kopelman JN #92/060	S	A Randomized Prospective Evaluation of Bladder Flap Closure at Time of Cesarean Section	210
Ma W #93/010	O	Correlation of Single-Void Urinary Protein to Creatinine Ratios vs 24-Hour Urinary Protein Excretion in Pregnant Patients	211
Magelssen DJ #93/112	O	A Randomized, Double-Blind, Placebo-Controlled Study of Parallel Design to Evaluate and Compare the Therapeutic Implant 5-FU-e TI (5003) With and Without Epinephrine to Its Placebo When Administered..	212
Markenson GR #93/070	C	The Effect of Nicotine and Cigarette Smoke Extract on Endothelium-Derived Vasoactive Substances Produced in the Doubly Perfused Placental Cotyledon Model	213
Markenson GR #93/083	O	A Randomized Trial of Low Dose Aspirin in Pregnancies with Unexplained Elevations of Maternal Serum Alpha-Fetoprotein	214
Markenson GR #92/090	C	The Effects of Estradiol and Progesterone on Vasoactive Substances in the Dually Perfused Cotyledon Model	215
Markenson GR #92/023	T	A Comparison of Amniotic Fluid Collected by Amniocentesis versus Amniotic Fluid Collected Via an Intrauterine Pressure Catheter in the Diagnosis of Chorioamnionitis in Laboring Patients at Term	216
Maslow AS #92/022	O	Continuous Infusion Epidural Analgesia: Its Effects on the Doppler Velocimetry of the Umbilical Arteries of Normotensive and Preeclamptic Patients in Labor	217
Potter ME #89/017	O	Surgical Management of the Bowel and Urinary Tract in Gynecologic Surgery (Swine Model)	218
Vanderlinde TM #93/075	C	The Management of Minimal Abdominal Trauma in Pregnancy	219
<b>Preventive Medicine Service</b>			220
Bradley KL #93/020	C	Hepatitis C and Sexual Transmission: A Case-Control Study	221
Fuery HA #92/076	S	Early Identification of and Assistance to Pregnant Women Subjected to Domestic Violence	222
Gunzenhauser JD #90/014	O	Assessment of Risk Factors for HIV Infection Among Active Duty U.S. Army Personnel with Documented Recent HIV-Antibody Seroconversion - Incident Cases	223
Krauss MR #93/009	O	Low-Dose Oral Contraceptives and Cardiovascular Disease	224
<b>Department of Pathology, Blood Bank</b>			225
Schmidt JA #93/024	C	An Anonymous Case-Control Study of Risk Factors for Exposure to the Hepatitis C Virus in Army Blood Donors	226

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Department of Pediatrics</b>			227
Beachy JC #93/052	O	Intrauterine Growth: Factors That Influence the Relationship Between Gestational Age and Birth Weight, Length, and Head Circumference	228
Beachy JC #93/095	O	Effect of Magnesium on Pulmonary Arterial Pressure and Ductal Patency in Newborn Lambs	229
Beachy JC #90/058	O	Neonatal Emergency Procedure Training in the Rabbit Model	230
Broadhurst RB #91/055	O	Use of the Children's Yale Brown Obsessive Compulsive Scale (CY-BOCS) Symptom Checklist as an Initial screening Interview for Identification of Obsessive Compulsive Disorder (OCD) and Related .....	231
Carter ER #93/040	O	The Short-Term Use of Helium-Oxygen Mixture in Children Hospitalized With Acute, Severe Asthma	232
Carter ER #93/041	O	The Short-Term Use of a Helium-Oxygen Mixture in Infants Hospitalized With Bronchiolitis	233
Carver TD #93/129	O	Placebo Controlled Trial of Cromolyn Sodium (Intal) in the Prevention of Airway Inflammation in Ventilated Premature Neonates	234
Kahn CA #92/044	C	Lead Levels and Their Relationship to Attention Deficit Hyperactivity Disorder and Developmental Delay	235
Krober MS #92/004	T	Incidence of Group A Beta Hemolytic Streptococcus Colonization and Infection in Association with Varicella	236
Krober MS #90/071	T	Pyridoxine as Specific Therapy and Prophylaxis in the Treatment of Theophylline-Induced Seizures in Mouse and Rabbit Models	237
Krober MS #93/022	O	A Randomized Controlled Trial of Penicillin to Evaluate the Clinical Response in Group C Streptococcal Pharyngitis	239
Krober MS #91/053	T	Role of Glutamine and 4-aminobutyraldehyde in Pyridoxine-Treated Theophylline Toxicity	240
Krober MS #89/076	T	Protective Role of Pyridoxine in Gentamicin Nephrotoxicity	241
Krober MS #92/007	C	A Comparative Study of the Safety and Efficacy of Clarithromycin and Eryped (Erythromycin Ethylsuccinate) Suspensions in the Treatment of Children with Community-Acquired Pneumonia	242
Krober MS #90/092	O	Core Project: Evaluation of Diagnostic Assays for Human Immunodeficiency Virus (HIV) in Children with Evidence of HIV Exposure or HIV Illnesses	243
Krober MS #90/093	T	Epidemiology of HIV in Pediatric and Perinatal Patients: A Natural History Study	244
Krober MS #90/107	T	Perinatal HIV Infection: Epidemiology and Natural History	245
Krober MS #91/018	T	Role of Pyridoxine in Gentamicin-Lasix Nephrotoxicity in Rabbits	246
Scott JS #89/071	T	Comparison of Effectiveness of Lidocaine HCL vs Hyaluronidase in the Early Treatment of Soft Tissue Extravasation Injuries in Swine	247
Stafford EM #92/067	C	Cervical Human Papillomavirus Infection Prevalence in Female ROTC College Cadets	248
White CB #93/046	O	Single Dose Cefixime Therapy for the Treatment of Uncomplicated Urinary Tract Infections in Female Children and Adolescents	249

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Department of Radiology</b>			250
Bauman JM #93/028	O	Quantitative Pulmonary Perfusion	251
Bauman JM #93/098	O	Establishing Normal Gastric Emptying Times for MAMC	252
Bauman JM #93/119	O	Gallbladder Ejection Fractions	253
Ho VB #93/124	O	Measurement Accuracy of Reformatted MR Images in Cardiac Imaging Using A Pig Cadaveric Model	254
Ho VB #93/053	C	Juvenile Huntington Disease: CT and MR Features	255
Ho VB #93/122	O	A Modern Approach to Congenital Metabolic and Neurodegenerative Diseases of Childhood	256
Ho VB #93/007	C	Scintigraphic Artifacts: A Systematic Approach	257
Ho VB #93/008	C	Bone Scintigraphy in Sports Medicine	258
Ho VB #93/146	C	Abnormal Soft Tissue Tc-MDP Uptake: Incidence and Clinical Significance	259
Ho VB #93/016	O	CT and MR Imaging of Radiculopathy	260
Ho VB #93/037	O	Arachnoid Granulations: MR Features	261
Ho VB #93/145	C	High Dose Gadoteridol MR in the Detection of Neuropathology	262
Ho VB #93/014	O	Normal CT and MR Anatomy of the "Lateral Recess"	263
Ho VB #93/078	C	Gadolinium Enhanced Computed Tomography (CT) in a Pig Model	264
Ho VB #93/071	C	Pineal Region Masses: A Simplified Approach to Differential Diagnosis	265
Ho VB #93/015	C	Von Hippel-Lindau Disease: Radiologic-Pathologic Correlation	266
Ho VB #93/054	O	Urologic Stone Conspicuity: Plain Films vs Computed Radiography	267
Meyer CA #93/113	O	A Clinical Comparison of Nodule Detection Utilizing A Modified ROC Study: Conventional vs. Digital vs. Digital-AMBER Chest Radiography	268
Parker JES #93/038	C	Nipple to Lesion Distance Discrepancy on Mammographic Craniocaudal and Mediolateral Oblique Views	269
Parker JES #93/050	T	Kinetics of D-Dimer Concentration After A Single Subtherapeutic Dose of Urokinase in Patients with Pulmonary Embolism or Deep Venous Thrombosis	270
Rovira MJ #93/039	O	Normal MR Angiography of the Cerebral Venous System	271
Stanford AN #90/079	T	Use of Metoclopramide With Chloral Hydrate for Sedation	272

<u>PL and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Department of Surgery, Anesthesia Service</b>			273
Burgess FW #93/030	C	An In Vitro and In Vivo Assessment of Elevated Magnesium Levels on the Visco-elastic Measurement of Whole Blood Clot Formation	274
Burgess FW #91/090	T	Selective Blockade of the Vagus Nerve to Relieve Referred Shoulder Pain Associated with Pulmonary Surgery in Human Subjects	275
Burgess FW #92/061	C	A Double Blind, Placebo-Controlled Comparison Between 0.125%, 0.25%, and 0.5% Ropivacaine, When Used for Post-operative Infiltration in Herniorrhaphies: A Dose Resposne Study	276
Gridley GD #92/046	O	Can the Combination of Intramuscular Ketorolac and Continuous Epidural Bupivacaine Eliminate the Need for Narcotic Analgesia Post-Thoracotomy	277
Helman JD #92/087	O	Patient-Controlled Analgesia and the Risk of Postoperative Myocardial Ischemia	278
Hughes WA #93/082	O	Allo-priming of Mivacurium Neuromuscular Blockade With Steroidal Nondepolarizers	279
Plyman ML #91/028	O	The Influence of Prophylactic Administration of Intravenous Crystalloid and Colloid Solutions on the Incidence of Hypotension Following Subarachnoid Anesthesia	280
Polaner DM #93/073	O	The Efficacy of Epinephrine as an Epidural Test Dose for Predicting Intravascular Injection During Halothane Anesthesia in Infants and Children	281
Walz EJ #92/008	O	Influence of Phrenic Nerve Blockade on the Incidence of Referred Shoulder Pain in Patients Undergoing Thoracic Surgery for Pneumonectomy	282
Walz EJ #92/047	O	Identification of the Optimal Bupivacaine Concentration for Epidural Analgesia in Combination with Patient Controlled Epidural Fentanyl Analgesia	283
<b>Department of Surgery, ENT Service</b>			284
Anderson PL #93/026	O	Atrial Natriuretic Factor as a Mediator of Airway Obstruction Induced Enuresis	285
Canonico DM #92/026	T	Shoulder Morbidity in Head and Neck Surgery	286
Edmond CV #93/160	O	Analyzing the Dynamic Behavior of the Eustachian Tube Through A Sonometric Monitor	287
Silveira JL #93/068	O	The Effect of Radial vs Circumferential Myringotomy on Ventilatory Tube Retention	288
<b>Department of Surgery, General Surgery Service</b>			289
Andersen CA #93/161	O	Multicenter, Single-Blind Clinical Trial To Determine the Efficacy of Dermagraft, A Living Dermal Replacement, in the Treatment of Full-Thickness Chronic Venous Insufficiency Ulcers	290
Kaufmann CR #85/021	O	Advanced Trauma Life Support Course	291
Place RJ #93/079	S	Serum Levels of Tumor Necrosis Factor in Postoperative Patients	292
Simmang CL #87/007	O	General Surgery Stapling Familiarization Lab (Swine Model)	293
Simmang CL #93/029	O	Laparoscopic Assisted Colon and Rectal Operations	294



<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Weber SE #93/069	O	Hemodynamic Consequences of Pneumoperitoneum in Patients with Cardiopulmonary Disease	295
<b>Department of Surgery, Ophthalmology Service</b>			296
Mader TH #93/111	O	Refractive Changes at Altitude Following Radial Keratotomy Surgery	297
Nekola MA #93/128	C	The Effect of Weightlifting on Intraocular Pressure	298
Ng JD #93/155	C	Comparison of Three Corneal Trephines for Penetrating Keratoplasties to Treat Large Central Corneal Perforations	299
Parmley VC #93/114	O	Clinical and Microbiological Study Comparing Ciprofloxacin Ophthalmic Solution to TOBREX Ophthalmic Solution for Treating Bacterial Conjunctivitis in Children	300
Parmley VC #92/092	C	Gram Negative Endotoxin Monoclonal Antibody as an Adjunct to Treating Gram Negative Endophthalmitis in the Rabbit	301
<b>Department of Surgery, Orthopedic Surgery Service</b>			302
Cosio MQ #86/016	O	Teaching Program for Practical Microsurgery	303
Crenshaw SM #93/081	O	Postarthroscopy Analgesia Following Intra-articular Morphine and Bupivacaine	304
Esplin VS #93/096	O	Thumb Flexor Retinaculum and Tendon Sheath Pulley Study	305
StLouis JS #90/015	T	Investigation of Cryotreatment on the Epiphysis of Growing Rabbit Bone	306
<b>Department of Surgery, Plastic Surgery Service</b>			307
Davis SM #92/099	O	The Implantation of Bone Morphogenetic Protein Using Vascularized Omentum in a Predetermined Size and Shape in Swine	308
<b>Department of Surgery, Urology Service</b>			309
Hansberry KL #91/098	O	Randomized Prospective Study Comparing Intermittent Pneumatic Compression of the Calf to Intermittent Sequential Pneumatic Compression of the Whole Leg	310
Knight RW #91/091	C	Transurethral Prostatectomy and Associated Erectile Dysfunction	311
Schwartz BF #93/132	O	Fluoroquinolones As Prophylaxis in Penile Prosthesis Surgery	312
Schwartz BF #93/045	O	The Normal Flora of the Human Epididymis	313
<b>Fort Ord MEDDAC</b>			314
Lee CB #93/055	O	Infant Feeding Practices in the Military Community: The Incidence and Duration of Breast Feeding in the Military Community and the Factors Affecting This Decision	315
Phillip DF #93/036	C	Seroprevalence of Human Babesia Infections in High Risk Individuals in Northern California: A Pilot Study	316
Vu KK #93/170	S	A Prospective Study of the Treatment of Functional Ovarian Cyst	317

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Fort Wainwright, AK</b>			318
Levine ME #91/054	C	Melatonin and Cortisol Secretion in the Arctic, Effects of Photoperiod on Circadian Rhythms and Mood	319
<b>Letterman MEDDAC</b>			320
Tobin LM #92/065	C	Racial Differences in Responses to the Rorschach Inkblot Test in a Psychiatric Population	321
<b>U.S. Department of Agriculture</b>			322
Burri BJ #92/001	S	Methods for Assessing Vitamin A Status in Healthy Adults	323
<b>Walter Reed Army Medical Center</b>			324
Rich IM #91/046	C	Pregnancy Attitudes, Ambivalence, and Symptom Distress	325
<b>Gynecology Oncology Group</b>			326
Potter ME #82/073	O	GOG 0026A: Master Protocol for Phase II Drug Studies in Treatment of Advanced Recurrent Pelvic Malignancies	327
Potter ME #82/007	O	GOG 0026C: A Phase II Trial of Cis-Platinum Diamminedichloride in Treatment of Advanced Pelvic Malignancies	328
Potter ME #88/067	O	GOG 0026DD: A Phase II Trial of Amonafide (NSC #308847) in Patients with Advanced Pelvic Malignancies	329
Potter ME #88/082	T	GOG 0026EE: A Phase II Trial of Didemnin B (NSC #325319) in Patients with Advanced Pelvic Malignancies	330
Potter ME #90/023	O	GOG 0026GG: A Phase II Trial of Fazarabine (ARA-AC,1-BETA-D-Arabinofuranosyl-5-Azacytosine, NSC 281272, IND 29722) in Patients with Advanced/Recurrent Cervical Cancer	331
Potter ME #91/008	O	GOG 0026II: Trial of 5-Fluorouracil and High Dose Leucovorin in Advanced Metastatic or Recurrent Pelvic Malignancies	332
Potter ME #91/085	O	GOG 0026KK: A Phase II Trial of Merbarone (NSC336628) in Patients with Advanced and Recurrent Epithelial Ovarian Carcinoma	333
Potter ME #93/153	O	GOG 0026LL: A Phase II Trial of Prolonged Oral Etoposide (VP-16) in Patients With Advanced Pelvic Malignancies	334
Potter ME #83/024	O	GOG 0026N: A Phase II Trial of Diahydroxyanthracenedione (DHAD) (NSC #30179) (CL232315) in Patients with Advanced Pelvic Malignancies	335
Potter ME #93/072	C	GOG 0026NN: A Phase II Trial of Piroxantrone in Patients With Advanced and Recurrent Ovarian Epithelial Carcinoma	336
Potter ME #83/026	O	GOG 0026Q: A Phase II Trial of Aminothiadiaazole in Patients with Advanced Pelvic Malignancies	337
Potter ME #85/087	O	GOG 0026U: A Phase II Trail of Ifosfamide (NSC #109724) and the Uroprotector Mesna (NSC #25232) in Patients with Advanced Pelvic Malignancies	338
Potter ME #86/075	T	GOG 0026W: A Phase II Trial of Echinomycin in Patients with Advanced Pelvic Malignancies	339
Potter ME #88/058	C	GOG 0026X: A Phase II Trial of Gallium Nitrate (NSC #15200) in Patients with Advanced Pelvic Malignancies	340

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Potter ME #81/079	O	GOG 0040: A Clinical Pathologic Study of Stage I and II Uterine Sarcomas	341
Potter ME #81/035	O	GOG 0041: Surgical Staging of Ovarian Carcinoma	342
Potter ME #81/105	O	GOG 0052: A Phase III Randomized Study of Cyclophosphamide Plus Adriamycin Plus Platinol Versus Cyclophosphamide Plus Platinol in Patients with Optimal Stage II Ovarian Adenocarcinoma	343
Potter ME #82/036	C	GOG 0063: A Clinical Pathologic Study of Stages IIB, III, and IVA Carcinoma of the Cervix	344
Potter ME #84/033	O	GOG 0072: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease	345
Potter ME #84/074	O	GOG 0078: Evaluation of Adjuvant VP-16, Bleomycin, and Cisplatin (BEP) Therapy in Totally Resected Choriocarcinoma, Endodermal Sinus Tumor, Embryonal Carcinoma and Grade 3 Immature Teratoma of the ...	346
Potter ME #86/089	O	GOG 0085: A Randomized Comparison of Hydroxyurea versus 5-FU Infusion and Bolus Cisplatin as an Adjuvant to Radiation Therapy in Patients with Stages II-B, III, and IV-A Carcinoma of the Cervix and...	347
Potter ME #93/044	C	GOG 0086O: A Phase II Trial of Taxol (NSC #125973) and G-CSF in Patients With Advanced or Recurrent Endometrial Carcinoma	348
Potter ME #87/013	O	GOG 0090: Evaluation of Cisplatin, Etoposide, and Bleomycin (BEP) Induction Followed by Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Consolidation in Advanced Ovarian Germ Cell Tumors	349
Potter ME #87/104	O	GOG 0092: Treatment of Selected Patients with Stage 1B Carcinoma of the Cervix After Radical Hysterectomy and Pelvic Lymphadenectomy: Pelvic Radiation Therapy versus No Further Therapy	350
Potter ME #89/036	O	GOG 0093: Evaluation of Intraperitoneal Chromic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma (Stage III)	351
Potter ME #87/028	O	GOG 0095: Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected IAi and IBi and IAii and IBii Ovarian Cancer, Phase III	352
Potter ME #87/091	O	GOG 0099: A Phase III Randomized Study of Adjunctive Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma	353
Potter ME #87/105	C	GOG 0100: Monoclonal Antibody Against Free Beta HCG to Predict Development of Persistent Gestational Trophoblastic Disease (PGTD) in Patients with Hydatidiform Mole	354
Potter ME #87/106	O	GOG 0101: A Phase II Evaluation of Preoperative Chemoradiation for Advanced Vulvar Cancer	355
Potter Me #93/065	O	GOG 0102N: Intraperitoneal Administration of Recombinant Alpha-2 Interferon Alternating with Cisplatin in Patients with Residual Ovarian Carcinoma	356
Potter ME #88/081	C	GOG 0106: Evaluation of the Serum Marker, CA-125, in the Management of Carcinoma of the Endometrium	357
Potter Me #89/037	C	GOG 0107: A Randomized Study of Doxorubicin (NSC #123127) versus Doxorubicin Plus Cisplatin (NSC #119875) in Patients with Primary Stage III and IV Recurrent Endometrial Adenocarcinoma	358

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Potter ME #89/052	O	GOG 0108: Ifosfamide (NSC #109724) and the Uroprotector Mesna (NSC #113891) with or without Cisplatin (NSC #119875) in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus	359
Potter ME #91/086	O	GOG 0109 (SWOG 8797): A Randomized Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy, versus Radiation Therapy Alone in Selected Patients with Stages ...	360
Potter ME #91/009	O	GOG 0110: A Randomized Study of Cisplatin versus Cisplatin Plus Dibromodulcitol (NSC #104800) versus Cisplatin Plus Ifosfamide and Mesna in Advanced Stage III or IV), Recurrent or Persistent ....	361
Potter ME #91/010	O	GOG 0111: A Phase III Randomized Study of Cyclophosphamide (NSC #26271) and Cisplatin (NSC #119875) versus Taxol (NSC #125973) and Cisplatin (NSC #119875) in Patients with Suboptimal Stage III and ...	362
Potter ME #91/011	O	GOG 0112: A Randomized Comparison of Chemoprophylaxis Using Methotrexate versus Routine Surveillance in the Management of the High Risk Molar Pregnancy	363
Potter ME #91/064	O	GOG 0113: An Evaluation of Hydroxyurea, 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy in Patients with Stages II-B, III, and IV-A Carcinoma of the Cervix and Negative .....	364
Potter ME #93/059	O	GOG 0114: A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide vs Intravenous Cisplatin and Taxol vs High Dose Intravenous Carboplatin Followed by Intravenous Taxol and ....	365
Potter ME #91/074	O	GOG 0115: Bleomycin (NSC #125066), Etoposide (NSC #141540) and Cisplatin (NSC #119875) (BEP) as First-Line Therapy of Malignant Tumors of the Ovarian Stroma (Granulosa Cell, Sertoli-Leydig Tumor, ....	366
Potter ME #93/060	C	GOG 0117: Adjuvant Ifosfamide and Mesna with Cisplatin in Patients with Completely Resected Stage I and II Mixed Mesodermal Tumors of the Uterus	367
Potter ME #93/061	O	GOG 0120: A Randomized Comparison of Hydroxyurea vs Hydroxyurea, 5-FU Infusion and Bolus Cisplatin vs Weekly Cisplatin as Adjunct to Radiation Therapy in Patients with Stages IIB, III, IVA Carcinoma..	368
Potter ME #93/062	C	GOG 0121: A Phase Two Trial of High Dose Megestrol Acetate (Megace) in Advanced or Recurrent Endometrial Carcinoma	369
Potter ME #93/063	O	GOG 0123: A Randomized Comparison of Radiation Therapy & Adjuvant Hysterectomy vs Radiation Therapy & Weekly Cisplatin & Adjuvant Hysterectomy in Patients with Bulky Stage IB Carcinoma of the Cervix	370
Potter ME #93/064	O	GOG 0125: Extended Field Radiation Therapy with Concomitant 5-FU Infusion and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to Para-aortic Lymph Nodes	371
Potter ME #93/152	O	GOG 0126B: Evaluation of Cisplatin (NSC #119875) and Cyclosporin in Recurrent, Platinum-Resistant and Refractory Ovarian Cancer	372
Potter ME #93/085	C	GOG 0127B: Evaluation of Isotretinoin and Alpha Interferon in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix	373
Potter ME #93/150	O	GOG 0127C: Evaluation of Cisplatin and Pentoxifylline in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix	374

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Potter ME #93/023	O	GOG 0132: A Phase III Randomized Study of Cisplatin versus Taxol versus Taxol and Cisplatin in Patients with Suboptimal Stage III and IV Epithelial Ovarian Carcinoma	375
Potter ME #93/006	O	GOG 0134: A Phase III Trial of Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma	376
Potter ME #93/139	O	GOG 0137: A Randomized Trial of Estrogen Replacement Therapy Versus No Estrogen Replacement in Women With Stage I or II Endometrial Adenocarcinoma	377
Potter ME #93/086	O	GOG 0138: A Phase II Trial of Cisplatin and Cyclophosphamide in the Treatment of Extraovarian Peritoneal Serous Papillary Carcinoma	378
Potter ME #93/087	O	GOG 0139: A Randomized Study of Doxorubicin Plus Cisplatin versus Circadian-Timed Doxorubicin Plus Cisplatin in Patients with Primary Stages III and IV, Recurrent Endometrial Adenocarcinoma	379
Potter ME #93/140	O	GOG 0140: An Assessment of Age and Other Factors Influencing Protocol Versus Alternative Treatments for Patients With Epithelial Ovarian Cancer Referred to Gynecologic Oncology Group Institutions	380
Potter ME #93/149	O	GOG 0143: Familial and Reproductive Factors in Ovarian Cancer	381
Potter ME #89/039	C	GOG 8809: Flow Cytometrically Determined Tumor DNA Content in Ovarian Tumors of Low Malignant Potential	382
Potter ME #90/026	O	GOG 8907: DNA Content of Hydatidiform Moles as a Predictor of Persistent Gestational Trophoblastic Neoplasia	383
<b>National Cancer Institute</b>			384
Downey GO #81/033	C	NCI 7602: All Stage IC and II 9A,B,C) and Selected Stage IAii and IBii Ovarian Cancer	385
<b>National Surgical Adjuvant Breast &amp; Bowel Project</b>			386
Ellis RB #93/171	O	NSABP B-21: A Clinical Trial to Determine the Worth of Tamoxifen in the Management of Patients with Node-Negative, Occult, Invasive Breast Cancer Treated by Lumpectomy	387
Rearden TP #93/147	O	NSABP R-03: A Clinical Trial to Evaluate the Worth of Preoperative Multimodality Therapy (5-FU-LV and RTX) in Patients with Operable Carcinoma of the Rectum	388
<b>Pediatric Oncology Group</b>			390
Cook BA #93/141	O	POG 8650: Intergroup National Wilms' Tumor Study - 4	391
Cook BA #93/164	O	POG 9047: Neuroblastoma Biology Protocol	392
Cook BA #93/135	O	POG 9226: Treatment of Stages I, IIA, and IIIA Hodgkin's Disease With ABVE and Low Dose Irradiation	393
Cook BA #93/148	O	POG 9233/34: A Phase III Randomized Trial of standard vs Dose-Intensified Chemotherapy for Children Less Than 3 Years of Age With A CNS Malignancy Treated With or Without Radiation Therapy	394
Cook BA #93/134	O	POG 9340/41/42: Treatment of Patients Greater than or = 365 Days At Diagnosis With Stage 4 and N-MYC Amplified Stage 2B/3 Neuroblastoma	395

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
<b>Puget Sound Oncology Consortium</b>			397
Downey GO #87/079	C	PSOC 615: Intraperitoneal Consolidation Therapy Following Second-Look Operation in Ovarian Cancer	398
Sowray PC #91/066	O	PSOC 1007: Adriamycin and Cefoperazone for Treatment of Carcinoma and Sarcoma Refractory to Adriamycin	399
<b>Southwest Oncology Group</b>			400
Davidson H #78/047	O	SWOG 7808: Combination Modality Treatment for Stage III and Stage IV Hodgkin's Disease, MOPP #6	401
Davidson H #79/096	O	SWOG 7827: Combined Modality Therapy for Breast Carcinoma, Phase III	402
Davidson H #84/018	O	SWOG 8216/38: Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer	403
Davidson H #83/056	O	SWOG 8294: Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer (ECOG, EST-1180), Intergroup Study	404
Davidson H #84/059	O	SWOG 8313: Multiple Drug Adjuvant Chemotherapy for Patients with ER Negative Stage II Carcinoma of Breast, Phase III	405
Sowray PC #86/007	O	SWOG 8417/19: Evaluation of Two Consolidation Regimens in the Treatment of Adult Acute Lymphoblastic Leukemia, Phase III	406
Davidson H #87/033	O	SWOG 8501 (INT 0051): Intraperitoneal Cis-platinum/IV Cyclophosphamide vs IV cis-platinum/IV Cyclophosphamide in Patients with Non-measurable (Optimal) Disease Stage III Ovarian Cancer, Phase III ....	407
Davidson H #87/107	O	SWOG 8507: Maintenance versus No Maintenance BCG Immunotherapy of Superficial Bladder Cancer, Phase III	408
Davidson H #88/003	O	SWOG 8520: Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II	409
Davidson H #85/073	O	SWOG 8590: Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck, Phase III (Intergroup Group.....	410
Davidson H #85/064	O	SWOG 8591: NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III - Intergroup	411
Sowray PC #87/045	O	SWOG 8600: A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-lymphocytic Leukemia	412
Davidson H #89/045	O	SWOG 8621: Chemohormonal Therapy of Postmenopausal Receptor-Positive Breast Cancer, Phase III	413
Davidson H #89/058	O	SWOG 8692 (INT 0075): Therapy in Premenopausal Women with Advanced, ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs the LH-RH Analog, Zoladex: Phase III, Intergroup	414
Davis RC #90/039	O	SWOG 8710: Trial of Cytectomy Alone Versus Neoadjuvant M-VAC + Cytectomy in Patients with Locally Advanced Bladder Cancer (INT-0080/EST-1877, CALGB-8891)	415
Davidson H #90/084	C	SWOG 8719: Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients Without Prior Endocrine Manipulation, Phase II	416

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Davidson H #88/065	O	SWOG 8736: Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy	417
Davidson H #88/076	O	SWOG 8738: Treatment of Extensive Non-small Cell Lung Cancer: Standard Dose Cisplatin versus High-Dose Cisplatin in Hypertonic Saline Alone versus High-Dose Cisplatin/Mitomycin-C, Phase III	418
Sowray PC #90/063	O	SWOG 8789: A Randomized Study of Etoposide + Cisplatin and Etoposide + Carboplatin (CBDCA) in the Management of Good Risk Patients With Advanced Germ Cell Tumors	419
Davis RC #90/040	T	SWOG 8793 (EST-3883): Randomized Phase III Evaluation of Hormonal Theray versus Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prost	420
Davidson H #88/066	O	SWOG 8796: Combination Chemotherapy for Advanced Hodgkin's Disease, Phase III Intergroup (INT 0074)	421
Rearden TP #93/165	O	SWOG 8807: An Investigation of the Relationship Between an Integrated, System Education Approach and Breast Self Exam (BSE) Compliance, Phase III	422
Sowray PC #90/064	O	SWOG 8809: A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas	423
Gomez PL #90/054	C	SWOG 8810: Six Courses of 5-Fluorouracil & Cisplatinum with Correlation of Clinical & Cellular DNA Parameters in Patients with Advanced, Untreated, & Unresectable Squamous Cell Carcinoma of the.....	424
Sowray PC #89/065	O	SWOG 8812: Treatment of Limited Small Cell Lung Cancer With Concurrent Chemotherapy, Radiotherapy, With or Without GM-CSF and Subsequent Randomization To Maintenance Interferon or No Maintenance	425
Davidson H #89/080	O	SWOG 8814 (ECOG 4188, NCCTG 883051): Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Breast....	426
Sowray PC #91/020	O	SWOG 8816: Study of 13-cis Retinoic Acid (Accutane) Plus Interferon-A (Roferon-A) in Mycosis Fungoides, Phase II	427
Sowray PC #91/087	O	SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol	428
Sowray PC #90/041	C	SWOG 8828: A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia	429
Sowray PC #92/055	C	SWOG 8842: Dihydroxyazacytidine in Malignant Mesothelioma, Phase II Study	430
Davidson H #90/027	O	SWOG 8851 (EST 5811, INT-0101): Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Zoladex + Tamoxifen) in Premenopausal Women with Axillary....	431
Davidson H #90/047	O	SWOG 8854: prognostic Value of Cytometry Measurements of Breast Cancer DNA from Postmenopausal Patients with Involved Nodes and Receptor Positive Tumors: A Companion Protocol to SWOG 8814	432
Gomez PL #91/067	O	SWOG 8855: Prognostic Value of Cytometry Measurements of Cellular DNA Parameters in Locally Advanced. Previously Untreated Head and Neck Cancer Patients	433

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Gomez PL #90/055	O	SWOG 8892 (EST 2388, RTOG 8817, INT 0099): A Study of Radiotherapy with or without Concurrent Cisplatin in Patients with Nasopharyngeal Cancer, Phase III	434
Davidson H #90/086	O	SWOG 8894: (INT-0105, EST-2889): A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Cancer	435
Davidson H #90/029	O	SWOG 8897 (EST-2188, CALGB-8897, INT-0101): Phase III Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History...	436
Davidson H #89/021	O	SWOG 8899: A Prospectively Randomized Trial of Low-Dose Leucovorin = 5-FU, High-Dose Leucovorin + 5-FU, Levamisole + 5-FU, or Low-Dose Leucovorin + 5-FU + Levamisole Following Curative Resection in...	437
Sowray PC #90/030	O	SWOG 8905: Phase II/III Study of Fluorouracil and Its Modulation in Advanced Colorectal Cancer	438
Davidson H #92/079	O	SWOG 8925: Evaluation of Cisplatin + VP-16 Followed by Mitotane at Progression if no Prior Mitotane or Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Patients with Advanced and .....	439
Sowray PC #90/112	C	SWOG 8931 (EST-3189): Phase III Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and 1 16-Week Multi-drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative..	440
Stapleton LM #91/089	O	SWOG 8947: Central Lymphoma Serum Repository Protocol	441
Phillips WA #91/006	O	SWOG 8952 (INT-0111), (CALG-8952), EST-5487): Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs MOPP/ABV Hybrid	442
Sowray PC #91/032	C	SWOG 8956: A Phase II Study of Cisplatin and 5-Fluorouracil Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder	443
Gomez PL #91/007	O	SWOG 8957: Feasibility Trial of Post-Operative Radiotherapy Plus Cisplatin Followed by Three Courses of 5-FU Plus Cisplatin in Patients with Resected Head and Neck Cancer, Phase II Pilot	444
Phillips WA #91/021	O	SWOG 8990: (ECOG-9228, INT-0103): Combined Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver	445
Davidson H #90/056	O	SWOG 8997 (ECOG 3887): Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide	446
Davidson H #93/056	O	SWOG 9003: Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Study for Untreated and Previously Treated Patients	447
Bertram KA #91/094	O	SWOG 9007: Cytogenetic Studies in Leukemia Patients, Ancillary	448
Stapleton LM #92/051	O	SWOG 9008: Trial of Adjuvant Chemoradiation After Gastric Resection for Adenocarcinoma, Phase II	449
Sowray PC #91/033	O	SWOG 9013 (RTOG 89-11, INT-0113): A Prospective Randomized Comparison of Combined Modality Therapy for Squamous Carcinoma of the Esophagus: Chemotherapy Plus Surgery Versus Surgery Alone for ....	450



<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Rearden TP #93/142	O	SWOG 9015: A Randomized Trial of Pre- and Post-Operative Chemotherapy Compared to Surgery Alone for Patients With Operable Non-Small Cell Carcinoma of the Lung, Phase III	451
Gomez PL #93/143	O	SWOG 9019: A Phase III, Randomized, Prospective Comparison Between Chemotherapy Plus Radiotherapy, and the Same Chemotherapy Plus Radiotherapy Together With Surgery for .... Non-Small Cell Lung Cancer	452
Stapleton LM #91/045	C	SWOG 9028: A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/Verapamil/Quinine for Induction	453
Sowray PC #92/040	O	SWOG 9030: Phase II Study of High Dose Ara-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia	454
Bertram KA #92/052	O	SWOG 9031: A Double Blind Placebo Controlled Trial of Daunomycin and Cytosine Arabinoside With or Without rhG-CSF in Elderly Patients With Acute Myeloid Leukemia, Phase III	455
Bertram KA #92/095	O	SWOG 9032: A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in Blast Phase Chronic Myelogenous Leukemia	456
Robson ME #93/067	O	SWOG 9034 (EST 3489, CALGB 9120): Phase III Study of Three Intensive Postremission Therapies in Adult Acute Nonlymphocytic Leukemia: Comparison of Autologous Bone Marrow Transplantation, Intensive....	457
Sowray PC #91/068	C	SWOG 9037: Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG 8897 (EST-2188, CALGB-8897, INT-0012)	458
Sowray PC #91/077	O	SWOG 9039: Evaluation of Quality of Life in Patients with Stage D2 Cancer of the Prostate Enrolled on SWOG 8894	459
Davidson H #91/069	O	SWOG 9040 (CALGB-9081, INT-0014): Intergroup Sectal Adjuvant Protocol, A Phase III Study	460
Rearden TP #92/002	O	SWOG 9045: Evaluation of Quality of Life in Patients with Advanced Colorectal Cancer Enrolled on SWOG 8905	461
Rearden TP #93/032	O	SWOG 9061 (EST-2190, INT 0121): A Phase III Study of Conventional Adjuvant Chemotherapy vs High Dose Chemotherapy and Autologous Bone Marrow Transplantation....Breast Cancer at High Risk of Recurrence	462
Rearden TP #93/144	O	SWOG 9107: A Phase II Pilot Study of High-Dose 24-Hour Continuous Infusion 5-FU and Leucovorin and Low-Dose PALA for Patients With Colorectal Cancer	464
Bertram KA #91/096	O	SWOG 9108 (CALGB-9011, NCIC-CTG CL.1): A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs Fludarabine Phosphate Plus Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic....	465
Rearden TP #92/104	O	SWOG 9110: A Phase II Evaluation of Diademnin B in Central Nervous System Tumors	466
Rearden TP #91/078	O	SWOG 9111: Post-Operative Adjuvant Interferon Alpha 2 in Resected High-Risk Primary and Regionally Metastatic Melanoma, Intergroup	467
Sowray PC #92/053	O	SWOG 9119: Primary Chemotherapy of Poor Prognosis Soft Tissue Sarcomas, Phase II	468
Rearden TP #93/088	O	SWOG 9122: Evaluation of 5-Fluorouracil by Intermittent Infusion in Combination With Alpha-Interferon for Patients with Advanced Renal Cell Carcinoma	469

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Ellis RB #93/138	O	SWOG 9124: Evaluation of Edatrexate (EDX) in Patients With Relapsed or Refractory Germ Cell Tumors, Phase II	470
Gomez PL #92/017	O	SWOG 9125: A Phase II Trial of CVAD/Verapamil/Quinine for Treatment of Non-Hodgkin's Lymphoma	471
Robson ME #93/154	O	SWOG 9126: A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in High Risk Acute Myelogenous Leukemia, Phase III	472
Robson ME #93/048	O	SWOG 9129: Phase III Randomized Study of All-Trans Retinoic Acid Versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia	473
Sowray PC #92/056	O	SWOG 9136: Biologic Parameters in Soft Tissue Sarcomas: A Companion Study to Select Southwest Oncology Group Clinical Trials with Soft Tissue Sarcoma Patients	474
Sowray PC #92/054	O	SWOG 9139: Adjuvant Therapy of Primary Osteogenic Sarcomas, Phase II	475
Willadsen DS #93/049	O	SWOG 9147: Evaluation of Tamoxifen in Desmoid Tumors, Phase II	476
Rearden TP #93/089	O	SWOG 9148: A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside ... Extensive Stage Small Cell and Non-small Cell Lung Carcinoma	477
Sowray PC #92/080	C	SWOG 9151: Evaluation of Topotecan in Hepatoma, Phase II	478
Rearden TP #93/042	O	SWOG 9152 (EST-4890): Prediction of Recurrence and Therapy Response in Patients with Advanced Germ Cell Tumors by DNA Flow Cytometry	479
Hu JSD #93/167	O	SWOG 9157: Trial of All Trans-Retinoic Acid in Hepatoma, Phase II	480
Rearden TP #93/097	O	SWOG 9205: Central Prostate Cancer Serum Repository Protocol	481
Hu JSD #93/107	O	SWOG 9210: A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction	482
Rearden TP #93/066	C	SWOG 9215: Quality of Life on Breast Cancer Adjuvant Trial (SWOG 8931)	483
Rearden TP #93/090	O	SWOG 9216: A Randomized Phase III Study of CODE Plus Thoracic Irradiation Versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer	484
Rearden TP #93/136	O	SWOG 9221, MDACC ID 91-025, INT-191-001: Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer	486
Hu JSD #93/108	O	SWOG 9237: Evaluation of Topotecan in Refractory and Relapsing Multiple Myeloma	487
Robson ME #93/109	O	SWOG 9240: A Phase II Trial of CVAD for Treatment of Non-Hodgkin's Lymphoma	488
Rearden TP #93/091	T	SWOG 9244 (MSKCC-92-106, NCI-T92-0130): A Randomized Study of Cisplatin (CDDP) & Etoposide versus Carboplatin (CBDCA) + Etoposide in the Treatment of Good Risk Patients With Advanced Germ Cell Tumors	489

<u>PI and No.</u>	<u>Status</u>	<u>Title</u>	<u>Page</u>
Robson ME #93/092	O	SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease	490
Robson ME #93/110	O	SWOG 9246: A Phase II Evaluation of Taxol in Patients with Relapsed Non-Hodgkin's Lymphoma or Relapsed Hodgkin's Disease	491
Ellis RB #93/137	O	SWOG 9248: A Phase II Trial of Paclitaxel (Taxol) in Patients With Metastatic Refractory Carcinoma of the Breast	492
Rearden TP #93/166	O	SWOG 9303: Phase III Study of Radiation Therapy, Levamisole, and 5-Fluorouracil versus 5-Fluorouracil and Levamisole in Selected Patients With Completely Resected Colon Cancer	493
<b>University of Washington Neuro-Oncology Group</b>			494
Davidson H #88/073	C	UWNG 86-01: Phase II Study of External Brain Irradiation and Hydroxyurea Followed by Procarbazine, CCNU, and Vincristine (PCV) for the Treatment of Primary Malignant Brain Tumors	495
Davidson H #88/017	O	UWNG 87-01: Phase II Study of TPDCFH for Recurrent Malignant Brain Tumor	496
Davidson H #89/013	O	UWNG 88-01: Phase II Study of High Dose Methotrexate and Craniospinal Irradiation for the Treatment of Primary Lymphoma of the Central Nervous System	497

DETAIL SHEETS FOR PROTOCOLS

ACTIVE DUTY STUDENT DETACHMENT, HSC

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/126		<b>Status:</b> On-going	
<b>Title:</b> The Effect of Body Position on Ventricular Arrhythmias in the Coronary Artery Disease Patient in the CCU					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Mar 94		
<b>Department:</b> Student Detachment, HSC			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Cheryl A. Creel, AN					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> ventricular arrhythmias, body position					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** 1. To determine if there is a difference in the onset of silent ischemia as evidenced by an ST segment shift (elevation or depression) and/or ventricular ectopy when the coronary artery diseased (CAD) patient is repositioned to the right or left lateral position from the supine position within the first 72 hours of admission to the Coronary Care Unit (CCU). 2. To determine if repositioning from the right or left lateral position to the supine will reduce the ST segment shift and/or ventricular ectopy. 3. To identify personal or illness-related factors that are associated with the onset of silent ischemic changes after repositioning.

**Technical Approach:** A convenience sample of the first 33 patients admitted to the CCU who meet the criteria and consent to participate will be chosen. The investigator will compare rhythm strips with 12 lead EKGs for basic rhythm and PR and ST segment baselines. The patient positioning protocol will be conducted on the following day. Patients will be placed on a cardiac monitor and 3 leads which best indicate potential areas of ischemia will be utilized. These areas will be identified either by the most recently documented heart catheterization results or by 12 lead EKGs which show ischemic changes in specific leads. If neither of these is available, the patient will be monitored in leads V1, V5, and AVF. Cardiac rhythm strips, B/P and SaO<sub>2</sub> values will be taken immediately after repositioning and then again at 5 minutes. After baseline data are obtained the patient will be repositioned 3 times and data collected.

A paired t-test will be used to determine whether there is an increase in silent ischemia after repositioning from supine to lateral and from lateral to supine. A Cramer Coefficient C will be the nonparametric analysis to measure the degree of association between personal and illness factors and the presence or absence of myocardial ischemia on the right or left lateral position.

**Progress:** This protocol is in the process of IRB review at the University of Washington. The project will begin when that approval is received.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/011		<b>Status:</b> Completed
<b>Title:</b> Sensitivity of Transiently-Evoked Otoacoustic Emissions in Monitoring Adult Cis-platin Patients				
<b>Start Date:</b> 10/02/92		<b>Est. Completion Date:</b> Nov 92		
<b>Department:</b> Student Detach, HSC		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ John E. Ribera, MC				
<b>Associate Investigators:</b>		George Haskell, Ph.D.		
<b>Key Words:</b> cancer,otoacoustic emissions,cisplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To evaluate the sensitivity of transiently-evoked otoacoustic emissions (TEOAEs) in monitoring ototoxicity in Cis-platin recipients. The questions being asked are: 1. How sensitive are TEOAEs in relation to the standard test (behavioral audiometry to include extended high frequencies) in early identification of hearing loss in patients receiving Cisplatin treatment? 2. Which of two transient stimuli (clicks or tone bursts) is more sensitive to change in cochlear function due to Cisplatin-induced ototoxicity?

**Technical Approach:** The sample population will be comprised of approximately 30 adult male and female subjects (40 years of age or older) from MAMC and Seattle VA Medical Center (SVAMC). Subjects will be placed in either the control group (those not receiving Cisplatin treatment) or the experimental group (Cisplatin recipients). Subjects will be screened via an intake history, middle ear test and audiogram. Once criteria for inclusion in the study have been met, subjects in both groups will be tested using the IL088 Otoacoustic Analyzer. The screening tests and emissions analysis will comprise the "baseline test" which will be administered to both groups with the experimental group being evaluated just prior to Cisplatin treatment. Both groups will be tested approximately 1-2 weeks (a.k.a. post-test #1) and subsequently 3-4 weeks post-baseline (a.k.a. post-test #2). The test protocol during each of the post-tests will be identical to the baseline test. This is a repeated measures design and will be analyzed using a repeated measures ANOVA to identify possible treatment effects. Other descriptive statistics will also be used as deemed appropriate. Results will be used to develop a clinical protocol for ototoxicity monitoring at MAMC and SVAMC.

**Progress:** No patients were enrolled at MAMC. Data analysis is being completed on patients that were enrolled at SVAMC. A dissertation will be written from that information.

DETAIL SHEETS FOR PROTOCOLS

BEHAVIORAL SCIENCES DIVISION, CLINICAL  
PSYCHOLOGY

## Detail Summary Sheet

<b>Date:</b> 30 Sep 93		<b>Protocol No.:</b> 93/025		<b>Status:</b> On-going	
<b>Title:</b> Sexual Harassment: Attitudes and Actions					
<b>Start Date:</b> 12/04/92			<b>Est. Completion Date:</b> Mar 93		
<b>Department:</b> BSD/Clinical Psychology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Mary G. Lambie, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> Sexual Harassment,attitudes,actions					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To assess the effects of gender, status, race and attitudes towards sexual harassment on perceptions of the seriousness of sexual harassment incidents, in determining what actions should be taken in sexual harassment cases and on perceptions of organizational response to harassment.

**Technical Approach:** Ranks E-1 to E-4, E-6 to E-8, O1 to O3, and O4 to O6, with O1 to O6 having been in leadership positions will participate in this study. Each subject will be asked to complete a personal data sheet. They will also be asked to complete a Sexual Harassment Attitude Scale (SHAS) developed by Mazer and Percival that has been modified somewhat to focus only on the work place (i.e. phrases such as in class, at school etc., were deleted).

They will then be given written narratives of sexual harassment incidents. After reading the narratives, they will be required to 1) determine the seriousness of the incident on a Likert-type scale 2) recommend what type of action (from a provided list) should be taken in each scenario and 3) select which action from the list they feel their command is most likely to take for each scenario.

Analysis of Variance will be performed for each dependent variable (perceived seriousness of sexual harassment incidents, rater's perceived seriousness of sexual harassment incidents, rater's actions for sexual harassment incidents, perceived organizational actions for sexual harassment incidents, and difference scored between rater's actions and perceived organizational actions). The SHAS will be treated as a continuous variable, and therefore will need to be analyzed using bivariate regression analysis for the dependent variables of seriousness of the incident and personal actions taken.

**Progress:** Data was collected from 408 active duty soldiers attending sexual harassment training. At this time no further data will be collected. Data analysis and final interpretation are in progress.



DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF CLINICAL INVESTIGATION

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/100		<b>Status:</b> On-going
<b>Title:</b> Thyroid Size in Children and Adolescents				
<b>Start Date:</b> 08/21/87		<b>Est. Completion Date:</b> Nov 91		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Dan C. Moore, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> thyroid size,adolescents				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		09/16/88

Study Objective: To establish normal dimensions  $\pm 2$  standard deviations (SD) for thyroid lobe length and width in children and adolescents. A goiter would then be defined as thyroid gland exceeding 2 SD of these dimensions.

Technical Approach: During the course of a routine physical examination, thyroid glands of 300 normal children and adolescents aged 6-20 years (20 at each age, 10 of each sex) will be measured in the following manner. With the neck extended, the thyroid isthmus is located with the index finger. The medial aspect of each lobe is followed to the apparent tip of each lobe. The upper tip of each lobe is located as the patient swallows with the index finger over each tip. The apparent inferior border of each lobe is located as the patient swallows with the index finger over the inferior portion of the gland. The lateral borders of the gland will be located with the index fingers placed medial to the sternocleidomastoid muscle as the gland moves as the patient swallows. The length will be measured as the distance from the apparent tip of each lobe to the apparent inferior border of each lobe. The width will be measured as the distance from the lateral borders of the gland. Means and SD will be calculated for length of each lobe and mid-isthmus width. For validation of measurement accuracy, 30 patients (2 each age, 1 each sex) will have the same measurements determined by thyroid ultrasound.

Progress: Enrollment into the study continues (n=265). No data analysis has occurred.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/091		<b>Status:</b> On-going
<b>Title:</b> A Phase III Open Protocol for a Multicenter Study for the Treatment of Central Precocious Puberty with D-Trp <sup>(6)</sup> -Des-Gly <sup>(10)</sup> -N-ethylamide-LHRH, A Long-Acting Analog of Luteinizing Hormone Releasing Factor (Deslorelin)				
<b>Start Date:</b> 07/20/90		<b>Est. Completion Date:</b> Nov 92		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Dan C. Moore, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> precocious puberty,deslorelin,LH				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	07/02/93

Study Objective: To treat patients who have central precocious puberty with Deslorelin in order to suppress pubertal development and excess growth, to restore gonadotropin and sex hormone levels to normal prepubertal levels, and to demonstrate the safety of such treatment.

Technical Approach: Central precocious puberty will be defined as: stage 2 pubic hair or greater, stage 2 breast or genital development or greater, pubertal LH and FSH peak following GnRH stimulation, and absence of peripheral origin of precocity (lack of adrenal or ovarian mass on ultrasound and normal serum hCG). After diagnosis and standard evaluations, patients will be given Deslorelin, 4 mcg/kg SC daily. At three month intervals, patients will be re-evaluated. A physical examination with pubertal staging will be done. Serum sex hormones and gonadotropins (before and post GnRH) will be measured and bone age will be determined. Treatment will be continued until the patient reaches an age at which pubertal development is deemed appropriate (usually 10-11 years) at which time therapy will be discontinued.

Progress: Treatment continues on 2 patients and data continues to be collected.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/092		<b>Status:</b> On-going	
<b>Title:</b> Characterization of LH Isoforms in Treated and Untreated Precocious Puberty					
<b>Start Date:</b> 09/06/91			<b>Est. Completion Date:</b> Jun 92		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Dan C. Moore, MC					
<b>Associate Investigators:</b> MAJ Jim Hansen, MC			CPT Katherine H. Moore, MS		
<b>Key Words:</b> precocious puberty,LH:isoforms					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$1843.00		/ /	

**Study Objective:** To determine the luteinizing hormone (LH) isoform pattern in precocious puberty and demonstrate whether there is a change in isoform pattern during therapy with gonadotropin-releasing hormone (GnRH) analogue (leuprolide) and to confirm whether changes in LH bioactivity correlate with parallel changes in LH isoform pattern during therapy.

**Technical Approach:** This is a collaborative study using serum obtained from subjects in the University of Iowa protocol entitled "New Treatments to Improve the Final Height of Children with Central Precocious Puberty". Paired frozen sera from 12 subjects, will be processed as follows: 1 ml of serum will be dialyzed against two changes of 2 liters of 0.025 M Tris (pH=9.3) for 2 hours and then applied to a 1.0 x 20 cm Mono P HR 5/20 column (4 ml column volume), which has been equilibrated with 15 column volumes of 0.025 M Tris (pH=9.3). The sample is eluted with 50 ml Polybuffer 96 (diluted 1:10 with water, pH=6.0) at 1 ml/min and collected in 2 ml fractions. To study LH isoforms which are present between pH 7 and 4, similar procedures will be used, substituting Polybuffer 74 and Tris protein precipitation with 0.5 ml of 1% BSA and 2.8 g of powdered ammonium sulfate. After thorough mixing and incubating at 20 deg C for 2 hr. the fractions are centrifuged at 1500 g for 30 minutes. Supernatant is discarded and precipitates are washed once with saturated ammonium sulfate and then reconstituted in 0.5 ml of assay buffer for LH RIA and bioassay. Aliquots of fractions which contain LH activity will be pooled for each chromatofocusing peak and analyzed for LH immunoactivity and bioactivity. Changes in bioactivity correlating with changes in chromatofocusing pattern will be sought in pre and post treatment sera.

**Progress:** Chromatofocusing of trough and peak, pre and post treatment samples was completed and initial work on the LH bioassay was begun. Initial analysis of LH RIA on chromatofocusing samples showed that Lupron treatment tended to reduce the basic:acidic (B:A) ratio of LH isoforms at the time of an LH peak.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/048		<b>Status:</b> On-going	
<b>Title:</b> Treatment use of Oxandrin (Oxandrolone) in Boys with Constitutional Delay of Growth and Puberty					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Dan C. Moore, MC					
<b>Associate Investigators:</b>			MAJ Robert A. Newman, MC		
<b>Key Words:</b> delayed maturation and growth,boys,oxandrin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To provide a means by which boys with constitutionally delayed growth and puberty can be treated with oxandrolone secondarily, data will be collected regarding the effect of therapy on growth and also of significant importance, boys receiving oxandrolone will be monitored for evidence of drug-induced side effects.

**Technical Approach:** Boys with constitutional delay of growth and puberty will receive oxandrolone orally as prescribed by the physician. The recommended daily dose based on the published medical literature is up to 0.1 mg/kg. The duration of oxandrolone therapy will be left to the discretion of the physician. However, the published medical literature reports the safe and effective use of oxandrolone at the recommended doses for 3 to 12 months. The primary determinants for cessation of therapy are (1) inappropriate skeletal maturation (2) failure of drug to produce desired effect (3) spontaneous Stage III pubertal development as evidenced by a testicular volume of >10 ml or a length (long axis) of >3.5 cm or (4) adverse effects. Clinic visits not less than every four months will include interval medical history clinical side effects and adverse drug events and a pertinent physical examination. Bone age analysis, hemoglobin, hematocrit, RBC, and IGF-I (somatomedin-C) will be done at baseline, at 6 and 12 months, and annually thereafter.

**Progress:** This is a treatment protocol with very strict criteria. We have had no patients to date that met the criteria.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/060		<b>Status:</b> Completed
<b>Title:</b> Thyroid Volume in Adolescents as Determined by Ultrasound				
<b>Start Date:</b> 05/03/91		<b>Est. Completion Date:</b> May 92		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Dan C. Moore, MC				
<b>Associate Investigators:</b>		MAJ James H. Timmons, MC		
CPT Janice C. Stracener, MC		LTC Thomas R. Babonis, MC		
<b>Key Words:</b> thyroid volume,ultrasound,adolescents				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To determine normal size (volume) of the thyroid gland in adolescence and to correlate it with clinical surface measurements, as well as other clinically important variables such as body weight or body mass index, height, and pubertal stage.

**Technical Approach:** Ten subjects of each sex at each age, between 12 and 18 years, with normal health and normal size thyroid gland will be studied. Height, weight, and Tanner stage will be recorded and the thyroid gland will be measured using standard surface measurement techniques. Subsets of 20 patients each will be examined by two examiners to determine inter-observer variability of measurement techniques and by the same examiner on two separate occasions to determine intra-observer variability of measurement. Thyroid volume will then be determined by ultrasound, on an Acuson 128 with a 5MHz short-focus linear array transducer. One set of 20 subjects, selected randomly, will undergo a second examination by the original examiner within one week of the initial examination to determine if measurements are reproducible. A second set of 20 subjects will have additional measurements performed with 5MHz and 7.5 MHz linear array transducers using a GE3600RT instrument at the time of the initial measurement to insure reproducibility of the measurements between instruments and at different frequencies of ultrasound. All measurements will be performed twice by each of two separate investigators to determine both intra-observer and inter-observer variability in the measurements. Method of Data Analysis: description of volume change by sex, age, pubertal stage, and body mass index comparison of sex and age differences by linear regression stepwise linear regression to determine best fit for influence on changing volume correlation coefficient to validate surface measurement versus volume determination.

**Progress:** Of the 28 patients who completed the study, it is hoped that 20 will have useful data. Data analysis is being delayed and will be combined with results of protocol 87/100.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/058		<b>Status:</b> On-going	
<b>Title:</b> Is Sex Hormone Binding Globulin Locally Produced in Breast Cancer Tissue?					
<b>Start Date:</b> 05/01/92			<b>Est. Completion Date:</b> Jun 94		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Katherine H. Moore, MS					
<b>Associate Investigators:</b> Louis A. Matej, B.S.			MAJ Kenneth A. Bertram, MC		
<b>Key Words:</b> SHBG, breast cancer					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
			<b>Periodic Review:</b>		//

**Study Objective:** To gain insight into the regulation of breast cancer growth and development and to correlate the estrogen and progesterone receptor status of breast cancer biopsy tissue with the presence of sex hormone binding globulin (SHBG) mRNA.

**Technical Approach:** SHBG is a high affinity binding protein for androgens and estrogens. This protein is normally produced in the liver, released into the blood and functions to regulate the amount of free androgen or estrogen available for action at target organs. Recently, receptors for SHBG have been identified on prostate carcinoma cells. Prostate cancer, like breast cancer, is generally considered to be modulated by steroids. One proposed consequence of the SHBG receptor on cancer cells is the additional targeting of steroid to the cells. SHBG may have a role independent of steroid action and may be a growth factor itself. One of the oncogenes that is important in breast cancer development is p53. It has been found recently that changes in p53 and SHBG may be linked. Both of these genes are on the short arm of chromosome 17 near an area prone to rearrangement and mutation. Breast cancer cell lines (MCF-7 and ZR75-1, initially) will be examined for the presence of SHBG and mRNA and for factors that regulate transcription. In addition, the investigators will probe for SHBG mRNA in primary breast cancer tissue obtained at biopsy and surgery. Cancer cell membranes and primary tissue will be assayed for the presence of SHBG receptors. Techniques used will include Northern analysis, RIA of the conditioned media for expressed SHBG, and western analysis to determine the form of p53 expressed in the cells (wild type vs mutant). This study will thus characterize a potentially new oncogene for breast cancer and lead to a greater understanding of the mechanisms of cancer formation.

**Progress:** Recently, receptors for SHBG have been identified on steroid responsive tissues, including prostate carcinoma and endometrium. The goal of this series of experiments was to determine if mRNA for SHBG is expressed in breast cancer cell lines and tumor tissue. Two estrogen receptor positive cell lines were used, the ZR-75-1 cells, but no detectable message from the MCF-7 cells. The ZR-75-1 cells were used for studies investigating the transcriptional regulation of SHBG mRNA, which indicated that thyroxine may increase levels of SHBG mRNA, and estrogen and insulin may reduce levels. When MCF-7 cells were re-examined for SHBG RNA using PCR, specific message could be detected. Also, evidence of alternative splicing of the SHBG mRNA in breast cancer cells was found. Finally, amplification of RNA extracted from breast tumor tissue by PCR revealed the presence of SHBG mRNA in estrogen receptor positive tumors.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/043		<b>Status:</b> Completed	
<b>Title:</b> Sex Hormone Binding Globulin (SHBG) Carbohydrate Function and Characterization					
<b>Start Date:</b> 03/01/91			<b>Est. Completion Date:</b> May 92		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Katherine H. Moore, MS					
<b>Associate Investigators:</b> MAJ John E. van Hamont, MS Louis A. Matej, B.S.			Philip H. Petra, Ph.D. CPT Robert M. Tuttle, MC		
<b>Key Words:</b> SHBG:carbohydrate function, SHBG:characterization, Animal Study					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 06/07/93

**Study Objective:** To determine if the carbohydrate composition of sex hormone binding globulin (SHBG) varies with physiological status between pregnant females and normal males and to determine the role of the carbohydrates covalently attached to SHBG in the biological functions of this glycoprotein.

**Technical Approach:** Each monomer of human SHBG contains three carbohydrate chains. Two are attached to asparagine residues (N linked) and one to a threonine (O linked). The N linked carbohydrates will be enzymatically removed with N-Glycanase and O linked carbohydrates will be removed with neuraminidase followed by O-Glycanase. The affinity and specificity of the modified proteins for dihydrotestosterone, testosterone, and estradiol will be determined using the DEAE-cellulose filter assay. Also the ability of the modified proteins to compete for prostate membrane receptors will be determined. Native SHBG will be labeled with <sup>125</sup>I Bolton-Hunter reagent, purified by chromatography on G-75, followed by Con-A chromatography. The ability of the deglycosylated SHBG to compete with the labeled SHBG will be determined and affinity calculated by scatchard analysis. SHBG was purified from pregnancy serum and normal male serum to determine if physiological condition affected the carbohydrate composition of SHBG. Normal serum levels of SHBG are 10 fold greater in pregnant women than normal men. One possible reason for the differences in levels could be serum half-life due to carbohydrate composition. The carbohydrate composition of the SHBG will be determined with an electrochemical detector after hydrolysis in trifluoroacetic acid. Serum half-life will be determined using rats as the experimental model. As rats do not possess a serum SHBG, natural protein can be injected (no <sup>125</sup>I label) and the clearance measured by IRMA. The animals will have chronically implanted cannulas, allowing repeated sampling from individual animals. Samples will be collected for 6 days.

**Progress:** Sex hormone binding-globulin is a homo-dimeric glycoprotein which functions as a steroid transport protein in serum. One interest in investigating the functional importance of the oligosaccharides is the investigation of their importance in steroid binding. SHBG was purified from human serum and asparagine and threonine linked oligosaccharides removed enzymatically. The efficacy of enzyme cleavage of sugars from the protein was confirmed with mass spectrometry and lectin blots. The affinity of steroids for SHBG was not affected by removal of the sugars. A second objective was to study SHBG produced under different physiological states to determine if the



sugar content of the protein was under hormonal control. SHBG was also purified from normal male serum and serum collected from pregnant women and purified to homogeneity. Neutral sugar and sialic acid content was analyzed by HPLC, using pulsed amperometric detection under alkaline conditions. Oligosaccharide content was similar between both sources of SHBG. To further investigate the influence of source of SHBG (i.e., male vs pregnant female), the metabolic clearance of SHBG also was investigated using rat models as they do not have a circulating SHBG, allowing the injected material to be directly measured by immunoassay. The clearance of SHBG also was compared between pregnant female rats and normal female rats to determine if pregnancy itself affected the serum half-life of SHBG. The clearance of male SHBG was not different from pregnant female SHBG, confirming the implication of the similarity of sialic acid content, that serum half-life should be similar. Also, the clearance of SHBG was similar in non-pregnant and pregnant animals, indicating that pregnancy did not influence the metabolic clearance of this carrier protein.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/109		<b>Status:</b> Completed	
<b>Title:</b> Characterization of Equine Inhibin Sequence Analysis and Carbohydrate Composition					
<b>Start Date:</b> 09/21/90			<b>Est. Completion Date:</b> Oct 92		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Katherine H. Moore, MS					
<b>Associate Investigators:</b>			Kristine M. Wiren, Ph.D.		
<b>Key Words:</b> equine inhibin,sequence,carbohydrate composition,animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$8870.00		06/07/93	

**Study Objective:** To purify equine inhibin from follicular fluid, to compare specific activity and carbohydrate chemistry to inhibin from other species, and to determine the sequence of equine inhibin and determine its homology to other known sequences.

**Technical Approach:** Inhibin, a heterodimeric protein, is a member of the transforming growth factor (TGF) family of proteins. These proteins have a variety of functions, including tissue regeneration and tumor growth. The structure of this family of proteins is remarkably conserved across species and through different protein members of the family, including such diverse proteins as xenopus vg-1 protein to inhibin. The classical function of inhibin is in the regulation of follicle stimulating hormone (FSH) release, but the mRNA for inhibin is found in many tissues, indicating a multifunctional role for this protein. The comparison of the amino acid sequence of inhibin from different species identifies important regions of the protein in its biological functions. The functions of horse inhibin will be tested both immunologically and with the in vitro biological assay, using cultured rat pituitary cells. The protein will be purified and the carbohydrate content determined. The sequence of the protein will be deduced from a cDNA library established from horse gonadal tissue. This comparison of a naturally occurring analogue will advance our understanding of the relationship of the protein structure to its many functions.

**Progress:** A manuscript was written and accepted by the Journal of the Society for the Study of Reproduction. A paper was presented at the Endocrine Society meeting in FY 92.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/005		<b>Status:</b> On-going	
<b>Title:</b> Veterinary Support Personnel and Investigator Training in Animal Care Procedures (Swine, Goat, Rabbit, Ferret, Rat, Mouse)					
<b>Start Date:</b> 12/06/91			<b>Est. Completion Date:</b>		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Douglas A. Powell, VC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer, alimentary tract,nasogastric tissue sampling,Animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$125.00	06/07/93	

**Study Objective:** (1) To help the Department of Clinical Investigation (DCI) technical staff remain proficient in basic technical skills as well as emergency care procedures that may arise during normal animal care (2) to teach investigators and technicians the basics of animal restraint and manipulation (3) to teach DCI technical staff basic surgical skills that will enable them to better assist investigators.

**Technical Approach:** Training sessions on handling animals, anesthesia, soft tissue surgery, blood withdrawal, injections, and necropsy techniques will be periodically held at the Department of Clinical Investigation. Swine, goats, rabbits, ferrets, mice, and rats will be used in these training sessions. All animals will be appropriately anesthetized except for injection techniques and IV blood withdrawal. All animals will be handled and utilized in accordance with The Guide for the Care and Use of Laboratory Animals (US Department of Health and Human Services), AR 70-18, and other applicable regulations.

**Progress:** Eight animals, used in other protocols, were utilized in the training of veterinary support personnel. Training included intubation and anesthesia procedures, venous and arterial access.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/074		<b>Status:</b> On-going
<b>Title:</b> Microbiological Analysis of Male NGU Specimens by Polymerase Chain Reaction: A Retrospective Study				
<b>Start Date:</b> 06/05/92		<b>Est. Completion Date:</b> Aug 92		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert S. Stewart, MS				
<b>Associate Investigators:</b>		MAJ Margot R. Krauss, MC		
<b>Key Words:</b> urethritis,polymerase chain reaction				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To perfect new PCR assays and to determine the prevalence rates by PCR in male NGU samples collected February through April 1989 for human papillomavirus (HPV), herpes simplex virus (HSV), human immunodeficiency virus (HIV), Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium and to compare prevalence rates from both culture and PCR methods for Chlamydia trachomatis.

**Technical Approach:** Approximately 200 male NGU urethral specimens were collected during the months of February through April 1989 for MAMC Protocol #89/19 "Urinalysis As A Screening Exam for NGU in Males Attending an STD Clinic." These samples were cultured for Chlamydia trachomatis and Ureaplasma urealyticum and the remaining fraction was stored frozen at -20 degrees Centigrade. These stored samples will be thawed, processed for DNA extration, and analyzed by PCR for organisms not previously suspected, including HPV, HSV, HIV, C. trachomatis, T. vaginalis, and M. genitalium.

**Progress:** PCR assay for Chlamydia trachomatis is in development. We are currently optimizing the sensitivity level with a goal of being able to detect 10-50 elementary bodies. The HPV assay is fully developed and has a sensitivity level of 30 viral gnomes. The assay for Ureaplasma urealyticum will not be run because those samples were completely consumed in the original study in 1988.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/075		<b>Status:</b> On-going
<b>Title:</b> Precise Tissue Distribution of DNA and Hormone Receptors in Breast Biopsies as Clinical Prognosticators: A Retrospective Study				
<b>Start Date:</b> 06/05/92		<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert S. Stewart, MS				
<b>Associate Investigators:</b>		Troy H. Patience, B.S.		
<b>Key Words:</b> breast biopsy,DNA,hormone receptors				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** To develop a computerized laser confocal microscope-based image analysis system which would provide more clinically significant information for breast cancer diagnosis than is currently available.

**Technical Approach:** A scanning laser confocal fluorescent microscope will be used to optically section breast tumor biopsies stained with DNA specific compounds and fluorochrome conjugated monoclonal antibodies. Nuclei flagged for further consideration by the computer will be analyzed by newly developed software which will contain tissue sensitive algorithms. Proximity relationships between aneuploid and hormone receptor deficient nuclei will be compared to normal nuclei within the same and adjacent fields. These proximity relationships, expressed as calculated values, will provide improved prognostic information when compared to the currently employed aneuploid (DNA indices) and proliferation (S-phase indices) determinations. Tissue sensitive proximity values for hormone receptors will also improve current prognostic correlations.

**Progress:** This project is pending MRDC funding. The grant is under review.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/073		<b>Status:</b> On-going
<b>Title:</b> Molecular Microbiology Assay Development				
<b>Start Date:</b> 06/05/92		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Clinical Investigation		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert S. Stewart, MS				
<b>Associate Investigators:</b>		M. J. Styner, B.S.		
<b>Key Words:</b> molecular microbiology assay				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

Study Objective: To develop and improve assays required for other new and ongoing protocols.

Technical Approach: The scientific literature will be searched continually for reports of new assays, techniques, and methods dealing with molecular biology as it applies to microbiological diagnostics. These improved techniques will be tested in the lab at the Department of Clinical Investigation and assays developed as needed for application in other protocols. These assays will be evaluated with cultured organisms and discarded medical samples and tissues to insure that the methods developed have clinical value and function properly with both controls and clinical materials.

Progress: The genotyping of HPV method utilizing the direct incorporation of dig-d-UTP is in development. Preliminary data leads us to expect a 10 to 100 fold increase in sensitivity over conventional electrophoretic detection of PCR product.

The assay for Mycoplasma genitalium is in development. Enhanced primers of Mycoplasma sp. are being synthesized for improved detection in tissue cultures.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/034		<b>Status:</b> On-going	
<b>Title:</b> Insulin-Like Growth Factor Binding Proteins in Prostate Carcinoma Cell-Lines					
<b>Start Date:</b> 01/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Clinical Investigation			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> M. J. Styner, B.S.					
<b>Associate Investigators:</b> CPT Katherine H. Moore, MS James R. Wright, M.T.			COL Stephen R. Plymate, MC Louis A. Matej, B.S. Kelly L. Thomsen-Archer, B.S.		
<b>Key Words:</b> protein,growth factor,prostate carcinoma					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** (1) To determine if insulin-like growth factor binding proteins (IGF-BP's, IBP's) are present in prostate cancer cell lines and to find which of the five IGF-BP's are expressed (2) to determine if different insulin and IGF levels affect the expression of IGF-binding proteins in the prostate cancer cell lines and (3) to see if there is an association between insulin and IGF levels and the expression of IGF-BP and SHBG in the prostate cancer cell lines.

**Technical Approach:** Northern analysis will be performed on total and messenger RNA extracted from prostate cancer cells using IGF-BP probes to detect the presence of an RNA message for the IGF-binding proteins and to get an idea of their relative sizes. Southern analysis will also be performed on total genomic DNA extracted from prostate cancer cell lines to further establish the presence of the genes for these binding proteins. Insulin will be administered to the prostate cancer cells in serum free media to determine if it is a regulatory factor of the IGF-BPs and analysis of its effect will be done by Western blot and Northern blot. IGF-I will also be used in cell treatments to determine its effects on the production of the IGF-BP's. SHBG probes will also be used on these blots to determine any correlation between the expression of IGF and SHBG binding proteins in these cells and their response to insulin and IGF levels.

**Progress:** Total RNA was extracted from prostate cancer cell lines DU 145, ALVA-41, ALVA-101 and a liver cancer cell line HEPG2 used for comparison using guanidinium/phenol extraction methods. Total RNA was size fractionated on a horizontal 6% formaldehyde agarose gel and transferred to a nylon membrane for hybridization. cDNA for hIGFBPs 1-5 was used for generating radio-labelled probes and hybridized to the Northern blots for analysis. Autoradiography reveals bands for IGFBP-1, 2, 3, 4 and 5 in the four cell lines studies.

Ligand blot analysis was performed on conditioned media from ALVA-101 and ALVA-41 cell lines using radio-labelled IGF-I. Autoradiography identified IGFBP bands binding at 25kDa and 30 kDa in both cell lines.

In summary: 1) expression of mRNA for IGFBP 1-5 is present in these cell lines and 2) IGF binding protein mRNA is translated into functional protein in the prostate cancer cell lines used.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF DENTISTRY



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/059		<b>Status:</b> Completed	
<b>Title:</b> The Influence of Prophylactic Administration of Intravenous Ondansetron on Post Operative Nausea and Vomiting and Length of Stay in the Post Anesthesia Care Unit					
<b>Start Date:</b> 05/03/91			<b>Est. Completion Date:</b> May 92		
<b>Department:</b> Dentistry			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Cecil R. Dorsett, DC					
<b>Associate Investigators:</b> COL Jerre M. Griffin, DE Mark J. Bergin-Sperry, RN			MAJ Frederick W. Burgess, MC MAJ Charles R. Weber, DC		
<b>Key Words:</b> postoperative nausea,vomiting,ondansetron					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 05/01/92

**Study Objective:** To determine if routine prophylaxis with intravenous ondansetron decreases the incidence of postoperative emetic episodes in patients undergoing oral and maxillofacial surgery procedures and to determine the relationship between prophylactic intravenous ondansetron and length of stay in the post anesthesia care unit.

**Technical Approach:** Eighty patients presenting for elective oral surgery, over the age of 18 years, who are scheduled for general anesthesia will be studied. All patients will receive the same anesthetic care program and will be randomized to receive either ondansetron IV at the beginning of the surgical phase of treatment or a saline placebo. Postoperative evaluation will include emetic episodes, time to awakening, time to orientation, and time to discharge. Antiemetic rescue will be provided if subjects experience three episodes of emesis in one hour or if the intensity of nausea and emesis requires immediate treatment. The administration of a rescue antiemetic will be considered to indicate insufficient efficacy of the antiemetic treatment. Subjects will be evaluated 18-24 hours postoperatively and again at a follow-up appointment within 4-7 days from surgery. Data analysis will be primarily focused on the difference in the incidence of vomiting occurring between the placebo and ondansetron treatment groups using chi-square analysis. Times to discharge from the postanesthesia care unit will be assessed for significance with the unpaired t test.

**Progress:** Fifty patients were studied (12 in FY 93). Data are being interpreted and a paper will be written..

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/062		<b>Status:</b> Completed
<b>Title:</b> Postoperative Complications in Operating Room Dentistry for Children				
<b>Start Date:</b> 05/01/92		<b>Est. Completion Date:</b>		
<b>Department:</b> Dentistry		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul J. Engibous, DE				
<b>Associate Investigators:</b>		LTC Herschel L. Jones, DE		
<b>Key Words:</b> dentistry,children,postoperative complications				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

Study Objective: To record the incidence and type of postoperative complications in operating room dentistry for children and to evaluate the possible effects of age, sex, anesthetic agent used, length of anesthesia, and total fluid deficit on the incidence of postoperative complications of pediatric dental patients treated in the operating room.

Technical Approach: Approximately 50 subjects, ages 1-12, will be studied. The operating room dentist will complete a questionnaire after the patient has been discharged following dental rehabilitation. The dentist will be asked to report on past history of motion sickness, postoperative nausea and/or vomiting, and fever and provide information on the age, sex, anesthetic agents used, time of anesthesia, length of time NPO, fluid replacement during surgery, and patient temperature. The patients will have a postoperative examination approximately two weeks after surgery as is currently required for standard practice. Association of procedural factors with complications and without complications will be tested. Discrete variables will be tested using a chi-square analysis. Continuous variables will be analyzed with a t-test.

Progress: A paper was written and accepted by the Education Committee of the Pediatric Dentistry Residency program.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 90/068	<b>Status:</b> Completed
<b>Title:</b> Parental Recall of Informed Consent for General Anesthesia Dental Procedures		
<b>Start Date:</b> 04/20/90	<b>Est. Completion Date:</b> Feb 91	
<b>Department:</b> Dentistry	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Paul E. Kittle Jr., DE		
<b>Associate Investigators:</b> LTC Herschel L. Jones, DE                      COL Gerald R. Aaron, DC		
<b>Key Words:</b> informed consent,dental		
<b>Accumulative MEDCASE Cost:</b> \$0.00	<b>Est. Accumulative OMA Cost:</b> \$0.00	<b>Periodic Review:</b> 05/03/91

**Study Objective:** To evaluate if, and to what level, parental recall of the aspects of informed consent for dental operating room procedures exists to evaluate whether selective listening (blocking out of disconcerting information) exists and to evaluate whether parental recall of the aspects of informed consent is better when the risks are presented in written or oral format.

**Technical Approach:** Parents of children 18 months through 6 years of age schedule for dental rehabilitation in the operating room due to the patient's young age, uncontrollable behavior, situational anxiety, and/or extent of dental care needed will be studied. An overview of the study will be explained to the parent(s) prior to the operating room interview. They will then be asked to fill out an intake questionnaire which will obtain information on the child's age, number of siblings, dental and medical history, the parent's educational level, and how the parent thinks the child will react to dentistry in general. With the parent, patient, and attending staff member present, the resident will proceed to give specific informed consent in either an oral and specific written format or in an oral and nonspecific written format. Following completion of the operating room case, a follow-up visit will be scheduled at either two weeks or two months at which time questionnaires will be administered to test the parents' recall of the specific procedures they were told might be accomplished. Data analysis will include descriptive (background variables and postoperative data) comparisons (contingency table using chi-square statistics) of background information versus postoperative questionnaire data at two weeks and again at two months and comparison of the postoperative questionnaire data at two weeks versus two months.

**Progress:** An abstract has been submitted for presentation. Thirty-eight patients were enrolled in the study and no adverse outcomes were experienced.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/098		<b>Status:</b> Completed
<b>Title:</b> Waste Anesthetic GAS (WAG) Exposure of Pediatric Dentists During Operating Room Dental Procedures				
<b>Start Date:</b> 08/07/92		<b>Est. Completion Date:</b>		
<b>Department:</b> Dentistry		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Paul E. Kittle Jr., DE				
<b>Associate Investigators:</b>		MAJ Curtis D. Goho, DC		
<b>Key Words:</b> waste anesthetic gas,pediatric dentists				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To ascertain the waste anesthetic gas (WAG) exposure level of pediatric dentists during operating room dental rehabilitation cases in which uncuffed nasal intubation is used; and to compare these levels with published data on WAG exposure for other operating room personnel during cases that routinely use cuffed endotracheal tubes.

**Technical Approach:** Fifty dentist exposed to WAG while performing dental procedures of at least one hour duration and utilizing an uncuffed endotracheal tube will be studied. Monitors will be attached to either the face mask or the collar of the dentist and halogenated anesthetic agents and nitrous oxide will be monitored. Background monitoring will be done utilizing the Miran infrared spectrophotometer monitor system and the 3M WAG monitoring system. Historical records for WAG exposure will be used as much as possible. Age of the dentist, anesthetic agent used, endotracheal tube size, and pressure at which leak around the tube was noted will be recorded. Pediatric dentist exposure levels will be compared to historical WAG exposure levels for the study site operating rooms as well as general published data on acceptable WAG exposure levels. Exposure levels will also be compared to simultaneous background WAG monitoring. Chi square will be used to evaluate the data, utilizing the SPSS computer statistical package.

**Progress:** An abstract has been submitted for publication.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/063		<b>Status:</b> Completed	
<b>Title:</b> Common Behavior Management Techniques Used in Pediatric Dentistry: Why Parents Accept or Object to Them					
<b>Start Date:</b> 05/01/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Dentistry			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Michael G. Page, DE					
<b>Associate Investigators:</b>			LTC Paul E. Kittle Jr., DE		
<b>Key Words:</b> pediatric dentistry, behavior					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To determine, as specifically as possible, why parents like or dislike various common behavior management techniques used in pediatric dentistry and to catalogue their feelings.

**Technical Approach:** The parents of pediatric dental patients being treated in the Pediatric Dentistry Residency Program will be shown 2-3 minute video vignettes of patients being treated using common behavior management techniques. The techniques that will be investigated will be voice control, tell-show-do, hand-over-mouth, active restraint by parent, active restraint by dental personnel, passive restraint (Papoose Board), nitrous oxide sedation, oral premedication and nitrous oxide, and general anesthesia. The viewers will have control of the video unit so that they will be able to view and respond at their own pace. There will be a short taped introduction explaining the purpose of the study and what behavior management techniques are. Each technique will be clearly identified on the tape and instructions for completing the questionnaire will also be provided on the tape. The parents will be told that the patient on the video is to undergo a routine operative procedure (stainless steel crown) and extraction of an abscessed tooth and that the procedure was successfully completed. The parents will be asked to respond to survey questions based on the video to elicit their attitudes toward the techniques presented. The subjects will also be asked to state their specific likes and dislikes of the techniques. After filling out the survey, they will be asked if their answers would have been different if the procedure the children underwent were only a simple filling as opposed to something more serious. The surveys will be tabulated and the likes and dislikes will be categorized.

**Progress:** A paper was written and accepted by the Education Committee of the Pediatric Dentistry Residency program.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/061		<b>Status:</b> Completed	
<b>Title:</b> Comparison of Induction and Recovery From Propofol-Nitrous Oxide versus Methohexital-Isoflurane-Nitrous Oxide Anesthesia in Ambulatory Oral Surgery Patients					
<b>Start Date:</b> 06/14/91			<b>Est. Completion Date:</b> Apr 92		
<b>Department:</b> Dentistry			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert J. Wygonski, DC					
<b>Associate Investigators:</b> COL Douglas B. Boyd, DC			MAJ Frederick W. Burgess, MC COL Jerre M. Griffin, DE		
<b>Key Words:</b> anesthesia,induction,propofol-nitrous oxide,methohexital-isoflurane-nitrous oxide					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
<b>Periodic Review:</b>					/ /

**Study Objective:** To determine if propofol-nitrous oxide anesthetic offers better induction, maintenance, and early recovery of general anesthesia and a significant difference in psychomotor and qualitative response during the intermediate recovery phase than methohexital-isoflurane-nitrous oxide anesthesia for ambulatory oral surgery patients.

**Technical Approach:** Subjects will undergo preoperative testing of recovery assessment tests (Trieiger Test and Continuous Performance Test) on the day of surgery to establish individual baseline scores. All patients will receive 3 mg d-turbocurarine and 0.2 mg glycopyrrolate prior to induction. After preoxygenation, anesthesia will be induced in Group I with propofol 2.5 mg/kg and in Group II with methohexital 1.5 mg/kg. Maintenance of anesthesia will be as follows: Group I - continuous infusion of propofol starting at 9 mg/kg/hr and titrated to effect Group II, isoflurane 0.0% to 2.0% titrated to effect. All other surgical/anesthesia procedures will be per standard protocol. Time from induction to termination of anesthesia, agent, end of procedure, and eye opening will be recorded as early recovery time. On arrival in the recovery room each patient will be given a subjective recovery score by the recovery room nurse. Each patient will receive a postanesthesia recovery score (PARRS) on arrival in the recovery room and every 15 minutes thereafter. Patients will repeat the Trieiger Test and the Continuous Performance Test at 20, 40, and 60 minutes post extubation. These measurements will be recorded as intermediate time. Patients will fill out a questionnaire 24 to 36 hours after anesthesia. This will be recorded as late recovery time. Data analysis will focus on the difference between the groups in reference to induction and recovery characteristics. Analysis of post anesthesia observations will be carried out by a chi-square analysis. The Treiger and Continuous Performance tests data will be analyzed by repeated measures ANOVA.

**Progress:** Psychomotor testing revealed no significant difference between the two groups. Postanesthetic adverse outcomes were significantly higher in Group II (nausea, vomiting and headache) than Group I. Both techniques provide safe and effective outpatient anesthesia.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF EMERGENCY MEDICINE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/100		<b>Status:</b> On-going	
<b>Title:</b> The Randomized Use of Helium-Oxygen Mixture for the Administration of . Bronchodilator Therapy in the Treatment of Bronchial Asthma					
<b>Start Date:</b> 09/04/92			<b>Est. Completion Date:</b> Jul 93		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Richard D. Brantner, MC					
<b>Associate Investigators:</b> CPT David A. Della-Giustina, MC			MAJ William T. Hurley, MC MAJ Linda M. Brantner, MC		
<b>Key Words:</b> asthma, helium-oxygen mixture, bronchodilator					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$315.00		/ /	

**Study Objective:** To determine the therapeutic role of Heliox in the administration of bronchodilator therapy for the treatment of acute exacerbations of bronchial asthma.

**Technical Approach:** Each patient (n=150) will be evaluated using peak flow rates and given supplemental oxygen. Patients with peak flow rates <180 L/m will be given prednisone, 60 mg, by mouth. Patients will then be randomized to a nebulized albuterol treatment administered either by the air driven method or by Heliox at a rate of 8 L/min. Albuterol treatment will continue as above every 30 minutes for a total of four treatments. Patients will be on continuous pulse oximetry monitoring. Repeat evaluations will consist of vital signs and physical examination to include respiratory rate and lung auscultation every 30 minutes. Peak flow/FEV<sub>1</sub> measurements will be obtained at entry and at 10 minutes after each nebulized bronchodilator treatment. A final peak flow/FEV<sub>1</sub> will be obtained 20 minutes after the last nebulizer treatment. Patients will be asked to respond to a questionnaire indicating the severity of presenting symptoms, the time to feeling improvement in respiratory effort, and the decrease in objective wheezing. Patients will be contacted by phone 48 hours after discharge to repeat the questionnaire. Groups will be compared for age, sex, history of severity of disease, initial pulse oximetry, and respiratory rate, using the t-test. Initial FEV<sub>1</sub> will be determined and percent predicted will be determined using the patient's age, sex, height, and weight, and groups compared as to severity using the t-test. Subjective rate of improvement in symptoms will be analyzed using the Mann-Whitney U Test. Both peak flow and FEV<sub>1</sub> measurements will be plotted and percentage of improvement from baseline determined. The percentage improvement in FEV<sub>1</sub> will be compared between the two groups using the t-test.

**Progress:** Study is ongoing. Interim data analysis will be performed at 50 patients.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/120		<b>Status:</b> On-going	
<b>Title:</b> The Randomized Use of Helium-Oxygen Mixture for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. A Blinded Trial					
<b>Start Date:</b> 06/09/93			<b>Est. Completion Date:</b> Dec 93		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Richard D. Brantner, MC					
<b>Associate Investigators:</b> CPT David A. Della-Giustina, MC CPT Bernard J. Roth, MC			CPT James W. Thompson, MC CPT Timothy R. Murray, MC		
<b>Key Words:</b> COPD, helium, oxygen					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$800.00		/ /	

**Study Objective:** To determine the therapeutic role of Heliox administration in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

**Technical Approach:** Patients presenting with an acute exacerbation of COPD and requiring urgent treatment and agree to participate will be randomized to receive either Heliox (a mixture of 75% helium and 25% oxygen) or nitrogen-oxygen (a mixture of 75% nitrogen and 25% oxygen). Pulse oximetry will be monitored and any patient whose level falls to less than 90% will receive supplemental oxygen at a rate sufficient to raise pulse oximetry to at least 90%. Spirometry will be performed to measure FEV<sub>1</sub>, FVC, and PEF<sub>R</sub>. Base line arterial blood gas analysis will be performed and an upright portable chest x-ray will be obtained. Patients will be asked to score the severity of symptoms and the time to relief of those symptoms. All patients will receive nebulized albuterol treatments every thirty minutes for a total of 3 treatments. Patients will be re-evaluated after each treatment and at the end of the 90 minutes study period all patients will be placed on room air. Ten minutes after discontinuation of heliox or nitrogen-oxygen treatment, an arterial blood gas will be obtained, spirometry performed and the patients will be instructed not to discuss or divulge the mode of treatment they received. Patients will be evaluated at this time by a pulmonologist who will be blinded as to the treatment used. After evaluation of the patient, baseline and end of study data a determination will be made for 1) probable admission, 2) possible admission, 3) or admission not necessary.

Biographical data will be evaluated using the t test. The subjective rate of improvement in symptoms between the groups will be analyzed using the Mann-Whitney U Test and percentage improvement in FEV<sub>1</sub> will be compared using regression analysis.

**Progress:** Study was delayed because of the need to obtain oxygen equipment/adapters. Enrollment is now underway.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/051		<b>Status:</b> On-going	
<b>Title:</b> The Use of Intravenous Morphine for Early Pain Relief in Patients With Acute Abdominal Pain					
<b>Start Date:</b> 02/05/93			<b>Est. Completion Date:</b> Mar 94		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Thomas F. Burke, MC					
<b>Associate Investigators:</b> CPT Sarah R. Mack, MC COL Preston L. Carter, MC			Steven A. Pace, MD CPT Ronald J. Place, MC		
<b>Key Words:</b> abdominal pain, morphine					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** To determine if treating patients with acute abdominal pain with intravenous morphine affects patient evaluation (both in ease and accuracy), outcome, and satisfaction with pain control.

**Technical Approach:** One hundred adult patients with abdominal pain sufficiently severe to warrant opiate analgesia and pain duration of < 48 hours will be asked to enter the study. Patients will undergo double blind randomization to either a morphine or saline arm early in the evaluation. After an examination and completing a patient self administered visual analog pain score (VAS), the patient will undergo intravenous access, placement of a cardiac monitor and continuous pulse oximetry. After morphine or saline is titrated to effect, further patient evaluation and care is no different than usual. Physician titration of "study drug" is by administering a 0.01 cc/kg (morphine = 10 mg/cc) initial bolus at a rate of 0.1 cc/minute followed by 0.2 cc every 5 - 10 minutes until one of the following endpoints is reached. 1) Reduction of pain such that the patient is comfortable and, upon being offered, requests no further analgesia. 2) Any respiratory or central nervous system depression. 3) Maximum dose of 2 cc (saline or 20 mg morphine) is given. 4) Any other unwanted effects. A repeat examination will be performed and self administered patient VAS 15 - 30 minutes after titration is completed. Patients will be questioned by phone one week after discharge and continue each week until such time that a definitive diagnosis is reached.

Method of data analysis: 1) Analysis of variance to compare the change in visual analog pain. 2) Compare the age (T-test) and sex distribution (Chi Square) between two groups. 3) Use Kappa or Chi Square to compare the following variables between the two groups: a) Concordance of the presumptive diagnosis and eventual diagnosis. b) Determine if study drug administration improved evaluation. c) Determine patient satisfaction.

**Progress:** Seventy-six patients have been entered into the study and followed closely to gain clinical outcome data. There have been no cases of study drug reaction and no cases of unexpected 72 hour returns. The study should be completed within the next 12 weeks.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 92/039	<b>Status:</b> On-going
<b>Title:</b> Treatment of Corneal Abrasions: Is Eye Patching Necessary?		
<b>Start Date:</b> 02/07/92	<b>Est. Completion Date:</b>	
<b>Department:</b> Emergency Medicine	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> CPT James M. Nold, MC		
<b>Associate Investigators:</b> CPT Lee E. Payne, MC, USAF CPT Jack K. Handley, MC		MAJ Andrew T. Guertler, MC CPT Jan Vanderlinde, MC
<b>Key Words:</b> corneal abrasion, patching		
<b>Accumulative MEDCASE Cost:</b> \$0.00	<b>Est. Accumulative OMA Cost:</b> \$0.00	<b>Periodic Review:</b> / /

**Study Objective:** To determine if eye patching results in faster healing or provides pain relief in patients with uncomplicated traumatic corneal abrasions.

**Technical Approach:** Approximately 300 patients diagnosed with a corneal abrasion will be randomized to either a patch or no patch. Patients with evidence of ocular pathology in addition to the corneal abrasion will be excluded from the study. The group with the patch will have bacitracin ophthalmic ointment instilled and the eye patched. Patients who are assigned to the no patch group will have bacitracin ointment placed in the eye and no patch. All patients will be reevaluated at 24 hour intervals. Persistent abrasions will be quantified and treatment will continue identical to initial treatment (single instillation of bacitracin). Follow-up at 24 hour intervals will continue until the abrasion is no longer evident on slit lamp examination. Specific quantification of the corneal abrasion, using the measuring reticule on the slit lamp, will be done at the initial evaluation and all subsequent evaluations. Patients will be given medication for pain control to be used every 4-6 hours as needed. Pain scores will be determined using a visual analog scale prior to leaving the emergency room and at 8 hour intervals until the abrasion has healed. Patients will be instructed to record time, type, and amount of analgesic used. Summary descriptive statistics will be used to assess basic data. Specific parameters to be compared between groups include time to healing and pain scores. Comparison of healing time between groups will be accomplished using the Mann Whitney test. Comparison of pain scores will be accomplished by analysis of variance of a single repeated measure.

**Progress:** Enrollment stands at 90 and continues. Interim analysis indicates no difference in groups but statistical analysis of significance/power is pending.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/043		<b>Status:</b> Completed	
<b>Title:</b> Utility of Sinus Tenderness as a Diagnostic Sign in Sinusitis					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Greer E. Noonberg, MC					
<b>Associate Investigators:</b>					
CPT Thomas F. Burke, MC			CPT Jonathan A. Perkins, MC		
MAJ Danny M. Douglas, MC			MAJ Roderick D. Moe, MC		
MAJ James H. Timmons, MC			COL W. Pierre Andrade		
COL James S. Brown, MC			MAJ Kevin L. Quinn, MC		
			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> sinusitis, diagnosis, tenderness					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To determine the predictive value of sinus tenderness in the diagnosis of acute sinusitis.

**Technical Approach:** Patients over 18 years of age with no prior history of documented sinusitis with symptoms within two weeks of onset of either headache or facial pain and purulent nasal discharge or nasal congestion will be evaluated. A routine physical examination including teeth inspection will be performed. In addition, percussion for sinus tenderness will be performed using a standard reflex hammer and measurement of sinus tenderness using a dolorimeter to measure pressure/pain threshold over the frontal and maxillary sinus areas of the face. The dolorimeter is a spring-loaded gauge with a range of 0 to 9 kgs with a protective rubber stopper attached to a plunger. The dolorimeter will be placed directly each area to be studied and force applied slowly and steadily from 0 to 9 kg in 5 seconds. The patient will be asked to identify when the pain begins (pain threshold) and the test will be stopped. A standard sinus CAT scan will be performed within 48 hours. Nasal endoscopy will be performed in all patients within 24-48 hours of enrollment. Middle meatus cultures will be taken by endoscopy. A 30 degree Hopkins Telescope will be used to examine the nasal cavity after anesthetizing the nose with particular attention given to the middle meatus region. Chi square analysis will be used to compare CAT scan to dolorimeter values.

**Progress:** Complaints of sinus pain had CT documented findings of sinusitis. Sinus tenderness has high sensitivity and poor specificity in diagnosing sinusitis and is therefore not a useful diagnostic test in assessing sinusitis.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/019		<b>Status:</b> Completed	
<b>Title:</b> The Effect of Calcium Administration on Albuterol's Ability to Lower Serum K+ in a Hyperkalemic Swine Model					
<b>Start Date:</b> 11/06/92			<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Michael W. Peterson, MC, USAF					
<b>Associate Investigators:</b>			LTC Blake P. Gendron, MC		
<b>Key Words:</b> hyperkalemia,calcium,albuterol,potassium,animal model,animal Study					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
				<b>Periodic Review:</b> 06/07/93	

**Study Objective:** To demonstrate that calcium administration does not interfere with the use of albuterol for hyperkalemia in an intact organism applicable to normal humans.

**Technical Approach:** This blinded, randomized, placebo controlled four armed study using nine swine will use the animals as their own controls. Two indwelling lines will be placed under anesthesia and the sites allowed to heal. The animals will be anesthetized for the experimental runs to alleviate any pain or anxiety. The animals will be intubated and nebulization will be given by fitting a small volume nebulizer in the inhalation circuit. Each animal will undergo four runs, one in each treatment arm. These will be separated by at least 5 days. The animals will be randomized to a latin square design to account for any gross changes in K+ physiology that order may induce. Hyperkalemia will be produced by the infusion of 2 meq/kg of KCL over 1 hour (the prestudy trial will determine the optimal K+ dose). The control runs will receive nebulized saline and a saline injection. Those on an albuterol run will have 0.4 mg/kg albuterol nebs and saline. Those on the albuterol and calcium run get albuterol nebs and an I.V. injection of calcium gluconate 0.15 ml/kg or 10% solution. When on the calcium run they get a saline neb and the calcium injection. The nebulization will be given by fitting small volume nebulizers into the inspiratory circuit. The animal will be on a Marquet EKG monitor throughout the experiment and rhythm along with heart rate will be recorded at pretreatment, every 4 min. during KCL infusion and at sample times. Blood specimens for K+ and venous pHs, will be obtained at designated times and analyzed on a Kodak Ectachem 700 device to determine that albuterol does indeed lower K+ in this new hyperkalemia model.

**Progress:** Due to the number of animals studied and some missing data, the results of the study were inconclusive.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 82/025		<b>Status:</b> On-going	
<b>Title:</b> Emergency Room Procedure Training					
<b>Start Date:</b> 02/19/82			<b>Est. Completion Date:</b> Feb 87		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Matthew M. Rice, MC					
<b>Associate Investigators:</b>			LTC Cloyd B. Gatrell, MC		
MAJ Steven C. Dronen, MC			COL Frederick Burkle, MC		
MAJ Mel D. Robinson, MC			LTC Samuel T. Coleridge, MC		
MAJ Stanley P. Liebenberg, VC					
<b>Key Words:</b> emergency room,training protocol,animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$1360.00		06/07/93	

Study Objective: To provide training to acquire the necessary manipulative skills in performing invasive, life-saving procedures for the Emergency Medicine Residency Program.

Technical Approach: The procedures listed below will be performed in two separate parts under the supervision of a staff member and the veterinarian assigned to Clinical Investigation. All animals will be anesthetized and then will be sacrificed immediately after the procedures. Part I consists of: 1. Femoral vein cutdown, 2. Peritoneal lavage, 3. Tube thoracostomy, 4. Thoracotomy, 5. Aortic cross-clamping, 6. Control of pulmonary hemorrhage, 7. Cardiac wound repair, 8. Endotracheal intubation, 9. Percutaneous transtracheal ventilation, 10. Cricothyroidotomy. Part II consists of: 1. Tissue pressure monitoring, 2. Arterial pressure monitoring, 3. Swan-Ganz catheter placement, 4. Transvenous ventricular pacemaker placement, 5. Transthoracic ventricular pacemaker placement, 6. Pericardiocentesis, 7. Segstaken-Blakemore tube placement, 8. Auto transfusion from hemothorax, 9. Twist drill decompression, 10. Skull trephination.

Progress: Four animals were used for training Emergency Medicine residents.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/016		<b>Status:</b> On-going	
<b>Title:</b> Pediatric Intubation Training Utilizing the Ferret Model					
<b>Start Date:</b> 01/19/90			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Emergency Medicine			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Matthew M. Rice, MC					
<b>Associate Investigators:</b> LTC Patrick C. Kelly, MC			LTC Cloyd B. Gatrell, MC		
<b>Key Words:</b> training protocol,pediatrics,intubation,ferret,animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$400.00		06/07/93	

**Study Objective:** To enhance the clinical skills of health care providers in managing pediatric airways, specifically intubations. This protocol will be used to support the Pediatric Advanced Life Support Course. The participants in this course are members of the Army, the Air Force, the Navy, and the Public Health Service.

**Technical Approach:** Ferrets will be anesthetized and course participants will be given the opportunity to intubate a ferret employing a laryngoscope and endotracheal tube. Administration and monitoring of anesthesia will be directly supervised or performed by the attending veterinarian. The veterinarian will be present at all times to assist, modify, or terminate the procedure.

**Progress:** Five animals were utilized (1 session) to facilitate intubation training.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/169		<b>Status:</b> On-going
<b>Title:</b> The Relationship of Intraocular Pressure and Symptoms of Acute Mountain Sickness at Moderate Altitude				
<b>Start Date:</b> 09/03/93		<b>Est. Completion Date:</b> Oct 93		
<b>Department:</b> Emergency Medicine		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Ian S. Wedmore, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> intraocular pressure,mountain sickness				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To determine if a relationship exists between intraocular pressure (IOP) and symptoms of acute mountain sickness (AMS) during acute exposure to moderate altitude (up to 14,000 feet).

**Technical Approach:** Members of an organized climb of Mount Rainier agreeing to participate in this study will have ocular pressures measured at 4 altitudes up to 4300 M. To facilitate measurement, 2 drops of proparacaine will be placed in each measured eye. Subjects will simultaneously complete a questionnaire commonly used for altitude research to look for symptomatology of AMS. Climbers who use no chemical AMS prophylaxis as well as those who use dexamethasone for AMS prophylaxis will be included in the study.

Results of IOP will be compared to AMS symptoms to determine if any correlation exists utilizing Pearson coefficient. A T test will be applied to baseline and higher altitude IOPs to determine if any significant change in IOP with altitude occurs.

**Progress:** The principal investigator is TDY; therefore a report is not available. The protocol will be reviewed for continuation when the PI returns to MAMC..



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/078		<b>Status:</b> Completed
<b>Title:</b> Oral Versus Intravenous Steroid: A Prospective Study in Acute Asthma				
<b>Start Date:</b> 06/15/90		<b>Est. Completion Date:</b> Feb 92		
<b>Department:</b> Emergency Medicine		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT David C. White, MC				
<b>Associate Investigators:</b> LCDR Richard S. Perren		MAJ Kirin M. Russell, MC LCDR Kyle D. Holmes, MC		
<b>Key Words:</b> asthma:acute,steroids:oral,steroids:IV				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To compare the efficacy of oral prednisone and intravenous methylprednisone in the treatment of adults with an acute asthma exacerbation by comparing FEV<sub>1</sub>, patient's subjective index, and physician evaluation of clinical course.

**Technical Approach:** The patient sample will be 100 patients, ages 18-45 years, presenting to the Emergency Room with exacerbation of asthma, unrelieved by the usual home treatment. Each patient will be evaluated by the physician and tested with a portable spirometer. Oxygen saturations will be recorded per pulse oximetry. Arterial blood gases may be used in place of pulse oximetry if the clinical situation dictates. The patient will then be randomized in a double blind fashion to receive either IV methylprednisolone and oral grape Tang or oral prednisolone mixed with grape Tang and normal saline IV. All patients will receive oxygen and a beta-agonist as per emergency room protocol, three treatments, 20 minutes apart. Patients will be evaluated with spirometry for FEV<sub>1</sub> on arrival and every hour for three hours. Patients will be discharged or admitted as clinical circumstances warrant. Discharge steroid dosing will be left to the discretion of the treating physician. Follow-up evaluation will consist of repeat vital signs (every 30 minutes), physician examination (after every treatment), patient symptom scale of 1 to 10 (every hour), and spirometry (every hour). Patients who are discharged will be contacted the following day for evaluation of subjective complaints and will be asked to rate themselves on the patient symptom scale. FEV<sub>1</sub> and FVC will be analyzed with repeated measures analysis of variance. Analog scaled variables like physician exam and subjective index will be analyzed with appropriate non-parametric methods.

**Progress:** Results show a selection bias of unclear etiology in which healthier individuals tended to be grouped in the placebo group. This resulted in a tendency for placebo-treated patients to do better than either oral or I.V. treated patients, as all patients improved. Secondary analysis of degree of improvement show statistically greater relative improvement in the I.V. treated group relative to presenting severity. This is arguably because of having greater "room for improvement". The study is terminated because it is felt that it would be unlikely to eliminate this bias with less than 120 patients (2.5 X current enrollment) which is an unattainable goal.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/097		<b>Status:</b> Terminated
<b>Title:</b> Pediatric Pain Assessment Survey				
<b>Start Date:</b> 08/07/92		<b>Est. Completion Date:</b>		
<b>Department:</b> Emergency Medicine		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT David C. White, MC				
<b>Associate Investigators:</b> MAJ Kerry R. Johnson, MC		Cami Tier, AN		
<b>Key Words:</b> pediatric pain,acute injuries,parental preferences				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

Study Objective: To correlate the amount of pain from an acute injury as assessed by pediatric patients, their parents, and the treating physician; to determine whether pediatric patients are more fearful of needles/IV's and their perceived pain when compared to acute pain; to determine if pediatric patients and parents think children feel pain more, less, or the same as adults; to determine if pediatric patients and/or parents prefer for the parents to be present or absent during treatment of acute painful injuries; and to assess parents opinions as to method of administering pain control for acute injuries to pediatric patients.

Technical Approach: Subjects will be children between 3 and 15 years of age who present to the Madigan emergency room with acute painful injuries. The child and parent will each complete a questionnaire regarding how they perceive pain and how it should be treated. The child will rate the pain using the facial pain scale and/or the visual analog scale at the time of presentation to the emergency room and at discharge. The parent and the physician will rate the pain on a visual analog scale at the time of presentation, at discharge, and during the procedure. The questionnaires will be compiled and the results analyzed using ANOVA with repeated measures for the pre- and post-treatment responses. Student's t test will be utilized to analyze data between the three groups. Chi-square analysis will be used to compare whether children or parents feel that kids feel pain more, less, or the same as adults and also to compare the parents rating of methods to provide pain relief.

Progress: The initiating PI (Dr. Johnson) was reassigned and was to re-write the questionnaire. The study was then to be conducted at both sites. Dr. Johnson has not contacted Dr. White regarding the study. Since he has failed to do this, Dr. White has decided that he will terminate the protocol at MAMC.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF FAMILY PRACTICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/076	<b>Status:</b> On-going
<b>Title:</b> Comparison of Family Practice (FP) In-Training Exam Scores Between Residents Who Have Done A General Medical Officer Tour of Duty After A FP Internship & Residents....Continuous 3 Year FP Residency		
<b>Start Date:</b> 04/02/93	<b>Est. Completion Date:</b> Jul 94	
<b>Department:</b> Family Practice	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ David D. Ellis, MC		
<b>Associate Investigators:</b> MAJ Steve Reissman, MC MAJ George Wakeman, MC LTC Ron Jones, MC		LTC Wayne A. Schirner, MC COL Earl Lorenzen, MC LTC Wayne Blount, MC
<b>Key Words:</b> residents, ITE		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	/ /

**Study Objective:** To compare Family Practice In-training Exam Scores (ITE) between residents who have completed a General Medical Officer tour of duty after a Family Practice Internship and Residents who have had a continuous three year Family Practice Residency.

**Technical Approach:** Data on those graduating from six Army FP residency programs will be requested from each program director. The program director will collect the data and send it to the investigator without information that identifies the respondents. The information provided will have personal, biographical, and educational information, plus military experience and ITE scores. The data will be arranged with follow-up retrieval as needed.

Data analysis will be done using a 2 tailed t-test to attempt to identify either a positive or negative difference in these two groups. Due to the "real world experience" of GMO residents, their ITE scores may actually be better than the CFP residents. On the other hand, if being away from a training environment for a period of time has caused a deterioration of scholastic level, we would hope to identify this as well.

**Progress:** Investigators have reviewed 200 academic records from 10 residency programs. After completion of data entry and determination of results, the study will be submitted to either Military Medicine or Family Medicine for publication.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/013	<b>Status:</b> On-going
<b>Title:</b> Exercise Blood Pressure and Heart Rate Response in Pregnancy As A Predictor of Preeclampsia		
<b>Start Date:</b> 11/06/92	<b>Est. Completion Date:</b>	
<b>Department:</b> Family Practice	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> CPT Brain C. Harrington, MC		
<b>Associate Investigators:</b>		
LTC Arthur S. Maslow, MC	CPT David N. Crouch, MC	
MAJ Wade A. Lillegard, MC	LTC John P. Kugler, MC	
CPT Janus D. Butcher, MC	CPT Monte C. Uyemura, MC	
<b>Key Words:</b> preeclampsia, exercise, heart rate		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** To determine if blood pressure and heart rate response to exercise can be used to predict the development of preeclampsia in pregnant women.

**Technical Approach:** An estimated 200 obstetric patients seen at MAMC Departments of OB/GYN and Family Practice who are nulliparous and have no history of hypertension, diabetes, heart disease or thyroid disease prior to pregnancy will be enrolled. Stationary bicycle exercise stress test will be performed prior to 20 weeks gestation. Blood pressure and heart rate response to exercise, the independent variables, will be monitored and documented at prescribed intervals during the test. The dependent variable will be the development of preeclampsia, and will be recorded as categorical data.

**Progress:** Having tested almost half of our needed total of subjects, we have developed a smooth reproducible testing system. Because of the lag time until delivery we do not have complete databases of all those tested. New research has been published on Aspirin use in pregnancy, adding to the information base for our study. The most significant problem so far has been time constraints for testing. Because of our full schedules we have had to add several month to our timetable.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/077		<b>Status:</b> Completed
<b>Title:</b> The Effect of Internship on Empathy				
<b>Start Date:</b> 04/02/93		<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Family Practice		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CDR W. R. Kiser, MC				
<b>Associate Investigators:</b> MAJ David MacDonald, MC		CPT Kim A. Dugger, MC MAJ Bruce M. LeClair, MC		
<b>Key Words:</b> empathy,internship				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** The purpose of this study is to determine the effect of the internship experience on the empathic construct of physicians-in-training.

**Technical Approach:** Interns at three military hospitals (MAMC, TAMC, DDEAMC) who both took part in a pre-internship Interpersonal Reactivity Index (IRI), a self reporting empathy measure, and provided their social security numbers will be individually and confidentially contacted by the investigators and requested to participate in this study. Those voluntarily agreeing to take part will be asked to again complete the IRI, to again provide their social security number, and to return the materials to the responsible associate investigator in a sealed envelope. The collected materials will be forwarded to the principal investigator for analysis.

The IRI yields interval level data and consists of 4 subscales, each examining one dimension of empathy. The data in each subscale, previously collected from pre-internship IRIs, will be compared to the post-internship data via the use of paired t-tests, to test the hypothesis that empathy, as measured by any of the subscales of the IRI, is significantly affected ( $p \leq 0.05$  2-tailed) by the internship experience.

Depending on the mix of the obtained sample, the group may be divided and the data examined along demographic lines as well (i.e. gender, specialty choice, professional degree etc.) to determine if these variables have an impact on the change in empathy over the period of internship.

**Progress:** Significant differences in empathic concern were found among female allopaths and in perspective taking among male osteopaths, with higher levels of empathy found in those interns entering primary care. A thesis was prepared and accepted for M.A. in Social Science at Pacific Lutheran University. A paper was also submitted for the Steiger award competition.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/083		<b>Status:</b> Terminated
<b>Title:</b> The Effect of Internship on Moral Reasoning				
<b>Start Date:</b> 07/02/92		<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Family Practice		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CDR W. R. Kiser, MC				
<b>Associate Investigators:</b> LTC John P. Kugler, MC		Donnie J. Self, Ph.D.		
<b>Key Words:</b> moral reasoning,internship				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** To determine if moral reasoning ability is affected by the experience of internship.

**Technical Approach:** The well publicized instances of dishonesty in biomedical research over the past several years stress the need to refocus attention to the ethical components of the medical profession and to ensure that the educational processes foster, rather than hinder, moral development. As a preliminary step toward this goal, it is important to discover what effect the components of the present medical education system have on moral reasoning. This study will examine the effect of the internship year as one component of the medical education system. Interns agreeing to take part in the study will be administered the Defining Issues Test (DIT) in the first month of internship and again in the month prior to the completion of the internship. The DIT is a questionnaire to help determine how people feel about social problems. This is done by having the individuals being tested read stories regarding social problems and then answer questions regarding their opinions on these problems. Demographic information important to describe the sample and to identify potential confounders will be obtained. The DIT yields interval level data. The dependent variable is the change in DIT scores pre and post internship and a t-test will be used to compare these differences. Comparisons will also be made between the pre and post internship DIT scores and the demographic information using chi-square analysis, t-test, and regression analysis where appropriate.

**Progress:** The number of subjects who returned the questionnaire was inadequate. Attempts are being made to use the data to begin a pilot study at Naval Station Jacksonville.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/058		<b>Status:</b> Completed
<b>Title:</b> An Analysis of Selected Elements of Family Function and Related Variable in Adolescent Pregnancy				
<b>Start Date:</b> 04/05/91		<b>Est. Completion Date:</b>		
<b>Department:</b> Family Practice		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LCDR Euelya L. Lewis				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> pregnancy:adolescent,family function,adolescent:female,parent participation				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		08/07/92

**Study Objective:** To compare family function (as measured by FACES III) family satisfaction and parent/adolescent communication of pregnant vs nonpregnant teens and observe the effect on teen pregnancy rate.

**Technical Approach:** Subjects will be contacted as they are identified through the organizations and schools who are participating, a total of 400 subjects is the target sample. In the instance where there are groups of subjects, a presentation will be made about the protocol. Prior to receiving the questionnaires, subjects will be given a consent form for themselves and a parent or guardian. Once parents/guardians who wish to participate are identified, they may be accessed in one of three ways: 1) personally contacted by PI, 2) brought home by the subject, 3) mailed to parent/guardian. The latter two are followed up by a phone call to reinforce and encourage participation and packet completion. Data will be analyzed using the chi-square method looking at the frequency distribution in the balanced mid-range and extreme family types of pregnant and nonpregnant teens. The data will also be used to compare balanced families vs those non-balanced families in the remaining four quadrants. The third method of analysis will employ a score called Distance from Center of Circumplex (DFC). This is a linear score used for correlational analysis and is an indication of the distance of an individual's cohesion and adaptability score from the center of the model. And finally, discriminant function analysis will be used to predict group membership or status on a categorical or nominal level variable on the basis of two or more independent variables.

**Progress:** No further work was done in FY 93. A thesis was written as a requirement for the degree of Master of Arts in Social Science.



### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/084		<b>Status:</b> On-going
<b>Title:</b> Back Pain in Aviators: A Descriptive Study of the Type of Care Received/Sought and Implications for Flight Status - Part Two				
<b>Start Date:</b> 07/02/92		<b>Est. Completion Date:</b> Mar 93		
<b>Department:</b> Family Practice		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LCDR Danell E. Lovins				
<b>Associate Investigators:</b> MAJ Daniel Fitzpatrick, MC		LTC John P. Kugler, MC		
<b>Key Words:</b> back pain,aviators				
<b>Accumulative</b> <b>MEDCASE Cost:</b>		<b>Est. Accumulative</b> <b>OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		//

Study Objective: (1) To determine if a difference exists in the type of health care behavior/preference between pilots with more flight hours (experience) and pilots with fewer hours (student pilots) and (2) to determine if a difference exists in the type of health care behavior/preference between those aviators who experience no pain, pain that does not interfere with lifestyle, and pain that interferes with lifestyle.

Technical Approach: Six hundred surveys will be distributed to initial phase, advanced phase, and instructor pilots (200 per group). The questionnaire will address affect on performance of duties, types of professional help sought, medications taken, if medication has been taken while flying, back injuries, back surgery, help sought outside the military health care system, avoidance of health care for fear of being taken off flying status, type of pain and how it was resolved, and if the subject had ever been grounded because of back pain. Data from both aviators who have experienced back pain and those who have not will be analyzed in this study. Analysis of variance (ANOVA) will be used to test for differences in flight hours by degree of back pain/discomfort. A post-hoc test will be used to isolate any differences noted in the ANOVA. An unpaired T test will be used to test for differences in the type of health care and amount of flying experience. ANOVA will be used to test for significance in differences in health care versus pain. Descriptive statistics will be used to describe the sample in this study.

Progress: Questionnaires have been mailed. No other report is available.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/093		<b>Status:</b> Completed	
<b>Title:</b> The Prevalence of Sexual Concerns in a Population of Women Who Have Sought Routine Gynecological Care & What Barriers Exist for the Discussion of Sexual Concerns With Physicians/Health Care Providers					
<b>Start Date:</b> 04/02/93			<b>Est. Completion Date:</b> Apr 93		
<b>Department:</b> Family Practice			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Margaret R. Nusbaum, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> sexual concerns, prevalence, barriers, discussion					
<b>Accumulative MEDCASE Cost:</b>		<b>\$0.00</b>	<b>Est. Accumulative OMA Cost:</b>		<b>\$0.00</b>
			<b>Periodic Review:</b>		<b>/ /</b>

**Study Objective:** To determine both the prevalence of sexual concerns, and the barriers to the discussion of sexual concerns by women with their physicians.

**Technical Approach:** Women who have had a pap smear at MAMC will be mailed an anonymous survey instrument. A follow up letter will be sent approximately two weeks after the initial mailing as a reminder and thank you for participation.

No names will be used other than for mailing purposes. A coding system will be used to identify the clinic and number of the survey mailed out. These codes will be maintained after mailing. No identifiers will be linkable to individual responders. All mailing information on the subjects will be destroyed upon return of surveys and completion of the study.

Descriptive statistics will be used. Correlations, regression techniques, and multivariate analysis will be used, based on descriptive statistic findings.

**Progress:** The results of the study suggest that women may have sexual concerns at the time of routine exams and health care providers should be a resource for addressing these concerns. Particular issues have greater concern for different age groups, supporting the need to address sexuality in a biopsychosocial or systems approach. Sexuality should be considered an integral part of health, quality of life, and general well being.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/085		<b>Status:</b> Terminated	
<b>Title:</b> Diagnoses Which Stimulate Physician Initiated Discussions About Advance Directives: A Survey of Practicing Physicians					
<b>Start Date:</b> 07/02/92		<b>Est. Completion Date:</b> Aug 92			
<b>Department:</b> Family Practice			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Jefferey Johnson, MC					
<b>Associate Investigators:</b> CPT Cliff A. Robertson, MC					
<b>Key Words:</b> advance directives,power of attorney,CPR					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$150.00		/ /	

**Study Objective:** To define which diagnoses prompt physicians to discuss terminal care issues such as advance directives, medical power of attorney, and cardiopulmonary resuscitation.

**Technical Approach:** A survey will be distributed to the medical and surgical staff assigned to Madigan (excluding the pediatric, pathology, and administrative departments). The survey will determine demographic data, the estimated frequency of patients with advance directives as well as the frequency of terminal care discussions between the physician and patient in the previous month. The pilot survey will ask the respondents to write in diagnosis which they feel would justify a discussion about advance directives or DNR orders. Results of the pilot survey will be used to formulate a list which will then be submitted in survey form to practicing physicians in Pierce County who are listed with the Washington State Medical Society. The results will be classified using simple descriptive statistics. A percent of those responding for each given specialty will be calculated by coding the mailed surveys. A comparison of advance directive utilization will be made between and among specialties. Diagnoses will be grouped and frequencies will be described and compared between specialties as well as compared by setting (outpatient vs inpatient). A list will be compiled of the 15 most common listed diagnoses from the initial MAMC survey which will be confirmed by the physicians in the county.

**Progress:** This was a pilot project with 23 physician respondents at MAMC. The original PI (CPT Robertson) left MAMC and the individual assigned to take over the protocol (CPT Johnson) was not aware that he was supposed to work on the project. Therefore, no further work has been done on the study and it has been terminated due to the departure this year of Dr. Johnson.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/123		<b>Status:</b> On-going
<b>Title:</b> Vasectomy Reversal: A Heuristic Investigation of the Experience				
<b>Start Date:</b> 06/09/93		<b>Est. Completion Date:</b> Apr 94		
<b>Department:</b> Family Practice		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Guy P. Runkle, MC				
<b>Associate Investigators:</b>		CDR W. R. Kiser, MC		
<b>Key Words:</b> vasectomy:reversal				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

Study Objective: To explore the experience of vasectomy reversal through heuristic methodology.

Technical Approach: Potential volunteers will be identified from the log of patients who have undergone vasectomy reversal will be contacted and the nature of the research design and purpose will be explained. Those who express interest in participating will be given a written description of the study to include time commitments and consent will be obtained.

Data collection will take place through extended interviews between the principal investigator and the research participants. The interview, to be recorded, will be unstructured and the goal will be to allow the participant to tell his story to a point of natural closing. After the interview, the tape will be transcribed and an individual portrait of the research subject's experience will be prepared. The participant will be provided a copy of the profile for his review and a second interview will be scheduled for feedback. The participant may elect to delete or correct information that he feels compromising or inaccurate in reflecting his experience. This will result in reiteration until the accuracy of the portrait is confirmed by the research participant.

This research will be submitted as the thesis requirement for an M.A. degree.

Progress: Data collection is in progress. Six subjects have been interviewed, and an additional six subjects have been identified as potential study participants. Initial analysis of the first five cases has been performed.

A tentative conceptual model has been developed from analysis of the first cases, and appears to have been highly salient in the interviews of subsequent participants. This model involves identification of goals, influences, alternatives and barriers to initial sterilization and other life circumstances changes following vasectomy sterilization reversal. Influences, alternatives and barriers to sterilization reversal are explored as well as stages of the sterilization process, consequences of sterilization reversal and changes following sterilization reversal.

DETAIL SHEETS FOR PROTOCOLS

I CORP SURGEON, FORT LEWIS, WA

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/047		<b>Status:</b> On-going
<b>Title:</b> Implementation of a Voluntary Fitness Program and Pilot Project and the Consequent Evaluation of Physical Fitness Levels of Pregnant Soldiers Before, During and After Pregnancy to Substantiate ....				
<b>Start Date:</b> 02/05/93		<b>Est. Completion Date:</b> Dec 93		
<b>Department:</b> I Corp Surgeon		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> SPC Wendy M. Urich				
<b>Associate Investigators:</b> Ann Lancaster, CHN		CPT Anne Grediagin, RD		
<b>Key Words:</b> pregnancy:specialized fitness regime				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> / /

**Study Objective:** To evaluate the benefits of a specialized exercise program for pregnant soldiers and to submit the findings to the U.S. Army Physical Fitness School for evaluation.

**Technical Approach:** Each pregnant soldier will be required to fill out a series of questionnaires regarding pre-pregnancy and current fitness levels, work conditions, and lifestyle habits. In addition, both project groups (the exercise group and the control group) will be asked to fill out additional questionnaires which will evoke subjective answers concerning the subjects's feelings about her current exercise regimen, the proposed exercise regimen, and her self esteem. Unit commanders will be asked to fill out a subjective questionnaire concerning their feelings of current pregnancy P.T. prescriptions and of the program in which their soldiers are currently involved. Each soldier will undergo a fitness evaluation which involves measures of: resting heart rate and blood pressure, body weight, subcutaneous skin fold, and cardiorespiratory fitness. An individualized program will be developed for soldiers of the Exercising Group. Health information classes covering various topics in pregnancy will be given twice weekly. The Unit-exercise groups will engage in unit-directed P.T., which follows usual prescription and current standards of exercise for pregnant soldiers. Fitness evaluations of both groups will be conducted at the end of the second trimester, mid-way of the third, and again postpartum. Subjective questionnaires will be completed again at the end of the second trimester. Within the 28th week of gestation, all participating individuals will undergo an ultrasound to determine fetal growth. The investigative staff will obtain postpartum information. Unit Commanders will be asked to assess subjects physical readiness through a standard Diagnostic P.T. Test to be administered within the 8th week after delivery. Physical data as per Army Regulation levels will be evaluated with a T-test to compare means between the exercise group and control group. Nominal data will be compared using a chi-square method of analysis. Use of either the chi-Square or T-test will be utilized depending on how the data is interpreted.

**Progress:** Thirty-two first trimester subjects, with uncomplicated pregnancies, were randomly assigned to one of two groups. Initial fitness assessments were completed. The exercise group subjects exercise three days per week, and control groups subjects exercise with their units following current Army training guidance.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
ALLERGY/IMMUNOLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/055		<b>Status:</b> Terminated	
<b>Title:</b> Multicenter Clinical Evaluation of Penicillin Skin Testing					
<b>Start Date:</b> 05/19/89			<b>Est. Completion Date:</b> Jun 90		
<b>Department:</b> Medicine/Allergy			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL James S. Brown, MC					
<b>Associate Investigators:</b>			COL W. Pierre Andrade		
COL Bernard Branch, MC			COL Richard W. Weber, MC		
MAJ Marcia L. Muggelberg, MC			MAJ Allen F. Kossoy, MC		
COL William F. Tuer, MC			Robert A. Ledoux		
COL Michael Martin, MC			CPT William L. Ebbeling, MC		
CAPT David Moyer, MC			CAPT Fang L. Lin, MC		
<b>Key Words:</b> penicillin skin testing					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To determine if there is a difference in the incidence of skin test positivity to the different skin testing reagents prepared by different methods in patients with a history of penicillin allergy as well as in subjects with no previous history of an adverse reaction to a penicillin-like drug.

**Technical Approach:** Allergists in the Army, Air Force, and Navy will participate in this multicenter study. Adult (>21 years) subjects (n=200) requiring penicillin skin testing will be questioned for prior exposure to beta lactam antibiotics and will receive prick skin testing, followed by intradermal skin testing for each reagent to which there is no significant prick skin test reaction, to PPL, fresh pen G, penicilloate (MDM-A), penicilloate (TS-Sullivan), and penilloate (MDM-B), in the usual concentrations, as well as routine histamine and diluent controls. The two penicilloates and the penilloate are not commercially available and will be prepared in a single batch at FAMC. MDM-A and MDM-B will be prepared following Saxon's clarification of Levine's method. Penicilloate TS will be made by Sullivan's method. A blood sample will be drawn from subjects with positive skin test reactions and frozen for use in a future in vitro study of comparative potency of the testing reagents. It is hoped that at least 200 subjects without history of adverse penicillin reaction will be tested and that at least 30 skin test positive patients will complete the comparative potency phase of the study. The number of history positive patients and the number of history-negative subjects in whom one or more skin test results are positive will be reported as a percentage of the total number of patients and subjects tested for each reagent. In the comparative potency evaluation, the Kruskal-Wallis test will be used to discern if there is a difference in the wheal size for penicilloate A vs penicilloate B vs MDM. If a difference is detected at the  $\alpha=0.05$  level, multiple comparisons will be made also at the  $\alpha=0.05$  level using a nonparametric modification of the Newman-Keuls method. Comparison of end point skin test reactivity for fresh and aged preparations for each reagent will be made at the  $\alpha=0.05$  level by means of the Mann-Whitney test.

**Progress:** No patients have been entered at MAMC since FY 90. Dr. Brown, who took over the protocol, has been unable to restart the study.



DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
CRITICAL CARE MEDICINE

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/159		<b>Status:</b> On-going
<b>Title:</b> Randomized Trial of E5 Antiendoxin Monoclonal Antibody in Patients With Severe Sepsis				
<b>Start Date:</b> 08/06/93		<b>Est. Completion Date:</b> Nov 94		
<b>Department:</b> Medicine/Crit Care Med		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Anthony S. Sado, MC				
<b>Associate Investigators:</b>		MAJ Kathleen M. Sheehan, MC		
<b>Key Words:</b> sepsis,monoclonal antibody				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

Study Objective: To determine whether the administration of E5 enhances survival in patients with severe sepsis due to documented gram-negative infection when compared to placebo.

Technical Approach: Hospitalized patients > 18 years who have a documented serious gram negative infection within 2 calendar days prior to entry will be screened for clinical signs of sepsis. Patients will be randomized to receive standard antibiotic therapy and E5 (monoclonal antibody) versus standard antibiotic therapy. E5 will be given over 1 hour on days one and two and the patients will be monitored for any adverse effects. All patients will be followed for survival at days 14 and 28.

Progress: Medication has not been received to initiate the study.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/131		<b>Status:</b> On-going
<b>Title:</b> Pilot Study - Thromboelastograph Assessment of Suspected Acute M.I./Unstable Angina Patients Pre- and Post- I.V. Magnesium Administration				
<b>Start Date:</b> 07/02/93		<b>Est. Completion Date:</b> Jan 94		
<b>Department:</b> Medicine/Crit Care Med		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kathleen M. Sheehan, MC				
<b>Associate Investigators:</b>		MAJ Doreen Saltiel, MC		
<b>Key Words:</b> myocardial infarction,magnesium,thromboelastograph				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$53.33	/ /

Study Objective: To determine the extent of anticoagulant effect of I.V. magnesium sulfate in patients admitted with suspected acute myocardial infarction or unstable angina.

Technical Approach: Acute myocardial infarction patients ordered to receive I.V. magnesium sulfate (2 gm bolus) will be entered into this pilot study to evaluate possible anticoagulant effects of magnesium. A sample of venous blood will be withdrawn with admission laboratories prior to magnesium level, and standard measures of coagulation (PT/PTT, thrombin time, and fibrinogen) will be performed. Approximately 15 minutes into the infusion, repeat coagulation studies will be obtained and repeat thromboelastograph will be available in approximately 60 minutes. Statistical method to be employed is paired t-test.

Progress: Five subjects have been entered, no significant differences have been noted..

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
CARDIOLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/074		<b>Status:</b> On-going	
<b>Title:</b> Transcatheter Closure of the Patent Ductus Arteriosus Using a Retrievable Coil Occlusion System in the Newborn Lamb Model					
<b>Start Date:</b> 04/01/93			<b>Est. Completion Date:</b> Aug 93		
<b>Department:</b> Medicine/Cardiology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick A. Cambier, MC					
<b>Associate Investigators:</b> MAJ Richard R. Gomez, MC			MAJ Karl C. Stajduhar, MC		
<b>Key Words:</b> Patent ductus arteriosus:Newborn lamb model,retrievable coil occlusion system,Animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$1662.00		06/07/93	

**Study Objective:** The trial outlined in this protocol is designed to evaluate the efficacy of a prototype wire coil device to occlude arteriovenous flow in the patent ductus arteriosus (PDA); establish the safety regarding deployment and retrievability of the system over a range of PDA internal diameters; and to assess the long-term histologic vascular sequelae of coil implantation.

**Technical Approach:** Animals will be kept NPO for 4 hours prior to the procedure. Intravenous access will be obtained via a catheter placed in the external jugular vein. After surface electrodes for cardiac monitoring are in place, appropriate anesthesia will be initiated and the animal will be intubated. Femoral artery and vein cutdowns will be completed and aortography of the transverse aortic arch will be performed to identify the patent ductus arteriosus (PDA). In the event a PDA is not noted via the aortogram, a limited main pulmonary arteriogram will be carried out to visualize the pulmonic diverticulum, and the PDA traversed via the pulmonic ostia. A guiding catheter will be used to engage the aortic ostium of the PDA. Although the majority of newborn lambs will have sufficiently large PDAs for deployment of the coil device, a small percentage of the PDAs may require pre-dilation using standard angioplasty techniques. In the event that the PDA is visualized via the pulmonary circuit, a guide wire will be inserted into the aorta via the PDA pulmonic diverticulum and advanced through the previously placed femoral arterial sheath. Over this wire, the guiding catheter will be advanced via the ascending aorta, engaging the PDA diverticulum at which time the coil device will be deployed into the PDA, and occlusion of flow documented by angiography. The coil will then be retrieved. The coil device will then be permanently deployed in the ductus arteriosus. In the event the PDA cannot be traversed, the coil will be placed into a collateralized end-artery (i.e. internal carotid), to permit testing of the flow occluding nature and retrievability of the device. After completion of this process the catheters will be removed and the animal recovered and maintained. At the end of the routine 3 week follow-up time period (in 2 - 3 animals, as long as 3 - 4 months), the animal will be euthanized. Necropsy will be performed to determine gross and histological appearance of the coil, specifically at the pulmonary and aorta ostia to determine intimal aortic injury or presence of thrombus.

**Progress:** Successful testing and deployment of 11 of the planned 12 retrievable coil occlusion devices has occurred. Successful results have provided further incentive to continue investigation of a second generation device. FDA testing is now underway.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/151		<b>Status:</b> On-going	
<b>Title:</b> Cardiac Safety of Sexual Intercourse Following Myocardial Infarction As Assessed by High Resolution Holter Monitoring					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Jul 94		
<b>Department:</b> Medicine/Cardiology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Cynthia L. Clagett, MC					
<b>Associate Investigators:</b>			MAJ Patrick A. Cambier, MC		
<b>Key Words:</b> intercourse,myocardial infarction,Holter monitoring					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
			<b>Periodic Review:</b>		/ /

**Study Objective:** (1) To determine the cardiac safety of sexual intercourse following myocardial infarction (MI) by directly assessing for the presence of ischemia and dysrhythmia using high resolution Holter monitor. (2) Determine if post myocardial infarction pre-discharge exercise tests predict who will be at risk for ischemia or dysrhythmia during sexual intercourse.

**Technical Approach:** Patients who have suffered an acute MI within the preceding month and have a stable sexual relationship as determined by the patient will be eligible for this study. After clinical evaluation, chart review and review of other tests deemed appropriate by the primary physician; the patients will undergo 24 hour outpatient Holter monitoring within 1 month after MI. During the monitor period, they will be asked to engage in their normal activity and to engage in sexual intercourse during this time. Patients will be asked to document any symptoms and record time of activities, specifically sexual intercourse, in a patient diary. If for any reason patients do not have intercourse or find the device inconvenient, they may choose to reschedule another monitoring period or to discontinue the study. A blinded investigator will review the monitor tapes. The number, duration, and time of onset and offset of ischemic episodes will be recorded. A period including sexual intercourse will be specifically analyzed. The presence of ischemia or dysrhythmia during the sex period will be compared to the remaining 24 hour period and to the findings on exercise testing.

The incidence of ischemia and dysrhythmia will be calculated with 95% confidence intervals for the proportions.

**Progress:** No status report was submitted by suspense date.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/018		<b>Status:</b> On-going	
<b>Title:</b> Cardiac Dimensions in Female Athletes					
<b>Start Date:</b> 11/06/92			<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Medicine/Cardiology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Alice M. Mascette, MC					
<b>Associate Investigators:</b> MAJ Karl C. Stajduhar, MC			MAJ Patrick A. Cambier, MC		
<b>Key Words:</b> cardiac dimensions,female athletes					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To non-invasively obtain cardiac dimensions in women engaged in regular vigorous aerobic and power training.

**Technical Approach:** Twenty volunteer female athletes engaged in regular vigorous aerobic activity and twenty volunteer female athletes engaged in regular power sports will undergo standard two dimensional echocardiography. Standard measurements of left ventricular wall thickness (septum and posterior wall) and cavity dimensions will be measured on-a-line from the parasternal long axis view at the time of study. The technical staff will be blinded as to the exercise interview conducted at the time of recruitment. The echocardiograms will be overread by two staff cardiologists and measurements recorded. Differences will be resolved by averaging results. A cohort of age, height, and weight-matched controls will be recruited and mean dimensions from their studies statistically compared with the athletes using the ANOVA test.

**Progress:** Forty-five subjects have been enrolled to date but attempts are still being made to enroll more weight lifters. The study has shown significantly increased left ventricular (LV) dimensions in aerobic and anaerobic athletes, increased maximum wall thickness in anaerobic athletes, and conflicting results on LV mass and mass index.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/103	<b>Status:</b> On-going
------------------------	-----------------------------	-------------------------

**Title:** A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of RheothRx Injection (Polaxamer 188) in Patients with Suspected Acute Myocardial Infarction

<b>Start Date:</b> 05/07/93	<b>Est. Completion Date:</b> May 94
-----------------------------	-------------------------------------

<b>Department:</b> Medicine/Cardiology	<b>Facility:</b> MAMC
--	-----------------------

**Principal Investigator:** COL Joseph A. Paris, MC

<b>Associate Investigators:</b> COL Roger F. Chamusco, MC MAJ Doreen Saltiel, MC MAJ James C. Mullin, MC MAJ Mark E. Peele, MC CPT Scott A. Sample, MC	LTC John M. Bauman, MC MAJ Alice M. Mascette, MC MAJ Karl C. Stajduhar, MC MAJ Patrick A. Cambier, MC CPT Michael A. Rave, MC
---	---

**Key Words:** myocardial infarction, RheothRx

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** (1) To evaluate the effect of RheothRx Injection, if any, on resultant myocardial infarct size, compared to placebo, when given to patients with suspected AMI who are not treated acutely with thrombolytic therapy or direct percutaneous transluminal coronary angioplasty (PTCA). (2) To assess the safety of RheothRx Injection in this patient population.

**Technical Approach:** This is a multicenter, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of RheothRx Injection in patients with suspected acute myocardial infarction who are not eligible to receive thrombolytic therapy or acute, direct PTCA. Such patients presenting with ongoing symptoms suspicious of AMI of at least 30 minutes in duration but within 6 hours since onset will be considered for enrollment in the study. Two hundred and fifty (250) patients will be enrolled at approximately ten to fifteen centers. Eligible patients will receive a 48 hour intravenous infusion of either RheothRx injection or placebo. All patients will receive aspirin throughout the hospitalization. Randomization to RheothRx injection or placebo will be stratified by the initial type of EKG abnormality (ST elevation or ST depression/ T wave inversion/ bundle branch block/ non-specific intraventricular conduction delay present at the time of enrollment and by the enrolling center. The safety of RheothRx will be evaluated using periodic laboratory tests, assessments of vital signs, physical examination, collection of adverse experiences, bleeding complications, and disease-related events. Efficacy will be assessed by measures of myocardial infarct size, left ventricular ejection fraction, and clinical outcome. Infarct size will be measured on days 5 - 10 by single photon emission computer tomography using technetium 99m sestamibi. Ejection fraction will be measured on days 5 - 10 by radionuclide ventriculography. Clinical outcome will be assessed by monitoring the occurrence of prospectively specified clinical events during the six-month period following randomization. Two composite scores of efficacy will be computed from the recorded events.

**Progress:** Thirteen patients have been enrolled in this randomized trial. Efforts to recruit study participants are ongoing.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/027		<b>Status:</b> On-going	
<b>Title:</b> Comparison of Intravenous Adenosine With Exercise in Thallium-201 SPECT in Patients With Left Bundle Branch Block					
<b>Start Date:</b> 12/04/92			<b>Est. Completion Date:</b> Jun 94		
<b>Department:</b> Medicine/Cardiology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Michael A. Rave, MC					
<b>Associate Investigators:</b>			MAJ Doreen Saltiel, MC		
COL Roger F. Chamusco, MC			MAJ Stephen E. Budd, MC		
LTC John M. Bauman, MC					
<b>Key Words:</b> left bundle branch block:adenosine and exercise					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$3000.00	/ /	

**Study Objective:** To determine if the diagnostic value of adenosine in conjunction with thallium-201 SPECT imaging is improved over standard thallium exercise testing in patients with left bundle branch block.

**Technical Approach:** Patients referred for ischemic heart disease will receive pharmacologic stress with adenosine at 0.14 mg/kg and an exercise thallium-201 SPECT imaging (using a symptom limited Bruce exercise protocol) approximately one week apart. A cardiac catheterization will be performed within four weeks of the scans. All thallium SPECT images will be evaluated by two experienced observers blinded to the clinical history and angiography results. The radio nuclide studies will not be matched for the same patient until all studies have been read. The cineangiograms will be reviewed by a single reviewer blinded to the results of the thallium imaging. At the end of enrollment the results of the imaging studies and cardiac cath lab evaluations will be paired up and analyzed.

**Progress:** Five patients have completed all three phases of the study to include exercise thallium, adenosine thallium, and cardiac catheterization. Thallium data is to this date still blinded. We feel that we have captured all patients meeting criteria and have at least offered them participation in the study; none have declined enrollment. Recruitment for the remaining participants is active.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
ENDOCRINOLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/020		<b>Status:</b> Completed	
<b>Title:</b> Evaluation of the Efficacy and Safety of Glimepiride versus Glyburide in Subjects with Noninsulin-Dependent Diabetes Mellitus (NIDDM)					
<b>Start Date:</b> 01/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL David L. Bunner, MC					
<b>Associate Investigators:</b> LTC H. Lester Reed, MC CPT Robert M. Tuttle, MC			LTC (P) Robert E. Jones, MS LTC Daniel H. Knodel, MC CPT Carl A. Gibson, MC		
<b>Key Words:</b> diabetes,noninsulin-dependent,glimepiride,glyburide					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** To evaluate the efficacy of Glimepiride and Glyburide as oral hypoglycemic agents over the dosing ranges tested in the treatment of subjects with non-insulin dependent diabetes mellitus and to compare the safety of Glimepiride and Glyburide in these subjects.

**Technical Approach:** This is a multicenter, double-blind, randomized, parallel design study. Patients will be entered in a four week washout period, utilizing placebo tablets. At the end of the four-week washout period, subjects will be stratified into two groups according to the fasting plasma glucose on Day 12: Group 1: low fasting plasma glucose = 160-240 mg/dl, and Group 2: high fasting plasma glucose = 240-300 mg/dl. Patients will then be randomized to receive either Glimepiride or Glyburide for a 12 week titration period and then for a 40 week maintenance period. Patients will have an eye examination and an electrocardiogram prior to randomization. The eye exam will be repeated at months 6 and 12 and the EKG will be repeated at month 12. Efficacy will be evaluated using fasting plasma glucose (each visit), and glycosolated hemoglobin (weeks 0 and 16 and months 6, 10, and 12) as the primary variables. Fasting insulin and C-peptide as well as two hour postprandial glucose, insulin, and C-peptide (week 0 and months 6 and 12) will be evaluated as secondary variables. Baseline demographic and background variables will be summarized by treatment group to assess the comparability of each group at the beginning of the randomization phase. Means and categories will be compared for between group homogeneity using either analysis of variance or Mantel-Haenszel tests. Safety data, including laboratory assessments and adverse events, will be tabulated and displayed for clinical review. Important changes from baseline in laboratory values will be summarized and adverse events will be tabulated according to body system.

**Progress:** Fourteen patients were entered. Two were dropped from the protocol for strictly technical reasons. Twelve completed the protocol. Data has been forwarded to the sponsor.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/101		<b>Status:</b> On-going
<b>Title:</b> Androgen Effects on Glucose Metabolism in Men				
<b>Start Date:</b> 05/07/93		<b>Est. Completion Date:</b> May 94		
<b>Department:</b> Medicine/Endocrinology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Barrett L. Chapin, MC				
<b>Associate Investigators:</b> COL Stephen R. Plymate, MC		LTC (P) Robert E. Jones, MS		
<b>Key Words:</b> metabolism, androgen				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** 1. To demonstrate that androgen administration to young men will result in enhancement of glucose metabolism via non-insulin mediated glucose uptake (NIMGU). 2. To demonstrate that the administration of androgen in this study will not result in adverse effects on the prostate, serum lipids, or blood pressure.

**Technical Approach:** Androgen will be administered to 20 healthy, young men. A companion study of 20 healthy, elderly men will be conducted at American Lake Veterans Hospital. The androgen will be administered to subjects as testosterone enanthate (TE), an androgen that can be aromatized to an estrogen, and testosterone deconate (TD), an androgen that is not aromatized to a potent estrogen, at 100 mg I.M. q week for 12 weeks in a cross-over design with a 10 week washout period. Ten subjects will receive the TD first and ten subjects will receive the TE first.

The major clinical tool used to study glucose and insulin metabolism will be the frequently sampled intravenous glucose tolerance test (FSIVGTT). In addition to the FSIVGTT, IGF-I, IGF-BPs, GH, lipids, strength, body composition, prostate studies (including PSA), digital examination, and ultrasound for residual urine volume and prostate size in each of the four time periods in which FSIVGTT is performed will be done (at baseline, during the first 12 week androgen treatment period, during the washout period, and during the second androgen treatment period).

Data will be expressed as the mean  $\pm$  standard error (SE). Tests will be done to determine whether the order in which the treatments are given affected the outcome (sequence effect) or whether the response seen in the first treatment period differed from that seen during the second treatment period (period effect). Data for which no sequence or period effect can be detected will be analyzed to establish (1) if the effect of androgen therapy on any measured variable differs depending upon whether TE or TD was used (a between-treatment analysis), and (2) if a given variable changed over time due to androgen therapy (within-treatment analysis). If no sequence or period effects are noted, the study will be analyzed as a crossover design. Paired data will be analyzed using a Student's t-test. An unpaired t-test will be used to test differences between groups.

**Progress:** No patients have been entered because the nurse instrumental in data collection was reassigned. With the arrival of a new nurse to assist with data collection the study will be restarted.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/102		<b>Status:</b> On-going	
<b>Title:</b> Evaluation of Calcium Metabolism After Biliopancreatic Bypass Surgery					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> Oct 93		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Barrett L. Chapin, MC					
<b>Associate Investigators:</b> LTC Daniel H. Knodel, MC MAJ John D. Ng, MC			LTC Homer J. Lemar Jr., MC COL Preston L. Carter, MC		
<b>Key Words:</b> metabolism,calcium,biliopancreatic bypass					
<b>Accumulative</b> <b>MEDCASE Cost:</b>		<b>Est. Accumulative</b> <b>OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To determine if there are changes in calcium metabolism after biliopancreatic bypass surgery, and if so, to characterize the biochemical profile of those changes.

**Technical Approach:** Patients who have had biliopancreatic bypass surgery within the previous three years will be invited to participate in this study. The control will be an equal number of patients who have had a different surgical procedure for obesity called vertical banded gastroplasty. These populations will be matched for age, sex, and amount of weight loss. It is assumed that the surgery of vertical banded gastroplasty does not cause calcium abnormalities. If the control group population has significant abnormalities in the biochemical evaluation of calcium metabolism, the protocol will be revised to add an additional control group. That group would consist of an equal number of age and sex matched people without any evidence of disease or obesity.

Evaluation of serum and urine markers of metabolic bone disease will be performed in each group. Tests performed to evaluate calcium metabolism will be serum calcium, albumin, alkaline phosphatase (a marker for bone turnover), magnesium, phosphorus, parathyroid hormone, 25-hydroxy vitamin D, 1.25-dihydroxy vitamin D, and a 24 hour urine collection for calcium and hydroxyproline (a marker for bone turnover). Evaluation of other fat soluble vitamins will be performed by checking prothrombin time (vitamin K) and serum carotene (vitamin A). Confirmation of normal liver function will be obtained with serum gamma glutamic aminotransferase. Confirmation of normal renal function will be obtained with serum creatinine and 24 hour urine creatinine.

If the serum carotene level is below normal, the patient will be referred to the Ophthalmology Service for formal testing for night blindness.

Statistical analysis between the study and control group will be performed with an unpaired T test or by ANOVA if a second control group is added.

**Progress:** Six study subjects and 5 controls have been entered.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/069		<b>Status:</b> On-going
<b>Title:</b> Phospholipid Composition of Human Epididymal and Ejaculated Spermatozoa				
<b>Start Date:</b> 06/05/92		<b>Est. Completion Date:</b> Jun 94		
<b>Department:</b> Medicine/Endocrinology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Robert E. Jones, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> spermatozoa,phospholipid,epididymus				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** (1) To determine the quantitative changes in sperm plasma membrane phospholipids and phospholipid-bound fatty acids as they traverse the epididymis and (2) to compare these results to the values obtained from ejaculated sperm.

**Technical Approach:** Thirty fertile volunteers undergoing elective vasectomy will be asked to provide two semen samples prior to surgery. During the surgical procedure, sperm will be obtained by milking the proximal end of the vas deferens and epididymis. The samples will be washed in a calcium free buffer, and the phospholipids will be extracted using chloroform and methanol. The extracted phospholipids will be kept under a nitrogen atmosphere at -70 degrees centigrade until they are assayed. Pooling of samples may be necessary to ensure adequate detection of minor phospholipids and fatty acids. The position and bonding of fatty acids will be determined through a combination of enzymatic and chemical hydrolysis. Quantification of fatty acids will be performed using gas chromatography, and either high performance liquid chromatography or quantitative thin layer chromatography to identify phospholipids. Results will be expressed by normalizing values to sperm number, to phospholipid phosphorous, or as a percentage of total sperm lipids of a similar class. The data will be handled using descriptive statistics, and the statistical analysis will employ an unpaired t test or an ANOVA when appropriate.

**Progress:** No further work was performed on this project during this fiscal year.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/023		<b>Status:</b> On-going	
<b>Title:</b> Investigations into the Mechanisms of Phospholipid Synthesis in Human Spermatozoa					
<b>Start Date:</b> 11/21/86			<b>Est. Completion Date:</b> Dec 87		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Robert E. Jones, MC					
<b>Associate Investigators:</b> CPT Kevin J. Carlin, MC			MAJ Charles J. Hannan, MC COL Stephen R. Plymate, MC		
<b>Key Words:</b> spermatozoa,phospholipid synthesis					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$1600.00		10/21/88	

**Study Objective:** To determine if sperm can replenish phospholipids after they have been partially hydrolyzed to the lyso-forms by the action of phospholipases A2 or A1 and to attempt to identify and characterize sperm acyl transferase.

**Technical Approach:** Acyl transferase, acyl CoA:1-acyl-sn-glycero-3-phosphocholine O-acyl transferase will be screened by coincubating human sperm with labeled fatty acids, CoASH, ATP, Mg<sup>2+</sup>, and Tris. The reaction will be terminated by delipidating the sperm with CHCl<sub>3</sub>: MeOH, and the organic phase will be chromatographed on silica gel TLC plates. These plates will be developed and spots will be scraped and counted. If the labeled fatty acid is found to be contained within a phospholipid region, cofunctioning of ligase and acyl transferase will be assumed to occur. Studies to characterize acyl transferase activity will be performed using an assay based on the liberation of CoASH which reacts with DTNB, resulting in a change in absorption at 414 nm. Either palmitoyl or docosahexaenoyl CoA will be used as the acyl donor to lyso-phosphatidyl choline. The conversion of lyso-phosphatidyl choline to phosphatidyl choline will be chromatographed. This assay will be optimized for pH, ionic strength, substrate levels and amount of enzyme before kinetic constants are determined. For carnitine-dependent transacylation, D, L-palmitoyl carnitine and lyso-phosphatidyl choline will be coincubated with washed sperm, delipidated and the products chromatographed as above. If the amount of lyso-phosphatidyl choline declines while phosphatidyl choline increases, a carnitine dependent mechanism will be presumed to exist. Alternatively, carnitine dependency could be screened by using 3H-palmitoyl carnitine to look for labeled phosphatidyl choline formation. The effect of 22:6 on 16:0 incorporation into phospholipids will be assessed by incubating unlabeled 22:6 with 3H-16:0 and following the appearance of 16:0 in phosphatidyl choline. Conversely, the effect of 16:0 on 14C-22:6 will be studied.

**Progress:** The complex regulatory kinetics of long chain fatty acid:CoASH ligase (AMP) have been lucidated and the manuscript has been published.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/038		<b>Status:</b> On-going	
<b>Title:</b> Detailed Studies Into Membrane Lipid Synthesis in Human Sperm					
<b>Start Date:</b> 02/16/90			<b>Est. Completion Date:</b> Feb 99		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Robert E. Jones, MC					
<b>Associate Investigators:</b> CPT Brenda K. Bell, MC			COL Stephen R. Plymate, MC		
<b>Key Words:</b> lipid synthesis,human sperm					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$3494.00
					<b>Periodic Review:</b> 04/05/91

**Study Objective:** To elucidate the biochemical pathways for membrane lipid synthesis (excluding cholesterol) present in freshly ejaculated human spermatozoa from donors of proven fertility.

**Technical Approach:** Sperm will be washed and the sample diluted to achieve a concentration of  $2 \times 10^8$  sperm/ml. The incubation buffer, optimized for fatty acid activation, will consist of 380 mM TRIS [pH 8.4], 20 mM ATP, 20 mM  $MgCl_2$ , 0.1 mM coenzyme A (CoASH), 5 mM dithiothreitol, and 10-50 mM fatty acid, either 3H-9,10-16:0, 14C-1-16:0, or 14C-1-22:6. The reaction will be initiated by the addition of 107 sperm. Blank incubations will be performed in the absence of CoASH or the specific starting substrate to investigate the metabolic mechanisms of lipid turnover. Methylation of phosphatidylethanolamine (PE) will be measured by incubating 3H-methyl-S-adenosylmethionine (SAM) with diacyl PE or a 14C labeled fatty acid, 3H-SAM and 1-acyl-2-lyso PE. Another pathway for plasmalogen or ether lipid synthesis in nongerminal tissues will be assessed by incubating sperm with 14C-22:6, 1-palmitoyl-3-lyso PI (phosphatidylinositol) or -PC (phosphatidylcholine) and 3H-1-hexadecanol in the aforementioned buffer. Alternatively, 3H-hexadecanol, 14C-22:6, unlabeled 16:0 will be coincubated with dihydroxyacetone phosphate (DHAP). The reaction will be terminated after 1 hour and lipids will be extracted and dried. Incorporation of labeled fatty acids into sphingomyelin (SM) will be determined by detection of the fatty acyl radiolabel in the SM region of the thin layer chromatography (TLC) plates. After resolubilization in chloroform and methanol, lipids will be separated on LK5 TLC plates. Standards will be run on each plate and spots corresponding to standards will be scraped and counted. Plasmalogen formation will be assessed by performing mild acid hydrolysis on the extracted phospholipids prior to TLC or before rechromatography and determining DPM's in the fatty aldehyde and lysophospholipid regions. The presence of ether lipids will be determined by their resistance to alkaline and enzymatic hydrolysis prior to TLC. Mono and diacyl phospholipid synthesis will be assessed by free fatty acid release from SM and by using phospholipases A2 (PLA2) and B (PLB).

**Progress:** Preliminary kinetic data on acyl transferase have been obtained suggesting that the enzyme has an acidic pH optimum, a  $K_m$  of 7-12  $\mu M$  and a  $V_{max}$  of 0.16  $\mu moles/10^7$  sperm/hour.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 83/081		<b>Status:</b> On-going	
<b>Title:</b> Studies on Fatty Acid Activation in Spermatozoa: Kinetics and Localization					
<b>Start Date:</b> 09/16/83			<b>Est. Completion Date:</b> Sep 84		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Robert E. Jones, MC					
<b>Associate Investigators:</b> COL Bruce L. Fariss, MC			COL Stephen R. Plymate, MC		
<b>Key Words:</b> spermatozoa,fatty acid					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
			\$785.00		04/05/91

**Study Objective:** To define the kinetic characteristics and cellular localization of the enzyme system responsible for the initiation of saturated fatty acid metabolism in spermatozoa.

**Technical Approach:** Normal human semen samples will be used to establish a ligase assay. Ligase activity will be measured using a sensitive radioligand/millipore filter procedure that utilizes (3H)-coenzyme A as the radioactive trace. Approximately 0.2 m C of (3H) will be present in each individual assay. The samples will be centrifuged at 2800g for 10 minutes at room temperature, the seminal plasma supernatant will be discarded, and the sperm pellet will be resuspended in an isotonic buffer. This sperm mixture will be recentrifuged and washed twice prior to use. After the final centrifugation, the pellet will be diluted in a potassium enriched buffer to achieve a sperm density of  $2 \times 10^8/\text{ml}$ . The assay mixture will contain palmitic acid, ATP,  $\text{Mg}^{++}$  and CoASH and will be initiated by the addition of the washed sperm preparation. Time and protein dependency curves will be run to determine the length of incubation needed to achieve first order kinetics in the measurement of initial velocities. Both Lineweaver-Burk plots and hyperbolic best-fit will be used to calculate approximate  $K_m$  values for each substrate. Temperature, pH curves, and rates with alternate substrates will also be run. Enzyme location/latency will be determined by assaying separate cell fractions prepared by sonication and differential centrifugation of the isolated sperm. The effects of sulphydryl reagents, albumin, and detergents will be studied to assist in estimation of latency.

**Progress:** There has been no further progress on this project during this fiscal year.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 88/026	<b>Status:</b> On-going
<b>Title:</b> Neutral and Polar Lipid Synthesis in Human Spermatozoa: A Correlation with Morphology and Function		
<b>Start Date:</b> 01/15/88	<b>Est. Completion Date:</b> Jun 89	
<b>Department:</b> Medicine/Endocrinology	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> COL Robert E. Jones, MC		
<b>Associate Investigators:</b> MAJ Karl E. Friedl, MC		COL Stephen R. Plymate, MC MAJ Charles J. Hannan, MC
<b>Key Words:</b> spermatozoa, lipids, morphology		
<b>Accumulative MEDCASE Cost:</b> \$40,000	<b>Est. Accumulative OMA Cost:</b> \$2000.00	<b>Periodic Review:</b> 04/05/91

Study Objective: To compare the rates of fatty acid activation to acyl CoA and subsequent disposal into neutral or polar lipids with sperm morphology or an assessment of sperm motility.

Technical Approach: The incorporation of palmitic (16:0) and docosahexaenoic acids (22:6) into neutral or phospholipids will be measured by incubating whole, fresh sperm with 3H-16:0 and 14C-22:6. Total lipids will be extracted using the method of Bligh and Dyer. The chloroform phase will be taken to dryness under N<sub>2</sub> at 42C C and subsequently reconstituted in a minimal volume of chloroform. The chloroform mixture will be applied to a silicic acid column and subsequently eluted with 20 ml chloroform followed by 20 ml of methanol. The chloroform fractions containing neutral lipids will be combined, evaporated, and repeatedly extracted to remove the free fatty acids. Both the methanol and chloroform elutes will be counted, and an aliquot of each will be chromatographed on silica gel G to ensure complete separation. Incorporation rates will be expressed as nmoles fatty acid incorporated/106 sperm or nmoles phospholipid P/hour. After extracting the sperm with 0.1% Triton X100, ligase activity will be measured. Both 16:0 and 22:6 will be used as substrates in the incubations. Ligase activity will be expressed as nmoles acyl CoA formed/min/mg protein. The seminal plasma concentrations of these compounds will be measured using an enzymatic spectrophotometric technique. These parameters will be considered separately in relationship to ligase activity and lipid synthesis. Semen samples will be handled and analyzed according to the current WHO guidelines. Morphology will be assessed on fixed smears, and motility will be objectively quantified with an automated semen analyzer. With the exception of the sperm density, the semen quality will be blinded to the person performing the biochemical analyses. Incorporation rates and the distribution of the fatty acid labels and ligase activity will be correlated with sperm morphology and motility of the semen sample using either linear regression or chi-square analyses.

Progress: No further progress has occurred on this study.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/070		<b>Status:</b> Completed	
<b>Title:</b> Characterization of Serovar-Specific Ureaplasma Antigens by Analysis with Monoclonal Antibodies					
<b>Start Date:</b> 08/19/88			<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> COL Robert E. Jones, MC					
<b>Associate Investigators:</b>			MAJ John E. van Hamont, MS		
<b>Key Words:</b> antigens,ureaplasma,monoclonal antibodies,Animal Study					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$3700.00		06/07/93	

**Study Objective:** To identify and define antigenic determinants specifically associated with the 14 serovars of Ureaplasma urealyticum.

**Technical Approach:** Mice will be immunized with ureaplasma serovar antigens by either intrasplenic injection of aqueous antigen or subcutaneous injection of antigen with adjuvant followed by an IV booster of aqueous antigen. The spleen cells from the immunized mice will then be fused with P.653 myeloma cells. The cell culture supernatants from the resulting hybridoma clones will then be screened for antibody reactive with homologous ureaplasma antigens as well as with growth medium components. The investigator will then characterize reactive monoclonals for serovar and subgroup specificity via the growth inhibition assay, metabolic inhibition assay, mycoplasmacidal assay, and direct fluorescent assay. The monoclonals identified as having type specificity will be used in the analysis of colloidal gold labeling procedures for localization of type-specific antigen by electron microscopy and for affinity column chromatography purification of type specific antigen from ureaplasma cell lysates. The monoclonals and antigens thus characterized will be used in the development of assays for future identification of clinical isolates of Ureaplasma and analysis of host serological responses.

**Progress:** No further work has been undertaken on this protocol in FY 93. Results suggest that, in a susceptible host, colonization with Ureaplasma urealyticum could induce antisperm antibodies capable of inhibiting spermatozoal mobility.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/068		<b>Status:</b> On-going
<b>Title:</b> The Time Course for Metabolic Responses to Thyroid Hormone: Specific Contributions of Muscle Efficiency and Resting Oxygen Utilization				
<b>Start Date:</b> 06/05/92		<b>Est. Completion Date:</b> Jan 94		
<b>Department:</b> Medicine/Endocrinology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Homer J. Lemar Jr., MC				
<b>Associate Investigators:</b>		COL David L. Bunner, MC		
LTC (P) Robert E. Jones, MS		CPT Carl A. Gibson, MC		
LTC H. Lester Reed, MC				
<b>Key Words:</b> thyroid hormone,muscle efficiency,oxyten utilization				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	//

**Study Objective:** To determine the relationship between serum thyrotropin (TSH) concentrations and the efficiency of skeletal muscle during a changing thyroid status; to identify if these measures of pituitary and peripheral thyroid hormone action covary with the same time constant in transition from hyperthyroidism to euthyroidism; and to assess the specific contribution of a changing muscle work efficiency to the increased oxygen utilization associated with excess states of thyroid hormone.

**Technical Approach:** Oxygen utilization will be measured with four submaximal bicycle ergometer workloads in 15 hyperthyroid patients undergoing treatment and 15 euthyroid control subjects. These workloads will support a linear regression analysis to determine muscle efficiency and resting oxygen use. This measure will be carried out before and biweekly during treatment for hyperthyroidism in order to determine the time course of tissue responses during normalization of serum thyroid hormones. Specifically, serum thyrotropin (TSH) will be simultaneously measured and the time course of normalizing sensitive assays of serum TSH and exercise kinetics will be contrasted as two tissue responses to this changing thyroid hormone status. Euthyroid controls will establish normal ranges and the test variability, while allowing comparisons between themselves and the hyperthyroid and hypothyroid subjects. The study population will include hyperthyroid patients who have elected radioactive iodine therapy for their disease and a control group of normal euthyroid patients who are taking a stable and fixed replacement dose of thyroid hormone.

**Progress:** Enrollment has been completed and only one subject remains active in the protocol. Preliminary data analysis reveals a clear correlation of thyroid function with oxygen consumption at submaximal levels of exercise. Thyroxine levels more closely parallel changes in oxygen consumption than do TSH levels which lag behind. Bicycle ergometry at submaximal stress is able to show changes in oxygen utilization associated with changing thyroid function.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/097		<b>Status:</b> Completed	
<b>Title:</b> The Use of Thyroid Tissue Obtained by Fine Needle Aspiration (FNA) as Substrate for Polymerase Chain Reaction (PCR) Amplification of Thyroglobulin and the Papillary Thyroid Cancer (PTC) Oncogene					
<b>Start Date:</b> 10/04/91			<b>Est. Completion Date:</b> Apr 92		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Peele, MC					
<b>Associate Investigators:</b>			CPT Robert M. Tuttle, MC		
<b>Key Words:</b> cancer:thyroid,PCR,thyroglobulin,FNA,PTC oncogene					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$1250.00	/ /	

**Study Objective:** 1. To show that thyroid tissue obtained by routing fine needle aspiration (FNA) can be used for the polymerase chain reaction (PCR) amplification of thyroidal genomic DNA and messenger RNA transcripts. 2. Utilize PCR to amplify DNA sequences unique to the RET and PTC (papillary thyroid cancer) oncogenes. The presence of PTC in FNA samples of thyroid nodules may represent a marker for papillary thyroid cancer. 3. Utilize reverse PCR to amplify specific thyroidal messenger RNA transcripts of the RET and PTC oncogenes. Reverse PCR amplification of thyroglobulin messenger RNA transcripts will serve as an internal control. 4. Develop a protocol for routine PCR amplification of FNA samples allowing timely study of oncogenes present in thyroid nodules with the ultimate goal of developing prognostic tests for primary thyroid neoplasms.

**Technical Approach:** Twenty patients undergoing fine needle aspiration of the thyroid for clinically indicated evaluation of thyroid nodules or masses will be offered participation in this study. Four to six aspirations will be performed as per the clinic routine. The aspiration needle will be rinsed into a centrifuge tube containing RPMI cell culture media. The adequacy of aspirated material present on slides prepared in the clinic for cytologic interpretation will be determined according to accepted guidelines. The purpose of the FNA is to provide adequate material for the cytologic evaluation. Clinical material present in excess of this standard will be considered for use in this protocol. Excess aspiration material will be collected by needle rinses into 1000 ul of either RPMI cell culture media or phosphate buffered saline (PBS). Cells will be rapidly pelleted by centrifugation after the rinse to remove excess plasma proteins. The cell pellet will be resuspended in 25 ul DEPC treated water and rapidly chilled to -70 deg C. This material will then be stored until laboratory study begins. PCR will be used to amplify thyroidal genomic and mRNA. The material collected from the FNA will be heated to 65 deg C in the presence of RNasin and hypotonic DEPC treated water to linearize the nucleic acids. The mRNA and DNA will serve as the templates for the PCR amplification. Three sets of PCR primers and oligomers will be synthesized. All the primer sets have an engineered span containing a restriction enzyme site (HINDIII) on the 5' portion to allow insertion of the amplified material into a sequencing vector. Thyroglobulin will be amplified as the positive control, the oncogenes PTC1 and RET will be amplified from aliquots of the same material. The first step in the amplification of the mRNA will be the synthesis of first strand complementary DNA. The cDNA and linearized DNA will be amplified as per standard PCR protocols for 35 cycles. The amplified products are separated on an agar gel and blotted onto a nylon membrane, the

blot will be probed with the specifically engineered oligonucleotide probes to determine the molecular identity of the amplified PCR products. Amplified fragments of interest will be cloned into an expression vector and sequenced using Taq polymerase and conventional dideoxynucleotide chain elongation termination.

Progress: FNA of thyroid cancer provides adequate material for successful amplification of normally expressed genes (Tg) and activated oncogenes (PTC).

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/081		<b>Status:</b> On-going	
<b>Title:</b> The Effect of Thyroid Hormone Suppression on Thyroid Nodules Found to be Indeterminate by Fine Needle Aspiration					
<b>Start Date:</b> 08/02/91			<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Robert M. Tuttle, MC					
<b>Associate Investigators:</b>			COL Robert E. Jones, MC		
MAJ John P. Kushner, MC			COL Ernest L. Mazzaferri, MC		
MAJ Arnold A. Asp, MC			MAJ James H. Timmons, MC		
<b>Key Words:</b> thyroid nodules,thyroid hormone suppression,needle aspiration					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To differentiate benign from malignant thyroid nodules in a subgroup of patients with indeterminate fine-needle thyroid biopsy cytology using thyroid hormone suppression by serially determining the volume of thyroid nodules using ultrasonography and by serially following thyroglobulin measurements during thyroid hormone suppression and to establish ultrasonographic criteria to define adequate thyroid hormone suppression.

**Technical Approach:** This is a multicenter study originating at MAMC in which 150 patients will be enrolled. Patients being evaluated for a solitary thyroid nodule or a dominant nodule in a multinodular thyroid who are found to have indeterminate cytology on a fine needle aspiration will be offered enrollment. The baseline evaluation will include thyroid function tests, thyroglobulin, and a thyroid ultrasound. The volume of the nodule will be determined using a digitizer pad and Sigma Scan software. The patient will be placed on a suppressive dose of L-thyroxine (as defined by an undetectable ultra sensitive TSH) and followed at 3 month intervals using repeat ultrasound examinations. The duration of the study is 6 months. At the end of the study, all patients will have their nodules removed unless, at the end of study, the nodule is <0.5 cm or has decreased to less than 75% of the original volume. The degree of suppression in nodule volume, if any, will be correlated with the final pathology of the nodule.

**Progress:** No status report was submitted by suspense date.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/127	<b>Status:</b> On-going
<b>Title:</b> Oncogene Activation in Neoplastic Thyroid Tissue Occurring After Exposure To A Nuclear Blast: The Marshall Island Experience		
<b>Start Date:</b> 06/09/93	<b>Est. Completion Date:</b> Jun 94	
<b>Department:</b> Medicine/Endocrinology	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> CPT Robert M. Tuttle, MC		
<b>Associate Investigators:</b>		
Sissy S. Jhiang, Ph.D.	COL Ernest L. Mazzaferri, MC	
CPT Rodger K. Martin, MS	MAJ Robert B. Ellis, MC	
Michael Bourneman, MC	MAJ Richard R. Gomez, MC	
Jean Howard, M.D.	Larry Sakas, MC	
	Goerge Begus, M.D.	
<b>Key Words:</b> thyroid,nuclear blast,ongogene activation		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$3174.00	/ /

**Study Objective:** 1. To determine the frequency of activation of the Papillary Thyroid Cancer (PCT/retTPC) oncogene in neoplastic thyroid tissue that developed after exposure to a nuclear blast. 2. To determine the frequency of K-ras point mutations in neoplastic thyroid tissue that developed after exposure to a nuclear blast. 3. To correlate the clinical course of these radiation induced thyroid cancers with the activation of each oncogene.

**Technical Approach:** Approximately 30 samples of paraffin embedded thyroidectomy samples from individuals with a documented presence in the Marshall Islands in 1954 and with a diagnosis of papillary thyroid cancer, follicular thyroid cancer, or other non-malignant neoplasia and any normal thyroid tissue available will be used to recover DNA and mRNA using techniques that have proven successful in our laboratory. These samples will be compared with samples from (1) Marshall Islanders not exposed to fallout that developed thyroid neoplasia (2) non-radiation induced thyroid neoplasia collected at Ohio State University (OSU) and Madigan Army Medical Center (MAMC). The paraffin blocks will be sectioned on a microtome using sterile technique and a new microtome blade for each block. A new histology slide will be prepared and reviewed to verify that thyroid tissue is present in the block and to re-confirm the diagnosis. The paraffin sections will be placed into a sterile 1.5 ml sterile microcentrifuge tube and sealed. A sample from each paraffin block will be blindly evaluated by both the laboratory at OSU and MAMC. The DNA and messenger RNA extracted from the paraffin embedded tissue will be examined to determine quality and quantity of extracts. Optical densities (OD 260/280) and agarose mini-gel electrophoresis will be done on sample extracts. Beta-2 microglobulin and the TSH receptor will be amplified with PCR to document integrity of the nucleic acids recovered. Samples in which the constitutively expressed messenger RNA's can be amplified with PCR will be used for oncogene amplification. The mRNA extract will serve as substrate for cDNA synthesis using the specific PTC downstream primer. The cDNA will then serve as substrate for PCR. After PCR, the mixture of amplified products generated from a specific primer set will be separated by size using standard agarose gel electrophoresis. Appropriate size markers will be used to provide size parameters of amplified products. Additional characterization of the PCR amplified product includes Southern hybridization studies with specific DNA oligomer probes. The oligonucleotide probes will be 3 prime tailing



with digoxigenin dUTP or 5 prime labelled with  $^{32}\text{P}$ . Chemilluminescent detection will be done using the Genius/Lumiphos detection method. This method has been used successfully in our lab to detect picomolar amounts of target DNA.

Statistically, the rates of activation of each oncogene in each subgroup will be compared using chi square testing. Unpaired t test and Fischer's exact test will be used to determine if oncogene activation is more frequent in metastatic disease versus non-metastatic disease and to compare baseline measurements between groups. Logistic regression analysis of those clinical variables shown to be significant by chi square will be used to determine which single or combination of variables correlate with oncogene activation. Finally, to determine whether the activation of the oncogene is a significant prognostic factor, univariate and multivariate Cox regression will be used defining failure as first recurrence or never disease free and assuming the oncogene activation was present at diagnosis.

Progress: No status report was submitted by suspense date.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/080		<b>Status:</b> On-going	
<b>Title:</b> A Prospective Evaluation of Gonadal Damage in Thyroid Cancer Patients Treated with Radioactive Iodine					
<b>Start Date:</b> 09/06/91			<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Robert M. Tuttle, MC					
<b>Associate Investigators:</b>					
COL Stephen R. Plymate, MC			COL Ernest L. Mazzaferri, MC		
COL Robert E. Jones, MC			David Gardner, MD		
MAJ Arnold A. Asp, MC			Christina Wang, MD		
William Bremner, MD, Ph.D.			MAJ Charles J. Hannan, MC		
<b>Key Words:</b> cancer:thyroid,gonads,radioactive iodine					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To determine whether radioactive iodine therapy given as treatment for thyroid cancer is associated with gonadal dysfunction in men by examining the effect of radiation exposure on serial semen analysis, serum follicle stimulating hormone (FSH) levels, serum inhibin levels, FSH response to gonadotropin releasing hormone (GnRH), and inhibin response to clomiphene stimulation.

**Technical Approach:** All euthyroid men undergoing thyroid surgery at the six participating institutions will be screened for entry into this protocol. This group will include at least 20 men with known thyroid cancer in whom RAI therapy may or may not be planned as was men undergoing non-cancer related thyroid surgeries. Those patients determined to be candidates for RAI ablation post-operatively by their primary physicians will constitute the study group. Those men who do not receive RAI post-operatively will constitute the control group. Both the control group and the study group will follow identical protocols. Initial entry labs will be drawn before surgery. Subsequent labs (testosterone, TSH, LH, semen samples, etc.) will be obtained just before RAI is administered and at 2, 4, 6, and 8 months after RAI administration. The control group will have identical samples obtained at 1, 3, 5, 7, and 9 months after surgery. Since 4-6 weeks is required post-operatively for the TSH to rise high enough to allow administration of RAI, this sample schedule will allow both groups to be sampled at the same time. In addition, GnRH and clomiphene stimulation will be done at months 5 and 9 after surgery in both groups. Semen analysis will be started with an estimation of motility using the World Health Organization graded scale of 1 - 4+. A portion of the sample will be frozen and a slide prepared for final interpretation at MAMC-DCI. This final interpretation will evaluate the specimen for sperm count and morphology. In this way all sperm counts can be done by a single investigator, minimizing or eliminating inter-observer variation. Repeated-measures ANOVA will be performed on the lab values taken over time to determine differences in control vs study groups.

**Progress:** No status report was submitted by suspense date.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/033		<b>Status:</b> Completed	
<b>Title:</b> Papillary Thyroid Cancer Oncogene: Prevalence, Specificity, and Clinical Significance					
<b>Start Date:</b> 02/05/93			<b>Est. Completion Date:</b> Dec 92		
<b>Department:</b> Medicine/Endocrinology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Robert M. Tuttle, MC					
<b>Associate Investigators:</b> CPT Rodger K. Martin, MS D. Caruso			CPT Katherine H. Moore, MS MAJ Richard R. Gomez, MC COL Ernest L. Mazzaferri, MC		
<b>Key Words:</b> oncogene:papillary thyroid					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$2234.00
					<b>Periodic Review:</b> / /

**Study Objective:** 1. To develop a technique that allows polymerase chain reaction amplification of thyroid genosmic DNA and messenger RNA sequences from paraffin embedded thyroid tissue. 2. To retrospectively examine all paraffin embedded thyroid cancer tissues available at Madigan Army Medical Center for the presence of the newly described papillary thyroid cancer oncogene (PTC) and its messenger RNA. 3. To correlate the clinical course of these thyroid cancers with the presence or absence of the PTC oncogene by retrospective chart review of files in the tumor registry. 4. To examine other abnormal but non-malignant thyroid tissue for the presence of the PTC oncogene. 5. To prospectively obtain fresh samples of all thyroid tissue surgically removed at MAMC for subsequent molecular analysis. 6. To design a rapid diagnostic test for the presence of the PTC gene.

**Technical Approach:** Recently a new oncogene (PTC) has been characterized that appears to be specific for papillary thyroid cancer. Furthermore, the presence of the PTC transforming gene may identify patients who are more likely to have aggressive thyroid malignancies. Studies of the prevalence and clinical significance of PTC have been hindered by the lack of fresh papillary thyroid cancer tissue and the need for long term follow-up. Both of these obstacles can be overcome at MAMC. The pathology archives at MAMC hold approximately 60 paraffin embedded thyroid cancer blocks as well as hundreds of non-malignant thyroid tissue blocks. The messenger RNA from these blocks will be recovered and subsequently amplified using standard PCR technology. Furthermore, the clinical case histories corresponding to these tissue blocks have been tracked on a yearly basis by the tumor registry. Ten year follow-up on many of these patients is available. By correlating the presence of the PTC transforming gene with numerous clinical characteristics, the role of PTC as a prognostic factor can be defined.

Determining the presence of the PTC transforming gene is too cumbersome and time consuming to be performed in a clinical laboratory. Therefore, a screening test for the PTC transforming gene needs to be developed that is more rapid and easier to perform.

In addition to examining paraffin embedded tissue, a library of freshly collected and frozen thyroid tissue will be assembled. A sample of all thyroids removed surgically at MAMC will be recovered and stored in the Department of Clinical Investigation. The tissue recovered would normally be discarded by the pathologist. In this way, a library of thyroid tissue of various pathologies can be assembled and used as an abundant source

of RNA and DNA for this and future studies.

Progress: This work demonstrates the mRNA recovered from routinely prepared, paraffin embedded neoplastic thyroid tissue can be amplified with RT-PCR and therefore be used to study mRNA expression in numerous paraffin blocks stored in pathology archives. Our data are consistent with the low rate of PTC activation reported by other groups and also suggest that activation of the PTC oncogene is more common in patients with metastatic papillary thyroid cancer than in those with localized disease. Because long term survival rates are poor in metastatic papillary thyroid cancer, activation of the PTC may be an important molecular marker for prognosis. Activation of the PTC oncogene is the first molecular abnormality reported in papillary thyroid cancer that is associated with a definite clinical outcome.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
GASTROENTEROLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/098		<b>Status:</b> Completed	
<b>Title:</b> Does Laparoscopy Add to the Diagnosis of Nonfocal Liver Disease?					
<b>Start Date:</b> 08/17/90			<b>Est. Completion Date:</b> Apr 92		
<b>Department:</b> Medicine/Gastroenterology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Michael F. Lyons II, MC					
<b>Associate Investigators:</b>			CPT Robert J. Lodato, MC		
MAJ Amy M. Tsuchida, MC			MAJ Gregory E. Schlepp, MC		
<b>Key Words:</b> liver disease,laparoscopy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To determine the diagnostic utility of laparoscopy in the evaluation of nonfocal liver disease and to compare the diagnostic accuracy (in the evaluation of diffuse liver disease) of a pinch biopsy to that of a core biopsy, both via laparoscopy.

**Technical Approach:** Fifty adult patients with elevated liver enzymes for >3 months and no prior liver disease or biopsies will be studied. Before entry patients will have a standard laboratory workup, abdominal CT and/or ultrasound and liver spleen scan. A detailed history and family history will be obtained. Laboratory testing to include liver function tests, total protein and albumin, glucose, iron, ferritin, TIBC, SPEP, HBV, AMA, ANA, HIV serology, CBC PT/PTT, and serum bile acids will be obtained and recorded. Two or more non-invasive imaging studies (LSS, U/S, or CT) will be done. Immediately prior to laparoscopy, one or more of the associate investigators will assess the non-invasive work-up and form a prelaparoscopy diagnosis for four groups: cirrhosis, chronic hepatitis, normal, and fatty change. Laparoscopy with biopsies will be done, using standard technique. During the laparoscopy (before biopsy results are known), the associate investigators will make a diagnosis based on the non-invasive workup and laparoscopic findings. The two diagnoses pre and post-laparoscopy will then be compared with the histologic diagnosis. The core biopsy histologic diagnosis will be compared to the pinch biopsy result. Four fold tables for chi square analysis will be used to compare the sensitivity, specificity, and positive and negative predictive values of the pre and post-laparoscopic diagnoses. Chi square analysis will be used to compare the accuracy of the pinch biopsy to that of the core biopsy.

**Progress:** Fifty subjects were entered which completed data collection. A paper was presented to American College of Gastroenterology, 56th Annual Scientific Meeting.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/051		<b>Status:</b> Terminated	
<b>Title:</b> A Long-Term Screening Project for the Prevention of Adenocarcinoma of the Esophagus in Patients with Barrett's Esophagus, Intestinal Metaplasia of the Stomach and Partial Gastrectomy for Peptic .....					
<b>Start Date:</b> 05/03/91			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Medicine/Gastroenterology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Michael F. Lyons II, MC					
<b>Associate Investigators:</b>			MAJ Amy M. Tsuchida, MC		
MAJ Gregory E. Schlepp, MC			COL Michael J. Carlon, MC		
MAJ Mark D. Brissette, MC					
<b>Key Words:</b> cancer:esophagus,Barrett's,stomach					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	07/02/92	

**Study Objective:** To prospectively follow patients with Barrett's Esophagus, intestinal metaplasia of the stomach, and post partial gastrectomy in an attempt to identify precancerous or early cancerous changes in tissues utilizing histology, flow cytometry, immunochemistry, and cytogenetics.

**Technical Approach:** Approximately 200 subjects with a diagnosis of Barrett's esophagus, gastric intestinal metaplasia by prior upper endoscopic biopsy or by history of partial gastrectomy for 10 or more years will be studied. After visualizing the esophagus, stomach, and duodenum, biopsies will be obtained from these areas as dictated by the subject's diagnosis. One half of the biopsy specimen will be processed for histology, classified according to the type of mucosa present, and designated negative, indefinite, or positive for dysplasia. Specimens forwarded for flow cytometry will be processed in the routine fashion. Data will be gathered and analyzed by an on-line computer. Cell cycle parameters will be analyzed using a first order polynomial S phase. By this nonlinear least squares curve-fitting technique, the G1/G0 (2N) and G2/M peaks (4N) are fit using normal distributions and the region between these two peaks is allotted to cells in DNA synthesis (S phase). Aneuploid peaks will be fit by inclusion of additional Gaussian peaks in the least squares analysis. If patients are identified as having indefinite or definite dysplasia or if they have increased S or G2/M flow cytometry fractions (S>7%, G2>6%) they will be contacted to undergo repeat endoscopy at three to six month intervals for closer surveillance. Otherwise, patients will undergo annual evaluation as outlined above. At the time of endoscopy, subjects will have serum drawn for analysis of mucin core protein and p53 antigen antibody production by immunochemical methods. Patient histology, immunochemistry, cytogenetics, and flow cytometry data will be followed over time. These data will be compared to determine if there is a correlation using Student's unpaired t-test to predict dysplasia or malignancy.

**Progress:** The study was never implemented because of lack of funding for flow cytometry.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/004		<b>Status:</b> Terminated
<b>Title:</b> A Multicenter, Randomized, Double-Blind, Placebo Controlled, Evaluation of Healing & Relapse Rate Following Oral GR122311X Compared With GR885202X, Ranitidine & Placebo in Patients With Duodenal Ulcer				
<b>Start Date:</b> 10/02/92		<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Medicine/Gastroenterology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Michael F. Lyons II, MC				
<b>Associate Investigators:</b> MAJ Gregory E. Schlepp, MC		MAJ Amy M. Tsuchida, MC MAJ William A. Pearce, MC		
<b>Key Words:</b> duodenal ulcer,ranitidine bismuth citrate				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> / /

**Study Objective:** To compare overall success rates of GR122311X 400 mg bid, GR88502X 240 mg bid, Ranitidine 150 mg bid, and placebo.

**Technical Approach:** Patients must be 18 to 80 years of age, have one endoscopically diagnosed duodenal ulcer measuring at least 0.5 cm but less than or equal to 2.0 cm in the largest diameter, and be an ambulatory outpatient.

The study will be conducted in two parts. Part 1 will be a four or eight week treatment phase, with assessments at baseline, Week 2, Week 4 and if required Week 8. Part 2 will be a 24 week post-treatment observation phase with assessments at 4, 8, 12, and 24 weeks after treatment ends.

Part 1 All patients will receive 4 weeks of treatment. At week four, patients will have an endoscopic examination. Unhealed patients will continue in the study for an additional four weeks of treatment and then return to the clinic for a Week 8 evaluation including endoscopy. Patients unhealed after 8 weeks of treatment will be withdrawn from the study.

Part 2 Patients with healed ulcers at Week 4 or Week 8 will enter the post-treatment phase. Patients will not be administered any study drug during this period but return for endoscopic examination and safety visits at 4, 8, 12 and 24 weeks after the end of treatment.

All patients will receive Maalox antacid tablets for pain relief, as needed, during Part 1 of the study and for persistent pain during Part 2.

**Progress:** The study was closed by the sponsor before HSC approval was obtained.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/005		<b>Status:</b> Terminated
<b>Title:</b> A Multicenter, Randomized, Double Blind, Placebo Controlled Evaluation of Healing & Relapse Rates Following Oral GR122311X Compared With GR88502X, Ranitidine & Placebo in Patients with Benign...				
<b>Start Date:</b> 10/02/92		<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Medicine/Gastroenterology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Amy M. Tsuchida, MC				
<b>Associate Investigators:</b> MAJ Gregory E. Schlepp, MC		MAJ Michael F. Lyons II, MC MAJ William A. Pearce, MC		
<b>Key Words:</b> gastric ulcer,ranitidine,bismuth,citrate				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> / /

**Study Objective:** To evaluate healing and relapse rates in patients with benign gastric ulcers following eight weeks treatment with either GR122311X 400 mg bid, GR88502X 240 mg bid, Ranitidine 150 mg bid, or placebo.

**Technical Approach:** This is a randomized, double-blind, placebo-controlled, parallel group study. Patients included will be 18 to 80 years of age with one gastric ulcer of at least 0.5 cm but less than or equal to 2.0 cm in the longest diameter.

The study will be conducted in two parts. Part 1 will be an eight week treatment phase with assessment at baseline, Week 4 and Week 8. During the treatment phase the patients will be randomized to receive one of the study medications, returning for evaluation and endoscopy at Week 4 and Week 8. Patients unhealed after 8 weeks of treatment will be withdrawn from the study.

Part 2 will be a 24 week post-treatment observation phase with assessments at 4, 8, 12, and 24 weeks after treatment ends. Patients developing an ulcer will be discharged from the study at the time of the corresponding endoscopy.

All patients will receive Maalox antacid tablets for pain relief, as needed, during Part 1 of the study and for relief of persistent pain during Part 2.

**Progress:** The sponsor closed the study to patient entry before HSC approval was obtained.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
HEMATOLOGY/ONCOLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/100	<b>Status:</b> On-going
<b>Title:</b> A Long Term Safety Evaluation of Kapanol and MS Contin in Patients With Moderate to Severe Cancer Pain		
<b>Start Date:</b> 05/07/93		<b>Est. Completion Date:</b> Jun 94
<b>Department:</b> Medicine/Hematology & Oncology		<b>Facility:</b> MAMC
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC		
<b>Associate Investigators:</b>		LTC Howard Davidson, MC
MAJ Timothy P. Rearden, MC		MAJ Mark E. Robson, MC
CPT Jennifer L. Cadiz, MC		CPT James S. D. Hu, MC
LTC Robert D. Vallion, MC		MAJ Richard C. Tenglin, MC
MAJ Patrick L. Gomez, MC		MAJ Luke M. Stapleton, MC
MAJ Robert B. Ellis, MC		CPT Diana S. Willadsen, MC
<b>Key Words:</b> cancer:pain relief,Kapanol,MS Contin		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** The purpose of this open-label extension study is to compare the long-term safety and efficacy of Kapanol (sustained-release morphine sulfate) capsules to MS Contin (controlled release morphine sulfate) tablets in patients with moderate to severe cancer pain. The primary parameters will be a comparison of morphine-related side effects, laboratory values, adverse events, and pain control.

**Technical Approach:** Ambulatory inpatients or outpatients with moderate to severe chronic pain due to disseminated or locally invasive cancer who were randomized into study CDD-14556 entitled "A Randomized, Double-Blind, Parallel Groups Study Comparing the Efficacy and Safety of Kapanol to MS Contin in the Management of Patients with Moderate to Severe Cancer Pain" are suitable for entry into this trial.

The final visit procedure results for CDD-14556 will be used for the initial visit for this extension trial. After providing written informed consent, each patient will be randomized to one of the following three treatment groups for initial treatment in this trial: A. Kapanol capsules - once every 12 hours (investigators may consolidate the total daily dose into one dose taken every 24 hours at their discretion if clinically appropriate); B. Kapanol capsules - once every 24 hours (investigators may divide this total daily dose into two q12h doses if clinically appropriate); C. MS Contin tablets - once every 12 hours

The dose of morphine selected at the initial visit will be based on the total daily dose of morphine (scheduled dose plus rescue) required during CDD-14556. Dose adjustments will be allowed during the trial. IRMS oral tablets will be available as rescue medication during this trial as needed without protocol restriction for all study patients.

Blood and urine specimens for laboratory analysis will be collected at intervals throughout the trial to insure patient safety.

The patient and the investigator will provide assessments of the patient's pain control at the time of each clinic visit.

**Progress:** The study has just started. There have been no significant findings.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/099		<b>Status:</b> On-going	
<b>Title:</b> A Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy and Safety of Kapanol to MS Contin in the Management of Patients With Moderate to Severe Cancer Pain					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> Dec 93		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>					
MAJ Timothy P. Rearden, MC			LTC Howard Davidson, MC		
CPT Jennifer L. Cadiz, MC			MAJ Mark E. Robson, MC		
LTC Robert D. Vallion, MC			CPT James S. D. Hu, MC		
MAJ Patrick L. Gomez, MC			MAJ Richard C. Tenglin, MC		
MAJ Robert B. Ellis, MC			MAJ Luke M. Stapleton, MC		
			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> Cancer:pain relief,severe,Kapanol,MS Contin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** The objectives of this trial are to compare the safety and efficacy of Kapanol sustained-release morphine sulfate capsules given every 12 hours and every 24 hours, to those of MS Contin controlled-release morphine sulfate tablets given every 12 hours in patients with moderate to severe cancer pain requiring treatment with opoid analgesics.

**Technical Approach:** Ambulatory inpatients or outpatients with moderate to severe chronic pain due to disseminated or locally invasive cancer who require narcotic analgesics for pain management will be invited to participate in this trial. After providing informed consent, each patient will be titrated to a stable dose of commercially available immediate-release morphine sulfate (IRMS) oral solution during the 3 to 14 day Lead-In Period. After reaching a stable total daily dose of morphine, each patient will be randomized to one of the following four groups as follows: A. Kapanol capsules - once every 24 hours; B. Kapanol capsules - once every 12 hours; C. MS Contin tablets - once every 12 hours; D. placebo to match active treatments.

Doses of the active treatments will be based on the total daily dose of IRMS after stabilization during the Lead-In Period. IRMS oral tablets will be available as rescue medication during the Treatment Period, as needed.

After seven days ( $\pm$  one day) of treatment, each patient will provide pain assessments in a diary card immediately before the morning dose, every two hours for 12 hours, and at 24 hours after the morning dose.

**Progress:** Enrollment has just begun. There have been no significant findings.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/009		<b>Status:</b> On-going	
<b>Title:</b> Fluconazole Versus Amphotericin B as Empiric Therapy in Febrile, Neutropenic Patients. University of Washington					
<b>Start Date:</b> 12/06/91			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>					
MAJ Paul C. Sowray, MC			LTC Howard Davidson, MC		
MAJ Patrick L. Gomez, MC			MAJ Luke M. Stapleton, MC		
MAJ Robert B. Ellis, MC			MAJ Robert L. Sheffler, MC		
CPT Jennifer L. Cadiz, MC			MAJ Richard C. Tenglin, MC		
			CPT James S. D. Hu, MC		
<b>Key Words:</b> neutropenia, fluconazole, amphotericin B					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$1836.00		/ /	

**Study Objective:** To compare the efficacy of fluconazole versus amphotericin B as empiric antifungal therapy in neutropenic patients with continued fever following initiation of empiric antibacterial therapy and to compare the toxicity profile of fluconazole and amphotericin B in these patients.

**Technical Approach:** Patients (n=48) with no documented bacterial source of infection who fail to defervesce after 72 hours of antibacterial antibiotic will be randomized into three groups. Group 1 patients with normal renal function will receive intravenous fluconazole, 800 mg day 1, followed by 400 mg IV daily. Group 2 patients with normal renal function will receive oral fluconazole, 800 mg day 1, followed by 400 mg daily. Group 3 patients with normal renal function will receive IV amphotericin B, 0.25 mg/kg Day 1, followed by 0.6 mg/kg/day. Appropriate premedication (e.g., hydrocortisone, meperidine, diphenhydramine, acetaminophen) will be administered as needed. Dosage will be adjusted appropriately (by extent of disease) for renal impairment. Patients who defervesce following initiation of antifungal therapy and in whom no infection is documented will continue therapy until bone marrow recovery occurs. Patients who remain febrile following initiation of antifungal therapy will be monitored closely with repeat cultures, chest radiographs, and other studies as indicated. If no infection is documented, patients will continue receiving antifungal therapy until afebrile and the ANC is above 500/mm<sup>3</sup> for two consecutive days. If a fungal infection is documented, patients receiving an antifungal drug to which the organism is sensitive will continue receiving that drug. If the organism is not sensitive to the study drug assigned to the patient, the study will be terminated and an appropriate antifungal agent begun. In either case, therapy will be continued for a length of time consistent with medically accepted guidelines. Dichotomous variables will be analyzed using either the chi square test or Fisher's exact test. Continuous variables will be analyzed using either ANOVA or T test for comparison. The results from patient randomization will be analyzed to ensure no significant differences in patient populations due to the randomization process alone. Beta errors will also be calculated.

**Progress:** There has been no significant progress on this project due to slow enrollment.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/001		<b>Status:</b> On-going	
<b>Title:</b> The Role of Bone Marrow Micrometastases in Breast Cancer. A Two-Year Study funded by the U.S. Army Medical Research and Development Command					
<b>Start Date:</b> 10/02/92			<b>Est. Completion Date:</b> Dec 94		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>					
MAJ George F. Hodeges, MC			CPT Katherine H. Moore, MS		
LTC Howard Davidson, MC			MAJ Mark D. Brissette, MC		
MAJ Mark E. Robson, MC			MAJ Luke M. Stapleton, MC		
MAJ Robert B. Ellis, MC			MAJ Patrick L. Gomez, MC		
CPT Jennifer L. Cadiz, MC			MAJ Timothy P. Rearden, MC		
CPT Richard C. Tenglin, MC					
<b>Key Words:</b> cancer:breast					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To determine if hormonal or chemotherapy will eradicate bone marrow micrometastases (BMM) in women with breast cancer and to determine if failure to eradicate BMM with system therapy is a prognostic factor for decrease disease-free survival.

**Technical Approach:** Women who are: (1) between the ages of 18 and 70 years with newly diagnosed or recurrent breast cancer and (2) will be receiving hormonal or chemotherapy will be invited to participate in this study. Bone marrow samples will be aspirated from each posterior iliac crest. The samples will be diluted with phosphate buffered saline (PBS) and layered onto a Ficoll-Hypaque density gradient and centrifuged. The cells at the interface layer will be collected and washed with RPMI-1640 plus fetal calf serum. The cells will then be suspended in PBS and placed, by single drops, onto microscope slides and dried. One slide will be stained with Wright's stain for cytological examination. Ten to twelve slides from each patient will be fixed with 100% ethanol and used for immunofluorescence studies.

The anti-cytokeratin monoclonal antibody AE-1 will be titrated against the MCF-7 breast cell line and the optimal concentration used against the bone marrow samples to detect breast cancer cells.

Tumor staging, histology, and hormonal status will be obtained from pathology and surgical reports. Hospital and clinic records will be reviewed to obtain data on the patient's clinical course to include treatment, disease free survival (DFS) and overall survival (OS). The Chi-squared test will be used to evaluate the relationship between the presence of BMM and other known prognostic factors. Standard survival analyses will be used to evaluate the relationship between BMM, DFS and OS.

**Progress:** Six patients entered. The protocol has been modified to allow women who are going to surgery to have the bone marrow aspirate done while anesthetized for surgery.

### Detail Summary Sheet

**Date:** 30 Sep 92      **Protocol No.:** 93/130      **Status:** On-going

**Title:** Interaction of Breast Cancer and Bone Marrow Cells in Long-Term Culture:  
Effects on Cell Growth, Growth Factor, and Cytokine Production

**Start Date:** 07/02/93

**Est. Completion Date:** Mar 97

**Department:** Medicine/Hematology &  
Oncology

**Facility:** MAMC

**Principal Investigator:** MAJ Kenneth A. Bertram, MC

**Associate Investigators:**

MAJ Richard R. Gomez, MC  
LTC Howard Davidson, MC  
MAJ Robert B. Ellis, MC  
MAJ Richard C. Tenglin, MC  
LTC Robert D. Vallion, MC

MAJ Luke M. Stapleton, MC  
MAJ Mark D. Brissette, MC  
MAJ Patrick L. Gomez, MC  
CPT Jennifer L. Cadiz, MC  
CPT James S. D. Hu, MC  
CPT Diana S. Willadsen, MC

**Key Words:** cancer:breast,cell:bone marrow,cell:growth,cell:cytokine

**Accumulative**

**MEDCASE Cost:**

\$0.00

**Est. Accumulative**

**OMA Cost:**

\$0.00

**Periodic Review:**

/ /

**Study Objective:** To study the interaction between breast cancer cells and bone marrow cells in a novel long term bone marrow culture system and the effects on cell growth, growth factors and cytokine production.

**Technical Approach:** This collaborative effort, with the American Lake and Seattle Veterans Administration Hospitals, will study women between the ages of 18 and 78 years with newly diagnosed or recurrent breast cancer. These patients must have sufficient tumor material remaining after all necessary tissue is used for pathologic diagnostic tests to inoculate the Long Term Bone Marrow Culture system and conduct baseline oncogene studies. The overall goal of this project is to establish co-cultures of bone marrow and tumor cells in perfusion bioreactors, examine the cultures for production of tumor and hematopoietic cells, and to characterize the resulting biologic effects of the cellular elements, specifically, compared to bioreactors with only normal bone marrow cells: (1) are there changes in the normal expression of Her-2/neu, p53, and nm23; (2) are there changes in the production of PDGF, bFGF, and IGF; and (3) are there changes in the production of TGF-beta, TNF-alpha, and MIP-1a.

**Progress:** Awaiting funding before the study begins.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/103		<b>Status:</b> On-going
<b>Title:</b> Dolasetron Mesylate Protocol MCPR 0031: A Double Blind, Randomized, Parallel Study of the Antiemetic Effectiveness of IV Dolasetron Mesylate vs IV Zofran in Patients Receiving Cisplatin Chemotherapy				
<b>Start Date:</b> 09/04/92		<b>Est. Completion Date:</b> Oct 93		
<b>Department:</b> Medicine/Hematology & Oncology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC				
<b>Associate Investigators:</b> CPT Curtis S. Hansen, RPH, MSC		MAJ Kenneth A. Bertram, MC		
<b>Key Words:</b> cisplatin,dolasetron mesylate,zofran,antiemetics				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To compare the effectiveness of a 2.4 mg/kg single IV dose of dolasetron mesylate to a 32 mg single IV dose of ondansetron for complete prevention of emesis due to  $>70$  mg/m<sup>2</sup> of cisplatin chemotherapy and to compare the effectiveness of a 1.8 mg/kg single IV dose of dolasetron mesylate to a 32 mg single IV dose of ondansetron and to the 2.4 mg/kg single IV dose of dolasetron mesylate for complete prevention of emesis due to  $>70$  mg/m<sup>2</sup> of cisplatin chemotherapy.

**Technical Approach:** This is a double-blind, randomized, stratified, parallel, multicenter study in which patients with confirmed malignant disease will receive either 1.8 mg/kg or 2.4 mg/kg of dolasetron mesylate or 32 mg of ondansetron. Six hundred patients (20 at MAMC) will be prospectively stratified as to cisplatin dose, i.e., 300 patients receiving 70 to 90 mg/m<sup>2</sup> versus 300 patients receiving  $>90$  mg/m<sup>2</sup>. The activity and duration of drug action will be evaluated for 24 hours. If the patient experiences at least three emetic episodes during the 24 hour evaluation period after the start of chemotherapy or request alternative antiemetic therapy, the investigator will initiate escape medication according to institutional practice. Safety, tolerance, and patient satisfaction will also be monitored.

**Progress:** We are continuing to enroll patients into the study. Data collection continues and analysis will be completed by the sponsor.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/072		<b>Status:</b> On-going	
<b>Title:</b> Prognostic Significance of Oncogene Amplification and Expression in Human Breast Cancer					
<b>Start Date:</b> 06/05/92			<b>Est. Completion Date:</b> Jun 93		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert B. Ellis, MC					
<b>Associate Investigators:</b> CPT Robert M. Tuttle, MC			MAJ Richard R. Gomez, MC CPT Katherine H. Moore, MS		
<b>Key Words:</b> cancer,breast,oncogene amplification					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> / /

**Study Objective:** To clarify the role of oncogenes and their products in the process of malignant transformation as well as determining if an oncogenetic profile of a particular cancer will provide clinically useful prognostic information.

**Technical Approach:** Although the presence of oncogenes in breast cancer is well documented, the clinical significance of these findings is uncertain. Furthermore, the role of oncogenes in premalignant lesions has not been determined. Many investigators speculate that the presence of certain oncogenes and their products may predict not only clinical course but also the tumor's response to both hormonal and chemotherapeutic intervention. This study will examine the significance of the amplification and expression of the oncogenes Her-2/neu, int-2, nm23, and hst-1 by screening paraffin embedded breast tissues collected over the last ten years at Madigan. Normal breast tissue, benign breast lesions thought to have a high malignant potential, carcinoma in situ, and frank breast cancer will be examined. This information will be compared with the patient's medical record in an effort to associate oncogene presence or function with medical outcome. The presence of these oncogenes in the DNA, as well as the expression of the oncogene's mRNA will be determined. Immunohistochemistry will be used to prove for the presence of the specific oncogene proteins. This work will clarify the role of oncogenes in the process of malignant transformation and lead to a better understanding of whether the oncogene profile of a particular breast cancer can provide prognostic information useful in the clinical management of patients with breast cancer.

**Progress:** The preliminary work of isolating mRNA from paraffin embedded breast tissue to include standardization of procedures is complete. 36 breast cancer samples from males treated in DoD facilities have been collected. We have also acquired and loaded into the database the basic diagnostic and treatment/survival data from the male breast cancer cases seen in DoD facilities.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/070		<b>Status:</b> On-going	
<b>Title:</b> Comparison of TLC D-99 Doxorubicin Liposome Injection versus Doxorubicin Injection in Metastatic Breast Cancer					
<b>Start Date:</b> 06/05/92			<b>Est. Completion Date:</b> Aug 95		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert B. Ellis, MC					
<b>Associate Investigators:</b>			COL Joseph A. Paris, MC		
LTC Howard Davidson, MC			MAJ Paul C. Sowray, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert L. Sheffler, MC		
CPT Jennifer L. Cadiz, MC			MAJ Richard C. Tenglin, MC		
CPT James S. D. Hu, MC					
<b>Key Words:</b> cancer,breast,TLC D-99 doxorubicin liposome,doxorubicin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		\$0.00	<b>OMA Cost:</b>		\$0.00
				/ /	

**Study Objective:** To compare the cardiac safety of TLC D-99 (liposomal doxorubicin) with free doxorubicin using echocardiography, left ventricular ejection fraction measurements, and endomyocardial biopsies and to compare the efficacy of TLC D-99 with free doxorubicin HCL in the treatment of metastatic breast cancer.

**Technical Approach:** This will be a multicenter, randomized, parallel, open, comparative study in patients with metastatic breast cancer to compare the safety and efficacy of TLC D-99 and free doxorubicin HCL. Third party blinding will be implemented for evaluation of all radionuclide cardiac angiographies and cardiac biopsies. Growth Colony Stimulating Factor (G-CSF) therapy will be routinely given to both treatment groups in an effort to reduce the myelosuppression associated with doxorubicin administration. Therapy with either treatment will begin at 75 mg/m<sup>2</sup>. Dose escalation and reduction steps will be done based on patient tolerance of the drug. Separate randomization series will be used for patients with and without previous exposure to doxorubicin. Cardiac toxicity will be monitored by serial EKG's, echocardiograms, and resting and stress radionuclide cardiac angiography. To document pathologic changes seen with doxorubicin exposure, endomyocardial biopsies will be collected at a cumulative dose of 450 mg/m<sup>2</sup>. With any clinical or laboratory evidence of cardiac dysfunction or with progressive disease, treatment will be discontinued and the patient offered an alternate treatment program.

**Progress:** One patient was enrolled with complete remission to single agent adriamycin. The patient was taken off the agent due to cardiac toxicity judged by endomyocardial biopsy and symptoms.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/121		<b>Status:</b> On-going	
<b>Title:</b> Clinical Significance of Lymphoid Aggregates in Bone Marrow					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> Oct 93		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT James S. D. Hu, MC					
<b>Associate Investigators:</b> MAJ George F. Hodeges, MC			MAJ Luke M. Stapleton, MC M. D. Brisette		
<b>Key Words:</b> bone marrow, lymphoid aggregates					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To determine the clinical significance of lymphoid aggregates in bone marrow biopsy specimens.

**Technical Approach:** Approximately 1000 consecutive bone marrow biopsy specimens will be analyzed for the presence of lymphoid aggregates by a hematopathologist who will be blinded to the patient's diagnosis. The lymphoid aggregates will be described by size (in microns), density, morphology, cytology, and distribution. After the clinical diagnosis is matched to the corresponding bone marrow specimen, analysis will be done to determine those features that correlate with a clinically benign or malignant lymphoid aggregate. Logistic regression and tabulation of above variables will be performed.

**Progress:** Review of 388 consecutive bone marrow biopsy specimens. Lymphoid aggregates were identified in 64. Of these, 20 were characterized by size, morphology, density, pattern of abutment, and cytology. Analysis of 2 year data with statistical analysis using chi-square revealed significant correlations with density and abutment.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/031		<b>Status:</b> Completed	
<b>Title:</b> A Multicenter Clinical Study Using A Technetium-Labelled Monoclonal Antibody for Imaging Patients With Small Cell Lung Cancer					
<b>Start Date:</b> 12/04/92			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC			LTC John M. Bauman, MC		
MAJ Patrick L. Gomez, MC			LTC Howard Davidson, MC		
MAJ Robert B. Ellis, MC			MAJ Kenneth A. Bertram, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
COL Stanton R. Brown, MC			MAJ Stephen E. Budd, MC		
			LTC Terry R. Minton, MC		
<b>Key Words:</b> cancer:lung,monoclonal antibody					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> / /

**Study Objective:** To evaluate the normal biodistribution and tumor localization of 99m-Tc labelled NR-LU-10 monoclonal antibody prepared with a NeoRX "OncoTrac" kit obtained from a new manufacturer. The results will be compared with historical results from studies with similar kits from a previous manufacturer.

**Technical Approach:** In-patients with small cell lung cancer will undergo standard staging to determine extent of disease. In addition, they will undergo a single scan using 5.0 - 10.0 mg NR-LU-10 (FAB) labeled with 15 - 30 mCi 99mTc, diluted in 30 mL of normal saline and administered by intravenous injection. Images will be obtained with a gamma camera 14 - 17 hours after injection. The data will be acquired, processed, and stored on a dedicated computer. If the antibody images reveal an abnormality in an otherwise unsuspected area, further diagnostic studies to evaluate this will be performed. Biopsies will be performed when feasible for histologic and immunohistochemical analysis. No therapeutic decisions will be made on the results of the scan.

**Progress:** Three patients have completed the study. Data forwarded to the sponsor and FDA application is in progress.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/133		<b>Status:</b> Terminated	
<b>Title:</b> A Multicenter Clinical Study to Compare Imaging of Non-Small Cell Lung Cancer With A Technetium-Labelled Monoclonal Antibody Produced by Two Different Manufacturers					
<b>Start Date:</b> 07/02/93			<b>Est. Completion Date:</b> Aug 94		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC			LTC John M. Bauman, MC		
MAJ Patrick L. Gomez, MC			LTC Howard Davidson, MC		
MAJ Robert B. Ellis, MC			MAJ Kenneth A. Bertram, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
LTC Robert D. Vallion, MC			CPT James S. D. Hu, MC		
			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> monoclonal antibody,cancer:non-small cell lung					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To compare the normal biodistribution and tumor localization of 99m-TC labelled NR-LU-10 Fab monoclonal antibody prepared with a NeoRx "OncoTrac" kit produced by two different manufacturers.

**Technical Approach:** In-patients with non-small cell lung cancer will undergo standard staging to determine extent of disease. This staging will, at a minimum, consist of a CT scan of the chest, liver, and adrenals. In addition, patients will undergo two scans 3 - 7 days apart using the technetium-labelled monoclonal antibody NR-LU-10. The two scans will be performed with kits from two different manufacturers. Sites of disease as determined by the monoclonal antibody scans will be compared with each other and with those delineated by conventional staging techniques. No therapeutic decisions will be made on the basis of the investigational scan.

**Progress:** Study closed by sponsor prior to HSC approval.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/105		<b>Status:</b> On-going	
<b>Title:</b> A Pilot Study of Granulocyte Colony-Stimulating Factor (G-CSF, Filgrastim) in the Empiric Treatment of Febrile Neutropenia Due to Myelosuppressive Chemotherapy					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> May 94		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b> CPT Steven E. Brilliant, MC			CPT Diana S. Willadsen, MC CPT Curtis S. Hansen, RPH, MSC		
<b>Key Words:</b> neutropenia, GCSF, chemotherapy					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** 1. To determine the median duration of neutropenia after admission for neutropenic fever in patients at Madigan Army Medical Center. 2. To determine whether a policy of delaying G-CSF therapy for 72 hours after admission with neutropenia and fever leads to prohibitively greater morbidity than a strategy of immediate administration of G-CSF.

**Technical Approach:** Patients with a non-myeloid malignancy who have received myelosuppressive chemotherapy and are admitted to Madigan Army Medical Center with a diagnosis of febrile neutropenia will be entered onto the study at the time of admission. Every attempt will be made to enroll consecutive patients with this diagnosis. Patients who received prophylactic G-CSF during the cycle in which they are admitted will be excluded, as will patients who are neutropenic before they receive chemotherapy. The first 10 patients (group I) will be observed to determine the duration of the nadir (absolute neutrophil count under 1000/mm<sup>3</sup>) after admission. The second 10 patients (group II) will receive G-CSF at a dose of 300 mcg/day by subcutaneous bolus if they fail to defervesce after 72 hours of broad spectrum empiric antibiotic therapy. Dose escalation will be instituted after 5 days of G-CSF therapy if criteria for discontinuation are not met. The last cohort of 10 patients (group III) will receive G-CSF within 12 hours of admission at the same dose as group II. The dose escalation scheme will be the same as for group II. Differences in mean and median nadir durations between the three groups will be evaluated by use of ANOVA analysis. Outcome of infection and in-hospital mortality will also be evaluated.

**Progress:** Seven patients have been entered to date. Data has not been analyzed due to ongoing accrual.

# Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 90/082	<b>Status:</b> Terminated
<b>Title:</b> A Pilot Study of Carboplatin and Daily Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer		
<b>Start Date:</b> 06/15/90	<b>Est. Completion Date:</b> Jun 93	
<b>Department:</b> Medicine/Hematology & Oncology	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC		
<b>Associate Investigators:</b>		
MAJ Everardo E. Cobos Jr., MC	LTC Howard Davidson, MC	
MAJ Kenneth A. Bertram, MC	MAJ Patrick L. Gomez, MC	
	MAJ Robert L. Sheffler, MC	
<b>Key Words:</b> cancer:lung:non-small cell,carboplatin,etoposide		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$3000.00	/ /

**Study Objective:** To evaluate the effects of carboplatin and oral etoposide in non-small cell lung cancer with respect to response rate, toxicities, and survival.

**Technical Approach:** Thirty subjects with histologic evidence of non-small cell lung cancer and no prior chemotherapy will be studied. Patients with CNS metastases and simultaneous neoplasms at another site will be excluded. Patients will receive chemotherapy in 28 day cycles. Each cycle will start on day 1. Carboplatin IV will be given on days 1 and 8. The total dose for both days will be determined by the formula  $5 \times (\text{creatinine clearance [ml/min]} + 25)$ . Etoposide will be given 50 mg/m<sup>2</sup> po days 1-14. If cycle 1 nadir AGC is >1000/microL and nadir platelet count is >75,000/microL, the patient will receive etoposide, 50 mg/m<sup>2</sup> po days 1-21 for future cycles. Patients will be evaluated for response after two cycles. Those who have at least a 25% reduction in the product of the bidimensional measurement of the marker lesion will receive two more cycles of therapy and then stop all therapy. Those who do not have a 25% reduction in the cross-dimensional product will stop treatment. Those patients who have non-measurable disease will receive two more cycles if there has been no deterioration in the performance status otherwise, they will also stop therapy. Toxicities will be described as the frequency per patient on study and per cycle of treatment. Response rates will be described using standard criteria. Survival will be measured from study entry. Survival will be displayed graphically and described as duration of survival per quartile of patients.

**Progress:** No patients were entered in FY 93. Nine subjects have been previously entered. Protocol is terminated because PI has left the Army.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/007		<b>Status:</b> Terminated	
<b>Title:</b> Treatment of Thrombocytopenia, Hemolytic Anemia, or Neutropenia with Ascorbic Acid					
<b>Start Date:</b> 11/17/89			<b>Est. Completion Date:</b> Oct 91		
<b>Department:</b> Medicine/Hematology & Oncology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> ascorbic acid,thrombocytopenia,hemolytic anemia,neutropenia					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$585.00		/ /	

Study Objective: To determine if chronic thrombocytopenia, hemolytic anemia, or neutropenia can be improved by ascorbic acid therapy.

Technical Approach: Evaluation will be undertaken of patients who have had a severe cytopenia for at least 30 days and which is expected to continue for a prolonged period. Patients with thrombocytopenia will be evaluated in three categories: thrombocytopenia due to (1) sequestration, (2) production defect, and (3) peripheral destruction. Patients with hemolytic anemia will be evaluated in both immune mediated and non-immune mediated categories. Patients with neutropenia will also be evaluated in immune mediated or nonimmune mediated categories. Fourteen patients per disease category will be studied. Patients will receive ascorbic acid, 2 grams by mouth, daily. Therapy will be continued for as long as effective. It will be discontinued if there is no response after four months of therapy. Serum creatinine and CBCs will be obtained weekly once the clinical condition stabilizes. The clinician will see patients after each blood specimen is obtained to note response and to observe for side effects. Statistical considerations: Each patient will be assessed for the categorical response variable (no response, partial response, or complete response) and the observed event rates will be documented for each disease category with Kruskal-Wallis non-parametric one way analysis of variance to compare rates for different groups. Each patient will be assessed for the continuous response variable of WBC, hemoglobin, platelet count, and absolute lymphocyte count. Observed mean levels for each group will be compared at days 0 and 28 and at time of maximal response by one way analysis of variance. Patients found to be responsive will be evaluated in a non-blinded fashion for crossover to stopping treatment. The crossover treatment will be assessed by the clinical response of each patient. If the study is positive, it will be expanded to include a control group.

Progress: Only one patient has been entered, in FY 91. Protocol is terminated because PI has left the Army.



DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
INFECTIOUS DISEASE SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/021		<b>Status:</b> Terminated
<b>Title:</b> A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of the Use of Weekly Azithromycin as Prophylaxis Against the Development of Mycobacterium avium Complex Disease in HIV Infected...				
<b>Start Date:</b> 11/06/92		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Medicine/Infectious Disease		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Ronald H. Cooper, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> HIV, Mycobacterium avium Complex Disease				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To evaluate the safety and efficacy of azithromycin administered once a week in the prevention of disseminated mycobacterium avium complex (MAC) in severely immunocompromised HIV infected patients with a CD4 count <100/ $\mu$ l.

**Technical Approach:** This is a study of the efficacy of azithromycin as prophylaxis against disseminated MAC in HIV infected patients. Patients with confirmed HIV infection and CD4 counts <100/ $\mu$ l will be enrolled. Two blood cultures will confirm MAC bacteremia is not present and stool cultures will be used to document colonization status.

Patients will then be randomized to received either double-blind treatment with azithromycin 1200 mg or matched placebo as a single dose once a week for a minimum of eighteen months or until an end-point is reached (the occurrence of MAC bacteremia or recovery of MAC from normally sterile tissue). Patients who complete eighteen months of therapy will remain in the study until the last patient completes the study (a period expected to be up to 24 months). Patients will be evaluated every 4 weeks. Venous blood will be collected for hematology and biochemistry assessment and blood cultures. Stool cultures will be repeated every 3 months and CD4 counts will be determined every 6 months.

Efficacy will be determined by comparison of the numbers of patients who are removed from each treatment group during the study due to development of MAC bacteremia.

**Progress:** A decision was made not to procede with the study due to unresolved questions about the placebo arm and the fact that enrollment in this study might preclude patients from other studies that could potentially offer them greater benefit.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/099		<b>Status:</b> Completed	
<b>Title:</b> Azithromycin in the Treatment of Nongonococcal Urethritis: A Multicenter Double-Blind, Double-Dummy Study Employing Doxycycline as A Comparative Agent					
<b>Start Date:</b> 10/04/91			<b>Est. Completion Date:</b> Aug 93		
<b>Department:</b> Medicine/Infectious Disease			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Ronald H. Cooper, MC					
<b>Associate Investigators:</b>			LTC Rodney A. Michael, MC		
<b>Key Words:</b> nongonococcal urethritis,azithromycin,doxycycline					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

**Study Objective:** To compare the efficacy and safety of azithromycin and doxycycline as treatment for nongonococcal urethritis in males.

**Technical Approach:** This will be a randomized, double-blind, double-dummy, comparative study of azithromycin versus doxycycline. Participants in this study will be patients with acute NGU. All patients must have a Gram-stained urethral smear with five or more PMNL per field (at least three non-adjacent oil immersion fields [X 1000]). All patients will be cultured at baseline. Those with positive cultures for gonorrhea will be discontinued from the study. All others, with or without positive cultures, will be followed. Patients will be randomly assigned in a 2:1 fashion to therapy with a single 1 gm oral dose of azithromycin or oral doxycycline, 100 mg b.i.d. x seven days, respectively, each with placebos for the alternate drug. Evaluations will be performed at baseline and at one and four weeks following completion of treatment. Laboratory safety profiles will also be obtained at these times. The primary measures of treatment efficacy will be the clinical and bacterial outcomes. The distribution of bacterial response will be compared between treatments using the chi-square statistic. If this test leads to a statistically significant result, the percentage of bacterial eradication will be compared using the Fisher Exact test. The percentage of clinical cures will be compared between treatments using the Fisher Exact test.

**Progress:** Data analysis is currently underway by the sponsor, and it is anticipated that this study will be presented at a future scientific meeting and that a manuscript will be prepared for publication.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/158		<b>Status:</b> On-going
<b>Title:</b> Study of Pyelonephritis in Women				
<b>Start Date:</b> 08/06/93		<b>Est. Completion Date:</b> Aug 95		
<b>Department:</b> Medicine/Infectious Disease		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Ronald H. Cooper, MC				
<b>Associate Investigators:</b>		MAJ Joseph T. Morris III, MC		
<b>Key Words:</b> pyelonephritis,women,ofloxacin,trimethoprim-sulfamethoxazole				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

Study Objective: (1) To investigate the epidemiology of acute pyelonephritis in young women by administering a standardized questionnaire; (2) to investigate the pathogenesis of acute, uncomplicated pyelonephritis in young women by determining secretor status and comparing it to a control population; (3) to evaluate a new therapeutic regimen in the treatment of acute uncomplicated pyelonephritis in young women.

Technical Approach: Fifty female patients between the ages of 18-45 with symptoms of UTI for 7 days or less (flank pain, pyuria, >1000 CFU/ml uropathogen) will be randomized to receive trimethoprim-sulfamethoxazole DS for 14 days or ofloxacin 400 mg QD for 10 days. Follow-up will be on day 3, at termination of treatment, and at 14 and 28 after treatment. At each follow-up visit, the patient will be administered a follow up UTI questionnaire and asked to submit a clean catch urine specimen for analysis and culture.

A subset of 10 secretors and 10 non-secretors will be asked to undergo pelvic examinations at days 14 and 28 after treatment for the purpose of collecting vaginal cells for in vitro studies of cellular receptors. In these same groups, buccal cells will also be collected for the same purpose.

Demographics, treatment effectiveness, and incidence of secretor status will be compared using chi-square. Where required to do small sample size, the Fisher Exact Test will be substituted for the chi-square test.

Progress: The drug has been obtained and enrollment will begin soon.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
INTERNAL MEDICINE SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/057		<b>Status:</b> On-going
<b>Title:</b> Swan Ganz Catheteers' Sepsis: Prospective Randomized Study of Replacement of Swan Ganz Catheters				
<b>Start Date:</b> 03/05/93		<b>Est. Completion Date:</b> Jan 94		
<b>Department:</b> Medicine/Internal Medicine <b>Facility:</b> MAMC				
<b>Principal Investigator:</b> CPT Kurt W. A. Grathwohl, MC				
<b>Associate Investigators:</b> CPT Bernard J. Roth, MC		CPT James W. Thompson, MC LTC Anthony S. Sado, MC		
<b>Key Words:</b> Swan Ganz catheters:replacement				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To determine the incidence of infection in Swan Ganz catheter and central venous lines in patients who have lines replaced every three days, every seven days, and for the life of the catheter.

**Technical Approach:** This study will include all patients greater than eighteen years of age who require swan ganz or central venous catheterization for longer than seventy hours duration and hospitalization in the medical or surgical intensive care unit. This includes triple-lumen, single-lumen and/or pulmonary artery catheters. All sites of access will be included. Pregnant females will be excluded.

Patients will be randomized into one of three groups. Group 1 will have catheter percutaneous sites changed every 3 days to a new site (the current standard of care at MAMC). Group 2 will consist of patients who have the catheter sites changed every 7 days to a new site (The standard of care at some institutions). Group 3 will include patients who have the CVC left in place until it is no longer clinically needed.

Patients will have the CVC/swan ganz placed according to the current protocol for IV insertion. Using sterile technique to include sterile gloves the nursing personnel will change the initial dressings and subsequent dressings every 48 hours. If signs of infection or erythema are apparent the nurse will call the house officer who will evaluate the catheter for removal or necessity of skin culture per the diagnostic criteria. If the catheter is to be removed, the physician will culture the skin and a catheter segment.

The three groups of patients will be compared using the chi-square method. Subgroup analyses may be undertaken to assess different durations of catheter longevity, total parenteral nutrition, and underlying disease. Logistic regression will be used for risk factor infection analysis

**Progress:** Thirteen patients have been entered.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/035		<b>Status:</b> Completed
<b>Title:</b> Deletion From the MAMC Formulary of Nifedipine XL, Patient Effects and Side Effects				
<b>Start Date:</b> 11/06/92		<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Internal Medicine		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Duane J. Jeffers, MC				
<b>Associate Investigators:</b> MAJ Francis J. Landry, MC		MAJ David L. Jones, MC		
<b>Key Words:</b> nifedipine XL:pharmacy deletion				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** To access the effect of deleting Nifedipine XL on MAMC patients who were previously treated with that medication and to assess whether the manner in which Nifedipine XL was discontinued significantly affected patient acceptance of this change.

**Technical Approach:** Pharmacy data for a period of 3 months prior to the deletion of Nifedipine XL from the formulary at MAMC will be collected and from that group a subset will be selected to comprise an anticipated sample size of 200 patients. Numbered questionnaires will be mailed to those patients along with a detachable explanation sheet and a self addressed return envelope. Patients who do not respond to the initial questionnaire will be mailed another copy of that questionnaire and will be called (two attempts) to encourage response. Responses will be tabulated in spread sheet format.

**Progress:** Data collection and analysis have been completed. Of the agents monitored for two months after intervention the total numbers of prescriptions did not decrease, but total drug costs fell remarkably. Cost savings have been progressive with a 21% overall savings achieved (projected \$943,000 per year). Results were presented in abstract form at local and national conferences. A manuscript is in progress.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 89/062	<b>Status:</b> Terminated
<b>Title:</b> Determination of the Sensitivity and Specificity of Light Reflection Rheography for the Diagnosis of Deep Venous Thrombosis in the Lower Extremity		
<b>Start Date:</b> 06/16/89	<b>Est. Completion Date:</b> Jun 90	
<b>Department:</b> Medicine/Internal Medicine <b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Duane J. Jeffers, MC		
<b>Associate Investigators:</b> Nancy N. Greenfield, M.S. SGT Charles Adams		MAJ Dipankar Mukharjee, MC Michael Bertoglio, B.S. COL Charles A. Andersen, MC
<b>Key Words:</b> Light reflection rheography,venous thrombosis		
<b>Accumulative MEDCASE Cost:</b> \$6000.00	<b>Est. Accumulative OMA Cost:</b> \$760.00	<b>Periodic Review:</b> / /

Study Objective: To measure the sensitivity and specificity of Light Reflection Rheography (LRR) relative to duplex scanning in the diagnosis of deep venous thrombosis (DVT) in the lower extremity.

Technical Approach: Two hundred (200) adult subjects referred for evaluation of suspected lower extremity DVT will be studied. Before entry, standard evaluations will be performed to include history and physical examination. Non-invasive venous evaluation and venography will be excluded. Patients will be tested for DVT using the established method of duplex scanning. Duplex scans will be interpreted and recommendations for patient care will be made based only on established methods. All patients will then be tested for DVT using LRR. Testing and interpretation of LRR will be done independently with the results of the duplex scanning blinded to the interpreter. The sensitivity and specificity of LRR relative to duplex scanning will be calculated.

Progress: Protocol terminated due to malfunction of the LRR device. The manufacturer has gone out of business and replacement parts are no longer available.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/163	<b>Status:</b> On-going
<b>Title:</b> Utility of the Physical Examination to Assess Extracellular Volume Status		
<b>Start Date:</b> 09/03/93	<b>Est. Completion Date:</b> Jul 94	
<b>Department:</b> Medicine/Internal Medicine <b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Mary Jo K. Rohrer, MC		
<b>Associate Investigators:</b>		
MAJ Francis J. Landry, MC	MAJ Howard M. Cushner, MC	
CPT Paul A. Lester, MC	MAJ Agnes K. Ohno, MC	
CPT Jeffrey R. Spina, MC	CPT Eric J. Ormseth, MC	
	Undefined investigator	
<b>Key Words:</b> physical examine, volume status		

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$285.00	/ /

**Study Objective:** To determine the sensitivity, specificity, and predictive value of clinical assessment in determination of extracellular volume status.

**Technical Approach:** A prospective study of 100 medicine ward patients ages 18-80. Patients will have one or more of the following: hyponatremia, elevated BUN of > 20, or elevated serum creatinine (absolute > 1.5). Physical exam will be performed prior to subjective history or chart review and before fluid resuscitation. Chart review will allow ordering of any pertinent test not found. Fluid resuscitation with NS, 2 liters over 24 hours, will be initiation. Post infusion labs will be drawn within 12 hours of infusion. The same investigator will repeat the post-infusion physical exam.

Blinded review of lab data, collected pre- and post-infusion, by two boarded nephrologist will serve as "gold standard" of volume status (volume depleted or not volume depleted). Five of seven predefined criteria must be met to be deemed "volume depleted". Subjects not responding within the 12 hour post volume repletion will be reviewed at 24-72 hours for further correction.

Analysis consists of 2 x 2 contingency tables with independent variable (physical exam criteria) and dependent variable (volume status).

**Progress:** Four patients have been enrolled in the month since approval. No conclusion can be made at this time.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
NEUROLOGY SERVICE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/066		<b>Status:</b> On-going	
<b>Title:</b> A Prospective Study of Headache in Pregnancy					
<b>Start Date:</b> 05/01/92			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> Medicine/Neurology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT Renee M. Bernier, MC					
<b>Associate Investigators:</b>			CPT Linda A. Marden, MC		
<b>Key Words:</b> headache,pregnancy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To prospectively characterize incidence, type, and outcome of headaches during pregnancy by following women from early first trimester to delivery.

**Technical Approach:** At the first obstetrics visit, patients (aged 15-45) in the first trimester of pregnancy will fill out a questionnaire regarding previous history of headaches and other related disorders prior to pregnancy. The questionnaire will cover frequency, duration, location, severity, associated symptoms, and type of pain of their headaches and will also cover headache occurrence from time of conception to time of first obstetrics visit. Patients will fill out a short follow-up questionnaire once a month as well as at the six weeks post-delivery appointment. The data will be studied first to determine overall incidence of headache in the study population. Reports of headache will then be analyzed to determine the class of headache and the frequency of each type will be determined. Time of onset will be studied to establish if certain classes of headache are more likely to occur during a particular segment of pregnancy. Subjects with new onset of migraine during pregnancy will be studied separately to determine if this group differs in time of onset and character. Outcome of pregnancy will then be studied in the headache and non-headache groups. These groups will be compared using a chi-square analysis to establish if there is any statistically significant increased morbidity associated with headache. Final outcome will be expressed as either increased morbidity or no increased morbidity associated with headache. Subtypes of headaches will be looked at for evidence of increased risk of morbidity within a specific subtype and new onset migraine will be studied separately for evidence of increased risk.

**Progress:** Enrollment was completed in Nov. '92. Chart review of delivery records is currently being completed to determine if headache is associated with increased morbidity.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/080		<b>Status:</b> On-going
<b>Title:</b> A Randomized Double-Blind, Cross-Over, Placebo-Controlled Clinical Trial of D-alpha-Tocopheryl Acetate (Vitamin E) as Add-On Therapy for Epilepsy in Adults				
<b>Start Date:</b> 04/02/93		<b>Est. Completion Date:</b> Dec 94		
<b>Department:</b> Medicine/Neurology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC William L. Clayton III, MC				
<b>Associate Investigators:</b> CPT Curtis S. Hansen, RPH, MSC				
<b>Key Words:</b> D-alpha-tocopheryl acetate,vitamin E,epilepsy				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** To prospectively determine the effect of Vitamin E on seizure control in adults with frequent seizures.

**Technical Approach:** Volunteers of either sex who are over 18 years of age with a seizure disorder requiring treatment with antiepileptic drugs will be included in this study. Patients will be requested to keep a seizure calendar which will be reviewed monthly. After an observation period of 3 months, used to calculate seizure frequency, the pharmacy will issue either Vitamin E or placebo to be taken in addition to standard antiepileptic therapy. After 6 months the pharmacy will cross over the placebo/Vitamin E groups. At the end of 9 months the study will be discontinued. The patients will be informed of the results of the study at its completion. Any patient who benefitted from Vitamin E will have the option of continuing therapy.

Statistical analysis will be by paired T-test for total number of seizures during the treatment period.

**Progress:** This project is awaiting funding.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/050		<b>Status:</b> On-going	
<b>Title:</b> Effects of Valproic Acid on Semen Parameters in Male Epileptics					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> Medicine/Neurology			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC William L. Clayton III, MC					
<b>Associate Investigators:</b>			COL Lawrence A. Marden, MC		
LTC (P) Robert E. Jones, MS			CPT Katherine H. Moore, MS		
James R. Wright, M.T.			Louis A. Matej, B.S.		
<b>Key Words:</b> epilepsy,semen parameters,valproic acid					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To prospectively determine the incidence of abnormalities in the semen of epileptic men who are taking valproic acid for seizure prophylaxis and to assess the effects of incubating valproic acid with sperm from nonepileptic donors in vitro.

**Technical Approach:** Valproic acid, a frequently used antiepileptic, may be linked to a reduction in sperm numbers and sperm function. This possible association is based upon a few case reports and scattered animal studies. In this prospective study, 50 men will be asked to provide two to three ejaculates every three months for one year. These samples will be reviewed for morphology and sperm counts as well as analyzed by computer to assess a variety of motility parameters. Items of particular importance during the computerized evaluation will include morphometric observations as well as movement parameters such as the amplitude of lateral head displacement and swimming velocities. Fixed, stained slides for subjective interpretation of morphology will also be obtained. In addition, the effects of valproic acid on sperm motility and sperm long chain fatty acid:coenzyme A ligase [AMP] will be measured in vitro. The in vitro studies will be conducted using normal semen samples discarded from the clinical semen analysis lab. Sperm concentrations will be handled using a repeated measures ANOVA to determine statistical significance.

**Progress:** Only one subject has consented for sperm analysis. He showed a 30 % drop in motility. This suggests that we should continue the study.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/094		<b>Status:</b> Completed
<b>Title:</b> Effects of Carnitine on Measures of Cognition, Mood, and Sleep in Adolescents with Epilepsy Treated with Valproate				
<b>Start Date:</b> 09/04/92		<b>Est. Completion Date:</b> Dec 92		
<b>Department:</b> Medicine/Neurology		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Joseph P. McCarty, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> epilepsy,carnitine,adolescents				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** To evaluate the effects of L-Carnitine therapy on energy levels and general sense of well-being in adolescent patients who have been previously diagnosed with epilepsy and who are currently receiving valproate as a treatment and to correlate any changes in measures of energy and general well-being with physiologic changes attributable to carnitine.

**Technical Approach:** Adolescent patients with epilepsy who are currently receiving valproate for control of seizures and who are presently under good control will be eligible for this study. Studies have indicated that one of the metabolic side effects of valproate is lowering of plasma carnitine concentration with a possible negative impact on fatty acid metabolism and resultant decrease in mood and energy levels. Patients will have baseline measures of general sense of well-being and cognition. They will then take carnitine or a placebo for six weeks. At the end of the six week period, data will be collected regarding energy levels and general sense of well-being. The patients will then switch to the opposite experimental treatment for another six week period. At the end of the second six week period the same data will be collected regarding energy level and general sense of well-being. For statistical analysis of psychological measures, changes in mood states and in cognitive scores from period 1 to period 2 in Group A (carnitine) will be compared to Group B (placebo) within each antiepileptic drug condition (valproate monotherapy vs polytherapy). Paired T-tests (parametric) or Wilcoxon Rank Sum tests (non-parametric) will be used for analysis. If changes are seen in the blood chemistry without concomitant changes in behavioral measures, baseline psychological measures will be examined as possible moderating variables.

**Progress:** This was a cooperative study with Children's Hospital in Seattle. Six patients were enrolled at MAMC with no identifiable effects on mood or cognition noted.

DETAIL SHEETS FOR PROTOCOLS

DEPARTMENT OF MEDICINE,  
PULMONARY SERVICE

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 83/026		<b>Status:</b> On-going
<b>Title:</b> GOG 0026Q: A Phase II Trial of Aminothiadiazole in Patients with Advanced Pelvic Malignancies				
<b>Start Date:</b> 11/19/82		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:pelvic,aminothiadiazole				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

Study Objective: To determine the efficacy of aminothiadiazole in patients whose advanced malignancies have been resistant to high priority methods of treatment.

Technical Approach: All patients with measurable gynecological cancer who have failed higher prior therapies will be offered aminothiadiazole as a Phase II drug to determine its efficacy. The drug will be given as 125 mg/m<sup>2</sup> I.V. once a week. Patients will continue to receive the agent until progression or adverse effects prohibit further therapy.

Progress: No patients were entered in FY 93. One patient was entered in FY 85 and died of the disease.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 85/087		<b>Status:</b> On-going	
<b>Title:</b> GOG 0026U: A Phase II Trail of Ifosfamide (NSC #109724) and the Uroprotector Mesna (NSC #25232) in Patients with Advanced Pelvic Malignancies					
<b>Start Date:</b> 09/20/85			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:pelvic,ifosfamide,uroprotector mesna					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/03/95

Study Objective: To determine the efficacy of ifosfamide plus mesna in patients whose advanced malignancies have been resistant to higher priority methods of treatment.

Technical Approach: All eligible patients who have failed higher priority therapies will be offered ifosfamide plus mesna as a Phase II drug regimen to determine its efficacy. Ifosfamide will be given at a dosage of 1.8 g/m<sup>2</sup> daily for five days and mesna will be given 400 mg/m<sup>2</sup> t.i.d. every four weeks. Patients will be followed for toxicities to the drug and the drug dosage will be modified according to the severity of the toxicities. Response to the drug will be followed; progression of disease and/or excessive toxicities will terminate the study for the patient.

Progress: No patients were entered in this study at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 86/075		<b>Status:</b> Terminated
<b>Title:</b> GOG 0026W: A Phase II Trial of Echinomycin in Patients with Advanced Pelvic Malignancies				
<b>Start Date:</b> 06/20/86		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:pelvic,echinomycin				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> 02/05/93

Study Objective: To screen for activity of new agents or drug combinations in patients with advanced malignancies. Its intent is to determine the efficacy of chemotherapeutic agents in patients whose advanced malignancies have been resistant to high priority methods of treatment.

Technical Approach: Echinomycin will be administered at a dosage of 1500 mcg/m every 4 weeks. An adequate trial is defined as receiving one dose of drug and alive at four weeks. Patients receiving one dose of drug and demonstrating progression < 4 weeks from study entry will be considered eligible for response and toxicity. Each patient will remain on study and continue to receive drug until disease progression or adverse effects prohibit further therapy.

Progress: No patients were entered at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/058		<b>Status:</b> Completed	
<b>Title:</b> GOG 0026X: A Phase II Trial of Gallium Nitrate (NSC #15200) in Patients with Advanced Pelvic Malignancies					
<b>Start Date:</b> 05/20/88			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:pelvic,gallium nitrate					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

**Study Objective:** To screen for activity of new agents or drug combinations in patients with advanced malignancies. Its intent is to determine the efficacy of chemotherapeutic agents in patients whose advanced malignancies have been resistant to high priority methods of treatment.

**Technical Approach:** Gallium nitrate will be given as a slow intravenous infusion over 30-60 minutes at a dose of 750 mg/m<sup>2</sup>. The dose will be repeated once every three weeks. Patients will be hydrated with at least three liters of fluid the day prior to treatment. An additional 500 cc normal saline will be infused in the two hours prior to administration of gallium nitrate. Hydration of three liters of fluid orally or intravenously will be continued during the first 24 hours after therapy. Patients receiving concurrent radiotherapy are ineligible for this study. An adequate trial will be defined as receiving one course of therapy and living three weeks. Each patient will continue receiving gallium nitrate until disease progression or death or until adverse effects prohibit further therapy.

**Progress:** No patients were entered in this study during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 81/079		<b>Status:</b> On-going
<b>Title:</b> GOG 0040: A Clinical Pathologic Study of Stage I and II Uterine Sarcomas				
<b>Start Date:</b> 05/15/81		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> sarcoma:uterine				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> 02/05/93

**Study Objective:** To determine the incidence of pelvic and aortic lymph node metastases associated with Stages I and II uterine sarcomas, the relationship of these node metastases to other important prognostic factors such as mitotic index of the tumor, and the complication rate of the procedures. These findings will then be used as a guide for treatment protocols.

**Technical Approach:** Patients with histologically proven uterine sarcoma clinical Stages I or II who undergo total abdominal hysterectomy, bilateral salpingo-oophorectomy, selective pelvic and para-aortic lymphadenectomy, peritoneal cytology sampling and omentectomy (optional) as described in the protocol are eligible. Patients who have had prior preoperative adjuvant pelvic radiation or chemotherapy will be ineligible. The following pathologic evaluation will be done: a. Peritoneal cytology will be evaluated for malignant cells. b. The uterus will be evaluated at least in regard to: (1) location of tumor; (2) depth of myometrial invasion; (3) differentiation of tumor; (4) size of uterus; (5) number of mitoses per 10 HPF; (6) histologic type of tumor. c. The adnexa will be evaluated for presence of metastasis. d. The lymph nodes will be evaluated as to metastasis and location and number of involved lymph nodes. After surgical staging, patients may be transferred to an appropriate treatment protocol if all criteria are met. If no protocol is available, further treatment will be at the discretion of the physician.

**Progress:** No patients were entered in this study during FY 93. One patient continues to be followed

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 81/035		<b>Status:</b> On-going
<b>Title:</b> GOG 0041: Surgical Staging of Ovarian Carcinoma				
<b>Start Date:</b> 01/16/81		<b>Est. Completion Date:</b>		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,surgical staging				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To determine the spread of ovarian carcinoma to intraperitoneal structures and retroperitoneal lymph nodes by direct examination, cytologic sampling, and biopsy; to establish a surgical protocol for patients entered into GOG ovarian cancer treatments protocols; to determine the complication rate of the procedures.

**Technical Approach:** This protocol is being performed as a statistical protocol on patients who have surgery as standard treatment. Eligible patients will be those who have Stages I, II, or III ovarian carcinoma. Patients undergoing total abdominal hysterectomy, bilateral or unilateral salpingo-oophorectomy, bivalving of the ovary, selective pelvic and para-aortic lymphadenectomy, omental biopsy, or peritoneal cytology sampling will be studied. They will not be given any preoperative treatment, but will be subjected to a completed and thorough evaluation before surgery. All patients will be explored and the steps for surgery will be as standard surgery dictates. Specific observations will be made as to the findings. If fluid is not present, washings will be taken from the inside of the abdomen to study cells. A thorough examination of all structures from the diaphragm to the pelvic floor will be carried out. After surgical staging, patients will be transferred to the appropriate treatment protocol or to standard treatment if no protocol is available.

**Progress:** No patients were enrolled during FY 93. In previous years, 13 patients were enrolled and 2 have been lost to follow up, 2 have died and 9 are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 81/105		<b>Status:</b> On-going	
<b>Title:</b> GOG 0052: A Phase III Randomized Study of Cyclophosphamide Plus Adriamycin Plus Platinol Versus Cyclophosphamide Plus Platinol in Patients with Optimal Stage II Ovarian Adenocarcinoma					
<b>Start Date:</b> 08/21/82			<b>Est. Completion Date:</b> Feb 94		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL Roger B. Lee, MC			COL William L. Benson, MC LTC Gordon O. Downey, MC		
<b>Key Words:</b> Cancer:ovarian, adenocarcinoma, cyclophosphamide, Adriamycin, Platinol					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

**Study Objective:** To determine, in optimal Stage III ovarian adenocarcinoma, if the addition of adriamycin to cyclophosphamide plus cis-platinum improves progression-free interval, frequency of negative second-look laparotomy and survival. This protocol replaces GOG #25.

**Technical Approach:** Eligible patients are those more than six weeks post-operative with proven primary Stage III ovarian adenocarcinoma confined to the abdominal cavity and its peritoneal surfaces with residual tumor masses after surgery no larger than 1 cm in diameter. Patients with prior chemo or radiotherapy are ineligible. Patients will be randomized to cyclophosphamide plus Platinol every three weeks for eight courses or to cyclophosphamide and Platinol plus adriamycin every three weeks for eight courses. After eight courses those with less than clinically complete response will go off study and be followed for survival; those with clinically complete response will have second-look surgery to validate the complete response or to remove residual tumor masses. Patients will then be followed for approximately five years for survival rates.

**Progress:** No patients were enrolled into this protocol at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 82/036		<b>Status:</b> Completed	
<b>Title:</b> GOG 0063: A Clinical Pathologic Study of Stages IIB, III, and IVA Carcinoma of the Cervix					
<b>Start Date:</b> 03/19/82			<b>Est. Completion Date:</b>		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:cervix,pathologic study					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

Study Objective: To evaluate the sensitivity and specificity of non-invasive procedures such as sonography, computerized transaxial tomography and lymphangiography in detection of metastases; to better understand the significance of various surgical and pathologic factors involved in staging and therapy for advanced cervical cancer. The accumulated clinical/surgical/pathological data may then play a role in modification or design of future protocols; to determine by observations of five-year survival and disease-free interval, the validity of current FIGO staging in comparison to histopathologic prognostic factors such as size of lesion, location of lesion, histology, grade, pelvic lymph node metastases, and aortic lymph node metastases, in patients with Stages IIB, III, and IVa carcinoma of the cervix.

Technical Approach: All eligible patients with invasive carcinoma of the cervix, Stages IIB through IVa, will undergo preoperative clinical staging, including traditional staging as permitted by FIGO rules. Extended clinical staging utilizing sonography, lymphangiography, and computerized transaxial tomography are mandatory. When these tests reveal an aortic nodal metastasis, the patient will have a fine needle biopsy; however, if the tests are negative, the patient will have an aortic lymphadenectomy. Patients who have a positive fine needle biopsy or positive aortic lymphadenectomy will undergo scalene node biopsy before consideration for a GOG treatment protocol. It is anticipated that all patients will be considered for entry into a GOG protocol for which they are suitable when such protocols are available.

Progress: No patients were enrolled in this study during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 84/033		<b>Status:</b> On-going
<b>Title:</b> GOG 0072: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phse II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease				
<b>Start Date:</b> 02/17/84		<b>Est. Completion Date:</b> Dec 88		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> tumor:ovarian,melphalan,cisplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To evaluate the biologic behavior of ovarian tumors of low malignant potential; to evaluate the effectiveness of chemotherapy against this disease (initially, a Phase II study of melphalan); and to evaluate the response rate to cisplatin in melphalan failures.

**Technical Approach:** Patients without prior chemotherapy or radiotherapy who have had adequate surgical staging will be eligible. Patients with no grossly visible residual disease will receive no treatment and be followed for 5 years if there is no subsequent disease. If there is no grossly visible clinically apparent residual for 12 months, the patients will have second look surgery and then proceed to melphalan treatment (5 days every four weeks) or follow-up (complete response). With progression after melphalan, patients will proceed to third look and cisplatin treatment (once every three weeks for eight weeks) or follow-up. If there is no evidence of response after three courses of cisplatin, the treatment will be discontinued. Patients who have progression during the first 12 months will be treated as above except they will proceed directly to melphalan treatment without second look surgery. Follow-up will be for a minimum of five years with clinical examination every three months for the first two years, then every six months thereafter.

**Progress:** No patients were enrolled at MAMC during FY 93. In previous years, 10 patients were enrolled, 1 has died and 9 are still being followed.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 84/074		<b>Status:</b> On-going	
<b>Title:</b> GOG 0078: Evaluation of Adjuvant VP-16, Bleomycin, and Cisplatin (BEP) Therapy in Totally Resected Choriocarcinoma, Endodermal Sinus Tumor, Embryonal Carcinoma and Grade 3 Immature Teratoma of the ...					
<b>Start Date:</b> 08/17/84			<b>Est. Completion Date:</b> Jul 89		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,teratoma,tumor:sinus,chemo,bleomycin,cisplatin					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

**Study Objective:** To evaluate the effect of adjuvant vinblastine, bleomycin, and cisplatin (VBP) chemotherapy in patients with endodermal sinus tumor and choriocarcinoma of the ovary (pure and mixed) after removal of all gross tumor; to evaluate the role of serum markers, especially alpha fetoprotein and HCG, in predicting recurrence; to evaluate the role of reassessment laparotomy in determining response, detecting early relapse, and planning further therapy; and to compare the biologic behavior of pure endodermal sinus tumors with mixed germ cell tumors containing endodermal sinus elements. Per addendum of Jan. 87: to evaluate the acute and chronic toxicity of this chemotherapy on gonadal and reproductive function.

**Technical Approach:** Patients with totally resected Stage I choriocarcinoma, endodermal sinus tumor, or embryonal carcinoma of the ovary with negative peritoneal washings, normal (or falling at a rate that does not suggest residual disease) serum AFP and beta-HCG levels, and adequate bone marrow, renal, and hepatic function will be studied. Stages II and III will also be eligible if all gross tumor is resected. After recovery from surgery, patients will receive 3 cycles of VBP therapy. Patients who show evidence of progression while on VBP therapy will be candidates for GOG Protocol 26. Patients completing three cycles of treatment clinically free of disease will undergo reassessment laparotomy. Patients with recurrent disease at reassessment laparotomy will be candidates for GOG Protocol 26. To be eligible a patient will receive at least one week of chemotherapy and live another two weeks. Each patient will remain on study until adverse effects prohibit further therapy or until evidence of progression is noted. Per addendum of Jan. 86: the title has been changed as shown above; vinblastine has been replaced by VP-16; Grade 3 immature teratoma has been added for entry and evaluation.

**Progress:** One patient was enrolled in FY 92 and is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 86/089		<b>Status:</b> On-going	
<b>Title:</b> GOG 0085: A Randomized Comparison of Hydroxyurea versus 5-FU Infusion and Bolus Cisplatin as an Adjuvant to Radiation Therapy in Patients with Stages II-B, III, and IV-A Carcinoma of the Cervix and...					
<b>Start Date:</b> 08/15/96			<b>Est. Completion Date:</b> Feb 94		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL Roger B. Lee, MC			COL William L. Benson, MC LTC Gordon O. Downey, MC		
<b>Key Words:</b> Cancer:cervical, carcinoma, hydroxyurea, 5-FU, Cisplatin, Radiotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		02/05/93	

**Study Objective:** To determine whether hydroxyurea or the combination of 5-FU and cisplatin is superior as a potentiator of radiation therapy in advanced cervical carcinoma and to determine the relative toxicities of hydroxyurea versus the combination of 5-FU and cisplatin when given concurrently with radiation therapy.

**Technical Approach:** Patients with invasive squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix, Stages II-B, III, and IV-A, who meet the eligibility requirements as listed in the protocol, will undergo clinical staging as permitted by FIGO rules. All patients will undergo surgical staging to include extraperitoneal sampling of the para-aortic lymph nodes, peritoneal cytology, and intraperitoneal exploration. Patients with cancer confined to the pelvis will receive pelvic irradiation and will be randomly assigned to receive either concomitant 5-FU and cisplatin or hydroxyurea. Patients with disease outside the pelvis are not eligible for this protocol. The study will continue as long as treatment protocols remain activated. The patients will be followed for two years and then every six months for three additional years.

**Progress:** This protocol was closed to patient entry in December 1990 because it was reported that the two patients entered on the study had died. After further review it was discovered that this was a mistake. Therefore, the protocol was reopened in Feb 93 in order to follow these two patients.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/044		<b>Status:</b> Completed	
<b>Title:</b> GOG 00860: A Phase II Trial of Taxol (NSC #125973) and G-CSF in Patients With Advanced or Recurrent Endometrial Carcinoma					
<b>Start Date:</b> 02/05/93			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:endometrial					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To evaluate the activity of Taxol in chemotherapy naive patients with advanced or recurrent endometrial carcinoma.

**Technical Approach:** Patients will be those who present with advanced, measurable adenocarcinoma of the endometrium documented histologically prior to entry in the protocol. They must not have a recent history of angina or congestive heart failure nor have active arrhythmias. Enrolled patients will be given Taxol as a 24-hour continuous infusion at an initial dose of 250 mg/m<sup>2</sup>/24 hour every 3 weeks following premedication with Benedryl, Decadron, and Cimetadine. This infusion will be repeated every 3 weeks (no treatment course is to begin until all toxicity from the previous course has resolved). Additionally, daily subcutaneous injections of G-CSF will be given beginning 24 hours after the completion of chemotherapy for 14 days or until the white blood cell count is > 10,000. During the course of therapy, weekly CBCs and platelet counts will be obtained to follow for bone marrow toxicity. Physical examinations will be performed at the time of every treatment. Radiologic imaging will be repeated every other cycle.

The principal parameters employed to evaluate the efficacy of each agent are: 1) The frequency and duration of objective response. 2) The frequency and severity of observed adverse effects. 3) Survival time for all patients. 4) Duration of progression-free interval for all patients.

**Progress:** One patient was enrolled and later died of the disease.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 87/013	<b>Status:</b> On-going
<b>Title:</b> GOG 0090: Evaluation of Cisplatin, Etoposide, and Bleomycin (BEP) Induction Followed by Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Consolidation in Advanced Ovarian Germ Cell Tumors		
<b>Start Date:</b> 10/17/86	<b>Est. Completion Date:</b> Indef.	
<b>Department:</b> GOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Mark E. Potter, MC		
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC
<b>Key Words:</b> tumor:germ cell:ovary,cisplatin,etoposide,bleomycin,VAC,vincristine,dactinomycin,cyclophosphamide,BEP		
<b>Accumulative MEDCASE Cost:</b>	\$0.00	<b>Est. Accumulative OMA Cost:</b> \$0.00
		<b>Periodic Review:</b> 02/05/93

**Study Objective:** To evaluate the effect of induction chemotherapy with cisplatin plus etoposide plus bleomycin (BEP) followed by consolidation with vincristine plus dactinomycin plus cyclophosphamide (VAC) in previously untreated patients with advanced ovarian germ cell tumors.

**Technical Approach:** After adequate recovery from surgery (if done) previously untreated patients will be treated by three courses of BEP followed by three courses of VAC. Patients exhibiting disease progression on either phase will be taken off study. Patients who had previous VAC or similar regimens will be treated with four courses of BEP. After recovery from BEP therapy, reassessment laparotomy will be performed in patients with negative markers who are clinically free of disease. Progressing patients will be removed from the study. Patients with no evidence of disease at second look will be followed. Patients with persistent disease at second look will be removed from the study. An adequate trial is defined as receiving two courses of the drug and living at least six weeks. Each patient will remain on study until adverse effects prohibit further therapy or until evidence of progression of disease.

**Progress:** No patients were entered in this study during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 87/104	<b>Status:</b> On-going
<b>Title:</b> GOG 0092: Treatment of Selected Patients with Stage 1B Carcinoma of the Cervix After Radical Hysterectomy and Pelvic Lymphadenectomy: Pelvic Radiation Therapy versus No Further Therapy		
<b>Start Date:</b> 08/21/87	<b>Est. Completion Date:</b> Indef.	
<b>Department:</b> GOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Mark E. Potter, MC		
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC COL Donald H. Kull, MC
<b>Key Words:</b> cancer:cervix,hysterectomy,lymphadenectomy,radiotherapy		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	02/05/93

**Study Objective:** To determine the value of adjunctive pelvic radiation in the treatment of Stage 1B carcinoma of the cervix but with selected high-risk factors; to determine the recurrence-free interval, survival and patterns of failure in those patients; and to determine the morbidity of adjunctive pelvic radiation following radical hysterectomy.

**Technical Approach:** All patients with Stage 1B cancer of the cervix who have been treated by radical hysterectomy and pelvic node dissection and found to have cancer confined to the cervix and who have a large tumor and/or lymph or blood vessel invasion.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/036		<b>Status:</b> On-going	
<b>Title:</b> GOG 0093: Evaluation of Intraperitoneal Chromic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma (Stage III)					
<b>Start Date:</b> 03/17/89			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:ovarian,chromic phosphate,laparotomy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$2416.00
			<b>Periodic Review:</b>		02/05/93

**Study Objective:** To evaluate the role of intraperitoneal chromic phosphate (32P) suspension therapy in patients with Stage III epithelial ovarian carcinoma who have no detectable evidence of disease at the second-look laparotomy and to evaluate disease free survival, sites and frequency of relapse, and the morbidity from intraperitoneal 32P therapy.

**Technical Approach:** Patients with primary histologically confirmed epithelial carcinoma of the ovary who are in complete clinical remission, with no persistent or recurrent cancer, and initial FIGO Stage III will be eligible. Patients with distant metastatic disease, previous pelvic or abdominal radiation therapy, previous or concomitant malignancies other than of skin (excluding melanoma), and borderline malignancy of the ovary will be ineligible. Patients will be randomized to one or two regimens. Regimen I will consist of 15 millicuries of intraperitoneal chromic phosphate suspension therapy, preferably within 10 days (but no more than six weeks) after second-look laparotomy. Patients will be randomized before second-look laparotomy and a dialysis catheter will be inserted during second-look laparotomy in those patients randomized to receive 32P. Patients will be rotated every 10 minutes (left side to back to right side) for two hours to facilitate distribution of the 32P. Anterior and lateral scans of the abdominal cavity will be done to evaluate adequate distribution in the peritoneal cavity of the 32P and to confirm that loculation has not occurred. Data collection will continue until disease progression or death.

**Progress:** No patients were entered in this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/028		<b>Status:</b> On-going	
<b>Title:</b> GOG 0095: Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected IAi and IBi and IAii and IBii Ovarian Cancer, Phase III					
<b>Start Date:</b> 11/21/86			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,cyclophosphamide,cisplatin,P32					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		02/05/93	

**Study Objective:** In definitively staged patients who have tumor involving one or both ovaries with pelvic extension and/or malignant ascites and/or positive peritoneal washings and in those Stage IAI and IBI patients with poorly differentiated tumors and stage IAII and IBII (all grades) to: compare the progression-free interval and overall survival of the two treatment regimens; determine the patterns of relapse for each form of therapy; and define the relative toxicities of the two treatment approaches.

**Technical Approach:** The study design will be a randomized comparison between the standard adjuvant treatment (P32) and an experimental arm of short term intensive adjuvant combination chemotherapy with cyclophosphamide/cisplatin. One to two weeks following surgery, P32 therapy will be started. Fifteen millicuries of chromic phosphate suspension mixed in 500 cc of normal saline will be infused into the peritoneal cavity via the peritoneal dialysis catheter after a technetium scan or abdominal x-rays with contrast material has demonstrated adequate distribution. In order to facilitate distribution of the P32, the patient will be turned every 15 minutes to the left side, onto the back, in Trendelenburg and reverse Trendelenburg positions, onto the right side and so on for two hours following the infusion. Chemotherapy will consist of cyclophosphamide, 1 mg/m<sup>2</sup> I.V., on day 1 plus cisplatin, 100 mg/m IV, on day 1 administered one hour after cyclophosphamide. Cycles of combination chemotherapy will be repeated every three weeks depending upon the time to recovery of the blood counts to pretreatment level. Cycles of chemotherapy will be repeated for a total of three cycles. Patient follow-up will continue until death, loss of follow-up, or termination of the study. Patients will remain on study until disease progression or adverse effects dictate otherwise. An adequate trial is defined as receipt of at least one course of therapy and one follow-up visit.

**Progress:** One patient was entered in FY 93 and is in follow-up. Five patients were entered in previous years and 1 remains in follow-up.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/091		<b>Status:</b> On-going
<b>Title:</b> GOG 0099: A Phase III Randomized Study of Adjunctive Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma				
<b>Start Date:</b> 06/19/87		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> COL William L. Benson, MC		COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:endometrial,radiotherapy				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

Study Objective: To determine if patients with intermediate risk endometrial adenocarcinoma who have no spread of disease to the lymph nodes benefit from postoperative pelvic radiotherapy and to evaluate how the addition of pelvic radiotherapy will alter the site and rate of cancer recurrence in these intermediate risk patients.

Technical Approach: Patients with primary histologically confirmed Grade 2 or 3 endometrial adenocarcinoma (endometrioid, villoglandular, mucinous and adenosquamous) and clear cell carcinoma will be eligible. Patients must have had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, selective pelvic and para-aortic node sampling, pelvic washings and found to be surgical Stage 1 with myometrial invasion. Following surgery, patients will be randomized to no additional treatment of pelvic radiation therapy to begin no later than eight weeks after surgery. Those randomized to radiation therapy will be treated with AP and PA parallel ports with each port being treated each day. A daily tumor dose of 180 cGy will be given to a total dose of 5040 cGy in approximately six weeks. Each patient will be followed with regular visits occurring every three months for the first two years, every six months for the third, fourth and fifth years, and yearly thereafter.

Progress: No patients were enrolled at MAMC during FY 93. The two patients enrolled in previous years are both in follow-up.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/105		<b>Status:</b> Completed	
<b>Title:</b> GOG 0100: Monoclonal Antibody Against Free Beta HCG to Predict Development of Persistent Gestational Trophoblastic Disease (PGTD) in Patients with Hydatidiform Mole					
<b>Start Date:</b> 08/21/87			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> hydatidiform moles,monoclonal antibody,free beta HCG,PGTD					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		02/05/93	

**Study Objective:** To measure the serum concentration of free beta HCG and total beta HCG in patients with molar pregnancies in order to determine whether the ratio of free beta HCG to total beta HCG may be of value in predicting which molar pregnancies will undergo spontaneous remission and which will subsequently develop into persistent gestational trophoblastic disease.

**Technical Approach:** Patients with gross and microscopically verified diagnosis of hydatidiform mole, either classic (true) or partial (incomplete), obtained by evacuation of the uterus with uterine conservation will be eligible. Patients will have a pelvic ultrasound within two weeks of evacuation and the first serum will be drawn within 48 hours (prior to if at all possible) of evacuation for beta HCG and free beta HCG determinations. Following histologic confirmation of the hydatidiform mole (within one week of evacuation) the patient will be placed on study. Serum samples will be obtained weekly until a negative assay is attained or until a plateau or rise in titer is observed. All patients will remain on study for a minimum of twelve weeks after primary evacuation of the molar pregnancy. After spontaneous remission, patients will have beta HCG titers monthly for six months (free beta HCG assay is not necessary). After persistent disease, the patient will remain on study until remission. The principle parameters employed to investigate the prediction of which molar pregnancies will undergo spontaneous remission and which will subsequently develop into persistent trophoblastic disease are free beta HCG, total HCG concentration, ratio of free beta HCG to total HCG, and remission of disease as determined by weekly titers.

**Progress:** No patients were entered in this study during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/106		<b>Status:</b> On-going	
<b>Title:</b> GOG 0101: A Phase II Evaluation of Preoperative Chemoradiation for Advanced Vulvar Cancer					
<b>Start Date:</b> 08/21/87			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC COL Donald H. Kull, MC		
<b>Key Words:</b> cancer:vulva,chemoradiotherapy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

**Study Objective:** To determine: the feasibility of using preoperative chemoradiotherapy to obviate the need for pelvic exenteration for patients with advanced vulvar cancer involving the proximal urethra, bladder, anal canal, or rectum; the feasibility of allowing a less extensive vulvar and vaginal resection in patients with a T3 primary tumor by using preoperative chemoradiotherapy; the survival rate for patients with Stage III or IV-A disease associated with this technique of therapy; the morbidity of a combined chemoradiosurgical approach to advanced vulvar cancer and to attempt to improve survival in patients with N3 groin nodes.

**Technical Approach:** Patients with primary, previously untreated, histologically confirmed invasive squamous or adenocarcinoma of the vulva clinically determined to be Stage III or IV will be treated with chemoradiation therapy according to the sub-stage. Regimen I: Patients with T4 or unresectable T3 primary tumor and NO or N1 groin nodes will receive a split course of radiation therapy to the vulva by AP-PA fields. Twice daily fractions of 150 cGY will be given on days 1-4 and 1'-4'; once daily fractions of 180 cGY will be given on days 5, 8-12 and 5', 8'-12'. A 1 1/2 to 2 1/2 week split will be allowed between the two courses. Total midplane dose will be 4560 cGY. During the twice daily radiation (days 1-4 and 1'-4'), patients will receive concurrent chemotherapy of 5-FU, 1000 mg/m<sup>2</sup> over 24 hours, allopurinol, 300 mg p.o., and cisplatin, 50 mg/m<sup>2</sup> IV, (days 1 and 1' only). Four to eight weeks following completion of chemoradiotherapy, patients considered to have resectable disease without the need for an exenterative procedure will undergo excision of the area previously replaced by primary tumor. An inguinal/femoral lymphadenectomy will also be performed. Regimen II: The same as Regimen I with the addition of radiation to the inguinal/femoral and low pelvic lymph

**Progress:** No patients were entered in this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/065		<b>Status:</b> On-going
<b>Title:</b> GOG 0102N: Intraperitoneal Administration of Recombinant Alpha-2 Interferon Alternating with Cisplatin in Patients with Residual Ovarian Carcinoma				
<b>Start Date:</b> 03/05/93		<b>Est. Completion Date:</b> Nov 94		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:ovarian carcinoma, interferon, cisplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		//

**Study Objective:** 1) To further evaluate the role of intraperitoneal chemotherapy in patients with recurrent refractory ovarian carcinoma. 2) To assess the hypothesis that alternating Cisplatin with Alpha-2 Interferon on two of the three off weeks results in improved response rates and less toxicity over concomitant administration of Cisplatin and Alpha-2 Interferon.

**Technical Approach:** Patients with persistent or recurrent ovarian carcinoma with less than or equal to 1 cm residual tumor and a previous documented response to Cisplatin chemotherapy will be treated with intraperitoneal Cisplatin 90 mg/m<sup>2</sup> on weeks 1, 5, 9 and 13 and intraperitoneal Alpha-2 Interferon 50 million units on weeks 2, 3, 6, 7, 10, 11, 14, and 15. Patients will be treated as an inpatient during each administration of chemotherapy. This will require a one day hospitalization for each weekly treatment. After the completion of the four treatment cycles a reassessment operation will be performed to evaluate response to therapy. This reassessment operation is strongly encouraged for all patients who have no evidence of disease at the completion of therapy. Patients participating in this study will have a intraperitoneal access port placed prior to the initiation of therapy. With any clinical evidence of progressive disease treatment will be discontinued and an alternative treatment plan will be determined by the patient and the GYN Oncology service.

**Progress:** No patients were entered in this study during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/081		<b>Status:</b> Completed	
<b>Title:</b> GOG 0106: Evaluation of the Serum Marker, CA-125, in the Management of . Carcinoma of the Endometrium					
<b>Start Date:</b> 09/16/88			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:endometrial,CA-125,serum marker					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	02/05/93	

**Study Objective:** To evaluate the sensitivity of CA-125 for endometrial carcinoma; to correlate CA-125 levels with surgical pathologic criteria (stage, grade, sites); to evaluate the efficacy of CA-125 in monitoring response to therapy (surgery, radiation, chemo, hormonal) in endometrial carcinoma; and to evaluate the efficacy of CA-125 in predicting survival and/or recurrence in endometrial cancer.

**Technical Approach:** Patients with endometrial carcinoma who are eligible for designated concurrently active GOG treatment protocols for endometrial cancer will be eligible. Specific protocols are selected to obtain a population of patients with tumor burdens and risks for recurrence appropriate to accomplish the study objectives. Serum for CA-125 will be collected according to a schema individually developed for each treatment protocol to be consistent with the regimen and anticipated findings. The collection schedules developed will follow the general schema that follows, modified as appropriate: 1. prior to surgery, if surgery is needed; 2. prior to initiation of therapy; 3. prior to each chemotherapy treatment; 4. monthly during hormonal therapy; 5. prior to initiation of postoperative radiation and at two week intervals during therapy; 6. at the completion of therapy; 7. at regular follow-up intervals, approximately every three months for the first year, every four months the second year, and every six months thereafter, on patients who are free of disease; 8. in patients who progress, follow-up blood samples will not be required after progression is well documented and sera at those time points has been obtained. The duration of this study will be determined by the designated concurrently active GOG treatment protocols with five years of follow-up thereafter.

**Progress:** No patients were entered in this study during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/037		<b>Status:</b> Completed	
<b>Title:</b> GOG 0107: A Randomized Study of Doxorubicin (NSC #123127) versus Doxorubicin Plus Cisplatin (NSC #119875) in Patients with Primary Stage III and IV Recurrent Endometrial Adenocarcinoma					
<b>Start Date:</b> 03/17/89			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:endometrial,doxorubicin,cisplatin					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		02/05/93	

**Study Objective:** To determine: whether the addition of cisplatin to doxorubicin offers significant improvement in the frequency of objective response; the duration of progression-free interval; and the length of survival as compared to doxorubicin alone.

**Technical Approach:** Patients will be randomized to either Regimen I or Regimen II. Regimen I: doxorubicin 60 mg/m<sup>2</sup> IV every three weeks to a maximum total dose of no greater than 500 mg/m<sup>2</sup>. Regimen II: doxorubicin 60 mg/m<sup>2</sup> IV every three weeks plus cisplatin, 50 mg/m<sup>2</sup> IV, every three weeks, to be continued to a maximum total dose of doxorubicin of 500 mg/m<sup>2</sup>. Each regimen will require both dose escalation and dose reduction in accordance with adverse effects observed on the previous course of therapy. Patients who reach maximum doxorubicin dose will undergo a complete re-evaluation. All therapy will then be stopped and the patient followed on no further therapy until progression of disease is documented. Further therapy at that point will be at the discretion of the investigator. Patients on no further treatment will be followed every three months for the first two years, then every six months for three years, and annually thereafter.

**Progress:** No patients were entered in this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/052		<b>Status:</b> On-going	
<b>Title:</b> GOG 0108: Ifosfamide (NSC #109724) and the Uroprotector Mesna (NSC #113891) with or without Cisplatin (NSC #119875) in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus					
<b>Start Date:</b> 04/21/89			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> tumor:uterus,ifosfamide,cisplatin,uroprotector mesna					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 02/05/93

Study Objective: To confirm reported high response rates of advanced or recurrent mixed mesodermal tumors of the uterus to Ifosfamide/ Mesna; to determine the toxicity and whether the addition of Cisplatin to Ifosfamide/Mesna improves response rates or survival in patients with these tumors.

Technical Approach: Patients will be randomized to either Regimen I or to Regimen II. Regimen I: Ifosfamide 1.5 g/m<sup>2</sup>/d IV for 5 days plus Mesna 120 mg/m<sup>2</sup> IV bolus 15 minutes prior to Ifosfamide, first day only; then 1.5 g/m<sup>2</sup>/d infusion over 5 days; repeated every 21 days. Regimen II: cisplatin 20 mg/m<sup>2</sup>/d IV for five days before administration of Ifosfamide as given in Regimen I; repeated every 21 days. The Ifosfamide starting dose will be 1.2 g/m<sup>2</sup> if the patient has had prior radiotherapy. One course of chemotherapy and living three weeks for repeat lesion measurement will be the minimal trial to evaluate response. One course (or part of one course) of therapy and receiving any follow-up information for observation of toxicity will be the minimal trial to evaluate toxicity.

Progress: No patients were entered in this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/086		<b>Status:</b> On-going	
<b>Title:</b> GOG 0109 (SWOG 8797): A Randomized Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy, versus Radiation Therapy Alone in Selected Patients with Stages ...					
<b>Start Date:</b> 08/02/91			<b>Est. Completion Date:</b>		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:cervix,5-Flourouracil,cisplatin,radiotherapy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
			<b>Periodic Review:</b>		02/05/93

**Study Objective:** To determine whether the combination of 5-fluorouracil (5-FU) and cisplatin used as an adjunct to radiation therapy will improve survival rate or progression-free survival and decrease extra pelvic failure compared to radiation therapy alone in patients with positive pelvic lymph nodes, positive parametrial involvement, or positive surgical margins following radical hysterectomy and lymph node dissection for Stages I-A2, I-B, and II-A carcinoma of the cervix and to determine the increase in toxicities due to 5-FU and cisplatin as an adjunct to radiation therapy versus radiation therapy alone.

**Technical Approach:** Patients must have primary, histologically confirmed, invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, clinical stages I-A2, I-B, or II-A and must have had a radical hysterectomy with total pelvic lymphadenectomy and para-aortic sampling. Patients must have, at surgical evaluation, either histologically confirmed positive pelvic lymph nodes, positive parametrial involvement, or positive surgical margins. Patients with confirmed positive para-aortic lymph nodes are not eligible. Patients must not have received prior chemotherapy, immunotherapy (including biologics), hormonal therapy, or pelvic irradiation. Patients will be randomly assigned to receive either 5-FU and cisplatin plus pelvic irradiation or pelvic irradiation alone. Patients with positive high common iliac lymph nodes will receive extended field para-aortic irradiation. Irradiation and chemotherapy will begin simultaneously within six weeks after surgery. Chemotherapy will be given once a week every three weeks for four cycles. Radiation therapy will be given for six weeks. After completion of therapy, patients will be followed every 3 months for two years and every 6 months thereafter. Formal analysis of progression-free and overall survival will be performed at 2 1/2 years after the start of patient accrual to determine if consideration should be given to early termination of either treatment arm.

**Progress:** No patients were enrolled at MAMC during FY 93. The one patient enrolled in previous years is still in follow-up.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/009		<b>Status:</b> On-going	
<b>Title:</b> GOG 0110: A Randomized Study of Cisplatin versus Cisplatin Plus Dibromodulcitol (NSC #104800) versus Cisplatin Plus Ifosfamide and Mesna in Advanced Stage III or IV), Recurrent or Persistent ....					
<b>Start Date:</b> 10/19/90			<b>Est. Completion Date:</b>		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:cervix,squamous cell,chemotherapy,cisplatin,dibromodulcitol					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$1440.00
			<b>Periodic Review:</b>		02/05/93

Study Objective: To determine if mitolactol plus cisplatin or ifosfamide plus cisplatin improves response rate, response duration, progression-free interval and/or survival in advanced squamous cervical cancer compared to cisplatin alone; and to compare the toxicity of these three regimens in advanced cervical cancer.

Technical Approach: Patients, with a Karnofsky performance scale of 50-100, who have histologically confirmed advanced, recurrent, or persistent squamous cell carcinoma of the cervix which is not suitable for curative treatment with surgery and/or radiotherapy will be eligible. Lesions must be measurable by physical examination or chest x-ray. Patients will be randomized to one of the following regimens: Regimen I: cisplatin 50 mg/m<sup>2</sup> every three weeks; Regimen II: cisplatin 50 mg/m<sup>2</sup> plus dibromodulcitol, 180 mg/m<sup>2</sup> daily x 5, every three weeks; Regimen III: cisplatin 50 mg/m<sup>2</sup> plus ifosfamide 5 gm/m<sup>2</sup> infused over 24 hours plus Mesna 6 gm/m<sup>2</sup> during and for 12 hours following ifosfamide, every three weeks. Therapy will continue for 6 courses or until cumulative adverse effects dictate cessation of therapy.

Progress: No patients were entered in this study during FY 93.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/010		<b>Status:</b> On-going
<b>Title:</b> GOG 0111: A Phase III Randomized Study of Cyclophosphamide (NSC #26271) and Cisplatin (NSC #119875) versus Taxol (NSC #125973) and Cisplatin (NSC #119875) in Patients with Suboptimal Stage III and ...				
<b>Start Date:</b> 10/19/90		<b>Est. Completion Date:</b>		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:ovarian,chemotherapy,cyclophosphamide,cisplatin,taxol				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To determine response rate, response duration, and survival in suboptimal Stage III and Stage IV ovarian cancer treated with different platinum-based combination chemotherapy regimens; to evaluate the relative activity of a new combination (cisplatin/taxol) as compared to the standard regimen (cisplatin/cyclophosphamide; to further evaluate the toxicities of the new combination of cisplatin/taxol in this larger patient population; and to compare the relative toxicities and therapeutic indices of the two regimens.

**Technical Approach:** Patients with established ovarian epithelial cancer, suboptimal (>1 cm in diameter) Stages III and IV who have had optimal surgery for ovarian cancer, with at least an exploratory laparotomy and appropriate tissue submitted for histologic examination, will be eligible. Following optimal initial surgery, patients will be randomized to either cisplatin plus cyclophosphamide or to cisplatin plus taxol given every 21 days for six courses. Patients with partial response, stable disease, or increasing disease will then go off study to be treated on other appropriate GOG protocols. Patients who are clinically free of disease at the completion of therapy will undergo a reassessment laparotomy to determine disease status unless CA-125 is >100. A 21 item patient self-report questionnaire and a five item nurse neurological assessment will be completed prior to the first course of therapy and at 4-6 weeks after the last course of therapy, regardless of the total number of courses. An adequate trial for response is defined as receiving one course of therapy and living three weeks for repeat measurement to be performed. An adequate trial for toxicity is defined as receiving one course of therapy and receiving any follow-up information for observation of toxicity.

**Progress:** No patients were enrolled at MAMC during FY 93. Two patients were enrolled in previous years and 1 is still in follow-up.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/011		<b>Status:</b> On-going
<b>Title:</b> GOG 0112: A Randomized Comparison of Chemoprophylaxis Using Methotrexate versus Routine Surveillance in the Management of the High Risk Molar-Pregnancy				
<b>Start Date:</b> 10/19/90		<b>Est. Completion Date:</b>		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> molar pregnancy, methotrexate, routine surveillance				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$18.00		02/05/93

**Study Objective:** To determine the incidence of post-molar trophoblastic disease after evacuation of the high risk molar pregnancy in those patients receiving chemoprophylaxis versus those randomized to usual post-evacuation surveillance; to evaluate the toxicity associated with chemoprophylaxis; and to develop a clinical pathologic scoring system for risk of post-molar trophoblastic disease which highly correlates with the serum free beta HCG assay.

**Technical Approach:** Patients who are categorized as at high risk for molar pregnancy and who have a gross and microscopically verified diagnosis of classic (true) hydatidiform mole, obtained by evacuation of the uterus with uterine conservation, will be eligible. Patients will be randomized to either a methotrexate prophylactic regimen or surveillance. Patients will have a pelvic ultrasound performed in the two week period prior to evacuation or in the two week period immediately following evacuation. The first HCG serum determination will be performed in the 48 hour period immediately prior to or after evacuation. HCG serum determinations will be repeated weekly. The methotrexate prophylactic regimen (40 mg/m<sup>2</sup> IM weekly x 3 courses) will be initiated within 14 days after evacuation and prior to obtaining the day 15 post-evacuation titer. If remission occurs, patients will have monthly beta HCG titers for 12 months, then every three months for one additional year. The principal parameters employed to examine the relative therapeutic value of chemoprophylaxis are the frequency of post molar trophoblastic disease after evacuation and the frequency and degree of toxicity associated with chemoprophylaxis.

**Progress:** No patients were entered in this study aty MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/064		<b>Status:</b> On-going
<b>Title:</b> GOG 0113: An Evaluation of Hydroxyurea, 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy in Patients with Stages II-B, III, and IV-A Carcinoma of the Cervix and Negative .....				
<b>Start Date:</b> 05/03/91		<b>Est. Completion Date:</b>		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:cervix,hydroxyurea,5-Fluorouracil,cisplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To evaluate the toxicity and feasibility of infusion 5-FU, cisplatin, and hydroxyurea, given concurrent with pelvic radiation therapy in patients with locally advanced cancer of the uterine cervix.

**Technical Approach:** Multiple studies have confirmed that the presence of metastases to para-aortic lymph nodes is a prognostic factor of greater significance than FIGO Stage. In addition, the pattern of failure in this group is vastly different, with one-half of the recurrences being outside the treated field. Because a major objective of this study is to evaluate local control and survival, this study will be open only to those patients with documented negative para-aortic nodes. All patients will undergo surgical staging to include extraperitoneal sampling of the para-aortic lymph nodes. Radiation therapy will be given by external beam therapy followed by intracavitary therapy. Cisplatin will be given IV on days 1 and 29 of external radiation therapy; 5-FU will be given IV on days 2, 3, 4, 5, 30, 31, 32, and 33 of external radiation therapy; and hydroxyurea will be given PO four days each week during external radiation therapy. After therapy, patients will be followed every three months for two years and then every six months for three years for progression free interval and survival.

**Progress:** No patients were enrolled at MAMC during FY 93. Two patients were enrolled in FY 92 and are in follow-up.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/059		<b>Status:</b> On-going
<b>Title:</b> GOG 0114: A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide vs Intravenous Cisplatin and Taxol vs High Dose Intravenous Carboplatin Followed by Intravenous Taxol and ...				
<b>Start Date:</b> 03/05/93		<b>Est. Completion Date:</b> Oct 96		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:ovarian carcinoma, cisplatin, cyclophosphamide, Taxol, carboplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

**Study Objective:** 1) To compare the efficacy of the combination of Cisplatin & Taxol to the standard therapy of Cyclophosphamide and Cisplatin in patients with optimally debulked Stage III Ovarian Carcinoma. 2) To investigate the theory that intravenous high dose therapy will render patients more sensitive to intraperitoneal therapy with Cisplatin and intravenous Taxol. The rate of fall of serum CA-125 will be correlated with response to chemotherapy.

**Technical Approach:** Patients who have had appropriate surgery for ovarian carcinoma with a histologic diagnosis of epithelial ovarian carcinoma, Stage III optimal, and who are not more than six weeks post-operative will be considered for this study. Upon entry, patients will be stratified according to whether or not gross residual disease is present (gross disease being any visible unresected tumor remaining after surgery). They will then be randomized to 1 of 3 regimens. Regimen I: - Cisplatin 75 mg/m<sup>2</sup> IV & Cyclophosphamide 750 mg/m<sup>2</sup> IV every 21 days X 6 courses. Regimen II: Taxol 135 mg/m<sup>2</sup> 24 hour continuous infusion, Day 1, Q 21 days followed by Cisplatin 75 mg/m<sup>2</sup>, Day 2 Q 21 days X 6 courses. Regimen III: Carboplatin (dose mg = target AUC X (GFR + 25) Q 4 weeks X 2 administered intraperitoneally through an implantable peritoneal dialysis catheter followed by Cisplatin 100 mg/m<sup>2</sup> intraperitoneally Q 21 days X 6 and Taxol 135 mg/m<sup>2</sup> IV X 6. While being treated, patients will have blood samples performed on a weekly basis to assess the serum CA-125 levels which will be correlated in response to chemotherapy. Response evaluations will be based on second-look surgical reassessment.

There will be two interim analyses conducted when approximately 188 patients and 375 patients are evaluable for second-look response. The critical values of the chi-square test statistic are 5.41, 5.41, and 3.283 at final analysis. These critical values correspond to the following probabilities (one-sided favoring the experimental therapy): 0.010, 0.010, and 0.035. The over-all error (rejecting either hypothesis) is 0.0754.

**Progress:** No patients were enrolled at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/074		<b>Status:</b> On-going	
<b>Title:</b> GOG 0115: Bleomycin (NSC #125066), Etoposide (NSC #141540) and Cisplatin (NSC #119875) (BEP) as First-Line Therapy of Malignant Tumors of the Ovarian Stroma (Granulosa Cell, Sertoli-Leydig Tumor, ...)					
<b>Start Date:</b> 07/12/91			<b>Est. Completion Date:</b>		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> tumor:ovarian stroma,chemo,bleomycin,etoposide,cisplatin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	02/05/93	

**Study Objective:** To assess the efficacy of bleomycin, etoposide (VP-16), and cisplatin (BEP) chemotherapy in patients with malignant tumors of the ovarian stroma as a first-line regimen.

**Technical Approach:** Eligible patients will be those with histologically confirmed primary Stages II, III, or IV with incompletely resected disease, recurrent or persistent tumor of the ovarian stroma (granulosa cell tumor, granulosa-theca cell tumor, Sertoli-Leydig cell tumor, androblastoma, gynandroblastoma, unclassified sex cord stromal tumor, or sex cord tumor with annular tubules). Patients will undergo, where appropriate, a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Omentectomy, cytologic washings, and other surgical staging such as pelvic and peri-aortic node sampling, multiple pelvic and diaphragmatic node biopsies are optional. Within 8 weeks of surgery, patients will be placed on BEP therapy: bleomycin IV push weekly for nine weeks, etoposide IV daily times five every three weeks for four courses, cisplatin IV daily times five, every three weeks for four courses. Complete responders or patients with nonmeasurable disease will undergo reassessment laparotomy not later than eight weeks following final course of therapy. To be evaluable for response, a patient will receive at least one course of chemotherapy. The efficacy of the three-drug combination will be evaluated by frequency of negative second-look and frequency and severity of acute toxicity.

**Progress:** The one patient enrolled at MAMC (FY 84) is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/060		<b>Status:</b> Completed
<b>Title:</b> GOG 0117: Adjuvant Ifosfamide and Mesna with Cisplatin in Patients with Completely Resected Stage I and II Mixed Mesodermal Tumors of the Uterus				
<b>Start Date:</b> 03/05/93		<b>Est. Completion Date:</b> Nov 94		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:uterine, mesodermal tumor, ifosfamide cisplatin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

Study Objective: To determine whether cisplatin and Ifosfamide/Mesna can reduce the recurrence rates in patients with completely resected Stage I or II mixed mesodermal tumors of the uterus.

Technical Approach: Following complete resection of Stage I and II mixed mesodermal tumors of the uterus the patients will receive Ifosfamide 1.5 mg/m<sup>2</sup> IV for four days. The Mesna dose 120 mg/m<sup>2</sup> IV bolus on day 1 THEN 1.5 gm/m<sup>2</sup>/day continuous IV infusion X 4 days plus Cisplatin 20 mg/m<sup>2</sup>/d. This therapeutic regime will be repeated every three weeks from day one for 3 cycles. After the completion of the chemotherapy, patients will be followed every three months for two years, then every six months for an additional three years.

The primary statistical parameters to be collected, analyzed and reported are: 1) Proportion of patients progression-free after 12 months of follow up. 2) Proportion of patients alive after 12 months of follow up.

Progress: No patients participated in this protocol at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/061		<b>Status:</b> On-going	
<b>Title:</b> GOG 0120: A Randomized Comparison of Hydroxyurea vs Hydroxyurea, 5-FU Infusion and Bolus Cisplatin vs Weekly Cisplatin as Adjunct to Radiation Therapy in Patients with Stages IIB, III, IVA Carcinoma..					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Oct 97		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:cervix, hydroxyurea 5-FU, cisplatin, radiation therapy					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** 1) To compare the relative efficacy of radiation sensitization of hydroxyurea alone or in combination with 5-Fluorouracil and Cisplatin versus Cisplatin alone in the treatment of Stages II-B through IV-A carcinoma of the cervix. 2) To determine the relative toxicities of these three different radiation sensitization schemes.

**Technical Approach:** Patients with locally advanced carcinoma of the cervix who have histologically confirmed negative para-aortic lymph nodes will be eligible for this study. Patients who consent will be randomized to three different treatment regimens. All treatment regimens will include the same radiation therapy technique given as standard therapy. Randomization will be between 1) Cisplatin 40 mg/m<sup>2</sup> IV q week X 6, (2) Cisplatin 50 mg/m<sup>2</sup> IV on days 1 & 29 with continuous infusion of 5-FU 1000 mg/m<sup>2</sup> on days 2 - 5 and 30 - 33 and hydroxyurea PO 2 mg/m<sup>2</sup> Mon/Thurs every week during radiation therapy (3) hydroxyurea PO 3 gm/m<sup>2</sup> Mon/Thurs every week during radiation therapy. Following therapy, patients will be monitored every 3 months for first 2 years and then every 6 months for the next 3 years.

To determine the efficacy of cisplatin, the principle parameters to be collected, analyzed and reported are: a) outcome variables (recurrence-free interval and survival) b) tumor characteristics c) host characteristics d) adverse effects (frequency and severity e) therapy administered.

Interim analyses will be conducted at approximately the 2nd, 3rd, 4th and 5th years using a global log-rank test. The goal will be to identify large differences in the recurrence free interval among the three treatment regimens. The interim log-rank test will be adjusted for important prognostic factors. The critical values of the chi-square test statistics are 11.1, 10.8, 10.6, 10.6, and 3.81. The last critical value is for the final analysis which will be a one-sided pair-wise test. These critical values correspond to the following tail probabilities from the two degrees of freedom chi-square distribution: 00.0039, 0.0045, 0.0050 and 0.0050. This early stopping rule will increase the type I error from 0.025 to 0.0386 for each test. The over-all type I error will be 0.0757.

**Progress:** No patients were enrolled at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/062		<b>Status:</b> Completed	
<b>Title:</b> GOG 0121: A Phase Two Trial of High Dose Megestrol Acetate (Megace) in Advanced or Recurrent Endometrial Carcinoma					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Nov 93		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer: endometrial, megestrol acetate, Megace					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> / /

**Study Objective:** 1) To evaluate the response rate and progression free interval in patients receiving high dose megestrol acetate (Megace) for advanced and recurrent endometrial carcinoma. 2) To determine toxicity of high dose megestrol acetate in such patients. 3) To determine if estrogen/progesterone receptor status is predictive of response.

**Technical Approach:** Patients with histologically confirmed advanced, persistent or recurrent endometrial carcinoma who have failed local therapeutic measures or are considered incurable with local therapy and have measurable disease consisting of abdominal, pelvic or other masses (which can be defined in at least two dimensions by palpation, x-ray, scans, or ultrasound) may be invited to participate.

Patients who agree to participate will be treated with Megace 800 mg/day PO in divided doses unless toxicity or disease progression requires discontinuing the medication. Patients will be evaluated by physical examination or x-ray studies every month for three visits and then every three months. If CT scans or ultrasounds are necessary for evaluation they will be performed every three months.

Data analyses to evaluate the effectiveness of therapy are: a) the frequency of complete (CR) and partial (PR) response; b) the duration of response; c) the frequency of observed adverse effects. A response (CR+PR) rate of 30% or more would be clinically significant and would indicate that further investigation of this therapy is appropriate. A response rate of 15% would indicate that the therapy has insufficient activity to warrant further investigation. A decision will be made after twenty evaluable patients are entered whether to continue accrual based on the number of responders observed and the observance of no atypical severe toxicity. The study will continue if there are 3 or more responses out of 20 evaluable patients.

**Progress:** There were no participants in the study from MAMC.



### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/063		<b>Status:</b> On-going	
<b>Title:</b> GOG 0123: A Randomized Comparison of Radiation Therapy & Adjuvant Hysterectomy vs Radiation Therapy & Weekly Cisplatin & Adjuvant Hysterectomy in Patients with Bulky Stage IB Carcinoma of the Cervix					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Oct 97		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:cervix, radiation therapy, cisplatin, hysterectomy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To evaluate the addition of weekly chemotherapy with Cisplatin during radiation therapy in patients with bulky Stage IB carcinoma of the cervix.

**Technical Approach:** This study randomizes patients to two different treatment regimens. Both regimens include radiation therapy followed by hysterectomy. Regimen I - Radiation Therapy Plus Adjuvant Hysterectomy - Patients will undergo combined external and intracavitary radiation therapy followed by extrafascial hysterectomy (total doses of 13000 cGy). Regimen II - Radiation Therapy Plus Weekly Cisplatin Infusion Plus Extrafascial Hysterectomy. Patient will undergo radiation therapy to receive a total dose of 13000 cGy using a combination of external and intracavitary radiation therapy. Each week during external radiation therapy and during the intracavitary applications the patient will receive an infusion of cisplatin 40 mg/m<sup>2</sup> not to exceed 70 mg maximum in any single infusion, up to a maximum of 6 doses of cisplatin. Extrafascial hysterectomy will be carried out no later than six weeks following the last day of treatment in both regimens.

The principal parameters to determine the efficacy of weekly cisplatin during radiotherapy are: 1) Outcome variables (recurrence-free interval (RF), survival and local control rate); 2) Tumor characteristics; 3) Host characteristics; 4) Adverse effects; 5) Therapy administered

**Progress:** No patients were enrolled at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/064		<b>Status:</b> On-going
<b>Title:</b> GOG 0125: Extended Field Radiation Therapy with Concomitant 5-FU Infusion and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to Para-aortic Lymph Nodes				
<b>Start Date:</b> 03/05/93		<b>Est. Completion Date:</b> Apr 95		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:cervical, radiation therapy, 5-FU, cisplatin, para-aortic lymph nodes				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

**Study Objective:** To evaluate the safety and efficacy of combined extended field radiation with cisplatin and 5-FU given as a radiation sensitizer.

**Technical Approach:** All patients who consent to participate in this study will be treated with both external radiation therapy and a local application of radiation therapy (brachy therapy). This technique is standard treatment in the management of cervical carcinoma. The treatment fields will be extended to include the para-aortic lymph nodes. Intravenous cisplatin and 5-FU will be administered during radiation. Cisplatin 50 mg/m<sup>2</sup> IV will be given on the first day of the first week and again four weeks subsequently in an intravenous bolus infusion. The 5-FU 1000 mg/m<sup>2</sup> will be given by a continuous infusion over four consecutive days (Days 2, 3, 4, 5, and 30, 31, 32, 33) starting on the second day of radiation therapy through the fifth and repeated four weeks later. Intracavitary radiation will be delivered by cesium utilizing standard or commonly used applicators providing that acceptable radiation dose symmetry can be determined. Following the completion of therapy, patients will be seen every three months for two years and every six months for an additional three years after which time they will be seen at yearly intervals.

The variables to be collected, analyzed and reported to evaluate the effectiveness of extended field radiation and cisplatin/5-FU are divided into the outcome variables and covariates. The Outcome Variables are: 1) Recurrence-free survival 2) Survival time 3) Morbidity of extended field radiation therapy and cisplatin/5-FU 4) and Degree of adherence to the protocol treatment.

**Progress:** No patients were enrolled at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/152		<b>Status:</b> On-going	
<b>Title:</b> GOG 0126B: Evaluation of Cisplatin (NSC #119875) and Cyclosporin in Recurrent, Platinum-Resistant and Refractory Ovarian Cancer					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Aug 94		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer:ovarian, cisplatin, cyclosporin					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** 1. To determine if the addition of cyclosporin to cisplatin therapy reduces drug resistance and thereby increases chemo-sensitivity of platinum refractory ovarian cancer to cisplatin. 2. To determine if the addition of cyclosporin to cisplatin is tolerated without significant toxicity.

**Technical Approach:** Patients with platinum refractory epithelial ovarian carcinoma who progress while on treatment or recur within six months of the most recent treatment with platinum containing compounds are eligible for this study. Patients will be treated as inpatients. Cyclosporin 4 mg/kg over two hours followed six hours later by cisplatin 75 mg/m<sup>2</sup> given at 1 mg/min followed the next day by cyclosporin 4 mg/kg (again over two hours). This cycle will be repeated every 21 days, until disease progression or significant toxicity precludes further treatment.

**Progress:** There have been no participants in the study during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/085		<b>Status:</b> Completed
<b>Title:</b> GOG 0127B: Evaluation of Isotretinoin and Alpha Interferon in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix				
<b>Start Date:</b> 04/02/93		<b>Est. Completion Date:</b> Mar 94		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> Cancer:cervix, isotretinoin, alpha interferon				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

Study Objective: To determine the activity of the combination of oral isotretinoin and interferon in the treatment of advanced or recurrent squamous cell carcinoma of the cervix.

Technical Approach: This study will assess the efficacy of daily oral isotretinoin at 1 mg/kg in combination with alpha interferon 6 million units per day subcutaneously in the treatment of recurrent curative therapeutic modalities. Patients eligible are patients who have been previously treated for advanced and recurrent Squamous Cell Carcinoma of the cervix including up to one previous chemotherapeutic regimen. Daily administration of these agents will be undertaken for a minimum of four weeks. If progression of disease or toxicity is significant, therapy will be discontinued. As long as a tumor response is noted therapy will continue at those doses. Once stabilization of the disease has been achieved or after a minimum of three months of treatment, a maintenance dose of isotretinoin at 0.5 mg/kg per day orally will be initiated and the alpha interferon will be reduced to 3 million units, three times a week subcutaneously. This maintenance therapy will continue until disease progression or irreversible side effects preclude further therapy. Tumor measurements by physical examination and, if necessary, radiological evaluation will be obtained during the course of treatment. After treatment is discontinued alternative treatment plans will be discussed with the patient.

Progress: No patients entered this study at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/150		<b>Status:</b> On-going
<b>Title:</b> GOG 0127C: Evaluation of Cisplatin and Pentoxifylline in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix				
<b>Start Date:</b> 08/06/93		<b>Est. Completion Date:</b> Aug 94		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:cervix, cisplatin, pentoxifylline				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** 1. To determine if the addition of methylxanthine pentoxifylline enhances the cytotoxicity of cisplatin in patients with recurrent or advanced squamous cell carcinoma of the cervix. 2. To determine if the side effects when combining pentoxifylline with cisplatin are acceptable.

**Technical Approach:** Patients with measurable, recurrent or advanced squamous cell carcinoma of the cervix consenting to participate will be entered into a treatment regimen consisting of cisplatin 75 mg/m<sup>2</sup> given every three weeks. Pentoxifylline will be given at 1600 mg orally every eight hours for nine doses (3 days). Treatment will continue for six cycles or until progression or toxicity precludes further therapy.

**Progress:** No patients entered this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/023		<b>Status:</b> On-going
<b>Title:</b> GOG 0132: A Phase III Randomized Study of Cisplatin versus Taxol versus Taxol and Cisplatin in Patients with Suboptimal Stage III and IV Epithelial Ovarian Carcinoma				
<b>Start Date:</b> 11/06/92		<b>Est. Completion Date:</b> Oct 95		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:ovarian, taxol, cisplatin				
<b>Accumulative MEDCASE Cost:</b> \$0.00		<b>Est. Accumulative OMA Cost:</b> \$0.00		<b>Periodic Review:</b> / /

**Study Objective:** To compare the efficacy of Cisplatin and Taxol alone and together in the treatment of advanced suboptimal Stages III or IV epithelial ovarian carcinoma and to determine which of the three regimens contributes most favorably to progression-free interval and survival.

**Technical Approach:** Patients with suboptimal Stages III or IV epithelial ovarian carcinoma will be randomized into one of three treatment regimens. Regimen I will be Cisplatin only, Regimen II Taxol only and Regimen III taxol plus Cisplatin. Patients will receive the chemotherapeutic regimen assigned at 21 day intervals for six cycles. Patients with clinical evidence of disease are strongly encouraged to undergo a second look laparotomy to assess response to treatment. Additionally patients will be followed for disease and survival.

The median time to progression for these women treated with a cisplatin-based regimen is 10.4 and 14.4 months with measurable disease and non-measurable disease respectively. The median time to death is 18.5 and 22.5 months respectively. The expected response rate in those women with measurable disease is 60%.

If one of these treatment regimens can increase the median time to progression by 40% (28.6% decrease in the relative failure rate), then this is considered clinically significant. A 30-month accrual period (600 patients) with an additional 12-month follow-up period will provide an 82.5% chance of detecting that one of these regimens provides this magnitude of treatment effect while limiting the type I error to 0.05. The null hypothesis being: the failure rates in each of the three treatment arms are equal.

There is an 80% chance of rejecting the null hypothesis significance if one of these regimens increases the frequency of clinical response by 19% (i.e. 60% to 79%) while limiting the type I error to 0.05.

**Progress:** No patients entered this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/006		<b>Status:</b> On-going
<b>Title:</b> GOG 0134: A Phase III Trial of Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma				
<b>Start Date:</b> 10/02/92		<b>Est. Completion Date:</b> Oct 95		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:ovarian, Taxol				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** 1. To determine if the dose of taxol affects response rate, progression free interval or survival in patients with platinum-resistant ovarian cancer. 2. To compare the toxicities of the three regimens. 3. To compare the efficacy and toxicity of two dose levels of G-CSF (5 ug/kg/day versus 10 ug/kg/day) in patients who receive the highest taxol dose (250 mg/m<sup>2</sup>). 4. To determine the relationship between peak taxol plasma concentration and toxicity/response.

**Technical Approach:** Patients with platinum-resistant ovarian carcinoma will be stratified according to the presence of measurable disease. They will then be randomized to Regimen I, II, IIIa, or IIIb. Regimen I: Taxol 135 mg/m<sup>2</sup> by 24 hr continuous infusion, Day 1, every 21 days x 6 doses. Regimen II: Taxol 175 mg/m<sup>2</sup> by 24 hr continuous infusion, Day 1, every 21 days x 6 doses. Regimen IIIa: Taxol 240 mg/m<sup>2</sup> by 24-hour continuous infusion Day 1 and G-CSF 5 ug/kg/day day 3 through the nadir until ANC is greater than or equals 10,000/ul, every 21 days. Regimen IIIb: Taxol 250 mg/m<sup>2</sup> by 24-hour continuous infusion Day 1 and G-CSF 10 ug/kg/day Day 3 through the nadir until ANC is greater or equals 10,000/ul, every 21 days. At the completion of six courses of therapy surgical reassessment, if done, should be performed in those patients with clinically complete responses within eight weeks following the last cycle of chemotherapy. Minimum length of trial to evaluate response is defined as receiving one course of therapy and surviving three weeks for repeat measurement to be performed.

**Progress:** No patients entered this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/139		<b>Status:</b> On-going
<b>Title:</b> GOG 0137: A Randomized Trial of Estrogen Replacement Therapy Versus No Estrogen Replacement in Women With Stage I or II Endometrial Adenocarcinoma				
<b>Start Date:</b> 06/09/93		<b>Est. Completion Date:</b> Nov 20		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:endometrial, estrogen replacement				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

Study Objective: To determine if the use of estrogen replacement therapy significantly increased the risk of developing recurrence of endometrial cancer after primary treatment.

Technical Approach: Patients entered into this study will be have endometrial cancer without evidence of metastatic disease beyond the uterus or cervix. Some patients will have been simultaneously entered into a protocol randomizing them to receive radiation or no radiation. Other patients will have received treatment with or without radiation as recommended by their primary physician and/or choice. Patients who are randomized to estrogen replacement therapy will be taking estrogen on a daily basis for the duration of the study. Starting @ .625 mg per day and increasing to a maximum of 1.25 mg per day as needed for hot flashes. Patients who do not receive estrogen replacement therapy will have blood samples obtained every 3 - 6 months for serum estradiol levels to insure the exclusion of an external source of estrogen. All patients will receive yearly mammograms. All other follow up is in a standard fashion.

Progress: No patients have been enrolled in the study at MAMC.



### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/086		<b>Status:</b> On-going
<b>Title:</b> GOG 0138: A Phase II Trial of Cisplatin and Cyclophosphamide in the Treatment of Extraovarian Peritoneal Serous Papillary Carcinoma				
<b>Start Date:</b> 04/02/93		<b>Est. Completion Date:</b> Dec 93		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> Cancer:papillary, cisplatin, cyclophosphamide				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To systematically evaluate through a large group cooperative study the clinical behavior of Extraovarian Peritoneal Serous Papillary Carcinoma to similarly staged ovarian carcinoma with a similar residual disease.

**Technical Approach:** Patients with advanced Extraovarian Peritoneal Serous Papillary Carcinoma with greater than 1 cm residual tumor at the completion of initial debulking surgery will be eligible for this protocol. This is largely a registry protocol, dictating the mode of standard treatment. This standard treatment utilizes Cyclophosphamide 750 mg IV per meter squared and Cisplatin 75 mg per meter squared administered at three week intervals for a total of six cycles. Subsequent to completion of chemotherapy, a second look procedure will be performed to ascertain disease status in those patients who have either demonstrated a complete response as noted on physical examination, radiologic studies or patients who never demonstrated measurable disease. A clinical-pathological correlation will be made with the disease progression as well as a comparison made to previous GOG protocols with similarly staged and graded ovarian tumors of serous origin. Patients will be followed in a standard fashion at three month intervals for at least two years and at potentially decreased intervals there after.

**Progress:** No patients entered this study at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/087		<b>Status:</b> On-going
<b>Title:</b> GOG 0139: A Randomized Study of Doxorubicin Plus Cisplatin versus Circadian-Timed Doxorubicin Plus Cisplatin in Patients with Primary Stages III and IV, Recurrent Endometrial Adenocarcinoma				
<b>Start Date:</b> 04/02/93		<b>Est. Completion Date:</b> Mar 96		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> Cancer: endometrial, doxorubicin, cisplatin, circadian timed doxorubicin				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

**Study Objective:** 1. To evaluate the potential benefit of the administration of Circadian-timed, chemotherapy versus standard administration of chemotherapy utilizing Doxorubicin and Cisplatin. 2. To evaluate the relative toxicities of these two techniques of administration.

**Technical Approach:** This study will assess the relative benefit either in improved response rate or decreased toxicity by changing the method of delivery of the chemotherapeutic agents from an arbitrarily administered event to a timed delivery method. Patients will be randomized to receive either standard Doxorubicin/Cisplatin infusions given at a dose of Doxorubicin 60 mg per meter squared, IV Push followed by Cisplatin 60 mg per meter squared over 30 minutes immediately following the Doxorubicin in one treatment regimen as opposed to Doxorubicin at the same dose given IV Push over 30 minutes at 6 a.m. with the Cisplatin at 60 mg per meter squared delivered over 30 minutes at 6 p.m. Both chemotherapeutic regimen would be delivered every 3 weeks for a maximum of eight treatments. Dose reduction would occur initially because of advanced age or previous pelvic radiation therapy. Only patients with advanced or recurrent measurable Adenocarcinoma, Adenoacanthoma, Adenosquamous carcinomas, whose potential for cure by radiation therapy or surgery, alone or in combination is very poor. Prior to each cycle of chemotherapy, patients will be evaluated by history, physical examination, and the usual radiologic test required for monitoring tumor response. The treatment will continue for a maximum of eight treatments or until the tumor progresses.

**Progress:** No patients entered this study at MAMC during FY 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/140		<b>Status:</b> On-going	
<b>Title:</b> GOG 0140: An Assessment of Age and Other Factors Influencing Protocol Versus Alternative Treatments for Patients With Epithelial Ovarian Cancer Referred to Gynecologic Oncology Group Institutions					
<b>Start Date:</b> 06/09/93			<b>Est. Completion Date:</b> May 94		
<b>Department:</b> GOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC					
<b>Associate Investigators:</b> None					
<b>Key Words:</b> cancer: ovarian, protocol enrollment					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To evaluate the reasons for inclusion or exclusion from GOG protocol studies.

**Technical Approach:** All patients with epithelial ovarian carcinoma, including borderline tumors who are primarily evaluated at MAMC will be eligible for participation in this study. All patients who have signed an informed consent will then have a questionnaire filled out regarding the relevant clinical material as well as selected underlying medical conditions; age, education, race, marital status, gravida and parity. Reasons for exclusion, either medical or other will be listed. Type of initial surgery performed, location of the surgery and types of subsequent therapy will also be entered on this questionnaire. After the completion of this study, which will include 800 subjects nationally, a GOG statistical office will analyze the data. Follow up of these patients is not a requirement of this study.

**Progress:** No patients entered this study at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/149		<b>Status:</b> On-going
<b>Title:</b> GOG 0143: Familial and Reproductive Factors in Ovarian Cancer				
<b>Start Date:</b> 08/06/93		<b>Est. Completion Date:</b> Aug 95		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer: ovarian, familial factors, reproductive factors				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

Study Objective: 1. To further define the epidemiologic pattern of patients with invasive ovarian carcinoma. 2. To store genetic material for comparison should a genetic marker be identified in the future utilizing risk factors for the development of ovarian cancer to target a patient population suitable for screening.

Technical Approach: Patients identified with invasive ovarian carcinoma will be asked to complete a questionnaire. Additionally, two tubes of blood will be obtained and forwarded for storage, for potential DNA analysis. This is an epidemiologic study and requires no follow-up of the patients.

Progress: No patients entered this study at MAMC during FY 93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/039		<b>Status:</b> Completed
<b>Title:</b> GOG 8809: Flow Cytometrically Determined Tumor DNA Content in Ovarian Tumors of Low Malignant Potential				
<b>Start Date:</b> 03/17/89		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> tumor:ovarian,low malignant potential,DNA,flow cytometry				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

Study Objective: To determine if the DNA content of borderline ovarian tumors (carcinoma of low malignant potential) can be correlated with extent/stage of tumor, potential for recurrence, and patient survival.

Technical Approach: This study proposed to determine the DNA content in paraffin-embedded tumor specimens in patients with any stage of disease entered on GOG Protocol #72. These data will be correlated with stage of disease at entry, as well as recurrence/ progression of disease. Specimens of recurrent tumor will also be analyzed to determine the effect of treatment on DNA content. At least one representative paraffin-embedded ovarian tumor specimen from the pretreatment laparotomy must be available as well as follow-up information including second look laparotomy findings (if done) or time to progression and follow-up after negative second look laparotomy and survival. When one or more of the blocks has been obtained, specimens for flow cytometric determination of tumor cell DNA content and, if possible, cell cycle distribution will be prepared by a modification of the method described by Hedley, et al (Cytometry 6:32733, 1985).

Progress: There was no activity at MAMC during FY 93 on this study.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/026		<b>Status:</b> On-going
<b>Title:</b> GOG 8907: DNA Content of Hydatidiform Moles as a Predictor of Persistent Gestational Trophoblastic Neoplasia				
<b>Start Date:</b> 01/19/90		<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> GOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Mark E. Potter, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> trophoblastic neoplasia,DNA,hydatidiform moles				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		02/05/93

**Study Objective:** To determine: if aneuploidy identifies a subset of high-risk hydatidiform moles; if ploidy status has sufficient predictive value to justify prophylactic chemotherapy of certain molar pregnancies; if proliferative activity, as estimated from cell cycle distribution, has any prognostic value; the number of paraffin blocks that constitutes an appropriate sampling of a molar pregnancy in order to establish presence of aneuploid cell lines; and if ploidy or proliferative index, as measured on either the mole or subsequent biopsy material, can predict the pattern of post-molar gestational trophoblastic neoplasia to be either metastatic or nonmetastatic and the response to various treatment regimens; and to assess persistence of ploidy status by comparing ploidy of molar tissue with ploidy status of subsequent tissue samples obtained after development of post-molar gestational trophoblastic disease.

**Technical Approach:** Flow cytometry will be used to measure ploidy and proliferative rate on archival tissues on patients identified as having complete hydatidiform mole pregnancies. These patients have previously been identified by entry on GOG Protocol #55. Results of lab measurements on tissue will be compared to clinical characteristics of post molar course, treatment received, if any, and response to such treatment. The incidence of aneuploidy in tissue samples from staging work-up in those patients who have developed persistent gestational trophoblastic neoplasia will be assessed. Information regarding cell cycle kinetics and growth fraction will be used to correlate tumor responses to treatment regimens in consideration of cell cycle phase specificity for various agents.

**Progress:** No patients entered this study at MAMC during FY 93.

DETAIL SHEETS FOR PROTOCOLS

NATIONAL CANCER INSTITUTE

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 81/033		<b>Status:</b> Completed	
<b>Title:</b> NCI 7602: All Stage IC and II 9A,B,C) and Selected Stage IAii and IBii Ovarian Cancer					
<b>Start Date:</b> 01/16/81			<b>Est. Completion Date:</b> Jun 85		
<b>Department:</b> NCI			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Gordon O. Downey, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,surgery,melphalan,radiotherapy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
			<b>Periodic Review:</b>		11/17/89

**Study Objective:** To define the natural history of patients treated with surgery plus either chemotherapy or radioisotope; to study the effect of various potential prognostic factors on the natural history of patients treated by each form of therapy; to determine the patterns of relapse for each form of therapy; to establish the value of various staging parameters on the stage of disease and its natural history.

**Technical Approach:** All patients with common epithelial ovarian cancer are eligible, if after definitive staging procedures the patient is zoned to be in Stages 2A, 2B, 2C, IAii, 1Bii, or 1Ai or 1Bi with poorly differentiated tumors. Patients with prior therapy are ineligible. Patients will be stratified by histology, histological grade, and stage group for Regimen I. Regimen I will have staging laparotomy, total abdominal hysterectomy and bilateral salpingo-oophorectomy with no macroscopic residual disease found. Patients will then be randomized to receive melphalan or radioisotopes. Regimen II will be stratified by histology, histological grade, and extent of disease after surgery. Patients will have staging laparotomy, total abdominal hysterectomy, and bilateral salpingo-oophorectomy. If IIB, IIC, residual disease is found, will be randomized to pelvic radiotherapy plus melphalan alone. If after 18 months of therapy, the patient remains free of disease, chemotherapy will be discontinued. Second look will be done if the patient is free of disease after 18 months of chemotherapy.

**Progress:** This study was closed to patient entry in September 1986. All subjects at MAMC are now deceased and the study has been closed.



DETAIL SHEETS FOR PROTOCOLS

NATIONAL SURGICAL ADJUVANT BREAST & BOWEL  
PROJECT

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/171		<b>Status:</b> On-going	
<b>Title:</b> NSABP B-21: A Clinical Trial to Determine the Worth of Tamoxifen in the Management of Patients with Node-Negative, Occult, Invasive Breast Cancer Treated by Lumpectomy					
<b>Start Date:</b> 09/03/93			<b>Est. Completion Date:</b> Sep 98		
<b>Department:</b> NSABP			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Robert B. Ellis, MC					
<b>Associate Investigators:</b>					
LTC Howard Davidson, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Richard C. Tenglin, MC			MAJ Mark E. Robson, MC		
CPT Diana S. Willadsen, MC			CPT James S. D. Hu, MC		
MAJ Richard F. Williams, MC			LTC Robert D. Vallion, MC		
			CPT John R. Caton, MC		
<b>Key Words:</b> cancer:breast, tamoxifen, lumpectomy					
<b>Accumulative MEDCASE Cost:</b>		<b>\$0.00</b>	<b>Est. Accumulative OMA Cost:</b>		<b>\$0.00</b>
				<b>Periodic Review:</b>	
				/ /	

**Study Objective:** This study's primary aim is to test the hypothesis that long-term treatment with tamoxifen (with and without breast radiation) is effective in prolonging disease free survival in patients with occult, invasive cancer.

**Technical Approach:** Patients who have had a lumpectomy with tumor free margins and negative axillary nodes will be randomly assigned to one of three groups: lumpectomy and breast irradiation plus placebo; lumpectomy and breast irradiation plus tamoxifen; or lumpectomy and tamoxifen with irradiation. Tamoxifen (10 mg BID) or placebo will be started within 35 days of surgery. Breast radiation will begin as soon as wound healing permits but within 56 days of lumpectomy. Patients will be followed, at least annually, thereafter. The primary endpoints to be used for statistical analysis will be ipsilateral breast tumor reoccurrence and disease free survival.

**Progress:** No patients have yet been enrolled.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/147		<b>Status:</b> On-going	
<b>Title:</b> NSABP R-03: A Clinical Trial to Evaluate the Worth of Preoperative Multimodality Therapy (5-FU-LV and RTX) in Patients with Operable Carcinoma of the Rectum					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Jul 98		
<b>Department:</b> NSABP			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			MAJ Richard C. Tenglin, MC		
CPT James S. D. Hu, MC			LTC Robert D. Vallion, MC		
CPT Diana S. Willadsen, MC			CPT John R. Caton, MC		
<b>Key Words:</b> cancer:rectum, 5-FU, leucovorin, radiotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** 1). To determine whether the administration of chemotherapy (5-FU-LV with radiotherapy preoperatively is more effective than the administration of the chemotherapy and radiotherapy postoperatively in improving disease-free survival and survival in patients with operable carcinoma of the rectum. 2). To determine if the administration of the above chemotherapy and radiotherapy preoperatively results in improvement local recurrence rates when compared with the regimen administered postoperatively in this population of patients. 3). To evaluate the response of rectal tumors to preoperative chemotherapy and radiotherapy and to correlate that response with disease-free survival and survival. 4). To assess the downstaging effect of preoperative chemotherapy and radiotherapy on the tumor size and the pathologic status of regional lymph nodes. 5). To estimate the proportion of patients who can be converted to sphincter-saving surgical procedures from abdominoperineal resection. Furthermore, to estimate the proportion of patients who can be converted from sphincter-saving surgical procedures to local excision alone.

**Technical Approach:** This trial in patients with operable adenocarcinoma of the rectum compares the worth of seven cycles of 5-FU (FU) + leucovorin (LV) and radiotherapy (RTX), where the first three cycles are given preoperatively and the remaining four postoperatively, to seven cycles of FU-LV and RTX given postoperatively

The patients will be randomized into 2 groups. Group 1 patients, in cycle 1, will receive LV 500 mg/m<sup>2</sup> by IV infusion and FU 500 mg/m<sup>2</sup> will be started 1 hr later. Treatment will be given weekly for 6 weeks followed by a rest period. Treatment will be restarted 21 days after the date of administration of the sixth dose of the previous cycle. Radiotherapy will begin after completion of cycle 1. FU 325 mg/m<sup>2</sup>/day and LV 20 mg/m<sup>2</sup>/day will be given for 5 days during the first and fifth weeks of radiotherapy (cycles 2 and 3). Surgery will be performed after completion of the radiation therapy. After recovery from surgery, four more cycles of FU with LV, as in cycle 1, will be given for a total of seven cycles

Groups 2 patients should have surgery performed no later than 3 weeks after randomization. Chemotherapy will begin after recovery from surgery is complete but no later than 4 weeks postoperatively. LV and FU will be administered as in Group 1. Radiotherapy will begin after completion of cycle 1. Cycle 4 should begin after

completion of radiotherapy when counts allow, but no later than 5 weeks. Four more cycles of FU with LV will be given for a total of seven cycles.

The primary endpoints are diseases free survival and survival.

Progress: No patients have yet been enrolled.

DETAIL SHEETS FOR PROTOCOLS

PEDIATRIC ONCOLOGY GROUP

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/141		<b>Status:</b> On-going
<b>Title:</b> POG 8650: Intergroup National Wilms' Tumor Study - 4				
<b>Start Date:</b> 06/09/93		<b>Est. Completion Date:</b> Oct 97		
<b>Department:</b> POG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Bruce A. Cook, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer;pediatric, Wilms'				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		/ /

**Study Objective:** To compare 1) the relapse-free and overall survival percentages of patients with: Stage I and II favorable histology (FH) and Stage I anaplastic Wilms' tumor (Ana), using conventional versus pulse intensive (P/I) chemotherapy with vincristine and actinomycin D; (2) Stages 3 and 4 FH, and Stages 1-4 clear cell sarcoma of the kidney using conventional versus P/I vincristine, actinomycin D, and Adriamycin plus radiation therapy; (3) Stages 2-4 Ana treated with vincristine, actinomycin D, and Adriamycin versus the same 3 drugs plus cyclophosphamide, and radiation therapy; and (4) Stages 2-4 FH and Stage 1-4 clear cell sarcoma of the kidney treated for 6 versus 14 months after nephrectomy.

**Technical Approach:** All patients will be <16 years of age, have had no prior chemo-radiation therapy, will have undergone nephrectomy, and will meet other criteria as stated in the protocol. Patients will be randomized as follows: Stage II/FH & Stage I Ana receive A + V (24 wks) or P/I A + V (18 wks), Stage II/FH receive A + V (22 vs 65 wks) or P/I A + V (60 wks), Stages III & IV FH & clear cell (I-IV) receive A + V + D (26 vs 65 wks) plus RT or P/I A + V + D (24 vs 54 wks) plus RT, and Stages II-IV Ana receive A + V + D + C (65 wks) plus RT or A + V + D + C (65 wks) plus RT. Legend: A = actinomycin D, V = vincristine, D = doxorubicin (Adriamycin), C = cyclophosphamide, and RT = radiation therapy.

**Progress:** There has been one patient enrolled at MAMC in FY93.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/164		<b>Status:</b> On-going
<b>Title:</b> POG 9047: Neuroblastoma Biology Protocol				
<b>Start Date:</b> 09/03/93		<b>Est. Completion Date:</b> Feb 96		
<b>Department:</b> POG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Bruce A. Cook, MC				
<b>Associate Investigators:</b>		COL Stephen R. Stephenson, MC		
<b>Key Words:</b> cancer:neuroblastoma, biology				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /

**Study Objective:** 1) To obtain tissue for the analysis of DNA content of neuroblastoma cells by flow cytometry. 2) To characterize neuroblastoma tumor DNA from POG patients genetically by analysis of N-myc amplification and LOH for chromosome 1p. 3) To develop a reference bank of genetically characterized tumor tissue and DNA that would be available for other studies.

**Technical Approach:** This is a non-therapeutic study intended to collect tissue from newly-diagnosed neuroblastoma patients  $\leq 21$  years. Viable tumor tissue, frozen tumor tissue (or marrow) and serum will be collected and forwarded to a designated study site.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/135		<b>Status:</b> On-going	
<b>Title:</b> POG 9226: Treatment of Stages I, IIA, and IIIA Hodgkin's Disease With ABVE and Low Dose Irradiation					
<b>Start Date:</b> 07/02/93			<b>Est. Completion Date:</b> Jun 95		
<b>Department:</b> POG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Bruce A. Cook, MC					
<b>Associate Investigators:</b>			COL Stephen R. Stephenson, MC		
<b>Key Words:</b> pediatric cancer: Hodgkin's disease					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
<b>Periodic Review:</b>					/ /

**Study Objective:** 1) To study the activity of four cycles of Adriamycin, bleomycin, vincristine and etoposide (ABVE) followed by 2550 cGy irradiation in clinically or pathologically staged I, II or IIIa Hodgkin's Disease; 2) establish the response (CR and PR) rate following four cycles of ABVE; 3) determine the incidence of major therapy related immediate and late effects of the above regimen; 4) reduce the morbidity associated with therapy without decreasing the efficacy of treatment in Early Stage Hodgkin's Disease; 5) correlate the results of clinical, imaging, and laboratory staging with surgical/pathological staging where performed.

**Technical Approach:** All patients meeting the enrollment criteria will receive 2 of the 4 courses of Adriamycin, Bleomycin, Vincristine on days 1 and 15, and Etoposide on days 1 through 5 (ABVE). Patients will be evaluated after the 2nd course and if a response is seen, then 2 more courses will be given. If no response is seen the treatment will be changed.

Patients will again be evaluated after the 4th cycle and irradiation (2550 cGy) given >28 but <40 days after ABVE. If 4 cycles ABVE + low-dose RT is determined to be worthy of further study as described above, current plans are to compare it to ABVE + MOPP + low dose RT in a randomized trial.

**Progress:** No patients have entered this study at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/148		<b>Status:</b> On-going	
<b>Title:</b> POG 9233/34: A Phase III Randomized Trial of standard vs Dose-Intesntified Chemotherapy for Children Less Than 3 Years of Age With A CNS Malignancy Treated With or Without Radiation Therapy					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Jun 95		
<b>Department:</b> POG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Bruce A. Cook, MC					
<b>Associate Investigators:</b>			COL Stephen R. Stephenson, MC		
<b>Key Words:</b> cancer:CNS, pediatric, chemotherapy, radiotherapy					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To develop effective methods of treatment for very young children with malignant brain tumors that will minimize late toxicities affecting immature and rapidly developing central nervous systems.

**Technical Approach:** Patients < 3 yrs of age with a primary intracranial malignancy will be randomized to one of two regimens. Patients assigned to Regimen A will receive six 12-week courses of chemotherapy, given over a total of 72 weeks. Each course consist of 3 drug cycles. Cycle A; vincristine and cyclophosphamide and Mesna will be given on weeks 1, 13, 25, 37, 49 and 61. Vincristine will be repeated on day 8 of this cycle. During Cycle B, patients will receive cisplatin on day 1 and VP-16 on days 3 and 4. Patients on Regimen B will receive eight 9-week courses of chemotherapy. Each course will consist of 2 consecutive cycles of one drug combination (Cycle X) followed by a cycle of another combination (Cycle Y). On Cycle X, vincristine, and Mesna will be given on day 1 of weeks 1, 4, 10, 13, 19, 22, 28, 31, 27, 40, 49, 55, 58, 64, and 67. On day 2 patients will receive cyclophosphamide and Mesna. On days 3-15 patients will receive G-CSF. On Days 8 and 15, vincristine will be given. Cycle Y will be given on weeks 7, 16, 25, 34, 43, 52, 61 and 70. On Day 1 of Cycle Y, cisplatin will be given. VP-16 will be given on days 3 and 4. On days 5-14 G-CSF will be administered.

Patients experiencing progression or recurrence of disease at any time during or within 12 months of chemotherapy will be encouraged to begin radiation therapy immediately. If disease recurs later than 12 months after completing chemotherapy, patients will be discontinued from the study.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/134		<b>Status:</b> On-going
<b>Title:</b> POG 9340/41/42: Treatment of Patients Greater than or = 365 Days At Diagnosis With Stage 4 and N-MYC Amplified Stage 2B/3 Neuroblastoma; A Pediatric Oncology Group Phase II Study				
<b>Start Date:</b> 07/02/93		<b>Est. Completion Date:</b> Aug 95		
<b>Department:</b> POG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Bruce A. Cook, MC				
<b>Associate Investigators:</b>		COL Stephen R. Stephenson, MC		
<b>Key Words:</b>				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	/ /	

**Study Objective:** 1) 9340 Stage 4 (only) - 1.1) To evaluate the response rate to and toxicity of Phase II single-agent chemotherapy (either continuous infusion Adriamycin, or Taxol) given prior to Phase III therapy to two successive subsets of untreated patients  $\geq$  365 days of age with INSS Stage 4 neuroblastoma (NB). 2) 9341-2 Stage 5 and N-myc amplified Stage 2B or 3 (Stage C) - 2.1) To measure response rates and toxicity, event-free survival (EFS), survival, and patterns of failure, of patients treated with 6 courses of induction chemotherapy: high dose platinum/VP-16 (HDP/VP), cyclophosphamide/Adriamycin/ vincristine (CAV), ifosfamide/VP (IFOS/VP), CBDCA/VP, HDP/VP, and CAV plus G-CSF, followed by local radiotherapy and autologous bone marrow transplantation (ABMT) (POG #9342). 2.2) To measure response rates, toxicity, EFS, survival, and patterns of failure of patients whose families decline ABMT, and therefore receive an additional 5 courses of therapy (IFOS/VP, CAV, HDP/VP, CAV, CBDCA/VP) plus G-CSF followed by local radiotherapy to the tumor bed. 2.3) To further evaluate the toxicity of autologous bone marrow transplantation (ABMT) using cyclophosphamide/VP/CBDCA ablation plus local radiotherapy.(POG #9342) 2.4) To measure EFS, survival, and patterns of failure of patients who achieve a complete response or partial response or mixed response at the end of induction chemotherapy prior to ABMT. 2.5) To further evaluate the biologic parameters of neuroblastoma as required for POG 9047, and to measure MDR-1 protein (P-glycoprotein) levels, which will be obtained at diagnosis and in marrow purgates and/or available tumor tissue during therapy, with correlation to clinical presentation at diagnosis, clinical course, response to therapy, and survival. To study the activity of four cycles of Adriamycin, bleomycin, vincristine and etoposide (ABVE) followed by 2550 cGy irradiation in clinically or pathologically staged I, II and IIIA, Hodgkin's Disease.

**Technical Approach:** Patients participating in this study will initially receive two courses of either Adriamycin (IV continuously over 3 days) or taxol (IV continuously over 24 hours). Following initial treatment, intensive therapy with High-dose combinations of 7 drugs will begin. HDP/VP (High-dose cisplatin and VP-16), CAV (Cyclophosphamide, Adriamycin and Vincristine), IFOS/VP (Ifosfamide and VP-16), CBDCA/VP (Carboplatin and VP-16) are the combinations that will be used.

If, after the High-dose therapy, immunofluorescent testing shows  $< 5\%$  tumor cells the patient will be eligible for autologous bone marrow harvest in preparation for autologous bone marrow transplantation (ABMT). After the marrow is harvested Radiation therapy will be administered to the primary tumor bed. Those refusing ABMT will also receive local radiation therapy and additional courses of the High-dose drug combinations. Also, patients who do not meet eligibility criteria for ABMT will be

given additional courses of CAV, HDP/VP, CAV and CBDCA/VP. Patients going on to ABMT will receive ablation therapy beginning 7 to 10 days following radiation therapy. A prescribed course of VP-16, CBDCA, and Cyclophosphamide will be given, careful hydration insured and, when completed, ABMT will be performed. GM-CSF will be given to all patients to enhance rapid bone marrow recovery. Response to ABMT will be evaluated and follow up continued.

Progress: No patients have entered this study at MAMC.

DETAIL SHEETS FOR PROTOCOLS

PUGET SOUND ONCOLOGY CONSORTIUM

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/079		<b>Status:</b> Completed	
<b>Title:</b> PSOC 615: Intraperitoneal Consolidation Therapy Following Second-Look Operation in Ovarian Cancer					
<b>Start Date:</b> 05/15/87			<b>Est. Completion Date:</b> Indef.		
<b>Department:</b> PSOC			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Gordon O. Downey, MC					
<b>Associate Investigators:</b> COL William L. Benson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,P32,cisplatin,5-Flourouracil					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
			\$0.00		11/17/89

**Study Objective:** To examine the effect of intraperitoneal therapy on disease free survival in patients with no disease or minimal residual disease following second-look surgery and to document the complication rate associated with the use of intraperitoneal chronic phosphate or chemotherapy in patients previously treated with systemic chemotherapy.

**Technical Approach:** Following standard induction chemotherapy, patients with Stage IIb, IIc, or III epithelial carcinoma of the ovary will have second-look laparotomy in the standard fashion. The second look procedure will include resection of any remaining female genital organs. If the patient has no evidence of gross persistent disease greater than 1.0 cm at the time of second look, a Tenckhoff catheter will be inserted. If the pathologic findings from the second look procedure show no evidence of persistent tumor, the patient will receive 15 millicuries of intraperitoneal P-32 in 1000-1500 ml of normal saline, with appropriate rotation of position to assure proper distribution of the P-32. If the patient has positive disease within the peritoneal cavity, she will receive chemotherapy with cisplatin (100 mg/m<sup>2</sup>) and 5-FU (1000 mg/m<sup>2</sup>) through the Tenckhoff catheter every three weeks for a maximum of four doses unless there are unacceptable side effects.

**Progress:** This study is closed to patient entry. One patient was entered in FY 87 and is now deceased.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/066		<b>Status:</b> On-going	
<b>Title:</b> PSOC 1007: Adriamycin and Cefoperazone for Treatment of Carcinoma and Sarcoma Refractory to Adriamycin					
<b>Start Date:</b> 06/14/91			<b>Est. Completion Date:</b>		
<b>Department:</b> PSOC			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>					
MAJ William A. Phillips			LTC Howard Davidson, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Luke M. Stapleton, MC		
MAJ Robert L. Sheffler, MC			MAJ Patrick L. Gomez, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
<b>Key Words:</b> adriamycin, cefoperazone					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** To determine the complete and partial response rates to a combination of adriamycin and cefoperazone in patients who have had progression of non-Hodgkin's lymphoma, small cell lung carcinoma, sarcoma, breast or ovarian carcinoma while on an adriamycin-containing chemotherapeutic regimen or have progressed within six months of receiving such a regimen and to determine the toxicities of the addition of high dose cefoperazone to adriamycin in the treatment of refractory malignant disease.

**Technical Approach:** Adriamycin has been used extensively in the therapy of a number of malignancies. In many instances, the malignant cells become resistant and adriamycin becomes ineffective and is one of the agents implicated in multiple drug resistance (MDR). Because of its clinical value, the mode of action of adriamycin and the possible mechanisms of drug resistance have been the subject of extensive research. Cefoperazone has been purported to act as a modulator of MDR. It is hoped that high-dose cefoperazone will block the MDR capability of the cancer cells which will allow the adriamycin to remain within the cancer cells for a longer period of time, thereby allowing patients to go back into remission. All patients will receive intravenous cefoperazone weekly at a dose of 5 grams in 30 minutes, followed by a continuous IV infusion for three hours at 4 grams per hour. After the 30 minutes loading dose, patients will be given a bolus of adriamycin. Patients will be reevaluated after eight weeks. Patients will continue on treatment until there is evidence of disease progression; there is a decrease in ejection fraction by MUGA scan to <40% or a fall of 20 percentage points; or the patient develops symptoms of congestive heart failure.

**Progress:** One patient entered in FY 91 is still being followed.

DETAIL SHEETS FOR PROTOCOLS

SOUTHWEST ONCOLOGY GROUP

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 78/047	<b>Status:</b> On-going
<b>Title:</b> SWOG 7808: Combination Modality Treatment for Stage III and Stage IV Hodgkin's Disease, MOPP #6		
<b>Start Date:</b> 07/31/78	<b>Est. Completion Date:</b> Jan 88	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Howard Davidson, MC		
<b>Associate Investigators:</b> LTC H. Irving Pierce, MC		COL Friedrich H. Stutz, MC Suresh B. Katakhar, M.D., DAC
<b>Key Words:</b> Hodgkin's disease:Stages III & IV,chemotherapy,modality RX		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	12/04/92

**Study Objective:** To attempt to increase the complete remission rate induced with MOP-BAP (nitrogen mustard, vincristine, procarbazine, prednisone, adriamycin, and bleomycin) alone utilizing involved field radiotherapy in patients with Stages III and IV Hodgkin's disease achieving partial remission at the end of 6 cycles; and to determine if immunotherapy maintenance with levamisole or consolidation with low dose involved field radiotherapy will produce significantly longer remission durations over a no further treatment group when complete remission has been induced with 6 cycles of MOP-BAP in Stages III & IV Hodgkin's.

**Technical Approach:** Patients (>15 yrs) must have histologic diagnosis of Hodgkin's disease; no prior chemotherapy. Patients with a history of congestive heart failure, valvular heart disease, or serious obstructive or restrictive pulmonary disease will be excluded. Normal marrow patients will receive six cycles of MOP-BAP. Impaired bone marrow patients will receive six cycles of MOP-BAP with dose modifications. Complete Remission (CR) patients with prior radiotherapy will be randomized to Treatment 3 (no treatment) or Treatment 4 (levamisole). CR patients without prior radiotherapy will receive Treatment 5 (radiotherapy). Partial remission (PR) patients without prior radiotherapy or residual bone marrow involvement will receive Treatment 6 (radiotherapy). PR patients with prior radiotherapy or those with residual bone marrow involvement will receive Treatment 7 (4 additional cycles of MOP-BAP); after 10 total cycles of MOP-BAP, patient will continue study on MOP-BAP therapy at the discretion of the investigator.

**Progress:** This study was closed to patient entry 1 Dec 87. Seven patients were enrolled in previous years and 5 are still being followed.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 79/096		<b>Status:</b> On-going	
<b>Title:</b> SWOG 7827: Combined Modality Therapy for Breast Carcinoma, Phase III					
<b>Start Date:</b> 09/21/79			<b>Est. Completion Date:</b> Sep 81		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b> Suresh B. Katakhar, M.D., DAC			COL Friedrich H. Stutz, MC COL Irwin B. Dabe, MC		
<b>Key Words:</b> cancer:breast,chemotherapy,modality therapy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 12/04/92

**Study Objective:** To compare the disease-free interval and recurrence rates in: (1) estrogen receptor positive (ER+) premenopausal patients with Stage II disease using combination chemotherapy alone vs combination chemotherapy and oophorectomy; (2) ER+ postmenopausal patients with Stage II disease using combination chemotherapy plus tamoxifen vs tamoxifen alone vs combination chemotherapy alone; (3) estrogen receptor negative (ER-) patients with Stage II disease using one vs two years of combination chemotherapy; to compare the effect of adjuvant therapy in Stage II breast cancer using partial mastectomy and radiation vs modified radical or radical mastectomy; to compare the effect of the various adjunctive therapy programs upon survival patterns; and to correlate the estrogen receptor status with disease-free interval and survival.

**Technical Approach:** Patients with a histologically proven diagnosis of breast cancer (Stage II or Stage III) with one or more pathologically involved axillary nodes will receive one of the following treatments: (CMFVP = cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone): (1) CMFVP for 1yr pre- or postmenopausal ER patients. (2) CMFVP for 2 yr pre- or postmenopausal ER patients. (3) CMFVP for 1 yr premenopausal ER+ patients. (4) Oophorectomy + CMFVP premenopausal ER+ patients. (5) Tamoxifen alone for 1 yr postmenopausal ER+ patients. (6) CMFVP for 1 yr postmenopausal ER+ patients. (7) Tamoxifen + CMFVP for 1 yr postmenopausal ER+ patients. Patients undergoing segmental mastectomy (lumpectomy) will receive 6 wks of radiation therapy in addition to the treatment they are randomized to receive.

**Progress:** Thirty-five patients were enrolled prior to closure of patient enrollment 15 Aug 90. Twenty-four patients are still being followed.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 84/018		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8216/38: Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer					
<b>Start Date:</b> 11/18/83			<b>Est. Completion Date:</b> Sep 85		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			COL William D. Belville, MC		
COL Friedrich H. Stutz, MC			COL Irwin B. Dabe, MC		
MAJ Thomas M. Baker, MC			MAJ Alfred H. Chan, MC		
MAJ Timothy J. O'Rourke, MC			MAJ Michael D. Stone, MC		
<b>Key Words:</b> cancer:bladder,BCG,adriamycin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		\$0.00	<b>OMA Cost:</b>		\$0.00
				12/04/92	

**Study Objective:** To compare the effectiveness of intravesical BCG immunotherapy with intravesical Adriamycin in chemotherapy with respect to disease-free interval and two-year recurrence rate; to compare the toxicity of topical immunotherapy and chemotherapy; and to obtain experience regarding disease-free interval and the recurrence rate in patients who develop tumor recurrence and are then crossed over to the alternative treatment arm.

**Technical Approach:** Following a standard transurethral resection, patients will be stratified by the presence or absence of documented carcinoma in situ and as to prior chemotherapy and then randomized to receive BCG immunotherapy or Adriamycin chemotherapy. Patients who develop tumor recurrence following treatment will be eligible for crossover to the other treatment arm.

**Progress:** This study was closed to patient entry 20 Dec 85. Three patients were enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 83/056	<b>Status:</b> On-going
<b>Title:</b> SWOG 8294: Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer (ECOG, EST-1180), Intergroup Study		
<b>Start Date:</b> 03/18/83	<b>Est. Completion Date:</b> Feb 85	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Howard Davidson, MC		
<b>Associate Investigators:</b>		LTC James E. Congdon, MC
COL Friedrich H. Stutz, MC		COL Irwin B. Dabe, MC
MAJ Timothy J. O'Rourke, MC		MAJ Alfred H. Chan, MC
MAJ Thomas M. Baker, MC		
<b>Key Words:</b> cancer:breast,surgery,biological parameters		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	12/04/92

**Study Objective:** To assess the impact of short-term intensive chemotherapy with CMFP to prevent disease recurrence and prolong survival in node negative patients with any size estrogen receptor negative tumors and node negative patients with estrogen receptor positive tumors whose pathological size is >3 cm; to assess the impact of surgical procedure, estrogen receptor status, menopausal status and tumor size; to develop guidelines referable to histopathological features of node negative tumors which are reproducible and to assess their prognostic impact for disease-free survival and survival; to assess the value to CEA in predicting recurrence and survival rates; to assess the natural history of a subgroup with node negative, estrogen receptor positive small tumors (3 cm).

**Technical Approach:** Patients will have laboratory evaluations to ensure that there is no evidence of disseminated disease. They will be stratified into a number of treatment groups based on the site of tumor, estrogen receptor status, age, and menopausal status. Patients with primary tumors less than 3 cm in diameter who are estrogen receptor positive will be followed by close observation only to determine the natural history of their tumor. All other patients who have a somewhat greater likelihood of relapse will be randomized to receive either close observation only or 6 cycles of systemic chemotherapy. The chemotherapy will consist of 4 agents: cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone given for six 28 day cycles. The dosage of the individual agents will be determined by body height and weight.

**Progress:** This study was closed to patient entry 15 May 88. Eleven patients were enrolled in previous years and 10 continue to be followed. One patients has expired.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 84/059		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8313: Multiple Drug Adjuvant Chemotherapy for Patients with ER Negative Stage II Carcinoma of Breast, Phase III					
<b>Start Date:</b> 05/18/84			<b>Est. Completion Date:</b> May 86		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			COL Friedrich H. Stutz, MC		
COL Irwin B. Dabe, MC			MAJ Thomas M. Baker, MC		
MAJ Timothy J. O'Rourke, MC			MAJ Michael D. Stone, MC		
<b>Key Words:</b> cancer:breast,chemotherapy,emergency room					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>OMA Cost:</b>			
\$0.00		\$0.00		12/04/92	

**Study Objective:** To compare through a randomized prospective study the recurrence rates and disease-free intervals for postoperative axillary node positive estrogen receptor negative breast cancer patients given adjuvant therapy with either short term intense chemotherapy (FAC-M) or one year standard chemotherapy (CMFVP); to compare the effect of these two adjuvant therapies on survival; to compare the relative toxicity of the two therapies; to compare the quality of life of patients with operable breast cancer randomized to receive one year of CMFVP or a short intensive regimen of FAC-M x 4 courses; and to compare a multiple item questionnaire for assessing quality of life.

**Technical Approach:** Women who have histologically proven breast cancer with axillary lymph node metastasis and negative estrogen receptors will be entered 14-21 days post-lumpectomy or within 14-42 days post-mastectomy and randomly assigned to receive: Arm I a tapering course of oral prednisone for 6 weeks, weekly IV vincristine for 10 weeks, weekly IV methotrexate, and weekly IV 5-FU plus daily oral cyclophosphamide for a total of one year; or Arm II four cycles of adriamycin (IV day 1), cyclophosphamide (IV day 1), 5-FU (IV days 1 and 8), and methotrexate (IV day 22). Each cycle will be five weeks and total duration of therapy in this arm is approximately 20 weeks. Questionnaires to compare quality of life will be completed at 72 hours prior to chemotherapy. Added to this protocol will be a sub-study to determine the prognostic significance of circulating human mammary epithelial antigens. This will involve blood tests prior to chemotherapy and then once every three months.

**Progress:** This study was closed to patient entry 15 Jun 90. Three patients were enrolled, 2 have died and 1 continues to be followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 86/007		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8417/19: Evaluation of Two Consolidation Regimens in the Treatment of Adult Acute Lymphoblastic Leukemia, Phase III					
<b>Start Date:</b> 10/18/85			<b>Est. Completion Date:</b> Sep 87		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
LTC Lauren K. Colman, MC			LTC Howard Davidson, MC		
MAJ Thomas M. Baker, MC			MAJ Michael D. Stone, MC		
CPT David R. Bryson, MC					
<b>Key Words:</b> leukemia:lymphoblastic,consolidation regimens					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To compare the effects on remission duration and survival of two consolidation regimens: the L-10-M consolidation used in SWOG 8001 versus a regimen employing daunomycin, cytosine, arabinoside, 6-thioguanine and escalating methotrexate/Lasparaginase in patients with adult lymphoblastic leukemia and to compare the toxicities of the two consolidation regimens.

**Technical Approach:** Patients will begin remission induction with vincristine, prednisone, adriamycin, methotrexate, cyclophosphamide, and adriamycin (36 days), followed by a 14 day rest period. On day 30, patients will have an Ommaya reservoir placed in the frontotemporal area of the skull. Patients failing to achieve an A1 marrow status on induction therapy will go off study. Patients with complete remission will be randomized to one of the following consolidation regimens: ARM I (L-10-M) methotrexate and Ara-c, daily x 5 on days 1, 36, and 71; Ara-c and 6-thioguanine every 12 hr for 12 doses on days 15, 50, and 85; methotrexate days 15, 17, 57, and 59; vincristine and prednisone days 50 and 57; L-asparaginase beginning day 99, three times weekly for a total of 6 doses, and cyclophosphamide day 110 following last dose of L-asparaginase. Arm II: daunomycin days 1-3, Ara-C continuous infusion days 1-5, 6-thioguanine every 12 hr days 15, followed by a 21-28 day rest period. Methotrexate every 10 days from 28-98, L-asparaginase every 10 days 29-99. After a 2-week rest period, maintenance therapy will begin with vincristine, prednisone, adriamycin, 6-mercaptopurine, methotrexate (IT), methotrexate PO, dactinomycin, vincristine, prednisone, BCNU, cyclophosphamide, 6-mercaptopurine, and methotrexate (repeated every 21 weeks for 36 months or until relapse. An adequate trial will be the completion of remission induction.

**Progress:** This study closed to patient entry 15 Jan 93. No patients were enrolled at MAMC in FY93 but 5 patients had been enrolled previously. All patients enrolled at MAMC have died but 1 patient has transferred in and is being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/033		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8501 (INT 0051): Intraperitoneal Cis-platinum/IV Cyclophosphamide vs IV cis-platinum/IV Cyclophosphamide in Patients with Non-measurable (Optimal) Disease Stage III Ovarian Cancer, Phase III ....					
<b>Start Date:</b> 01/16/87			<b>Est. Completion Date:</b> Dec 89		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Thomas M. Baker, MC		
COL Irwin B. Dabe, MC			LTC Lauren K. Colman, MC		
MAJ David M. Dunning, MC			MAJ Ruben D. Sierra, MC		
CPT David R. Bryson, MC			COL Roger B. Lee, MC		
<b>Key Words:</b> cancer:ovarian,chemotherapy,IP,IV cyclophosphamide,cisplatinum					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To perform a Phase III randomized trial of intermediate dose intraperitoneal (IP) cis-platinum and intravenous (IV) cyclophosphamide vs intermediate dose IV cis-platinum and cyclophosphamide for optimal Stage III ovarian cancer; to evaluate the comparative toxicities of the two regimens; and to determine, in the setting of a prospective randomized trial, if the human tumor clonogenic assay with a wide range of drug concentration testing can accurately predict pathologic complete response to two-drug combination therapy in the setting of systemic and IP drug administration.

**Technical Approach:** Only patients with epithelial neoplasms will be eligible. Patients will be stratified by amount of residual disease and performance. They will be randomized to Arm I or Arm II. Arm I: IV cisplatin, 100 mg/m<sup>2</sup> plus IV cyclophosphamide, 600 mg/m<sup>2</sup> every 28 days for six courses. Arm II: IP cisplatin, 100 mg/m<sup>2</sup> plus IV cyclophosphamide, 600 mg/m<sup>2</sup>, every 28 days for six courses. Patients with partial or no response will go off study. Those with clinical complete response will undergo second look laparotomy. Those with residual tumor at second look laparotomy will be taken off study and entered in an appropriate protocol. Those with pathologic complete response will be followed by observation only until evidence of progression of disease appears. All patients who receive any amount of chemotherapy will be evaluable for toxicity. Patients who receive at least two courses of therapy will be evaluable for response and survival.

**Progress:** This study was closed to patient entry 15 Jul 92. One patient was entered in Dec 86 and refused second look surgery so he was taken off the protocol, but is being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/107		<b>Status:</b> On-going
<b>Title:</b> SWOG 8507: Maintenance versus No Maintenance BCG Immunotherapy of Superficial Bladder Cancer, Phase III				
<b>Start Date:</b> 08/21/87			<b>Est. Completion Date:</b> Aug 90	
<b>Department:</b> SWOG			<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Howard Davidson, MC				
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC	
COL William D. Belville, MC			COL Victor J. Kiesling, MC	
LTC Lauren K. Colman, MC			MAJ Thomas M. Baker, MC	
MAJ David M. Dunning, MC			MAJ Ruben D. Sierra, MC	
CPT Denis Bouvier, MC				
<b>Key Words:</b> cancer:bladder,BCG,immunotherapy				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>	
\$0.00		\$0.00	12/04/92	

**Study Objective:** To compare the effectiveness of intravesical and percutaneous BCG immunotherapy given on a maintenance versus no maintenance schedule with respect to disease-free interval and rate of tumor recurrence in patients with transitional cell carcinoma of the bladder; to assess the toxicity of maintenance and no maintenance BCG immunotherapy; and to assess the association of intermediate strength PPD skin test reactivity with disease free status in patients treated with BCG immunotherapy.

**Technical Approach:** Patients will be stratified according to prior chemotherapy, disease type, and PPD skin test conversion. One week following a standard transurethral resection, BCG, 120 mg lyophilized BCG organisms will be diluted in 50.5 cc of sterile, preservation-free saline. Fifty cc will be administered intravesically and 0.5 cc will be administered percutaneously. The BCG administration will be repeated weekly for a total of six weeks. Patients will then be randomized to the BCG maintenance or no maintenance arms. The BCG maintenance arm will consist of weekly intravesical and percutaneous BCG immunotherapy administrations repeated for three consecutive weeks at three months, six months, and every six months thereafter for a total treatment period of 36 months. Patient removal from the study will be determined by the type of tumor. Any patient with progression of disease, defined by an increase in tumor grade or stage beyond the highest previous grade or stage or an increase in the number or frequency or recurrences will be removed from the study.

**Progress:** This study closed to patient entry 15 Dec 88. Eleven patients were entered in the study and 10 are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/003		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8520: Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II					
<b>Start Date:</b> 10/16/87			<b>Est. Completion Date:</b> Sep 90		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Thomas M. Baker, MC		
COL Irwin B. Dabe, MC			LTC Lauren K. Colman, MC		
MAJ David M. Dunning, MC			MAJ Ruben D. Sierra, MC		
CPT Denis Bouvier, MC			COL William D. Belville, MC		
<b>Key Words:</b> cancer:penis,cis-diamminedichloroplatinum,methotrexate,bleomycin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To determine the response rate in patients with advanced epidermoid carcinoma of the penis treated with cisplatin, methotrexate, and bleomycin and to evaluate the toxicity of this three-drug combination in this patient population.

**Technical Approach:** Cis-platinum, 75 mg/m<sup>2</sup>, will be administered by IV infusion at 1 mg/min in normal saline (1 mg/cc) on day 1. Prior to, during, and after treatment with cis-platinum, the patient will be vigorously hydrated, intravenously and orally. Lasix, 40 mg IV bolus, will be given prior to cis-platinum. Patients will also receive methotrexate, 25 mg/m<sup>2</sup>, IV bolus on days 1 and 8 and bleomycin, 10 units/m<sup>2</sup>, IV bolus on days 1 and 8. Courses will be repeated every 21 days provided absolute granulocyte count is >1500/ ml and platelet count is >100,000/ ml. Dosage modifications will be made for all three drugs following the initial and all subsequent cycles of chemotherapy, using standard Southwest Oncology Group chemotherapy toxicity criteria for any of the following toxicities: hematopoietic, renal, pulmonary, and neurotoxicity. Chemotherapy with bleomycin will be discontinued when a total cumulative dose of 200 units/m<sup>2</sup> has been reached. Two cycles of chemotherapy will constitute an adequate trial. Patients with stable or responding disease will continue on treatment beyond two cycles until evidence of disease progression or unacceptable toxicity. Patients who have achieved a complete remission will discontinue all chemotherapy after six cycles. Patients who achieve a complete response will receive 6 courses of treatment.

**Progress:** No patients have been entered in this study at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 85/073		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8590: Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck, Phase III (Intergroup Group.....					
<b>Start Date:</b> 06/28/85			<b>Est. Completion Date:</b> May 87		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Thomas M. Baker, MC		
COL Friedrich H. Stutz, MC			COL Irwin B. Dabe, MC		
COL William J. Gernon, MC			MAJ Timothy J. O'Rourke, MC		
MAJ Michael D. Stone, MC			CPT David R. Bryson, MC		
LTC Donald B. Blakeslee, MC					
<b>Key Words:</b> head & neck,surgery,chemotherapy,radiotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To test whether the addition of chemotherapy to surgery and radiotherapy prolongs disease-free survival and survival between the two study groups; to test whether the addition of chemotherapy to surgery and radiotherapy increases local control rates at the primary site and/or the cervical neck nodes; and to determine if the patterns of failure have been changed with the addition of chemotherapy.

**Technical Approach:** After surgery, patients will be randomized to either chemotherapy plus radiation therapy or radiation therapy alone. In the chemotherapy plus radiation therapy group, the chemotherapy will start 2-4 weeks after surgery and the radiotherapy will start approximately two weeks after completing chemotherapy. In the radiation therapy alone group, the radiation therapy will begin 2-4 weeks after surgery. Chemotherapy will be cisplatinum give day 1 and 5 FU given days 1-5 and repeated every 21 days for three courses. Patients who develop local or distant recurrence following therapy will be treated at the physician's discretion.

**Progress:** This study was closed to patient entry 1 Feb 90. Three patients were entered in previous years.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 85/064		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8591: NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III - Intergroup					
<b>Start Date:</b> 05/24/85			<b>Est. Completion Date:</b> Apr 87		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Thomas M. Baker, MC		
COL Friedrich H. Stutz, MC			COL Irwin B. Dabe, MC		
MAJ Jens A. Strand, MC			MAJ Timothy J. O'Rourke, MC		
MAJ Michael D. Stone, MC			CPT David R. Bryson, MC		
<b>Key Words:</b> cancer:colon,levamisole,5-Fluorouracil					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To assess the effectiveness of levamisole alone and levamisole plus 5-FU as surgical adjuvant regimens for resectable colon cancer; to compare each regimen to untreated controls to determine whether it yields improved survival and if it yields improved time to recurrence, with evaluations conducted independently in patients with Dukes stage B and Dukes stage C lesions.

**Technical Approach:** Patients with adenocarcinoma arising in the colon who have had a potentially curative section will be eligible. The patients with modified Dukes B2 (serosal penetration) or B3 (invasion of adjacent organs by direct extension) will be randomized to either follow-up without adjuvant therapy or adjuvant therapy with levamisole plus 5-FU. Patients with modified Dukes Stage C (involvement of regional lymph nodes) will be randomized to follow-up without adjuvant therapy, adjuvant therapy with levamisole alone, or adjuvant therapy with levamisole plus 5-FU.

**Progress:** This study was closed to patient entry 21 Oct 87. Seven patients were enrolled in previous years and 6 are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 87/045		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8600: A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-lymphocytic Leukemia					
<b>Start Date:</b> 02/27/87			<b>Est. Completion Date:</b> Feb 90		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
LTC Lauren K. Colman, MC			LTC Howard Davidson, MC		
MAJ Thomas M. Baker, MC			MAJ David M. Dunning, MC		
MAJ Ruben D. Sierra, MC			CPT David R. Bryson, MC		
<b>Key Words:</b> leukemia:non-lymphocytic,Ara-C,daunorubicin,cytosine arabinoside					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To compare, among patients with acute nonlymphocytic leukemia, the rate of complete remission produced by induction regimens of either standard dose cytosine arabinoside and daunorubicin or high-dose cytosine arabinoside and daunorubicin; to compare the duration of complete remission and of disease-free survival among patients who receive one of the three combinations of induction and consolidation regimens listed below; to determine the comparative toxicities of these three programs, and to determine the feasibility of implementing a predetermined approach to supportive care for these patients in a multi-institutional cooperative group setting.

**Technical Approach:** Patients will be stratified according to age and institution. Induction therapy will consist of standard dose Ara-C plus daunorubicin (Arm I) or high dose Ara-C + daunorubicin (Arm II). Patients requiring a second cycle of induction will receive the same doses as cycle 1, following the recovery of hematologic toxicities. Consolidation chemotherapy will begin when bone marrow and blood counts have recovered or on day 28 after the last induction cycle. Patients initially randomized to Arm I will be randomized to Arm III (high dose, one cycle only) or Arm IV (standard dose, two cycles). Patients initially randomized to Arm II (high dose) will be assigned to Arm III. Following the completion of consolidation, no further therapy will be given and patients will be followed only. Supportive care will include a predetermined antibiotic regimen determined by the physician.

**Progress:** This study was closed to patient entry 1 Dec 91. Of the seven patients enrolled at MAMC, 5 have died and 2 are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/045		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8621: Chemohormonal Therapy of Postmenopausal Receptor-Positive Breast Cancer, Phase III					
<b>Start Date:</b> 03/17/89			<b>Est. Completion Date:</b> Mar 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
CPT Denis Bouvier, MC			MAJ Kenneth A. Bertram, MC		
<b>Key Words:</b> cancer:breast,postmenopausal,chemohormonal therapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$2316.00		12/04/92	

**Study Objective:** To compare initial combined chemo-hormonal therapy with initial hormonal therapy with respect to survival; to compare chemo-hormonal therapy using tamoxifen with that using DES with respect to survival; and to compare combined chemohormonal therapy with initial hormonal therapy with respect to response in patients with measurable disease.

**Technical Approach:** Postmenopausal females with recurrent or disseminated breast cancer, tumor positive for estrogen receptor or progesterone receptor, and adequate bone marrow and hepatic function will be eligible. Patients who have received prior hormonal therapy or chemotherapy will not be eligible. Prior adjuvant chemotherapy will be allowed if disseminated disease developed more than six months after completing adjuvant therapy, except for tamoxifen and DES. Patients with a history of deep vein thrombosis, cerebral embolus, stroke, congestive heart failure, or ischemic heart disease will not be eligible. No concurrent malignancy is allowed except for cured non-melanoma skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for five years. Patients will be stratified by dominant disease (osseous vs soft tissue vs visceral) and disease status. Descriptive factors will be prior adjuvant therapy; presence or absence of ascites or pleural effusions; performance status; disease free interval; number of metastatic sites, and receptor status. Patients will be randomized to: Arm I (DES); Arm II (Tamoxifen); Arm III (DES + 5-FU + cyclophosphamide + methotrexate); or Arm IV (Tamoxifen + 5-FU + cyclophosphamide + methotrexate). Patients who respond (or have prolonged disease stabilization at six months and then relapse) to tamoxifen or DES will be treated with sequential secondary and tertiary hormonal therapy if they continue to have endocrinereceptor tumors. Patients with progressive disease or short term stable disease will go off study.

**Progress:** One patients was enrolled in this study prior to closure to patient entry 1 Aug 91. This patient continues to be followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/058		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8692 (INT 0075): Therapy in Premenopausal Women with Advanced, ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs the LH-RH Analog, Zoladex; Phase III, Intergroup					
<b>Start Date:</b> 05/19/89			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Kenneth A. Bertram, MC			CPT Denis Bouvier, MC		
<b>Key Words:</b> cancer:breast,surgical oophorectomy,Zoladex,ER,PgR positive					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To compare the response rate, the time to treatment failure, and survival of medical castration using Zoladex to surgical castration in premenopausal women with advanced, ER+ or PgR+ breast cancer; to assess the response rate to surgical castration in patients failing to respond to or relapsing on Zoladex and the response rate to Zoladex in patients failing to respond to or relapsing on surgical castration; to compare toxicities of medical castration and surgical castration; to assess the value of post-treatment hormone levels in predicting response to medical castration; and to assess the effect of long term Zoladex treatment on hormone levels in responding patients.

**Technical Approach:** Patients must have a performance status of 02. Patients with extensive liver metastases, lymphangitic lung metastases, or prior hormone therapy or chemotherapy for advanced disease will be ineligible. Prior adjuvant chemotherapy is allowed; adjuvant tamoxifen is allowed provided relapse occurred > 6 months after completion of therapy. Patients will be stratified by disease status, dominant site of disease, performance status, and prior adjuvant tamoxifen (yes or no). Patients will be randomized to receive either surgical oophorectomy or Zoladex, 3.6 mg subcutaneously every four weeks. Surgical castration patients clearly progressing after six weeks will be crossed over to Zoladex. Patients then developing progressive disease will be taken off study. Zoladex patients with clearly progressive disease after six weeks will cross over to surgical oophorectomy. Upon development of progressive disease, patients will be removed from the study.

**Progress:** No patients have been enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/039		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8710: Trial of Cytectomy Alone Versus Neoadjuvant M-VAC + Cytectomy in Patients with Locally Advanced Bladder Cancer (INT-0080/EST- 1877, CALGB-8891)					
<b>Start Date:</b> 02/16/90			<b>Est. Completion Date:</b> Mar 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Rodney C. Davis, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Mark H. Kozakowski, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
CPT Denis Bouvier, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert L. Sheffler, MC			LTC John A. Vaccaro, MC		
<b>Key Words:</b> cancer:bladder,cystectomy,M-VAC					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To study insulin induced hypoglycemia as a model of acute stress and to determine if the change in testosterone seen with acute stress is related to cortisol alone or whether it can also be seen with the stimulation of other adrenal precursor products.

**Technical Approach:** Ten healthy male volunteers (18-35 years) who are without evidence of current acute or chronic illness will have an insulin tolerance test done with blood samples drawn for cortisol, testosterone, immunoactive LH, bioactive LH, estradiol, and glucose, every 15 minutes for one hour prior to the human insulin bolus to establish baseline values. Blood samples will continue to be drawn every 15 minutes for 180 minutes after injection of the insulin. SHBG will be measured on the first and last sample and endorphin levels will be measured at baseline and at times corresponding to maximal hypoglycemia. A standard multiple dose metyrapone test will be performed one month from the insulin tolerance test. Just before the first dose and four hours after the last dose, serum samples will be obtained for cortisol, estradiol, immunoactive LH, bioactive LH, testosterone, ACTH, SHBG, endorphins, and 11-deoxycortisol. The relationship of bioactive LH to immunoactive LH will be compared using the biologic to immunologic ratio both before and during the acute stress. The data from the metyrapone test will be used to determine if metyrapone can cause a decrease in serum testosterone acutely. Again, the B/I ratio will be compared pre and post-test. Changes in serum concentrations of the measured hormones will be analyzed by repeated measures analysis of variance.

**Progress:** No patients have been entered in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/084		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8719: Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients Without Prior Endocrine Manipulation, Phase II					
<b>Start Date:</b> 06/15/90			<b>Est. Completion Date:</b> May 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Everardo E. Cobos Jr., MC		
MAJ Paul C. Sowray, MC			MAJ Mark H. Kozakowski, MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> cancer:prostate,Didemnin B,Ifosfamide,Mesna,endocrine resistance					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To evaluate the likelihood of response for each regimen in order to assess whether either treatment should be advanced to further studies; to evaluate the qualitative and quantitative toxicities of the regimens; and to explore the response rate, toxicity, and time to progression of patients with no prior or concomitant endocrine treatment who are treated with Ifosfamide/ Mesna for measurable Stage D2 prostatic cancer.

**Technical Approach:** Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate and advanced (Stage D2) disease with objective evidence of progression following prior endocrine treatment. Newly diagnosed Stage D2 patients without prior endocrine manipulation will be placed directly on Arm II. Patients will be randomized to either Arm I (Didemnin B, IV, once every 28 days) or to Arm II (Ifosfamide and Mesna, IV, days 1-5, every 21 days). After two courses of treatment, patients will be evaluated, and will continue on the same arm until progression of disease.

**Progress:** This study was closed to patient entry 15 Mar 93. No patients were entered at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/065		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8736: Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy					
<b>Start Date:</b> 07/15/88			<b>Est. Completion Date:</b> Jun 91		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
CPT Denis Bouvier, MC			MAJ Steven S. Wilson, MC		
MAJ Rahul N. Dewan, MC					
<b>Key Words:</b> lymphoma:non-Hodgkin's,radiotherapy,CHOP,chemotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To evaluate, in a cooperative group setting, the difference in survival, time to treatment failure, and toxicity of two curative approaches to the treatment of patients with localized, intermediate or high grade non-Hodgkin's lymphoma.

**Technical Approach:** All patients must have biopsy proven non Hodgkin's lymphoma of intermediate or high grade histology except lymphoblastic lymphoma. Patients must have had all visible tumor removed (excisional biopsy) and must have clinically adequate liver and myocardial function to begin treatment at full doses. Patients with known central nervous system disease, previous cancer with a possibility for recurrence which might affect survival or prior chemo or radiotherapy will be ineligible. All patients will be stratified at the time of initial registration by the following: (1) age (<65 years vs >65 years); (2) Stage (I or Ie vs nonbulky II or IIe); (3) histology (diffuse large cell vs other); (4) location of disease (GI involved vs non-GI, abdominal vs non-GI, other); (5) all disease resected vs residual measurable disease. Patients will be randomized to CHOP\* (Arm I) or to CHOP plus radiation therapy (Arm II). A complete course of chemotherapy on Arm I will consist of the administration of CHOP every 21 days for eight consecutive cycles unless progressive disease develops. A complete course of chemotherapy for Arm II will consist of the administration of CHOP every 21 days for three consecutive cycles unless progressive disease develops. Radiation therapy will begin immediately after the third cycle of CHOP. Radiation therapy dose, duration, and treatment volume will be determined jointly by the radiation oncologist and the medical oncologist. All patients will be followed at three month intervals until death. CHOP: Cyclophosphamide, 750 mg/m<sup>2</sup> IV, day 1; Doxorubicin, 50 mg/m<sup>2</sup> IV, day 1; Vincristine, 1.4 mg/m<sup>2</sup> IV, day 1; Prednisone, 100 mg/day po, days 1-5.

**Progress:** Eight patients have been enrolled at MAMC (2 in FY93) and all continue to be followed.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/076		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8738: Treatment of Extensive Non-small Cell Lung Cancer: Standard Dose Cisplatin versus High-Dose Cisplatin in Hypertonic Saline Alone versus High-Dose Cisplatin/Mitomycin-C, Phase III					
<b>Start Date:</b> 09/16/88			<b>Est. Completion Date:</b> Sep 91		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b> MAJ Mark H. Kozakowski, MC MAJ Kenneth A. Bertram, MC			COL Irwin B. Dabe, MC CPT Denis Bouvier, MC		
<b>Key Words:</b> cancer:lung:non-small cell,cisplatin,mitomycin-C					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		12/04/92	

**Study Objective:** To compare standard dose cisplatin chemotherapy to high dose cisplatin in hypertonic saline alone to high dose cisplatin/mitomycin-C in a randomized study with stratification for known important prognostic factors with regard to response rate, response duration, and survival duration; and to compare the relative toxicities of these three chemotherapy regimens in patients with extensive non-small cell lung cancer.

**Technical Approach:** Patients will be randomized to one of the following arms: Arm I: standard dose cisplatin (50 mg/m<sup>2</sup>, IV) every four weeks for a maximum of eight cycles; ARM II: high dose cisplatin alone (100 mg/m<sup>2</sup>, IV) every four weeks for a maximum of four cycles; ARM III: high dose cisplatin (100 mg/m<sup>2</sup> IV) plus mitomycin-C (8 mg/m<sup>2</sup> IV) given every four weeks for a maximum of four cycles. All patients will have an initial assessment of response after two cycles and then reassessment after four cycles of therapy. Patients on Arm I who respond to treatment may receive continued therapy to a maximum of eight cycles. Upon progression of disease, unacceptable toxicity, or patient request, patients will be taken off treatment. All patients will be followed until death.

**Progress:** This study was closed to patient entry 1 Jun 90. Five patients were enrolled at MAMC in previous years and 2 continue to be followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/063		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8789: A Randomized Study of Etoposide + Cisplatin and Etoposide + Carboplatin (CBDCA) in the Management of Good Risk Patients With Advanced Germ Cell Tumors					
<b>Start Date:</b> 04/20/90			<b>Est. Completion Date:</b> Apr 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> tumor:germ cell,etoposide,cisplatin,carboplatin,CBDCA					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

Study Objective: To determine in a randomized trial the differences in response, toxicity, time to relapse, and survival between two active chemotherapy regimens; etoposide + cisplatin and etoposide + carboplatin, for good risk patients with germ cell tumors.

Technical Approach: Patients with active advanced Stage II or Stage III testicular nonseminomatous germ cell tumor with a probability of complete response of >0.5 will be eligible. Patients will be randomized to Treatment Arm A (carboplatin + etoposide, given every 28 days for four cycles) or Treatment Arm B (cisplatin + etoposide every 21 days for four cycles). Following completion of chemotherapy, a complete assessment of all sites of disease will be performed. Following completion of four cycles of chemotherapy and radiographic and marker assessment, surgical resection of all residual masses will be done if deemed necessary by the principal investigator. If no residual malignant tumor or only mature teratoma is completely resected at surgery, no further therapy will be administered. If residual malignant tumor is found but is completely excised, then two more cycles of treatment will be administered. If residual malignant tumor is found but is unresectable, then the patient will receive additional therapy with standard GCT regimens or other therapy as may be indicated at the discretion of the treating physician.

Progress: This study closed to patient entry 15 Dec 90. One patient was enrolled at MAMC and is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/040		<b>Status:</b> Terminated	
<b>Title:</b> SWOG 8793 (EST-3883): Randomized Phase III Evaluation of Hormonal Therapy versus Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prost					
<b>Start Date:</b> 02/16/90			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Rodney C. Davis, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Mark H. Kozakowski, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
CPT Denis Bouvier, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert L. Sheffler, MC			LTC John A. Vaccaro, MC		
<b>Key Words:</b> cancer:prostate,hormonal therapy,lymphadenectomy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To determine the time to progression and survival in patients with histologically confirmed Stage D1 adenocarcinoma of the prostate, following radical prostatectomy and pelvic lymphadenectomy, treated with no immediate hormonal therapy compared to those treated immediately with hormonal therapy; to determine the effect of early hormone therapy on local control of D1 prostate cancer; to determine whether the effects of hormonal manipulation on progression or patterns of failure are modified by tumor grade, prior TUR, number and grade of involved nodes; to determine if an initially elevated acid phosphatase level predicts a poor response to therapy; to determine whether pretreatment hypogonadism is predictive of a poor response to hormonal therapy; and to evaluate the role of the prostate specific antigen in assessing response, progression, and survival.

**Technical Approach:** Patients must have undergone a radical prostatectomy within 12 weeks prior to randomization and must have no evidence of disease. Patients with a history of previous hormonal, radiation, systemic or intravesical chemotherapy, a history of other neoplasms in the past 5 years, and those previously treated for prostate cancer (except for prostatectomy and/or pelvic lymph node dissection) are ineligible. Patients will be randomized to hormonal therapy (Zoladex or orchiectomy) or to observation. The treating physician, after consultation with the patient, will determine if the patient receives Zoladex or orchiectomy therapy. Patients randomized to observation, who subsequently progress systemically, will have hormonal management instituted within 6 weeks of systemic progression. Patients randomized to hormonal therapy or who are later put on hormonal therapy will be taken off study if disease progression occurs.

**Progress:** This study was terminated Mar 93 due to poor patient accrual. No patients were enrolled in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/066		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8796: Combination Chemotherapy for Advanced Hodgkin's Disease, Phase III Intergroup (INT 0074)					
<b>Start Date:</b> 07/15/88			<b>Est. Completion Date:</b> Jun 91		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b> CPT Denis Bouvier, MC			COL Irwin B. Dabe, MC		
<b>Key Words:</b> Hodgkin's Disease, chemotherapy					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 12/04/92

Study Objective: To compare the effectiveness of the MOPP/ABV hybrid with sequential MOPP---->ABVD in patients with advanced or recurrent Hodgkin's disease and to determine which regimen is superior with respect to the following parameters: complete response rate, duration of complete response, freedom from progression, and survival.

Technical Approach: Patients must have histologic confirmation of Hodgkin's disease with no prior chemotherapy. Patients will be stratified according to age, prior radiotherapy, bulky disease, and performance status. They will then be randomized to MOPP repeated every 28 days for 6 cycles (Arm I) or to MOPP/ABV Hybrid repeated every 28 days for six cycles (Arm II). Patients on Arm I with a complete response will go on to ABVD repeated every 35 days for three cycles. Those with partial response will receive two MOPP cycles and then go on to ABVD for three cycles. Those with no change will go off study. Those patients on Arm II with complete response will receive two more cycles of MOPP/ABV. Those with partial response will continue MOPP/ABV to complete response or until a maximum of 12 cycles. Those with no change will be taken off study. MOPP: Nitrogen mustard, 6 mg/m<sup>2</sup> IV, days 1 and 8, Vincristine, 1.4 mg/m<sup>2</sup> IV, days 1 and 8, Procarbazine, 100 mg/m<sup>2</sup> PO per day x 14 days, Prednisone 40 mg/m<sup>2</sup> PO per day x 14 days. ABVD: Adriamycin, 25 mg/m<sup>2</sup> IV, days 1 and 15, Bleomycin, 10 units/m<sup>2</sup> IV, days 1 and 15, Vinblastine, 6 mg/m<sup>2</sup> IV days 1 and 15, DTIC, 375 mg/m<sup>2</sup> IV, days 1 and 15. The MOPP/ABV hybrid consist of the MOPP regimen plus adriamycin, 35 mg/m<sup>2</sup> IV, day 8; bleomycin, 10 units/m<sup>2</sup> IV day 8; and vinblastine, 6 mg/m<sup>2</sup> IV, day 8.

Progress: This study was closed to patient entry 1 Aug 89. On patient was enrolled at MAMC (FY88)

## Detail Summary Sheet

**Date:** 30 Sep 92      **Protocol No.:** 93/165      **Status:** On-going

**Title:** SWOG 8807: An Investigation of the Relationship Between an Integrated, System Education Approach and Breast Self Exam (BSE) Compliance, Phase III

**Start Date:** 09/03/93      **Est. Completion Date:** Sep 98

**Department:** SWOG      **Facility:** MAMC

**Principal Investigator:** MAJ Timothy P. Rearden, MC

<b>Associate Investigators:</b>	MAJ Luke M. Stapleton, MC
LTC Howard Davidson, MC	MAJ Kenneth A. Bertram, MC
MAJ Patrick L. Gomez, MC	MAJ Mark E. Robson, MC
MAJ Robert B. Ellis, MC	MAJ Richard C. Tenglin, MC
CPT James S. D. Hu, MC	LTC Robert D. Vallion, MC
CPT Diana S. Willadsen, MC	CPT John R. Caton, MC

**Key Words:** cancer:breast, self exam

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** This is a short-term randomized Phase III cancer control study to compare three educational approaches for teaching breast self exam (BSE) to healthy women who do not have learning disabilities.

**Technical Approach:** Healthy women, 20-65 years, with no history of breast cancer and consenting to participate will be administered the Intake Compliance Measurement Evaluation, scheduled for a six month follow-up visit, and told they will receive a phone contact at six and 12 months. They will then be randomized to one of three arms. ARM I participants will receive BSE instruction by physician only; ARM II will receive physician instruction + BSE class by a registered nurse; ARM III will receive physician instruction + BSE class + reinforcements in the form of calendar sticker, phone calls and monthly follow-up reminders. All BSE participants will receive a packet of educational material and be able to demonstrate a knowledge of the steps/methods for effective BSE.

Accuracy and frequency of BSE will be evaluated at six months. The Compliance Measurement Evaluation will again be administered and the participant will be asked to demonstrate BSE on the breast plate model. Twelve month follow up will be conducted by phone to determine accuracy and frequency (utilizing the Compliance Measurement form). All data will be submitted to the SWOG statistical center.

**Progress:** No patients have been enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/064		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8809: A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas					
<b>Start Date:</b> 04/20/90			<b>Est. Completion Date:</b> Apr 94		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> lymphoma,alpha-interferon,ProMACE-Mopp,chemo					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To compare the disease-free survival of patients with low grade malignant lymphoma who receive alpha-interferon consolidation therapy after intensive induction with chemotherapy, with or without radiation therapy, to those who receive induction therapy alone; to determine the complete response rate, response duration, and survival of low grade lymphoma patients treated with ProMACE-MOPP; and to compare the toxicities of induction and induction plus consolidation therapy in this patient population.

**Technical Approach:** Patients must have biopsy proven, measurable, Stage III or IV non-Hodgkin's lymphoma of low grade histology. Patients will receive 6 cycles of induction chemotherapy (ProMACEMOPP, days 1-8) unless progressive disease develops during this treatment. At the completion of induction therapy, patients will be restaged to assess response. Patients whose clinical disease has disappeared and who appear to be in complete remission will undergo a complete radiographic and laboratory evaluation for evidence of persistent lymphoma approximately one month after completion of chemotherapy. If no evidence of disease is found these patients will be randomized to Alpha IFN or observation. Patients in partial response and whose bone marrow remains positive after 6 cycles of induction chemotherapy will receive 2 additional cycles of chemotherapy and then be reevaluated. If the bone marrow remains involved or the patient has less than a partial response after a total of 8 cycles, the patient will be removed from further protocol therapy. If after 8 cycles, the bone marrow is negative and the patient is in partial response, the patient will receive radiotherapy. Complete responders after induction chemotherapy; complete responders after induction chemotherapy plus radiation therapy; and partial responders after chemotherapy plus radiation therapy will be randomized to consolidation alpha interferon or observation, approximately one month after completion of therapy.

**Progress:** Three patients have been entered at MAMC (1 in FY93). All patients are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/054		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8810: Six Courses of 5-Fluorouracil & Cisplatinum with Correlation of Clinical & Cellular DNA Parameters in Patients with Advanced, Untreated, & Unresectable Squamous Cell Carcinoma of the.....					
<b>Start Date:</b> 03/16/90			<b>Est. Completion Date:</b> Mar 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Mark H. Kozakowski, MC		
MAJ Everardo E. Cobos Jr., MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
MAJ Michael R. Morris, MC					
<b>Key Words:</b> cancer:head & neck,DNA,5-Fluorouracil,cisplatinum					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$8200.00		12/04/92	

**Study Objective:** To evaluate, following three and six courses of treatment, the likelihood of increased numbers of patients achieving complete response rates when given three additional courses of the same regimen; to evaluate the qualitative and quantitative toxicities of 5-fluorouracil and cisplatinum following three and six courses of treatment; and to evaluate by serial biopsy and flow cytometry the correlation of the cellular DNA parameters of degree of aneuploidy (DNA index) and proliferative activity (SPF) with the patients clinical characteristics, tumor morphology, cytotoxic response, disease free interval, and survival.

**Technical Approach:** Patients must have a histologically confirmed diagnosis of advanced unresectable squamous cell carcinoma of the head and neck, Stage IV, and not be eligible for SWOG protocol of higher priority. Nasopharyngeal primary tumor will be excluded. Biopsy specimens for flow cytometry will be taken before treatment. Patients will be treated with three courses of 5-FU and cisplatinum combination chemotherapy. Patients achieving a partial response or complete response will continue for an additional three courses of therapy. Patients who have no response after three courses will be taken off study and a biopsy will be taken for flow cytometry. Patients will have a triple endoscopy and re-biopsy of the primary site and lymph nodes for flow cytometry analysis within four weeks of completion of treatment following the full six courses of therapy or at any time that disease recurs. All patients will be followed until death.

**Progress:** No patients entered at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/065		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8812: Treatment of Limited Small Cell Lung Cancer With Concurrent Chemotherapy, Radiotherapy, With or Without GM-CSF and Subsequent Randomization To Maintenance Interferon or No Maintenance					
<b>Start Date:</b> 06/16/89			<b>Est. Completion Date:</b> Jun 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			COL Irwin B. Dabe, MC		
LTC Howard Davidson, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Kenneth A. Bertram, MC			CPT Denis Bouvier, MC		
MAJ Mark H. Kozakowski, MC					
<b>Key Words:</b> cancer:lung:small cell,chemo,radiotherapy,GM-CSF,interferon					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>\$0.00</b>	<b>OMA Cost:</b>		<b>\$0.00</b>
				<b>12/04/92</b>	

**Study Objective:** To compare the days of neutropenia, the days of leukopenia, the incidence and severity of infections, the incidence and duration of fever, the days on antibiotics, and the days of hospitalization between patients receiving GM-CSF and those not receiving it; to evaluate the toxicities of GM-CSF; to evaluate the ability of rHuIFN  $\alpha 2$  a to prolong remission duration and survival; and to evaluate the toxicities of rHuIFN  $\alpha 2$  a.

**Technical Approach:** Patients must have histologically proven small cell carcinoma of the lung. Prior to treatment patients will be staged as to the extent of disease. Only patients with limited disease are eligible for this study. Patients must have evaluable or measurable disease, a pretreatment WBC  $>4,000$  ml, absolute granulocyte count  $>1500$  ml, platelet count  $>100,000$ /ml, serum creatinine of  $<2.0$  mg%, creatinine clearance of  $>50$  ml/min, and performance state of 0-2 by SWOG criteria. Pregnant patients or those with prior radiation therapy, chemotherapy, colony stimulating factors, or interferon are not eligible. Patients with malignant pericardial or pleural effusions, a past medical history of congestive heart failure, extensive pulmonary disease, poor pulmonary reserve, or a history of seizures are ineligible. Patients will be stratified at initial registration by institution and at second registration according to performance status (0-1 vs 2); sex; response; and induction arm. Patients will be randomized to receive induction chemotherapy (cis-platinum + VP-16) and concurrent chest radiotherapy with or without GM-CSF. Consolidation chemotherapy will be as in induction but with no radiotherapy. Those patients achieving a complete remission will be randomized to receive or not receive maintenance therapy with recombinant alpha interferon. All patients who have achieved a complete response by week 33 will receive prophylactic cranial irradiation to the brain. Patients with stable disease, progression, or relapse at any point will be taken off study.

**Progress:** This study closed to patient enrollment 1 Jan 92. Three patients were enrolled at MAMC, 2 have died and 1 is still being followed.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/080		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8814 (ECOG 4188, NCCTG 883051): Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Breast....					
<b>Start Date:</b> 09/15/89			<b>Est. Completion Date:</b> Sep 99		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Paul C. Sowray, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> cancer:breast,chemoendocrine therapy,CAF,tamoxifen					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$8692.00	12/04/92	

**Study Objective:** To compare disease-free survival and overall survival of postmenopausal primary breast cancer patients with involved axillary nodes and positive estrogen and/or progesterone receptors treated with standard adjuvant therapy with long-term Tamoxifen or with chemoendocrine therapy with CAF, followed by long-term Tamoxifen or with concurrent chemoendocrine therapy with Tamoxifen and CAF and to compare the relative toxicity of the three therapies.

**Technical Approach:** Tumors must be pathologic stage T1, T2, or T3; N; MO (Stage II or selected Stage IIIA). Patients must have histologically proven adenocarcinoma of the breast with at least one positive lymph node (tumor and/or nodes must not be fixed). Patients must have undergone a radical, modified radical, or breast sparing procedure plus axillary dissection (level I or level II). Patients with bilateral breast cancer are ineligible. Estrogen and progesterone receptors must be assayed and one and/ or the other must be positive by the institutional laboratory standards of >10 fmol/mg protein. Prestudy studies must reveal no evidence of metastatic disease. Prior hormonal or chemotherapy is not allowed and prior postmenopausal estrogen therapy is allowed but must be discontinued before registration. Stratification factors will include: involved nodes (1-3, >4); PgR+ (ER positive or negative) vs PgR(ER positive); time from surgery to randomization (<6 vs >6 weeks). Patients will be randomized to one of three treatment arms: Arm I: Tamoxifen x 5 years, Arm II: Intermittent CAF x 6 courses followed by Tamoxifen x 5 years, Arm III: Intermittent CAF x 6 courses with concurrent Tamoxifen x 5 years.

**Progress:** Six patients have been entered in this study at MAMC (1 in FY93). All six of the patients are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/020		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8816: Study of 13-cis Retinoic Acid (Accutane) Plus Interferon-A (Roferon-A) in Mycosis Fungoides, Phase II					
<b>Start Date:</b> 12/07/90			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC			MAJ William A. Phillips		
MAJ Patrick L. Gomez, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Robert L. Sheffler, MC			MAJ Kenneth A. Bertram, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
<b>Key Words:</b> mycosis fungoides, retinoic acid, interferon-A					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		12/04/92	

Study Objective: To evaluate the response rate of mycosis fungoides treated with the drug combination of 13-cis retinoic acid (Accutane) plus alpha interferon (Roferon-A) and to assess the qualitative and quantitative toxicities of the regimen in a phase II study.

Technical Approach: Mycosis fungoides is an uncommon lymphoma manifesting initially with skin presentation, but the disease is felt to be incurable. The regimen will be 13-cis retinoic acid, 1.0 mg/kg/day, po in two divided doses (plus vitamin E, 400 IU/day) and alpha interferon,  $3 \times 10^6$  microgm/m<sup>2</sup> subcutaneously, three times per week. After eight weeks of treatment, patients with progressive disease will go off treatment. Patients with stable disease or partial or complete remission will be treated for eight more weeks. At this point, patients who have not demonstrated a partial response will be taken off study. Patients who have partial or complete response will be treated for an additional one (complete response) or two years (partial response).

Progress: This study closed to patient entry 3 Jan 93. One patient was enrolled in FY92 and is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 91/087	<b>Status:</b> On-going
------------------------	-----------------------------	-------------------------

**Title:** SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol;  
Companion Protocol to SWOG Studies: 8516, 8736, 8809, 8907, and 8954

<b>Start Date:</b> 08/02/91	<b>Est. Completion Date:</b>
-----------------------------	------------------------------

<b>Department:</b> SWOG	<b>Facility:</b> MAMC
-------------------------	-----------------------

**Principal Investigator:** MAJ Paul C. Sowray, MC

<b>Associate Investigators:</b>	
MAJ Luke M. Stapleton, MC	LTC Howard Davidson, MC
MAJ Everardo E. Cobos Jr., MC	MAJ Patrick L. Gomez, MC
MAJ Robert B. Ellis, MC	MAJ Robert L. Sheffler, MC
CPT Jennifer L. Cadiz, MC	MAJ Richard C. Tenglin, MC
MAJ Kenneth A. Bertram, MC	CPT James S. D. Hu, MC

**Key Words:** lymphoma:tissue procurement

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	12/04/92

**Study Objective:** To acquire fresh snap-frozen lymphoma tissue to establish a central lymphoma tissue repository; to establish a standard set of procedures for routine acquisition, banking, and study of lymphoma tissues within the cooperative group; to use repository tissue to establish clinical correlations via presently activated phenotyping studies and future projected molecular studies assessing specimen DNA and RNA status; and to determine if pretreatment phenotype or genotype predict patient outcome with respect to complete response rate, time to progression, and survival using prospective trial designs.

**Technical Approach:** Patients will be treated according to guidelines outlined in the specific SWOG studies. Treatment decisions will not be based on findings of the Central Lymphoma Laboratory, although clinical variables will be correlated with laboratory findings. The tissue samples will be taken from the pretreatment diagnostic biopsy or rebiopsy based on clinical decisions. Fresh biopsies (from any organ site) will be snap-frozen and submitted with one stained (hematoxylin and eosin) histologic section with accompanying pathology report. The H&E stained slide and report will accommodate morphologic correlation with immunologic findings. Tissue section analysis will be performed at the University of Arizona using three stage immunohistochemistry. Future molecular studies entailing hybridization studies of RNA and DNA fragments using DNA probes will be performed as outlined in future protocols.

**Progress:** This is a companion study using tissue from other SWOG protocols. Thus far 2 samples have been collected (none in FY93).

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/041		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8828: A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia					
<b>Start Date:</b> 02/16/90			<b>Est. Completion Date:</b> Feb 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> leukemia:myeloid,carboplatin,CBDCA					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To evaluate the complete remission rate of carboplatin (CBDCA) in patients with relapsed or refractory acute myeloid leukemia (AML); to assess the qualitative and quantitative toxicities of these patients; and to identify the pattern of treatment failure by the criteria of Preisler.

**Technical Approach:** Patients must have a bone marrow aspiration and biopsy demonstrating AML with FAB subtype M1-M7. Patients must be in relapse or must have had a treatment failure of Preisler type 1 or 2 on the most recent induction attempt. Patients must have received only one prior remission induction regimen for AML. Patients with prior CML or myelodysplastic syndrome or those who have received prior radiotherapy or chemotherapy for non-AML conditions are ineligible. Induction: Carboplatin, 300 mg/m<sup>2</sup>/day continuous intravenous infusion daily for 5 days. Second induction course: If the bone marrow on Day 21 shows >10% blasts and cellularity >30%, patients will be treated with carboplatin 300 mg/m<sup>2</sup>/day continuous intravenous infusion daily for 5 days beginning Day 22. Patients who do not achieve a remission after two induction courses will be removed from protocol treatment. Consolidation: If A-1 marrow is achieved: carboplatin 210 mg/m<sup>2</sup>/ day continuous intravenous infusion daily for 5 days. Patients will receive only one consolidation course. There will be no maintenance treatment. Patients will be removed from the protocol at any time unacceptable toxicity occurs.

**Progress:** No patients were enrolled at MAMC

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/055		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8842: Dihydroxyazacytidine in Malignant Mesothelioma, Phase II Study					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b> Dec 94		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC			LTC Howard Davidson, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, mesothelioma					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To assess the response rate and survival of patients with unresectable malignant mesothelioma treated with Dihydroxyazacytidine (DHAC, NSC-264880); to further evaluate the toxicity of DHAC given by continuous infusion; and to prospectively evaluate the use of CA-125 as a tumor marker in mesothelioma.

**Technical Approach:** Mesothelioma is an uncommon tumor and, if not localized, is not amenable to therapy with either surgery or radiation therapy. Chemotherapy has shown moderately good response rates. Whether there has been any benefit in survival is unclear. Therefore, use of a new agent which may have activity against mesothelioma will be undertaken. DHAC causes an inflammatory response in the pleura and it is felt that in the presence of a malignancy of the pleura, this anti-tumor continuity response may be tumoricidal. Therefore, all patients on the study will receive two cycles of DHAC by continuous infusion over five days. Cycles will be repeated every four weeks. Patients will continue to receive treatment if they have a partial response or stable disease; otherwise they will be taken off the medication.

**Progress:** This study was closed to patient entry on 15 Nov 92. No patients were enrolled at MAMC.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/027		<b>Status:</b> On-going
<b>Title:</b> SWOG 8851 (EST 5811, INT-0101): Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Zoladex + Tamoxifen) in Premenopausal Women with Axillary....				
<b>Start Date:</b> 01/19/90		<b>Est. Completion Date:</b> Dec 99		
<b>Department:</b> SWOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC				
<b>Associate Investigators:</b>		MAJ Paul C. Sowray, MC		
MAJ Mark H. Kozakowski, MC		MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC		CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC		MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> cancer:breast,chemotherapy,chemohormonal therapy,premenopausal				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$8200.00	12/04/92

**Study Objective:** To compare the recurrence rates, disease-free intervals, relative toxicities, and hormone-receptor-positive survival for premenopausal women with axillary lymph node-positive breast cancer given adjuvant therapy with combination chemotherapy using cyclophosphamide, doxorubicin, and 5-FU (CAF) alone or CAF followed by Zoladex, or CAF followed by Zoladex plus Tamoxifen; and to assess the effect of CAF, CAF plus Zoladex, and CAF plus Zoladex and Tamoxifen on hormone levels (LH, FSH, and estradiol) in these patients.

**Technical Approach:** Patients will be nonpregnant females who have undergone excision of the primary breast tumor mass, proven histologically to be invasive breast adenocarcinoma and must have one or more pathologically involved axillary nodes. Patients who undergo total mastectomy may receive post-operative radiotherapy at the discretion of the investigator. Patients who have had prior hormonal therapy or chemotherapy for breast cancer are ineligible. Patients will be randomized to CAF alone for six cycles or to CAF for 6 cycles followed by monthly Zoladex for 5 years, or to CAF for 6 cycles followed by daily Tamoxifen and monthly Zoladex for 5 years. Adjuvant therapy will be instituted as soon as possible after mastectomy or lumpectomy. The interval between definitive surgery and initiation of adjuvant chemotherapy will not be >12 weeks. When planned, radiation therapy may be administered prior to or after (within 4 weeks of) completion of 6 cycles of adjuvant chemotherapy.

**Progress:** Six patients have been enrolled at MAMC (3 in FY93). These patients are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/047		<b>Status:</b> On-going
<b>Title:</b> SWOG 8854: prognostic Value of Cytometry Measurements of Breast Cancer DNA from Postmenopausal Patients with Involved Nodes and Receptor Positive Tumors: A Companion Protocol to SWOG 8814				
<b>Start Date:</b> 03/16/90		<b>Est. Completion Date:</b> Mar 98		
<b>Department:</b> SWOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC				
<b>Associate Investigators:</b> None				
<b>Key Words:</b> cancer:breast,DNA,cytometry,postmenopausal				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		12/04/92

**Study Objective:** To determine if ploidy analysis of breast cancer by routine clinical flow cytometry (CFM) technique can predict response to therapy and survival of patients registered to SWOG 8814 and to determine if ploidy analysis by image processing technique more accurately predicts patient response to therapy and survival than ploidy analysis by flow cytometry.

**Technical Approach:** Two paraffin blocks, one representing the highest grade region of the primary tumor, the second representing the highest grade regional metastasis in a positive lymph node, will be used. From each of these blocks, two to five sections will be cut and a nuclear suspension prepared. From each suspension, a cytospin preparation will be prepared and stained with Dif-Quik to ensure that the cells present in the H & E slide are represented adequately in the nuclear preparation. A second cytospin preparation will be prepared for staining by the Feulgen technique for image processing DNA analysis. The remainder of the nuclear preparation will be stained with propidium iodide following RNase digestion for FCM DNA analysis. Cox regression modeling will be used to explore the prognostic value of ploidy status as determined by FCM and by image processing, in conjunction with the covariates tumor size, age, ER and PgR levels, and number of nodes.

**Progress:** This is a companion study using tissue from SWOG 8814. Three samples were used in FY93. A total of 7 samples have been studied.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/067		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8855: Prognostic Value of Cytometry Measurements of Cellular DNA. Parameters in Locally Advanced, Previously Untreated Head and Neck Cancer Patients					
<b>Start Date:</b> 06/14/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>					
MAJ Paul C. Sowray, MC			LTC Howard Davidson, MC		
MAJ Robert L. Sheffler, MC			MAJ Everardo E. Cobos Jr., MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
<b>Key Words:</b> cancer:head & neck,cytometry,DNA					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>		
\$0.00		\$0.00	12/04/92		

**Study Objective:** To evaluate the prognostic value of cellular DNA parameters of degree of DNA aneuploidy (DNA index) and proliferative activity (SPF) in predicting treatment response, time to treatment failure, and survival in patients with squamous cell carcinoma of the head and neck treated initially with cytotoxic therapy and to assess the correlation of DNA index and SPF with other patient clinical characteristics.

**Technical Approach:** Squamous cell cancers of the head and neck display a high degree of responsiveness to chemotherapy and/or radiotherapy, but a significant minority are exquisitely resistant to these treatment modalities. This will be a companion study to all SWOG head and neck cancer protocols utilizing chemotherapy as initial treatment and will use the patients registered on those studies. This study will use flow cytometrically determined cellular parameters, particularly cellular DNA content, to help identify prognostic outcome in this group of tumors. Specimens will be obtained at the time of biopsy for diagnosis, at completion of therapy if the tumor persists, or if a biopsy is performed to confirm a clinical complete response or document recurrence. All resected specimens will be sent for flow cytometry analysis. The degree of DNA aneuploidy (DNA index) and proliferative activity (SPF) will be determined by flow cytometry. These measurements will be correlated with the clinical characteristics of the patient at the time of biopsy to help predict treatment response, time to treatment failure, and survival in patients with squamous cell carcinoma of the head and neck.

**Progress:** No patients have entered this study at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/055		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8892 (EST 2388, RTOG 8817, INT 0099): A Study of Radiotherapy with or without Concurrent Cisplatin in Patients with Nasopharyngeal Cancer, Phase III					
<b>Start Date:</b> 03/19/90			<b>Est. Completion Date:</b> Mar 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Mark H. Kozakowski, MC		
MAJ Everardo E. Cobos Jr., MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
MAJ Michael R. Morris, MC					
<b>Key Words:</b> cancer:nasopharyngeal,5-Fluorouracil,cisplatin,radiotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$3900.00		12/04/92	

**Study Objective:** To compare radiotherapy with radiotherapy and concurrent cisplatin, followed by three courses of 5-FU + cisplatin for complete response rate, time to treatment failure, overall survival, pattern of recurrence, and qualitative and quantitative toxicities.

**Technical Approach:** To be eligible, patients must have histologically proven nasopharyngeal carcinoma (excluding adenocarcinoma), Stage III or IV with no evidence of distant metastatic disease, and must not be eligible for higher priority SWOG studies. Patients will be randomized as follows: Arm I: radiation therapy alone for approximately 7 weeks; Arm II: 3 courses of cisplatin (days 1, 22, and 43) concurrent with radiotherapy followed by three courses of 5-FU + cisplatin. Measurable disease must be assessed at least every eight weeks the first year of follow-up. Patients will be seen in follow-up every two months the second year, every three months the third year, and every four months thereafter. A tumor biopsy for flow cytometry will be obtained if tumor recurs.

**Progress:** One patient was enrolled in FY91 and is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/086		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8894: (INT-0105, EST-2889): A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Cancer					
<b>Start Date:</b> 06/15/90			<b>Est. Completion Date:</b> Apr 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>					
MAJ Mark H. Kozakowski, MC			MAJ Paul C. Sowray, MC		
MAJ Patrick L. Gomez, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Kenneth A. Bertram, MC			CPT Denis Bouvier, MC		
LTC John A. Vaccaro, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> cancer:prostate,orchiectomy,flutamide					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		12/04/92	

**Study Objective:** To compare survival, progression free survival, and qualitative and quantitative toxicities between patients with orchiectomy alone and patients with orchiectomy plus Flutamide.

**Technical Approach:** Patients must have a histologically proven diagnosis of pathologic stage D2 adenocarcinoma of the prostate with evidence of metastatic disease. Patients must not have had prior hormonal therapy, chemotherapy, or biological response modifiers. Patients will be randomized to bilateral orchiectomy plus placebo po three times a day with meals or to bilateral orchiectomy plus Flutamide po three times a day with meals. Upon disease progression, patient treatment will be unblinded. Patients treated with Flutamide will be taken off protocol. Patients treated with placebo will be offered flutamide given according to the protocol guidelines until the next evidence of progression at which time they will be taken off study.

**Progress:** Three patients have been entered in this protocol (1 in FY93). Two patients are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/029		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8897 (EST-2188, CALGB-8897, INT-0101): Phase III Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History...					
<b>Start Date:</b> 01/19/90			<b>Est. Completion Date:</b> Jan 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Paul C. Sowray, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
<b>Key Words:</b> cancer:breast,chemotherapy,endocrine therapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$5000.00		12/04/92	

**Study Objective:** To compare disease-free survival and overall survival of high risk primary breast cancer patients with negative axillary lymph nodes treated with standard adjuvant chemotherapy for 6 cycles; either CMF (cyclophosphamide, methotrexate, 5-FU) or CAF (cyclophosphamide, adriamycin, 5-FU); to assess the value of the addition of tamoxifen for five years compared to no tamoxifen in these patients; to compare the toxicity of the therapies; to assess the prognostic significance of DNA flow cytometry in patients with small, occult invasive breast cancer treated by local therapy only; and to evaluate the disease-free survival and survival of low risk invasive breast cancer patients determined by receptor status, tumor size, and % S phase treated by local therapy only.

**Technical Approach:** Patients must have undergone a radical, modified radical, or breast sparing procedure plus level 1 and 2 axillary lymph node dissection. Patients with bilateral breast cancer, prior hormonal or chemotherapy, or previous or concurrent malignancy are ineligible. Low risk patients will be followed but will not receive adjuvant therapy. High risk patients will be randomized to: (1) CMF x 6 cycles; (2) CAF x 6 cycles; (3) CMF x 6 cycles followed by tamoxifen; or (4) CAF x 6 cycles followed by tamoxifen. Patients will start adjuvant chemotherapy within 12 weeks of definitive surgery. Patients who have had a breast sparing procedure and axillary dissection will receive radiation therapy, either before or after CMF or CAF (at the discretion of the treating physician). Radiotherapy and tamoxifen may be given together. Patients will be removed from the study for unacceptable toxicity, development of local/regional or metastatic disease; or noncancer related illnesses that prevent continuation of therapy or regular follow-up. Patients will be followed until death.

**Progress:** This study was closed to patient entry 1 Feb 93. Nine patients were enrolled in previous years.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/021		<b>Status:</b> On-going
<b>Title:</b> SWOG 8899: A Prospectively Randomized Trial of Low-Dose Leucovorin = 5-FU, High-Dose Leucovorin + 5-FU, Levamisole + 5-FU, or Low-Dose Leucovorin + 5-FU + Levamisole Following Curative Resection in...				
<b>Start Date:</b> 02/17/89		<b>Est. Completion Date:</b> Feb 92		
<b>Department:</b> SWOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC				
<b>Associate Investigators:</b>		COL Irwin B. Dabe, MC		
MAJ Mark H. Kozakowski, MC		CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC		MAJ Everardo E. Cobos Jr., MC		
<b>Key Words:</b> cancer:colon,resection,chemotherapy,leucovorin,levamisole				
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$50.00	12/04/92

**Study Objective:** To assess the effectiveness of 5-FU + high-dose Leucovorin as surgical adjuvant therapy for resectable colon cancer, when compared to surgery alone.

**Technical Approach:** Patients must have received a potentially curative surgery for colon cancer with neither gross nor microscopic evidence of residual disease following the complete resection. The resected specimen must pathologically verify a diagnosis of modified Duke's B-2, B-3, or C. The primary tumor must be above the peritoneal reflection. Patients may not have had any prior chemotherapy nor exposure to 5-FU. Patients must be maintaining oral nutrition and be ambulatory 50% of the day and have adequate bone marrow function. Patients may not have a concurrent second malignant disease nor any previous malignant tumor within three years. Patients will be stratified by extent of invasion (limited to bowel wall vs into or through serosa vs perforation vs adherence to adjacent organs vs invasion of adjacent organs); extent of regional nodal metastases (none vs 0-4 vs >4); regional/ mesenteric implants resected enbloc (yes/no); and obstruction (yes/no). RANDOMIZE TO: (1) Observation; (2) Leucovorin 20 mg/m<sup>2</sup> + 5-FU 425 mg/m<sup>2</sup>; days 1-5; repeat at 4 and 8 wks, then every 5 wks for a total of 6 courses; (3) Leucovorin 500 mg/m<sup>2</sup> + 5-FU 600 mg/m<sup>2</sup>; Leucovorin by IV 2 hour infusion, 5-FU IV push beginning 1 hr after start of Leucovorin infusion, repeated weekly for 6 wks, followed by a 2-wk rest period, each 8-wk cycle (1 course) will be repeated for 4 courses. Revision (Jan 90): Observation arm closed (due to positive results seen in SWOG 8591); two new arms added (5-FU + levamisole & 5-FU + low dose leucovorin + levamisole).

**Progress:** Seventeen patients were enrolled at MAMC prior to closure to patient entry on 30 Jul 92. Three patients have died from their disease and 14 continue to be followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 90/030	<b>Status:</b> On-going
<b>Title:</b> SWOG 8905: Phase II/III Study of Fluorouracil and Its Modulation in Advanced Colorectal Cancer		
<b>Start Date:</b> 01/19/90	<b>Est. Completion Date:</b> Jun 92	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC		
<b>Associate Investigators:</b> LTC Howard Davidson, MC MAJ Patrick L. Gomez, MC MAJ Robert L. Sheffler, MC	MAJ Mark H. Kozakowski, MC MAJ Everardo E. Cobos Jr., MC MAJ Kenneth A. Bertram, MC	
<b>Key Words:</b> cancer:colorectal,5-Fluorouracil,leucovorin,PALA		
<b>Accumulative</b> <b>MEDCASE Cost:</b> \$0.00	<b>Est. Accumulative</b> <b>OMA Cost:</b> \$20780.00	<b>Periodic Review:</b> 12/04/92

**Study Objective:** To determine and compare response rates and toxicities of 5-fluorouracil given by different schedules and/or with biochemical modulators to patients with advanced colorectal cancer and to compare patient survival on the different 5-FU regimens.

**Technical Approach:** All patients must have disseminated or recurrent colorectal cancer. Patients will be randomized to one of seven regimens: Arm I: 5-FU, IV push x 5 days every 5 weeks; Arm II: Low dose Leucovorin, IV push x 5 days followed by 5-FU IV push x 5 days every 4 weeks x 2, then every 5 weeks; Arm III: High dose Leucovorin IV, Days 1, 8, 15, 22, 29, 36 followed by 5-FU (same days) every 8 weeks; Arm IV: 5-FU continuous infusion, days 1-28, every 5 weeks; Arm V: 5-FU continuous infusion, days 1-18 preceded by Leucovorin IV push, days 1, 8, 15, 22 every 5 weeks; Arm VI: 5-FU alone, 24 hour infusion, days 1, 8, 15, 22, every 4 weeks; Arm VII: PALA IV, days 1, 8, 15, 22 followed by 5-FU, 24 hour infusion, days 2, 9, 16, 23, every 4 weeks. Patients will be continued on study until progression of disease or unacceptable toxicity. Patients will be followed to death.

**Progress:** Two patients have been enrolled prior to FY93. One patient has died and the other is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/079		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8925: Evaluation of Cisplatin + VP-16 Followed by Mitotane at Progression if no Prior Mitotane or Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Patients with Advanced and .....					
<b>Start Date:</b> 06/05/92			<b>Est. Completion Date:</b> Jul 97		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC		MAJ Paul C. Sowray, MC			
MAJ Patrick L. Gomez, MC		MAJ Kenneth A. Bertram, MC			
MAJ Robert L. Sheffler, MC		MAJ Robert B. Ellis, MC			
MAJ Richard C. Tenglin, MC		CPT Jennifer L. Cadiz, MC			
		CPT James S. D. Hu, MC			
<b>Key Words:</b> cancer, adrenal, cisplatin, mitotane, VP-16					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To evaluate response and response duration of patients with adrenocortical carcinoma treated with combination chemotherapy consisting of cisplatin and etoposide and of patients who receive mitotane after progression on the above chemotherapy (if no prior treatment with mitotane); to evaluate the qualitative and quantitative toxicities of these therapies; and to evaluate and compare tumor morphology of patients with rare tumor.

**Technical Approach:** Patients will be placed in one of two treatment groups. Patients in Group A will not have received any prior chemotherapy. Patients in Group B will have received prior treatment with Mitotane. Eligible patients in Group A and Group B will be treated with cisplatin plus etoposide every 21 days for a total of 12 months or until progression of disease occurs. Group A patients who develop progressive disease will be treated with Mitotane. Group B patients who progress will be taken off protocol.

**Progress:** No patients have been enrolled in this study at MAMC

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/112		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8931 (EST-3189): Phase III Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and 1 16-Week Multi-drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative..					
<b>Start Date:</b> 09/21/90			<b>Est. Completion Date:</b> Sep 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ William A. Phillips			MAJ Patrick L. Gomez, MC		
MAJ Luke M. Stapleton, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC					
<b>Key Words:</b> cancer:breast,cyclophosphamide,doxorubicin,5-Fluorouracil					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To compare disease-free and overall survival and toxicities in node positive receptor-negative breast cancer patients receiving adjuvant CAF or a 16-week multidrug chemotherapy regimen.

**Technical Approach:** Patients must be female and must have undergone excision of the primary breast tumor mass, proven histologically to be invasive breast adenocarcinoma, and must have one or more pathologically involved axillary nodes. Prior malignancies are limited to a curatively treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer if the patient has been disease-free > five years. Patients who have had prior hormonal therapy or chemotherapy for breast cancer are ineligible. Patients will be stratified by the number of positive axillary nodes, menopausal status, and pathologic size of the primary tumor at the largest dimension. Patients will be randomized to CAF (cyclophosphamide, doxorubicin, and 5-FU), given every 28 days for six cycles or a 16-week multidrug regimen: cyclophosphamide, doxorubicin, vincristine, methotrexate, 5-FU (600 mg/m<sup>2</sup>), and leucovorin, given weeks 1, 3, 5, 7, 9, 11, 13, and 15, with 5-FU, 300 mg/m<sup>2</sup>, given on alternate weeks.

**Progress:** The study was closed to patient entry in April 93. No patients were enrolled at MAMC.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 91/089	<b>Status:</b> On-going
<b>Title:</b> SWOG 8947: Central Lymphoma Serum Repository Protocol; Companion Protocol to SWOG Studies 8516, 8736, 8809, and 8816		
<b>Start Date:</b> 08/02/91	<b>Est. Completion Date:</b>	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Luke M. Stapleton, MC		
<b>Associate Investigators:</b>		
MAJ Paul C. Sowray, MC	LTC Howard Davidson, MC	
MAJ Everardo E. Cobos Jr., MC	MAJ Patrick L. Gomez, MC	
MAJ Robert B. Ellis, MC	MAJ Robert L. Sheffler, MC	
CPT Jennifer L. Cadiz, MC	MAJ Richard C. Tenglin, MC	
MAJ Kenneth A. Bertram, MC	CPT James S. D. Hu, MC	
<b>Key Words:</b> lymphoma:serum repository		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	12/04/92

**Study Objective:** To establish a central lymphoma serum repository that will serve as a resource to provide specimens for current and future scientific studies and to utilize the Southwest Oncology Group clinical data base to perform clinicopathologic correlations with the results of those studies.

**Technical Approach:** No therapy will be utilized in this study and patient treatment will not be based on this study. Patients must meet the eligibility criteria and be registered to one of the following SWOG protocols: 8516, 8809, 8736, or 8816. Ten cc's of blood will be drawn prior to protocol treatment and shipped to the SWOG Lymphoma Serum Repository at Loyola University Medical School.

**Progress:** This is a companion protocol to other SWOG studies. Two specimens have been collected (none in FY93).



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/006		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8952 (INT-0111), (CALG-8952), EST-5487): Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs MOPP/ABV Hybrid					
<b>Start Date:</b> 10/19/90			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ William A. Phillips					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Patrick L. Gomez, MC		
MAJ Luke M. Stapleton, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC					
<b>Key Words:</b> Hodgkin's disease,ABVD,MOPP,ABV Hybrid					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To compare ABVD to the MOPP/ABV hybrid as therapy for patients with advanced Hodgkin's disease in terms of complete response rates, disease-free survival, failure-free survival, and both immediate and long term toxicities; to compare the rate of drug delivery of the anti-neoplastic agents, especially the comparative dose rate of ABV in the two treatment groups; and to examine the prognostic importance of time to response, performance status, age, presence of bulky disease, C-reactive protein, erythrocyte sedimentation rate, and prior radiotherapy on survival.

**Technical Approach:** Until recently, MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) was the standard therapy for advanced Hodgkin's disease. In recent studies, the efficacy of AVBD (doxorubicin, bleomycin, vinblastine, DTIC) containing regimens has been equivalent to or superior to MOPP alone. Eligible patients will be those with histologically documented Hodgkin's disease so advanced that chemotherapy is the treatment of choice. Patients will be randomized to ABVD (all drugs given IV, days 1 and 15) or the MOPP/ABV hybrid (nitrogen mustard and vincristine IV day 1, oral procarbazine days 1-7, oral prednisone days 1-14, and doxorubicin, bleomycin, and vinblastine IV day 8. Cycles will be repeated every 28 days for 6 cycles unless disease progression is documented. At the end of 6 cycles, patients identified to be in complete response will receive an additional two cycles. Patients in partial response will be treated until they reach a complete response and then receive two further cycles for a maximum of 10 cycles.

**Progress:** No patients have been entered in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/032		<b>Status:</b> Completed	
<b>Title:</b> SWOG 8956: A Phase II Study of Cisplatin and 5-Fluorouracil Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder					
<b>Start Date:</b> 02/01/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>					
MAJ Luke M. Stapleton, MC			MAJ William A. Phillips		
MAJ Patrick L. Gomez, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Robert B. Ellis, MC			MAJ Robert L. Sheffler, MC		
			CPT Jennifer L. Cadiz, MC		
<b>Key Words:</b> cancer:bladder,cisplatin,5-Fluorouracil					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		12/04/92	

**Study Objective:** To assess efficacy and feasibility of utilizing cisplatin (CDDP) and 5-fluorouracil infusion (5-FU-I) in patients with advanced and/or recurrent carcinoma of the urinary bladder and to evaluate the toxicity of cisplatin and 5-FU in this group of patients.

**Technical Approach:** Bladder cancer is the sixth most common cancer in the United States, accounting for 10,000 deaths per year. Treatments have been developed which provide 15% long term disease-free survival equated with cure. However, the toxicities have been profound, including treatment related mortalities. As a consequence, this potential less toxic regimen has been devised for evaluation in metastatic bladder cancer. In this study, all patients will receive the same treatment which includes cisplatin on the first day of treatment and continuous infusion of 5-FU on each of the first five days of treatment. These treatments will be repeated every 21 days. Patients response to treatment will be assess every other course (every six weeks). The patients will continue on therapy until they have progression of disease.

**Progress:** This study was closed to patient entry on 15 June 93. No patients were enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/007		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8957: Feasibility Trial of Post-Operative Radiotherapy Plus Cisplatin Followed by Three Courses of 5-FU Plus Cisplatin in Patients with Resected Head and Neck Cancer, Phase II Pilot					
<b>Start Date:</b> 10/19/90			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ William A. Phillips		
MAJ Luke M. Stapleton, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC					
<b>Key Words:</b> cancer:head & neck,radiotherapy,cisplatin,5-Fluorouracil					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>\$0.00</b>	<b>OMA Cost:</b>		<b>\$9130.00</b>
					<b>12/04/92</b>

Study Objective: To evaluate the feasibility of administering three courses of chemotherapy to resected patients who have received cisplatin and radiation therapy post-operatively and to evaluate the qualitative and quantitative toxicities.

Technical Approach: Patients who have had resected squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx are eligible for the study. Chemotherapy used prior to surgery or radiotherapy in untreated head and neck cancer patients has produced particularly high rates of response. However, previous studies have shown that 20-25% of these patients will refuse further surgery or radiotherapy because of an initial good overall response with chemotherapy alone. To avoid this problem, the chemotherapy in this study will be given after surgery, along with radiation and as maintenance afterwards. Cisplatin, 100 mg/m<sup>2</sup>, on days 1, 22, and 43 will be given concomitant with radiation therapy. Three to four weeks post-radiation therapy, maintenance chemotherapy will be started. Maintenance chemotherapy will consist of cisplatin, 100 mg/m<sup>2</sup>, day 1 every 21 days for three courses and 5-FU, 1000 mg/m<sup>2</sup>, days 1-4, every 21 days for three courses.

Progress: One patient was enrolled in FY92 and is still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/021		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8990: (ECOG-9228, INT-0103): Combined Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver; Surgical Resection of Hepatic Metastases in Combination with Continuous .....					
<b>Start Date:</b> 12/07/90			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ William A. Phillips					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Luke M. Stapleton, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC			COL Joseph F. Homann, MC		
<b>Key Words:</b> cancer:colorectal,resection,chemotherapy,liver					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To study the effects of long-term continuous infusion of Floxuridine (FUDR) intra-arterially and 5-FU systemically as therapy for liver metastases from colorectal primaries and to study the incidence of recurrence and time to recurrence in patients with 1-3 hepatic metastases treated with resection and continuous infusion of 5-FU into the systemic venous system and FUDR into the hepatic artery.

**Technical Approach:** This study attempts to combine surgical resection with long term hepatic artery infusion of chemotherapy and continuous infusion 5-FU. Patients with histologic confirmation of colorectal primary carcinoma and evidence of 1-3 liver metastases wither on CAT scan, liver scan or previous laparotomy, with no metastatic disease other than to the liver will be randomized to either surgery plus observation or sugary plus FUDR and 5-FU. FUDR will be given 0.1 mg/kg/day continuously for 14 days via Infusaid pump or arterial subcutaneous device. This cycle will be repeated every 28 days for 4 cycles. 5-FU will be given 200 mg/m<sup>2</sup>/day IV continuously for 14 days via permanent IV access device beginning of day 15 of each 28 day cycle and repeated for 4 cycles. When FUDR therapy ends, the IV dosage of 5-FU will be escalated to 300 mg/m<sup>2</sup>/day IV continuously for 14 days and repeated every 28 days for eight more cycles.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 90/056		<b>Status:</b> On-going	
<b>Title:</b> SWOG 8997 (ECOG 3887): Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide					
<b>Start Date:</b> 03/16/90			<b>Est. Completion Date:</b> Mar 93		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Paul C. Sowray, MC		
MAJ Mark H. Kozakowski, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Patrick L. Gomez, MC			CPT Denis Bouvier, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
LTC John A. Vaccaro, MC					
<b>Key Words:</b> cancer:testicular,chemotherapy,cisplatin,bleomycin,ifosfamide					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$12862.00		12/04/92	

**Study Objective:** To determine the objective response rate and duration of remission of BEP compared to VIP combination chemotherapy; to determine the toxicity of VIP compared to BEP combination chemotherapy; to confirm the efficacy and toxicity of intravenous Mesna as a urothelial protective agent.

**Technical Approach:** Patients must have a histologic diagnosis of advanced disseminated germ cell tumor and no prior chemotherapy or radiation therapy. Patients will be randomized to VIP (cisplatin, ifosfamide, mesna, and etoposide) to BEP (cisplatin, etoposide, and bleomycin). The regimen will be repeated every three weeks for four cycles. Bleomycin will be omitted for postsurgery chemotherapy in BEP patients. Patients in complete remission at the end of four courses of therapy will receive no further treatment. If there is radiographic or serologic evidence of persistent disease and residual tumor is surgically resectable, surgery will be performed. Patients who have complete or near complete resection of residual radiographic abnormalities with the pathologic finding of fibrosis/necrosis and those who have complete resection of mature or immature teratoma will receive no further treatment. Patients who have complete resection of residual disease which histologically shows viable carcinoma will receive two more courses of the original induction therapy. If residual tumor is deemed unresectable, patients will be followed monthly until disease progression with no further therapy. If relapse occurs in complete or partial responders less than 4 weeks after day 1 of the last course of induction therapy, the patient will be taken off study.

**Progress:** Prior to closure to patient entry (9 Apr 92) two patients had been enrolled at MAMC. One patient is still being followed (one died Jan 93).

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/056		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9003: Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Study for Untreated and Previously Treated Patients					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Mar 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
MAJ Kenneth A. Bertram, MC			MAJ Patrick L. Gomez, MC		
MAJ Timothy P. Rearden, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> Waldenstrom's Macroglobulinemia					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$3352.00		/ /	

**Study Objective:** 1) To estimate response rates and survival in patients with Waldenstrom's Macroglobulinemia (WM) receiving fludarabine, with stratification according to whether they have prior therapy. 2) To define prognostic factors that may relate to response, time to progression and overall survival, separately for newly diagnosed and previously treated patients. 3) To estimate the associated hematologic and non-hematologic toxicities.

**Technical Approach:** Persons with a diagnosis of WM and meeting enrollment criteria can be registered for this study. After the initial workup, to include bone marrow aspiration, those patients without symptoms and with no progression of the disease will be entered in the Observation phase. If they are symptomatic or have progression of the disease or if onset of symptoms and/or progression occurs during the Observation phase immediate Re-registration to the Treatment phase will occur. Fludarabine 30 mg/m<sup>2</sup> IV will be administered on days 1 - 5. This schedule will be repeated every 28 days for 4 cycles until the patient's condition is stable without remission, progression occurs, or the disease is stable. If the disease becomes stable without remission or progresses, treatment will be stopped. If there is complete remission, partial remission or improvement the patient will receive an additional 4 cycles of therapy or 2 cycles beyond maximum response, whichever occurs earlier.

**Progress:** Two patients were enrolled this fiscal year.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/094		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9007: Cytogenetic Studies in Leukemia Patients, Ancillary					
<b>Start Date:</b> 09/06/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert L. Sheffler, MC		
MAJ Robert B. Ellis, MC			MAJ Richard C. Tenglin, MC		
CPT Jennifer L. Cadiz, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer:leukemia,cytogenetic studies					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To estimate the frequencies and prognostic significance of cytogenetic abnormalities in marrow or blood cells of leukemia patients prior to treatment on SWOG protocols and at various times in the course of treatment; to estimate correlations between the presence of cytogenetic features and of clinical, pathophysiological, cellular, or molecular characteristics in these patients; and to provide quality control for all SWOG cytogenetic data.

**Technical Approach:** The complex nature and diversity of numerical and structural chromosomal changes in hematologic malignancies have been increasingly recognized in the last 15 years as cytogenetic techniques have improved and the knowledge base expanded. It has been shown that the majority of malignancies have non-random chromosomal anomalies such that specific cytogenetic aberrations are generally associated with particular leukemia subtypes. Previous studies have shown the remarkable consistency of the recurring chromosome abnormalities in the leukemias and their current and potential usefulness as diagnostic and prognostic indicators. Strong correlations with certain clinical immunological and morphologic features have been shown and in certain cases a molecular mechanism has been discovered. Large prospective studies which include responsiveness to the various treatments have not been done and for most leukemias the molecular mechanisms and correlations remain to be elucidated. Patients on this study must be registered on one of the following SWOG protocols: 8326, 8600, 8612, 9034, 9108, and all new leukemia protocols approved as of 1990 by SWOG. Patients will receive treatment as directed by the treatment protocols and the treatment protocols will specify when specimens are to be submitted for cytogenetic analysis. Bone marrow samples will be submitted whenever possible, unless the treatment protocol specifies otherwise. However, if the marrow is not aspirable ("dry tap"), a peripheral blood sample will be submitted. A patient may only be registered on this protocol once. Data will be collected by major categories of leukemia: first line AML, first line ALL, relapsed AML, chronic phase CML, CML patients in acceleration or blast crisis; and hairy cell leukemia. The study will be open for accrual of patients for a minimum of five years. The smallest group of patients (CML in acceleration or blast crisis) is expected to have at least 100 patients by that time.

**Progress:** Five patients (4 in FY93) have been entered in this study at MAMC and are being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/051		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9008: Trial of Adjuvant Chemoradiation After Gastric Resection for Adenocarcinoma, Phase II					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b> Mar 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Luke M. Stapleton, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Rahul N. Dewan, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, gastric, adenocarcinoma, chemoradiation					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

Study Objective: To evaluate the possible benefit of adjuvant chemoradiation therapy in patients with resected gastric cancer to include: comparison of overall and disease free survival between patients being treated with surgical resection only and those being treated with surgery plus adjuvant therapy; comparison of incidence and patterns of disease failure between surgery and surgery plus adjuvant therapy treated patients; and assessment of patient tolerance of upper abdominal chemoradiation after gastric resection.

Technical Approach: Patients will be randomized to either observation or adjuvant therapy. Adjuvant therapy will consist of one course of 5-FU and Leucovorin given IV. Four weeks later the patient will receive a second course of 5-FU with Leucovorin with concomitant radiation therapy. While receiving radiation therapy, the patient will receive a third course of 5-FU and Leucovorin, which will occur during the fifth week of radiation therapy. After completing radiation therapy, the patient will receive two additional courses of chemotherapy to begin approximately 35 days after completion of radiotherapy.

Progress: No patients have been enrolled at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/033		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9013 (RTOG 89-11, INT-0113): A Prospective Randomized Comparison of Combined Modality Therapy for Squamous Carcinoma of the Esophagus: Chemotherapy Plus Surgery Versus Surgery Alone for ....					
<b>Start Date:</b> 02/01/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ William A. Phillips			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert L. Sheffler, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
COL Joseph F. Homann, MC			COL Daniel G. Cavanaugh, MC		
MAJ Everardo E. Cobos Jr., MC					
<b>Key Words:</b> cancer:esophagus,chemotheray,surgery,modality therapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To compare, using a prospective controlled randomized study design, the outcomes of therapy of surgery alone versus pre and postoperative chemotherapy and surgery for patients with local regional esophageal cancer (outcome is defined as survival and relapse pattern); to assess the toxicities of a multimodality approach to esophageal carcinoma involving systemic chemotherapy and surgery (the toxicities of surgical resection as initial therapy or following chemotherapy will be assessed as operative morbidity and mortality); to compare the local and distant control rates with the two approaches and to define the pattern of failure; and to compare the impact on overall and disease free survival of multimodality therapy with surgery alone.

**Technical Approach:** Esophageal cancer is seen in over 10,000 patients a year in the United States and only about 7% of these patients are cured as demonstrated by a five year survival. This study is designed to see whether or not giving chemotherapy will improve that survival. To be eligible patients must have histologic proof of squamous cell carcinoma of the esophagus, disease limited to the total regional area (clinical stage T1-T3, NX,MO), no prior surgery, radiation therapy, or chemotherapy, and adequate bone marrow, liver function, renal function, and pulmonary reserve. Patients must be physiologically fit for proposed chemotherapy and surgery and be greater than 18 years of age. Patients will be randomized to surgery alone, or to receive three cycles of preoperative cisplatin and 5-FU and then to undergo definitive surgery followed by two more cycles of cisplatin and 5-FU, starting two to six weeks after surgery.

**Progress:** Two patients have entered this study (1 in FY93) and both are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/142		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9015: A Randomized Trial of Pre- and Post-Operative Chemotherapy Compared to Surgery Alone for Patients With Operable Non-Small Cell Carcinoma of the Lung, Phase III					
<b>Start Date:</b> 06/09/93			<b>Est. Completion Date:</b> Jun 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>					
LTC Howard Davidson, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert B. Ellis, MC			MAJ Mark E. Robson, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
LTC Robert D. Vallion, MC			CPT James S. D. Hu, MC		
			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer: non-small cell, lung					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** To: 1) compare the survival experience of patients with clinical stages T2N1, T1N1, T2N0 T3N0, and T3N1 NSCLS (mediastinoscopy negative) (Clinical stages 1b, 11, 111a) treated with either surgical resection alone (control) or a regimen of pre- and post-operative chemotherapy (experimental arm); 2) estimate the response rate to pre-operative chemotherapy; 3) test the association between response to pre-operative chemotherapy and survival of those patients who receive chemotherapy; 4) establish the toxicity, including operative complications, of combined pre- and post-operative chemotherapy.

**Technical Approach:** Young adult patients with non-small cell carcinoma of the lung who are mediastinoscopy negative will be randomized to ARM I pre-operative chemotherapy and then surgical resection followed by post-operative chemotherapy or ARM II surgical resection alone. Chemotherapy will be with VP-16 IV days 1-3 and carboplatin IV on day 1 for each of 2 cycles. Cycles will be 21 days duration. Patients whose tumors do not progress will have the tumor surgically resected, followed by an additional 3 courses of the same chemotherapy.

**Progress:** No patients have been enrolled in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/143		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9019: A Phase III, Randomized, Prospective Comparison Between Chemotherapy Plus Radiotherapy, and the Same Chemotherapy Plus Radiotherapy Together With Surgery for .... Non-Small Cell Lung Cancer					
<b>Start Date:</b> 06/09/93			<b>Est. Completion Date:</b> May 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Timothy P. Rearden, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:non-small cell lung					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>OMA Cost:</b>			
\$0.00		\$0.00		/ /	

**Study Objective:** (1) To assess whether concurrent chemotherapy and radiotherapy, followed by surgical resection, results in a significant improvement in progression-free, overall, and long-term survival compared to the same chemotherapy plus standard radiotherapy alone for patients with stage IIIa (N2 Positive) and selected IIIB non-small cell lung cancer. (2) To evaluate the patterns of local and distant failure for patients enrolled in each arm of the study, in order to assess the impact of the therapy on local control and distant metastasis.

**Technical Approach:** Patients with regionally advanced non-small cell lung carcinoma will be randomized to one of two arms. Arm I: patients will receive induction radiation therapy to a "tight" field to 4500 cGy. They will receive concurrent cisplatin on days 1 and 8 and on days 29 & 36 with VP-16 days 1-5, repeated on days 29-33 (2 cycles). After completion of induction, patients will be re-evaluated for extent of disease. If there is no progression of the disease, patients will go to exploratory thoracotomy for complete removal of the primary lesion and sampling of nodes.

If the tumor is unresectable or the margins are positive or the mediastinal nodes are positive, an additional 2 cycles of chemotherapy with a radiation boost will be given. Patients who complete the induction phase but have persistent supraclavicular node metastases will also receive 2 more cycles of concurrent chemo-radiotherapy will not go to surgery.

Arm II patients receive "standard" lung field radiation therapy to 4500 cGy and concurrent cisplatin and VP-16 for 2 cycles.

One week prior to completing radiation therapy, patients will be re-evaluated for response. Those patients with no evidence of distant metastases or local progression will continue radiation therapy with no break for an additional 1600 cGy with a boost. They will also receive 2 more cycles of chemotherapy concurrent with radiation.

Any patient who shows local or distant progression after induction chemo-radiation will be taken off protocol..

**Progress:** One patient entered this study in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/045		<b>Status:</b> Completed	
<b>Title:</b> SWOG 9028: A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/Verapamil/Quinine for Induction; (2) Alpha-2b Interferon or Alpha-2b Interferon Plus ..					
<b>Start Date:</b> 03/01/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Luke M. Stapleton, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ William A. Phillips		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC					
<b>Key Words:</b> myeloma,alpha 2b interferon, VAD, VMCP					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To determine if multidrug resistance can be prevented during remission induction by adding chemosensitizers (verapamil or quinine) to the VAD (vincristine, adriamycin, and dexamethasone); to determine if Interferon alone or plus VMCP (vincristine, melphalan, cytoxan, and prednisone) represents better maintenance therapy for myeloma; to examine the prognostic significance of pretreatment LDH level, Ki-67 level, and presence of P-glycoprotein; and to evaluate the relationship between the magnitude of cytoreduction and survival.

**Technical Approach:** Previously untreated patients with all stages of multiple myeloma are eligible. Protein criteria must be present but patients with IgM myeloma are not eligible. Patients must not have symptoms of congestive heart failure and may not be on digitalis preparations, beta blockers, or calmodulin inhibitors. Cardiac ejection fraction must be at least 50%, the EKG must be free of serious cardiac arrhythmias, and systolic blood pressure must be >90 mm/Hg. Patients who have had a prior malignancy within the last five years except for basal or squamous cell carcinoma or in situ cervical cancer are not eligible. Patients will be randomized to VAD every 21 days or to VAD plus verapamil and quinine every 21 days. Patients with >75% disease regression and at least 6 months of treatment and those with at least 50% regression after 9 months of treatment will be randomized to maintenance therapy. Maintenance therapy will consist of either alpha-2B interferon 3 times weekly or to alpha-2B interferon plus CVMCP 3 times weekly every 3 months until relapse.

**Progress:** No patients entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/040		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9030: Phase II Study of High Dose Ara-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia					
<b>Start Date:</b> 02/07/92			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Patrick L. Gomez, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
MAJ Robert B. Ellis, MC			MAJ Richard C. Tenglin, MC		
CPT Jennifer L. Cadiz, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, leukemia, lymphocytic, ara-C, mitoxantrone					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

Study Objective: To assess the complete response rate achieved in adult patients with relapsed or refractory ALL using the combination of high-dose Ara-C with mitoxantrone and to evaluate the toxicities associated with this induction regimen.

Technical Approach: Patients who have relapsing or refractory acute lymphocytic leukemia (ALL) have only one chance of being cured, and that is by a bone marrow transplant, which is available only to about one in four patients. For those patients without the possibility of bone marrow transplant, more effective chemotherapy regimens need to be developed. Preliminary studies suggest the effectiveness of high-dose Ara-C and mitoxantrone, in combination. On this study, patients would receive Ara-C once daily for five days and mitoxantrone will be given as a 30 min infusion beginning 12-20 hours after the first dose of Ara-C (one dose only). Both drugs will be given at very high doses. This will be a one time only regimen that will not be repeated.

Progress: No patients have been enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/052		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9031: A Double Blind Placebo Controlled Tiral of Daunomycin and Cytosine Arabinoside With or Without rhG-CSF in Elderly Patients With Acute Myeloid Luekemia, Phase III					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b> Jun 94		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, leukemia, myeloid					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To compare the complete response rates and duration of survival in patients 56 or older with acute myeloid leukemia (AML) when treated with standard doses of cytosine arabinoside (Ara-C) and daunorubicin (DNR), with or without recombinant human granulocyte-colony stimulating factor (rhG-CSF); to assess the frequency and severity of toxicities of the two treatment regimens; to compare the duration of neutropenia and thrombocytopenia, the total number of febrile days, the number of days of antibiotic therapy, the number and type of infection episodes, and the number of hospital days in patients treated with or without rhG-CSF; and to correlate biological parameters including cell surface immunophenotype, ploidy, and cytogenetics with clinical response.

**Technical Approach:** Patients aged 56 and older with AML will be randomized to receive treatment with either Ara-C/DNR plus rhG-CSF or Ara-C/DNR plus placebo (Ara-C days 1-7, C/DNR days 1-3, and blinded drug begins on day 10) Patients who had regrowth of leukemia during this course of treatment will receive a second identical course of treatment except the blinded drug will not be started until the marrow shows <5% blasts. The blinded drug will not be given in the second induction course if the patient has regrowth of leukemia following the first induction course. Following completion of induction therapy, patients who achieve complete remission will be registered to receive two cycles of post-remission therapy, utilizing the same regimen to which they were originally randomized.

**Progress:** Two patients have been enrolled in this study in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/095		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9032: A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in Blast Phase Chronic Myelogenous Leukemia					
<b>Start Date:</b> 08/07/92			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Patrick L. Gomez, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, myelogenous, leukemia					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To compare the duration of survival in patients with chronic myelogenous leukemia (CML) in blast phase, when treated with either chemotherapy (Ara-C/Daunomycin) alone or chemotherapy plus the resistance modifier, cyclosporine-A (CyA); to estimate the frequency of P-glycoprotein expression and its association with blast lineage and prognosis; and to compare the frequency and severity of toxicity of the two treatment regimens.

**Technical Approach:** Patients will be randomized to receive treatment with either Ara-C/Daunomycin alone or Ara-C/Daunomycin + CyA. If the day 14 bone marrow shows less than or equal to a 50% reduction in the absolute blast count per 500 cell differential compared with the pretreatment bone marrow, the patient will be considered a treatment failure and removed from the study. If there is more than a 50% reduction in the blast count as stated above, but the patient has not achieved a complete remission or restored chronic phase status, a second course of the original induction regimen will begin on or after day 21. Patients who do not achieve complete remission or restoration of chronic phase after two inductions will be removed from the protocol. Patients who achieve complete remission or restored chronic phase will receive one course of consolidation therapy (same regimen as for induction therapy).

**Progress:** No patients have been entered at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/067		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9034 (EST 3489, CALGB 9120): Phase III Study of Three Intensive Postremission Therapies in Adult Acute Nonlymphocytic Leukemia: Comparison of Autologous Bone Marrow Transplantation, Intensive....					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Apr 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Timothy P. Rearden, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
CPT James S. D. Hu, MC			MAJ Richard C. Tenglin, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:leukemia, autologous bone marrow, allogenic bone marrow, idarubicin, Ara-C, busulfan, cyclophosphamide					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** 1. To compare complete remission (CR) duration and survival in de novo acute myelogenous leukemia resulting from post-remission therapy with 4-HC treated marrow versus conventional chemotherapy versus one course of high-dose cytarabine. 2. To examine differences in outcome for allogeneic bone marrow transplantation versus consolidation therapy or autologous transplant. 3. To examine the results of differing post-remission therapies in patient subsets defined by age, cell surface markers, and karyotype abnormalities.

**Technical Approach:** Patients having morphologic proof of non-lymphocytic leukemia, who have not been previously treated with radiation therapy or cytologic chemotherapy, are eligible for this study. Following registration, induction with Idarubicin 12 mg/m<sup>2</sup>/day on days 1, 2, & 3 and Cytidine 25 mg/m<sup>2</sup> IV push, then 100 mg/m<sup>2</sup> by continuous infusion on days 1, 2, 3, 4, 5, 6, & 7. Patients will receive a second course of the induction medication (Ida/Ara-C) if a remission is not achieved from the first. Patients failing to receive a complete remission (CR) after the 2nd induction Ida/Ara-C course are off study. Patients achieving CR who have a histocompatible sibling will receive an Allogeneic Bone Marrow Transplantation (using Busulfan-Cyclophosphamide as the preparative regimen. Patients not qualified for allogeneic transplant will then be randomized to either an Autologous Bone Marrow Transplantation or Consolidation Chemotherapy with Cytarabine 3 gm/m<sup>2</sup> IV over 1 hour every 12 hours X 12 doses (6 days). The preparative therapy for the autologous transplant is Busulfan 1 mg/kg q6 hr X 16 (4 days) followed by Cyclophosphamide 50 mg/kg IV q.d. X 4.

**Progress:** One patient entered in this study in FY93.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/068		<b>Status:</b> Completed	
<b>Title:</b> SWOG 9037: Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG 8897 (EST-2188, CALGB-8897, INT-0012)					
<b>Start Date:</b> 06/14/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ William A. Phillips			MAJ Luke M. Stapleton, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC					
<b>Key Words:</b> cancer:breast,prognostic factors,recurrence,survival					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To measure histologic and nuclear grade, estrogen and progesterone receptors, HER-2 oncogene, cathepsin D, EGF receptor, PS2, and hsp 27, 70, and 90 in paraffin-embedded histopathological specimens; and to correlate the above factors with biological and clinical features including recurrence and survival in patients entered on SWOG 8897.

**Technical Approach:** There is now evidence in prospective randomized clinical trials that adjuvant endocrine therapy and adjuvant chemotherapy can be of benefit in axillary node-negative (ANN) breast cancer patients. This study will be done in concert with a current prospective trial (SWOG 8897) of ANN good risk patients assigned to observation or chemo plus or minus endocrine therapy based upon low and high proliferative rate and in tumors too small for estrogen receptor measurement. In the paraffin-embedded histopathological specimens submitted to the laboratory for DNA flow cytometry, extra 5 microgram sections will be cut for measurement of histological and nuclear grade, estrogen and progesterone receptors; HER-2 oncogene; cathepsin D; EGF receptor; PS2; and hsp 27, 70, and 90. This represents the most popular proposed prognostic factors for predicting recurrence and survival in ANN patients. A critical aspect of this study will be the multivariate analysis (Cox model) which will indicate the relative importance of these factors as well as tumor size and DNA flow cytometry in predicting recurrence and survival in good risk ANN patients. This study should help decide if prognostic factors can and should be used in treatment decisions in ANN patients.

**Progress:** This is a tissue study involving patients that are registered on other protocols. One patient was enrolled prior to study closure to patient entry, 15 May 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/077		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9039: Evaluation of Quality of Life in Patients with Stage D2 Cancer of the Prostate Enrolled on SWOG 8894					
<b>Start Date:</b> 07/12/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>					
MAJ William A. Phillips			LTC Howard Davidson, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Luke M. Stapleton, MC		
MAJ Robert L. Sheffler, MC			MAJ Patrick L. Gomez, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
<b>Key Words:</b> cancer:prostate,quality of life					
<b>Accumulative MEDCASE Cost:</b>		<b>\$0.00</b>	<b>Est. Accumulative OMA Cost:</b>		<b>\$0.00</b>
				<b>Periodic Review:</b> 12/04/92	

**Study Objective:** To compare three primary quality of life endpoints according to treatment assignment: (1) treatment specific symptoms, (2) physical functioning, (3) emotional functioning; and to compare four secondary quality of life variables, according to treatment assignment: (1) general symptoms, (2) role functioning, (3) global perception of quality of life, (4) social functioning.

**Technical Approach:** This cancer control intervention study measures quality of life in patients with advanced carcinoma of the prostate, specifically SWOG protocol 8894: Treatment of Stage D2 Carcinoma of the Prostate Comparing Orchiectomy +/- Flutamide. The presence or absence of flutamide provides the intervention for this cancer control companion study. Thus, the benefits of randomization, uniform patient selection, and treatment standardization are transferred to the quality of life investigation. The comparison of quality of life measurements between treatment arms will complement the analysis of survival and response data for patients registered to SWOG 8894 and become a critical consideration if no difference is demonstrated in survival between the treatment arms. The Quality of Life Questionnaire will be completed at study entry and at 1, 3, and 6 months after study entry.

**Progress:** One patient was enrolled in this protocol in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/069		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9040 (CALGB-9081, INT-0014): Intergroup Sectal Adjuvant Protocol, A Phase III Study					
<b>Start Date:</b> 06/14/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>					
MAJ Paul C. Sowray, MC			MAJ Everardo E. Cobos Jr., MC		
MAJ Rahul N. Dewan, MC			MAJ Patrick L. Gomez, MC		
MAJ Robert L. Sheffler, MC			MAJ Steven S. Wilson, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
<b>Key Words:</b> cancer;rectum,5-Fluorouracil,leucovorin,levamisole					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		12/04/92	

**Study Objective:** To determine the relative efficacy of: 5-FU; 5-FU plus leucovorin; 5-FU plus levamisole; and 5-FU plus leucovorin and levamisole when combined with pelvic radiation therapy in the treatment of Stages B-2 and C (TNM Stage II and III) rectal cancer. End points used will include local recurrence rates, probability of distant metastases, disease free survival rates, and overall survival.

**Technical Approach:** This will be a 4-armed study with the same radiation therapy program in all arms, but with varying drug regimens as listed in the objective. 5-FU with radiation therapy will comprise the control arm of the study. Patients will be randomized to treatment arms and they will be stratified by type of operation (abdominal perineal or anterior resection); nodal involvement (none, 1-3, or >3); and invasion through bowel wall or into adjacent organs (none, through muscularis propria, or adherence to or invasion of adjacent organs or structures). Each drug regimen will be given alone on days 1-5 and 29-33, followed by radiation therapy (five weeks) with concomitant chemotherapy on days 57-60 and 85-88. The chemotherapy regimen will then be repeated beginning 28 days after the completion of radiation therapy on days 1-5 and 29-33. If evidence of recurrence is obtained, protocol treatment will be discontinued and the patient followed until death. In the absence of recurrent disease, follow-up observations will be continued for a minimum of 5 years after surgery.

**Progress:** This study was closed to patient entry on 22 Nov 92. Three patients were enrolled in previous years and continue to be followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/002		<b>Status:</b> On-going
<b>Title:</b> SWOG 9045: Evaluation of Quality of Life in Patients with Advanced Colorectal Cancer Enrolled on SWOG 8905				
<b>Start Date:</b> 10/04/91		<b>Est. Completion Date:</b> Jun 92		
<b>Department:</b> SWOG		<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC				
<b>Associate Investigators:</b>		MAJ Paul C. Sowray, MC		
<b>Key Words:</b> cancer,colorectal,quality of life				
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>
\$0.00		\$0.00		12/04/92

**Study Objective:** (1) To compare the following primary aspects of quality of life according to treatment assignment: treatment specific symptoms, physical functioning, and emotional functioning; and (2) to compare four secondary quality of life variables according to treatment assignment: general symptoms, role functioning, social functioning, and global perception of quality of life.

**Technical Approach:** This cancer control intervention study measures quality of life in patients with advanced colorectal cancer; specifically, patients registered on SWOG 8905: Phase II/III Study of 5-FU and Its Modulation in Advanced Colorectal Cancer. SWOG 8905 compares survival, response rates, and toxicities of 5-FU given by different schedules and/or with biochemical modulators (seven arms). Thus, the benefits of randomization, uniform patient selection, and treatment standardization are transferred to the quality of life investigation. The comparison of quality of life measurements between treatment arms will complement the analysis of survival and response data for patients registered to SWOG 8905 and become a critical consideration if no difference is demonstrated in survival between the treatment arms. A Quality of Life questionnaire will be administered prior to treatment, and at 6, 11, and 21 weeks after randomization on SWOG 8905.

**Progress:** This study was closed to patient entry 15 Jan 93. Two patients were enrolled in previous years and are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/032		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9061 (EST-2190, INT 0121): A Phase III Study of Conventional Adjuvant Chemotherapy vs High Dose Chemotherapy and Autologous Bone Marrow Transplantation....Breast Cancer at High Risk of Recurrence					
<b>Start Date:</b> 12/04/92			<b>Est. Completion Date:</b> Nov 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:breast, chemotherapy, bone marrow transplantation					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>OMA Cost:</b>			
\$0.00		\$0.00		/ /	

**Study Objective:** To compare the sites and rates of recurrence, disease-free survival and overall survival, and toxicity of adjuvant chemotherapy (CAF) with adjuvant chemotherapy plus high-dose therapy with cyclophosphamide and the TEPA with autologous marrow infusion in patients with breast cancer with 10 or more positive lymph nodes.

**Technical Approach:** Patients will be stratified according to estrogen receptor status, age, and menopausal status and then randomized to receive radiotherapy plus tamoxifen or high-dose chemotherapy and autologous bone marrow transplantation. Both arms will receive cyclophosphamide 100 mg/m<sup>2</sup> PO X 14 days, doxorubicin 30 mg/m<sup>2</sup> IV days 1 & 8, and flurouracil 500 mg/m<sup>2</sup> IV days 1 & 8 repeated every 28 days x 6 cycles (CAF). Patients receiving CAF without bone marrow transplantation will begin radiation therapy within 4 weeks of the last dose of chemotherapy or when the WBC > 2900 and Platelets > 100,000. Patients randomized to receive high-dose chemotherapy will have bone marrow harvested no sooner than 4 weeks nor longer than 8 weeks after the last previous dose of myelotoxic chemotherapy. The CBC must be normal and the bone marrow normocellular and free of tumor by bilateral iliac crest biopsy within 4 weeks prior to storage. After the bone marrow is harvested, high-dose chemotherapy of cyclophosphamide 6000 mg/m<sup>2</sup>/96 hr and ThioTEPA 800 mg/m<sup>2</sup>/96 hr (4 days), will be given by continuous infusion over 4 days, days -6 to -2. Autologous bone marrow reinfusion will be on day 0. Patients receiving BMT will again be randomized to receive GM-CSF as a daily 2, 6 or 24 hour intravenous infusion beginning 2-4 hours after bone marrow infusion. GM-CSF will be initiated at a dose of 250 mcg/m<sup>2</sup>/d. Treatment will continue until the patient has achieved an absolute neutrophil count (ANC) of ≥ 1000 cells/ul on 3 consecutive days or a planned duration of 28 days of treatment.

Tamoxifen 20 mg PO q.d. will be given to all patients who are estrogen or progesterone receptor positive after the completion of all chemotherapy for 5 years. For patients not randomized to receive transplant, Tamoxifen should be initiated 28 days after the start of the last CAF cycle. Patients randomized to receive transplant should begin Tamoxifen following transplant when WBC > 4000 and/or ANC > 2000. Patients will be taken off-study if there is development of metastatic disease at any time while therapy is ongoing.

Measurement of effect is recurrence, disease-free survival or survival (survival is measured from the date of randomization to date of death).

At measured times during the study a Breast Chemotherapy Questionnaire (BCQ) will be completed to separately document the changes in psychosocial function that occur on the two regimens. Not all subjects will complete the questionnaire at all time points, but if at least 150 per arm have complete data, the width of a 95% confidence interval on the mean change in scores would be about  $\pm 0.09$ .

The BCG will also be used to make comparisons between regimens. A 2 degree of freedom test based on the difference of the means of the 36 week evaluation and the difference of the means of the 52 week evaluation will be used. Then using the variance information given above, the variance of the difference of means at either time should have a variance of about 0.0099, and the covariance between the two times should be about 0.0079. If there is a constant difference in the scores, then the distribution of the test statistic would be approximately noncentral chi-square with 2 degrees of freedom and centrality parameters  $113 \cdot d \cdot d$ . For a 5% level test, this gives a power of 82% for detecting a difference of  $d = 0.3$ .

Progress: No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/144		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9107: A Phase II Pilot Study of High-Dose 24-Hour Continuous Infusion 5-FU and Leucovorin and Low-Dose PALA for Patients With Colorectal Cancer					
<b>Start Date:</b> 06/09/93			<b>Est. Completion Date:</b> Jun 96		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> Cancer:colorectal, 5-FU, Leucovorin, PALA					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** To evaluate response rates and toxicities of 5-FU 2600 mg/m<sup>2</sup> as a 24 hour continuous intravenous infusion given once a week, in combination with Leucovorin 500 mg/m<sup>2</sup> as a 24 hour continuous infusion and PALA 250 mg/m<sup>2</sup> intravenously.

**Technical Approach:** Patients with histologically proven diagnosis of colorectal cancer with distant metastasis who have received no more than one adjuvant chemotherapy will receive PALA IV on day 1 and Leucovorin and 5-FU 24 hours later. This regimen will be repeated on 7 day cycles and will continue until disease progression.

**Progress:** One patient entered this study at MAMC in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/096		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9108 (CALGB-9011, NCIC-CTG CL1): A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs Fludarabine Phosphate Plus Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic....					
<b>Start Date:</b> 09/06/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Kenneth A. Bertram, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert L. Sheffler, MC		
MAJ Robert B. Ellis, MC			MAJ Richard C. Tenglin, MC		
CPT Jennifer L. Cadiz, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer:leukemia,B-cell,fludarabine phosphate,chlorambucil					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>OMA Cost:</b>			
\$0.00		\$0.00		12/04/92	

**Study Objective:** To compare in previously untreated CLL patients the response rates and progression free survival with the following three therapeutic regimens: (1) fludarabine phosphate, (2) chlorambucil, and (3) fludarabine phosphate plus chlorambucil; to determine whether the quality of life (need for transfusions, incidence of infections, and performance status) is superior using any of the three regimens; and to determine whether these two drugs are non-cross-resistant by a crossover design for patients failing to respond to the single agent to which they were initially randomized.

**Technical Approach:** B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. This study is designed to compare a new drug, fludarabine, (Arm I) to standard therapy, chlorambucil (an alkylating agent, Arm II), and to the combination of fludarabine and chlorambucil (Arm III). The drugs will be administered every four weeks until patients reach a complete remission or maximally beneficial response (up to one year of treatment). Patients with progressive disease on Arm I or II will crossover to the other single agent arm. After completing the prescribed treatment arm, patients may be re-entered if they relapse. Patients will be randomly assigned, with equal probabilities, to one of the three treatment arms. Randomization will be stratified by risk group and duration of disease with treatment allocations being adjusted as necessary to avoid treatment imbalance within institutions.

**Progress:** No patients entered at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 92/104	<b>Status:</b> On-going
<b>Title:</b> SWOG 9110: A Phase II Evaluation of Didemnin B in Central Nervous System Tumors		
<b>Start Date:</b> 09/04/92	<b>Est. Completion Date:</b> Sep 95	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC		
<b>Associate Investigators:</b>		
MAJ Luke M. Stapleton, MC	LTC Howard Davidson, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Robert B. Ellis, MC	MAJ Mark E. Robson, MC	
MAJ Richard C. Tenglin, MC	CPT Jennifer L. Cadiz, MC	
LTC Robert D. Vallion, MC	CPT James S. D. Hu, MC	
	CPT Diana S. Willadsen, MC	
<b>Key Words:</b> cancer:nervous system		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	12/04/92

**Study Objective:** To evaluate the likelihood of response in order to assess whether didemnin B should be advanced to further studies and to evaluate the qualitative and quantitative toxicities of didemnin B.

**Technical Approach:** Didemnin B will be administered IV over 30 mins once every 28 days. Patients will be evaluated for response at least every two courses of treatment. Those achieving complete response, partial response or stable disease will continue on study. Liver function tests and measurable and evaluable disease will be assessed at least every other course of therapy (every eight weeks). Didemnin B therapy and parameters will continue at these intervals until progression of disease occurs.

**Progress:** Two patients were entered into this study in FY 93. One patient continues to be followed (1 patient expired.) The study was closed to patient entry 15 Nov. 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 91/078		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9111: Post-Operative Adjuvant Interferon Alpha 2 in Resected High-Risk Primary and Regionally Metastatic Melanoma, Intergroup					
<b>Start Date:</b> 07/12/91			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Patrick L. Gomez, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert L. Sheffler, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC			MAJ Paul C. Sowray, MC		
<b>Key Words:</b> melanoma,interferon alpha 2					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>\$0.00</b>	<b>OMA Cost:</b>		<b>\$0.00</b>
					<b>12/04/92</b>

**Study Objective:** To establish the efficacy of one year at maximally tolerable dosages (IV and SC) interferon alpha-2 as an adjuvant to increase the disease free interval and overall survival in patients at high risk for recurrence after definitive surgery for deep primary lesions or after regional lymph node recurrence; and to evaluate the efficacy and tolerance of long-term alpha-2 at 3 MU/d (Sc TIW) as an adjuvant in similar patients in comparison to 1 year of treatment of maximally tolerable dosages.

**Technical Approach:** Patients must fulfill one of the following criteria: TA NO MO - Deep primary melanoma (>4.0 mm Breslow depth) with or without lymph node involvement; T1-4 N1 MO - Primary melanoma with regional lymph node metastases found at lymphadenectomy, but clinically undetectable (occult); T1-4 N1-2 MO - primary melanoma with clinically apparent (overt) regional lymph node metastases confirmed by lymphadenectomy; or T1-4 N1-2 MO - recurrence of melanoma at the proximal regional lymph node(s) resection. Patients must have an ECOG performance status of 0 or 1. This is a three arm Phase III study. Patients will be randomized to treatment groups and staged according to the criteria above plus the number of nodes positive at lymphadenectomy. Arm A will be alpha-2 interferon at high dose for one year. Arm B will be alpha-2 interferon at low dose for two years or more. Arm C will consist of observation alone. This study is designed to utilize group sequential analysis procedure to allow multiple comparisons throughout the trial without inflating the Type I error rate. At each planned analysis, two treatment comparisons, one year vs observation and two year vs observation, will be performed using a logrank test stratified by stage of disease. If either one of these primary comparisons crosses the group sequential boundary, then the observation arm may be dropped.

**Progress:** No patients were enrolled at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/053		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9119: Primary Chemotherapy of Poor Prognosis Soft Tissue Sarcomas, Phase II					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, soft tissue sarcoma, chemotherapy					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** To evaluate, in patients with high grade soft tissue sarcoma of the extremity, the trunk, or the head and neck, the efficacy of primary chemotherapy, wide surgical resection, adjuvant chemotherapy, and radiotherapy on local control, metastasis free survival, and overall survival; To evaluate the utility of tumor response to primary chemotherapy as an indicator of local and systemic disease control in high grade soft tissue sarcoma; and to evaluate the toxicity of primary chemotherapy, surgery, adjuvant chemotherapy, and radiation therapy in this patient population. Secondary objectives include those listed for SWOG 9136, a companion protocol studying biologic parameters.

**Technical Approach:** Patients with a high grade soft tissue sarcoma of the extremity, trunk, or head and neck area are eligible. Patients will receive chemotherapy using the drugs adriamycin, DTIC, and ifosfamide, given concurrently for three cycles at 21 day intervals. Patients will then undergo wide surgical excision of the primary tumor. Following recovery from surgery, patients with partial or complete response or stable disease will receive another three courses of therapy, followed four weeks after completion of chemotherapy by radiation therapy to the whole area (days 1-5 for 6-8 weeks).

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/088		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9122: Evaluation of 5-Fluorouracil by Intermittent Infusion in Combination With Alpha-Interferon for Patients with Advanced Renal Cell Carcinoma					
<b>Start Date:</b> 04/02/93			<b>Est. Completion Date:</b> Aug 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>					
MAJ Kenneth A. Bertram, MC			MAJ Luke M. Stapleton, MC		
MAJ Mark E. Robson, MC			MAJ Patrick L. Gomez, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
CPT James S. D. Hu, MC			MAJ Richard C. Tenglin, MC		
CPT Diana S. Willadsen, MC			LTC Robert D. Vallion, MC		
<b>Key Words:</b> Cancer:renal cell, 5-FU, alpha-interferon					
<b>Accumulative MEDCASE Cost:</b>		<b>\$0.00</b>	<b>Est. Accumulative OMA Cost:</b>		<b>\$0.00</b>
					<b>Periodic Review:</b> / /

**Study Objective:** 1. To evaluate the response rate of advanced renal cell carcinoma to treatment with 5-FU and Alpha-Interferon. 2. To evaluate the toxicities of 5-FU and Alpha-Interferon in this patient population.

**Technical Approach:** Patients with histologically proven renal cell carcinoma which is either metastatic and/or recurrent and bi-dimensionally measurable disease and whose measurements have been provided from x-rays, scans, or physical exam obtained within the past 14 days will be invited to participate in this study.

5-Fluorouracil 750 mg/m<sup>2</sup>/day IV (continuous infusion) on days 1 - 5 q3 weeks and Alpha Interferon 5X10<sup>6</sup> U/m<sup>2</sup> SC on days 1,3,5 q3 weeks will be given. The first dose of interferon will be given at the beginning of 5-FU infusion. The second and third dose may be given in the evening. Pretreatment with acetaminophen 650 mg 1 hour prior to Interferon and as needed to reduce fever will be given.

The 5-FU treatment may be administered as an outpatient using a portable infusion pump capable of delivering the stipulated dosage of 5-FU at a rate of 2 ml per hour. Patients will be evaluated in the clinic weekly by a physician.

**Progress:** One patient was enrolled at MAMC in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/138	<b>Status:</b> On-going
<b>Title:</b> SWOG 9124: Evaluation of Edatrexate (EDX) in Patients With Relapsed or Refractory Germ Cell Tumors, Phase II		
<b>Start Date:</b> 07/02/93	<b>Est. Completion Date:</b> Aug 98	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Robert B. Ellis, MC		
<b>Associate Investigators:</b>		
LTC Howard Davidson, MC	MAJ Luke M. Stapleton, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Mark E. Robson, MC	MAJ Timothy P. Rearden, MC	
CPT James S. D. Hu, MC	MAJ Richard C. Tenglin, MC	
CPT Diana S. Willadsen, MC	LTC Robert D. Vallion, MC	
<b>Key Words:</b> cancer:germ cell, edatrexate		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** (1) To assess the rate and duration of response to Edatrexate; (2) to evaluate the patterns of toxicity (qualitative and quantitative) in patients treated with Edatrexate.

**Technical Approach:** Adult patients with relapsed or refractory gonadal or extragonadal germ cell carcinomas will be treated with edatrexate 80 mg/m<sup>2</sup> once weekly for 4 weeks by intravenous bolus injection. After a 1 week rest, patients will be re-treated. One course of therapy consists of 2 cycles (10 weeks) of edatrexate. Therapy will continue until disease progression, unacceptable toxicity or patient withdrawal. Standard response criteria will be utilized to judge response.

**Progress:** There are no participants in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/017		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9125: A Phase II Trial of CVAD/Verapamil/Quinine for Treatment of Non-Hodgkin's Lymphoma					
<b>Start Date:</b> 12/06/91			<b>Est. Completion Date:</b> Oct 92		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Patrick L. Gomez, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Paul C. Sowray, MC			MAJ Luke M. Stapleton, MC		
MAJ Kenneth A. Bertram, MC			MAJ Robert L. Sheffler, MC		
MAJ Robert B. Ellis, MC			MAJ Richard C. Tenglin, MC		
CPT Jennifer L. Cadiz, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, non-Hodgkin's lymphoma, CVAD, verapamil, quinine					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		12/04/92	

**Study Objective:** (1) To evaluate the effectiveness of the CVAD chemotherapy regimen (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) when administered in combination with chemosensitizers (verapamil and quinine) which are intended to block the emergence of multidrug resistance in previously untreated patients with intermediate and high grade non-Hodgkin's lymphoma. The effectiveness of CVAD plus verapamil and quinine will be based on the estimate of the complete response rate and the time to treatment failure. (2) To assess the toxicities and side effects associated with the CVAD regimen when combined with verapamil and quinine. Secondary objectives are to further investigate the utility of the proliferative rate (determined by Ki-67 monoclonal antibody), the importance of cell-cell recognition molecules, the role of host response, and the value of detectable levels of p\_glycoprotein as prognostic indicators of outcome in conjunction with companion study SWOG 8819; and to further utilize the central serum repository enabling clinicopathologic correlations with the results of studies on the material collected (see companion study SWOG 8947).

**Technical Approach:** Currently, regardless of the regimen used, 30 to 60% of advanced stage non-Hodgkin's lymphoma patients will relapse and the emergence of clinical drug resistance is a significant problem in these patients. In this study, patients will receive oral verapamil and quinine on days 1-6 as chemosensitizers. They have been shown to reverse the multidrug resistance associated with P-glycoprotein. Starting on day 2, patients will receive a continuous infusion of Adriamycin and vincristine for four days, Cytosan will be given IV on Day 2 and oral decadron will be given days 2-5. Patients with documented progressive disease at any time will be taken off protocol treatment. Patients with stable disease will receive 2 courses (6 weeks) of chemotherapy. Patients responding to treatment will receive a maximum of 8 courses of chemotherapy. Patients will be restaged upon completion of the treatment program to assess response, with a complete laboratory and radiographic evaluation one month after the completion of therapy. All patients will be followed until death.

**Progress:** This study was closed to patient entry 15 Feb 93. Two patients were enrolled in previous years and are still being followed.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/154		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9126: A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in High Risk Acute Myelogenous Leukemia, Phase III					
<b>Start Date:</b> 08/06/93			<b>Est. Completion Date:</b> Sep 94		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Patrick L. Gomez, MC		
MAJ Kenneth A. Bertram, MC			MAJ Timothy P. Rearden, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
CPT Diana S. Willadsen, MC			LTC Robert D. Vallion, MC		
MAJ Richard F. Williams, MC			CPT John R. Caton, MC		
<b>Key Words:</b> cancer:leukemia, cyclosporine, Ara-C, daunorubicin					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** 1. To compare the complete remission rate and duration of survival in patients with high-risk AML when treated with either chemotherapy (Ara-C /Daunomycin) alone or chemotherapy plus the resistance modifier cyclosporine-A (CyA). 2. To estimate the frequency of p-glycoprotein expression and the correlation with prognosis in patients with relapsed AML, primarily refractory AML, and secondary AML.

**Technical Approach:** Patients will be randomized to receive either high-dose Ara-C 3 g/m<sup>2</sup>/d on days 1-5 and daunorubicin 45 mg/m<sup>2</sup>/d on days 6-8, a standard induction regimen for poor-prognosis AML or the same therapy plus cyclosporine A. The cyclosporine A will be given as a loading dose of 6.0 mg/kg IV over 2 hours on day 6 starting 8 hours before the daunorubicin, then 4.0 mg/kg over the next 6 hrs, then 16 mg/kg continuous 24 hr infusion beginning concurrently with the daunorubicin on days 6-8. Bone marrow aspirate and biopsy should be performed on day 14 of induction. Subsequent marrow evaluations should be performed every 7 - 14 days to assess response and recovery period to the next course of chemotherapy.

Patients achieving remission will go on to consolidation. Therapy will consist of the same drugs and dosages except ARA-C will be given on days 1-3 and daunomycin on days 4-6. Cyclosporine A will be given on days 4 - 6 as outlined above. No additional protocol directed treatment will be conducted after consolidation.

**Progress:** One patient was enrolled in this study at MAMC in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/048		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9129: Phase III Randomized Study of All-Trans Retinoic Acid Versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia					
<b>Start Date:</b> 02/05/93			<b>Est. Completion Date:</b> Jan 96		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Timothy P. Rearden, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:leukemia, promyelocytic					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** The objectives of this study are: (1) to compare the complete remission rate and disease-free survival of all-trans retinoic acid (TRA) to that achieved with conventional remission induction therapy, including cytosine arabinoside (Ara-C) plus daunorubicin (DNR) in patients with previously untreated acute promyelocytic leukemia (APL); (2) to compare the toxicities of TRA to those of Ara-C plus DNR as induction therapy in APL; (3) to determine the value of maintenance therapy with TRA.

**Technical Approach:** Patients with morphologically proven acute promyelocytic leukemia, untreated with radiation therapy or cytotoxic chemotherapy, will be considered for inclusion into this study. This study is designed as a Phase III prospective trial which involves two randomizations. Patients will be initially randomized to either TRA or Daunorubicin plus Cytosine Arabinoside as induction therapy. Consistent with other SWOG studies, one or two cycles of Daunorubicin plus Cytosine Arabinoside will be permitted to achieve complete remission (CR) since approximately 20% of patients not achieving CR with one cycle do so with a second cycle. Following two cycles of consolidation chemotherapy for patients achieving CR, patients will be randomized (second randomization) to either maintenance TRA or observation until relapse. Ancillary laboratory studies will explore biological correlations of TRA responsiveness and the pathophysiology of the coagulopathy.

**Progress:** One patient was enrolled in this study at MAMC in FY93.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/056		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9136: Biologic Parameters in Soft Tissue Sarcomas: A Companion Study to Select Southwest Oncology Group Clinical Trials with Soft Tissue Sarcoma Patients					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
MAJ George F. Hodeges, MC					
<b>Key Words:</b> cancer, soft tissue sarcomas,biologic parameters					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		<b>\$0.00</b>	<b>OMA Cost:</b>		<b>\$0.00</b>
				<b>12/04/92</b>	

**Study Objective:** (1) To develop a cooperative group mechanism to study biologic parameters of soft-tissue sarcomas in patients entered onto companion SWOG protocols (see SWOG 9119).;(2) To determine cellular DNA content parameters (DNA CCP) (DNA Ploidy, S-Phase Fraction) of soft tissue sarcomas and to evaluate the effect of these parameters on disease free survival and overall survival. To study the changes in DNA CCP as a result of chemotherapy, and the relationship of these changes to prognosis in patients with soft tissue sarcoma.;(3) To characterize cytogenetic aberrations of soft-tissue sarcomas in the study population. To evaluate the relationship of defined cytogenetic abnormalities to prognosis.;(4) To estimate the level of expression of the multi-drug resistant (MDR) phenotype in untreated soft-tissue sarcoma, and the effect of chemotherapy treatment on the expression of MDR. To evaluate the impact of MDR expression on response to chemotherapy, disease free survival, and overall survival. ;(5) To provide a repository of frozen tissue for future molecular studies in this group of patients.

**Technical Approach:** As a companion protocol to SWOG 9119 (adjuvant soft-tissue sarcoma trial), DNA CCP, tumor karyotypes, and estimation of the expression of the MDR phenotype of sarcomas entered onto trial will be done.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 92/054		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9139: Adjuvant Therapy of Primary Osteogenic Sarcomas, Phase II					
<b>Start Date:</b> 04/03/92			<b>Est. Completion Date:</b>		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC					
<b>Associate Investigators:</b>			LTC Howard Davidson, MC		
MAJ Luke M. Stapleton, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Robert B. Ellis, MC		
MAJ Robert L. Sheffler, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
<b>Key Words:</b> cancer, osteogenic sarcoma					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	12/04/92	

**Study Objective:** To estimate the time to treatment failure and survival rate of the three drug combination, Adriamycin, cisplatin, and ifosfamide, as an adjunctive treatment of osteosarcoma of the extremity; to evaluate histopathologic tumor necrosis following preoperative therapy with this regimen; to assess the feasibility of determining histopathologic tumor necrosis in a cooperative group setting; to assess the influence of clinical prognostic variables on disease outcome; and to assess the toxicity of this regimen.

**Technical Approach:** Primary osteosarcoma is an uncommon malignancy but it is associated with only a 20% cure rate, if no more than surgery is used. Chemotherapy increases survival to above 50%, but whether or not this survival could be further increased has to be determined. The current study uses three drugs (Adriamycin, cisplatin, and ifosfamide) in an alternating fashion with the intent of optimizing treatment prior to surgery. Once four cycles of treatment have been completed, surgery will be undertaken. After recovery from surgery, four more cycles of chemotherapy will be given.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/049	<b>Status:</b> On-going
<b>Title:</b> SWOG 9147: Evaluation of Tamoxifen in Desmoid Tumors, Phase II		
<b>Start Date:</b> 02/05/93	<b>Est. Completion Date:</b> Jan 95	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> CPT Diana S. Willadsen, MC		
<b>Associate Investigators:</b>		
LTC Howard Davidson, MC	MAJ Luke M. Stapleton, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Mark E. Robson, MC	MAJ Timothy P. Rearden, MC	
CPT Jennifer L. Cadiz, MC	MAJ Robert B. Ellis, MC	
CPT James S. D. Hu, MC	MAJ Richard C. Tenglin, MC	
	LTC Robert D. Vallion, MC	
<b>Key Words:</b> cancer:desmoid tumor		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** To assess the response rate of fibromatosis to treatment with tamoxifen. To assess the clonality of fibroblasts using a molecular probe for an x-linked enzyme.

**Technical Approach:** Patients having histologically proven and fully resectable desmoid tumors will be considered for this study. At the time of biopsy, estrogen and progesterone protein assays of the tumor will be done and again at resection. The patient will be placed on Tamoxifen 10 mg PO BID for 6 weeks. At 6 weeks a repeat CT scan or MRI (repeat scan should be the same type as the initial scan) will be done to assess the response. If the objective status at 6 weeks is stable or progressive, surgical excision may proceed. If there is an objective response, treatment will continue another six weeks and after CT scan or MRI excision will proceed. Post-operative or intraoperative radiotherapy will be at the discretion of the treating physician.

Clonality studies will be carried out utilizing restriction fragment length polymorphism techniques with a molecular probe encoding for the enzyme phosphoglycerate kinase. Patients whose tumors would be acceptable for cloning would be "informative females".

If none of the first 20 patients respond to treatment, the study will be closed, and tamoxifen concluded to be inactive. If at least one response is observed, 20 additional patients will be accrued. Five or more responses out of 40 will be considered as evidence warranting further study of tamoxifen.

**Progress:** There have been no patients enrolled in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/089		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9148: A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside ... Extensive Stage Small Cell and Non-small Cell Lung Carcinoma					
<b>Start Date:</b> 04/02/93			<b>Est. Completion Date:</b> Apr 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>					
LTC Howard Davidson, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert B. Ellis, MC			MAJ Mark E. Robson, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
LTC Robert D. Vallion, MC			CPT James S. D. Hu, MC		
			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:small cell, cancer:Non-small cell, cisplatin, hydorxyurea, Ara-C, G-CSF					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** 1. To evaluate the response rate of this 3-drug program in patients with extensive non-small cell lung cancer. 2. To evaluate the response rate of this program in patients with extensive-stage small cell lung cancer. 3. To assess the qualitative and quantitative toxicities of this regimen in each patient population.

**Technical Approach:** Patients with histologically or cytologically proven disease who have not received prior chemotherapy for lung carcinoma and entering this study will have received blood work and/or other body fluid analyses, x-ray, scans or physical examination used for tumor measurement within the 14 days prior to registration.

Patients will receive allopurinol, 600 mg po, at least 12 hours before start of therapy, and then 300 mg po q.d. continuously until off study. Patients will be hydrated with normal saline, 150 ml/hr or higher rate to maintain urine output  $\geq 100$  cc/hr with intake and output measurements every 4 hours. The hydration must begin at least 8 hours prior to the start of chemotherapy and continue for at least 12 - 24 hours after completion of cisplatin (or until adequate oral intake, whichever is longer). Patients will received Hydroxyurea 1260 mg/m<sup>2</sup> in 150 ml 0.9 NS or D5 0.9 NS IVPB over 1 hour via an infusion pump followed immediately by Ara-C 100 mg/m<sup>2</sup> plus hydroxyurea 5040 mg/m<sup>2</sup> mixed in the same bag of 1 liter of NS or D5NS and given IVPB over exactly 12 hours using an infusion pump. At the start of the last hour of Ara-C plus hydroxyurea, piggyback Mannitol, 25 gms in 100 ml D5W will be infused into the chemotherapy line over 1 hour. Cisplatin 100 mg/m<sup>2</sup> in 250 ml NS or D5NS IVPB via an infusion pump will be administered immediately upon completion of the Ara-C, hydroxyurea, and Mannitol. This regimen will be completed every 28 days if absolute granulocytes are  $> 1500$ , platelets are  $> 100,000$ , and measured creatinine clearance  $> 50$ . The treatment should be delayed one week, then a second and third week until these criteria are met. If the parameters are not up to these levels after three 1-week delays the patient will be removed from the study.

**Progress:** There have been no patients enrolled in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 92/080	<b>Status:</b> Completed
<b>Title:</b> SWOG 9151: Evaluation of Topotecan in Hepatoma, Phase II		
<b>Start Date:</b> 06/05/92	<b>Est. Completion Date:</b> Jun 95	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Paul C. Sowray, MC		
<b>Associate Investigators:</b>		
MAJ Luke M. Stapleton, MC	LTC Howard Davidson, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Robert L. Sheffler, MC	MAJ Robert B. Ellis, MC	
MAJ Richard C. Tenglin, MC	CPT Jennifer L. Cadiz, MC	
	CPT James S. D. Hu, MC	
<b>Key Words:</b> cancer, hepatoma, topotecan		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	12/04/92

Study Objective: To evaluate the response rate of hepatomas treated with topotecan and to evaluate the qualitative and quantitative toxicities of topotecan administered in a Phase II study.

Technical Approach: Hepatoma is an uncommon malignancy which is usually far advanced by the time diagnosis is made. The median survival after diagnosis is six months. There is no effective chemotherapeutic regimen for this disease. Topotecan is a new chemotherapeutic agent which has been shown to have activity in early cancer trials. An attempt will therefore be made to see whether or not topotecan will be effective against hepatomas. Patients will receive topotecan through an IV for five consecutive days. This treatment will be repeated every three weeks. Patients will continue on this schedule as long as they show either complete response, partial response, or stable disease. If the disease progresses, the patient will be taken off study.

Progress: This study was closed to patient entry, 15 Jun 93. No patients were entered at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/042		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9152 (EST-4890): Prediction of Recurrence and Therapy Response in Patients with Advanced Germ Cell Tumors by DNA Flow Cytometry					
<b>Start Date:</b> 02/05/93			<b>Est. Completion Date:</b> Jan 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>					
LTC Howard Davidson, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert B. Ellis, MC			MAJ Mark E. Robson, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
LTC Robert D. Vallion, MC			CPT James S. D. Hu, MC		
			CPT Diana S. Walladsen, MC		
<b>Key Words:</b> cancer: germ cell, DNA flow cytometry					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** (1) To determine the proliferative activity and presence of aneuploidy within paraffin-embedded histopathologic specimens from patients with advanced disseminated (poor prognosis) GCT; (2) to correlate proliferative activity and aneuploidy with clinical features including response to therapy, relapse-free survival, and overall survival in patients entered on ECOG protocol EST 3887/SWOG 8997/CALGB 8991; Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin plus Etoposide with either Bleomycin or Isosfamide.

**Technical Approach:** All pathologic materials will be obtained during the routine diagnostic evaluation of patients registered on EST 3887/SWOG 8997 CALGB 8991. Following pathologic analysis of blocks to determine adequacy of tissue, tissue will be prepared for flow cytometry analysis. Three 50 micron sections will be cut, deparaffinized and rehydrated, enzymatically digested, and stained with the DNA intercalating agent propidium iodide. The florescence of propidium iodide-stained nuclei will be measured on a Coulter 753 tunable dye laser following filtration through a 53 micron nylon mesh. Evaluation of the DNA index (ploidy status) and proliferative activity (cell cycle compartment analysis and proliferative index) will then proceed.

**Progress:** Two patients were enrolled in FY93. One patients is still be followed and the other died of the disease.

### Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/167	<b>Status:</b> On-going
<b>Title:</b> SWOG 9157: Trial of All Trans-Retinoic Acid in Hepatoma, Phase II		
<b>Start Date:</b> 09/03/93	<b>Est. Completion Date:</b> Sep 98	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> CPT James S. D. Hu, MC		
<b>Associate Investigators:</b>		
LTC Howard Davidson, MC	MAJ Luke M. Stapleton, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Mark E. Robson, MC	MAJ Timothy P. Rearden, MC	
MAJ Richard C. Tenglin, MC	MAJ Robert B. Ellis, MC	
CPT Diana S. Willadsen, MC	LTC Robert D. Vallion, MC	
	MAJ Richard F. Williams, MC	
<b>Key Words:</b> cancer:hepatoma, all trans-retinoic acid		
<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** (1) To evaluate the response rates in patients with hepatomas treated with all trans-retinoic acid; (2) To evaluate the qualitative and quantitative toxicities of all trans-retinoic acid administered in a Phase II study; (3) To describe the number of responses for (a) high versus medium versus low alphafetoprotein and (b) for patients positive and negative for hepatitis B.

**Technical Approach:** Patients must have a histologically proven, unresectable, bidimensionally measurable hepatoma. They will be described according to: (1) Alpha-fetoprotein level, (2) Hepatitis-B antigen, (3) SWOG performance status, (4) Prior RT or surgery for hepatoma. This is a primary treatment and includes no plans for any concurrent treatment of the primary tumor. Patients will receive All-trans retinoic acid 50 mg/m<sup>2</sup> t.i.d. x 21 days followed by 7 days of rest. Therapy will be open-ended for responding or stable disease patients who are not experiencing serious toxicities. Disease assessment will be done at least every 8 weeks. Statistical evaluation will be based on time to treatment failure/time to death.

**Progress:** No patients have been entered in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/097		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9205: Central Prostate Cancer Serum Repository Protocol					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> Mar 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
MAJ Kenneth A. Bertram, MC			MAJ Patrick L. Gomez, MC		
MAJ Mark E. Robson, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC			MAJ Richard C. Tenglin, MC		
CPT James S. D. Hu, MC			LTC Robert D. Vallion, MC		
CPT Diana S. Willadsen, MC					
<b>Key Words:</b> Cancer:prostate, serum repository					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** 1. To store serum of patients with confirmed adenocarcinoma of the prostate entered onto clinical trials conducted by the SWOG Genitourinary Committee. 2. To provide the serum of the above patients entered onto SWOG studies for specific clinical-laboratory investigations outlined on separate SWOG protocols approved by the Genitourinary Committee Tumor Biology Subcommittee.

**Technical Approach:** This serum bank is to provide the opportunity for study of new or existing markers or other tests in a prospective or retrospective fashion, in order to test their usefulness as diagnostic or management tools in prostate cancer at all stages. Specific information regarding the nature of individual tests to be conducted on the serum samples of these patients will be described in individual protocols.

All serum samples (approx. 3 - 5 cc) will be collected from patients in the frequency and timing indicated on specific protocols. Samples will be spun 15 minutes after collection and stored at a minimum of -20 C. Samples will be frozen and shipped to the Serum Bank Coordinator.

**Progress:** One patient was entered in this study in FY93.



## Detail Summary Sheet

**Date:** 30 Sep 92      **Protocol No.:** 93/107      **Status:** On-going

**Title:** SWOG 9210: A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction; (2) Randomization of Prednisone Dose Intensity for ....

**Start Date:** 05/07/93      **Est. Completion Date:** May 98

**Department:** SWOG      **Facility:** MAMC

**Principal Investigator:** CPT James S. D. Hu, MC

<b>Associate Investigators:</b>	MAJ Luke M. Stapleton, MC
MAJ Kenneth A. Bertram, MC	MAJ Patrick L. Gomez, MC
MAJ Timothy P. Rearden, MC	MAJ Mark E. Robson, MC
MAJ Robert B. Ellis, MC	CPT Jennifer L. Cadiz, MC
MAJ Richard C. Tenglin, MC	LTC Robert D. Vallion, MC
CPT Diana S. Willadsen, MC	

**Key Words:** Cancer:myeloma, VAD-P, VAD-P,Quinine

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** (1) To compare the effectiveness of the VAD-P chemotherapy regimen when administered alone or in combination with the chemosensitizer quinine intended to block the emergence of multidrug resistance during remission induction in previously untreated patients with multiple myeloma; (2) To evaluate the chemosensitizing potential of quinine to reverse drug resistance in myeloma patients randomized to VAD-P induction who fail to achieve at least 25% regression with chemotherapy alone. 3. To compare the value of alternate day prednisone 10 mg versus 50 mg for remission maintenance for patients proven to achieve at least 25% regression.

**Technical Approach:** Patients with proven multiple myeloma (all stages) who have not received prior chemotherapy are eligible for participation in this trial. A dynamic allocation scheme will be used to randomize patients to one of the two induction treatment arms.

**INDUCTION:** ARM I patients will receive Vincristine 0.4 mg IV q.d. on days 1-4, Doxorubicin 9 mg/m<sup>2</sup> q.d. IV on days 1-4, Dexamethasone 40 mg q.d. PO on days 1-4, and Prednisone 50 mg Q.O.D. on days 9, 11, 13, 15, 17, and 19. This cycle will be repeated Q 21 days for a minimum of 6 to 8 cycles (6 months) or a maximum of 17 cycles (12 months). Patients who fail to achieve  $\geq 25\%$  tumor regression after 12 months of treatment on Arm I (VAD-P) or relapse or progress on Arm I, will be eligible for crossover to VAD-P/Q.

ARM II and Crossover schedule patients will receive VAD-P as outlined above on days 2-5 and will also receive Quinine 400 mg t.i.d. on days 1-6 (VAD-P/Q).

Patients with  $\geq 25\%$  tumor regression after 9 to 12 months of induction therapy or patients who achieve  $\geq 50\%$  tumor regression after 6 months of induction therapy will be randomized to either of two maintenance regimens. If, in the judgement of the physician the patient will continue to benefit from induction therapy, they may continue up to 12 months.

**MAINTENANCE:** ARM III patients will receive Prednisone, 10 mg Q.O.D., until relapse and ARM IV patients will receive Prednisone 50 mg Q.O.D. until relapse.

**Progress:** No patients have entered this study at MAMC.

# Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/066		<b>Status:</b> Completed	
<b>Title:</b> SWOG 9215: Quality of Life on Breast Cancer Adjuvant Trial (SWOG 8931)					
<b>Start Date:</b> 03/05/93			<b>Est. Completion Date:</b> Mar 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:breast					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** To determine if adjuvant chemotherapy given to breast cancer patients for SWOG 8931 has an adverse effect on performance status and lifestyle.

**Technical Approach:** This companion protocol will assess the quality of life for breast cancer patients undergoing adjuvant chemotherapy on SWOG 8931. This protocol requires that the patient complete a quality of life questionnaire at set time intervals.

Comparison will be made of biodemographic characteristics of patients on the quality of life study with patients on the parent trial to determine the extent to which the quality of life samples are representative of the samples in the parent trial.

**Progress:** No patients were entered at MAMC prior to closure to patient entry, 29 Apr 93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/090	<b>Status:</b> On-going		
<b>Title:</b> SWOG 9216: A Randomized Phase III Study of CODE Plus Thoracic Irradiation Versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer				
<b>Start Date:</b> 04/02/93	<b>Est. Completion Date:</b> Mar 98			
<b>Department:</b> SWOG	<b>Facility:</b> MAMC			
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <b>Associate Investigators:</b>  LTC Howard Davidson, MC  MAJ Patrick L. Gomez, MC  MAJ Robert B. Ellis, MC  MAJ Richard C. Tenglin, MC  LTC Robert D. Vallion, MC </td> <td style="width: 50%; vertical-align: top;"> MAJ Luke M. Stapleton, MC  MAJ Kenneth A. Bertram, MC  MAJ Mark E. Robson, MC  CPT Jennifer L. Cadiz, MC  CPT James S. D. Hu, MC  CPT Diana S. Willadsen, MC </td> </tr> </table>			<b>Associate Investigators:</b> LTC Howard Davidson, MC MAJ Patrick L. Gomez, MC MAJ Robert B. Ellis, MC MAJ Richard C. Tenglin, MC LTC Robert D. Vallion, MC	MAJ Luke M. Stapleton, MC MAJ Kenneth A. Bertram, MC MAJ Mark E. Robson, MC CPT Jennifer L. Cadiz, MC CPT James S. D. Hu, MC CPT Diana S. Willadsen, MC
<b>Associate Investigators:</b> LTC Howard Davidson, MC MAJ Patrick L. Gomez, MC MAJ Robert B. Ellis, MC MAJ Richard C. Tenglin, MC LTC Robert D. Vallion, MC	MAJ Luke M. Stapleton, MC MAJ Kenneth A. Bertram, MC MAJ Mark E. Robson, MC CPT Jennifer L. Cadiz, MC CPT James S. D. Hu, MC CPT Diana S. Willadsen, MC			
<b>Key Words:</b> Cancer:lung, cisplatin, adriamycin, vincristine, etoposide, cyclophosphamide, irradiation				
<b>Accumulative MEDCASE Cost:</b> \$0.00	<b>Est. Accumulative OMA Cost:</b> \$0.00	<b>Periodic Review:</b> / /		

**Study Objective:** To determine if chemotherapy dose intensification and thoracic irradiation will improve the response rate and overall survival rate in patients with extensive small cell lung cancer.

**Technical Approach:** Patients with extensive, measurable or evaluable disease will be randomized to 1 of 2 arms. Those randomized to Arm 1 will receive CODE (cisplatin, vincristin, doxorubicin, and etoposide) administered as follows: Cisplatin 25 mg/m<sup>2</sup> IV over 15 minutes weekly; Vincristine 1 mg/m<sup>2</sup> IV over 15 minutes weeks 1, 2, 6, 8; Doxorubicin 40 mg/m<sup>2</sup> IV over at least 10 minutes weeks 1, 3, 5, 7, 9; Etoposide 80 mg/m<sup>2</sup> IV over 20 - 30 minutes day 1 of weeks 1, 3, 5, 7, 9 and Etoposide 80 mg/m<sup>2</sup> PO days 2 & 3 of weeks 1, 3, 5, 7, 9. Those randomized to Arm 2 will receive alternating CAV/EP scheduled as follows: Cyclophosphamide 100 mg/m<sup>2</sup> IV 100 mg every 1 - 2 minutes of weeks 1, 7, 13; Doxorubicin 50 mg/m<sup>2</sup> IV over at least 10 minutes on day 1 of weeks 1, 7, 13; and Vincristine 1.2 mg/m<sup>2</sup> IV over 2 - 3 minutes day 1 of weeks 1, 7, 13 and Etoposide 100 mg/m<sup>2</sup> IV over 20 - 30 minutes days 1, 2 & 3 of weeks 4, 10, 16; Cisplatin 25 mg/m<sup>2</sup> VI over 15 minutes days 1, 2, & 3 of weeks 4, 10, 16. Supportive drugs (corticosteroid, gastroprotective agent, antifungal agent, prophylactic antibiotic Colony-stimulating factor, will be given according to set criteria.

After complete protocol cytotoxic chemotherapy, all patients will be re-staged, with repeat of any investigation that was abnormal prior to entry. If a patients should refuse re-staging, but appears on the available evidence to be in complete response, prophylactic cranial irradiation may be offered at the discretion of the investigator.

Patients on ARM 1 who achieve a complete response or partial response at the primary site with a complete response at all known metastatic sites will receive both thoracic irradiation to the mediastinum and site of the primary and prophylactic cranial irradiation beginning 3 to 4 weeks after completion of systemic therapy. These may be given concurrently and are obligatory.

Patients on Arm II who achieve a complete response will receive at least prophylactic cranial irradiation and this is obligatory. Other radiation therapy for patients in this arm is non-obligatory but may be given at the discretion of the investigator and should begin 3 to 4 weeks after completion of systemic therapy.

Progression-free survival will be compared between treatment arms. Generalized Wilcoxon and log-rank statistics will be used to compare survival experience between the two arms. A Cox proportional hazards model will be used to assess prognostic factors, and treatment effect will be tested after controlling for important prognostic variables. Response rates and toxicities between the two treatment arms will be compared by Fisher's exact test. Logistic regression will be used to assess and adjust for prognostic factors with respect to complete response.

Some patients responding to the CODE regimen will not be able to continue the weekly chemotherapy because of unacceptable constitutional toxicity or patient refusal. These patients should be offered the standard regimen (alternating CAV and EP) as they may be able to tolerate a chemotherapy program allowing sufficient time between treatments to convalesce from side effects.

Progress: No patients have entered the study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/136		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9221, MDACC ID 91-025, INT-191-001: Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer					
<b>Start Date:</b> 07/02/93			<b>Est. Completion Date:</b> Jul 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Mark E. Robson, MC		
MAJ Robert B. Ellis, MC			CPT Jennifer L. Cadiz, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> cancer:non-small cell lung, 13-cis retinoic acid					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$0.00		/ /	

**Study Objective:** To evaluate: (1) the efficacy of 13-cis-retinoic acid (13-cRA) in reducing the incidence of SPTs in patients who have been treated for Stage I non-small cell lung cancer with complete surgical resection; (2) the qualitative and quantitative toxicity of 13-cRA in a daily administration schedule; and (3) compare the overall survival of patients treated with 13-cRA vs. patients treated with placebo.

**Technical Approach:** Patients enrolling into this study will be stratified according to histology, T stage and smoking status then registered into a Single-Blind, 8 week run-in period to test compliance. All patients will receive placebo during this period. After Run-in the patients will be randomized into a double-blind trial to receive 13-cRA (30 mg p.o./d x 3 yrs vs. Placebo (30 mg p.o./d x 3 yrs). Each group will have a 4 year follow-up period.

The final analysis will be undertaken shortly after seven years. The primary hypothesis for the study is whether 13-cRA lowered the rate of second primary tumors (SPT). All patients randomized will be grouped according to the assigned treatment. Patients who are either purely lost to follow up or died without a SPT occurring will be included in the actuarial analysis with a censored status on the last day of contact. The primary hypothesis of treatment benefit will be tested using the proportional hazards model.

**Progress:** No patients have entered the study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/108		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9237: Evaluation of Topotecan in Refractory and Relapsing Multiple Myeloma					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> May 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> CPT James S. D. Hu, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Kenneth A. Bertram, MC		
MAJ Patrick L. Gomez, MC			MAJ Timothy P. Rearden, MC		
MAJ Mark E. Robson, MC			MAJ Robert B. Ellis, MC		
CPT Jennifer L. Cadiz, MC			MAJ Richard C. Tenglin, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> Cancer: myeloma; topotecan					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost.</b>	\$0.00	/ /	

**Study Objective:** (1) To evaluate the response rate for refractory myeloma treated with topotecan; (2) To evaluate the qualitative and quantitative toxicities of topotecan administered in a Phase II study; (3) To measure topoisomerase levels in multiple myeloma cells.

**Technical Approach:** Patients with proven multiple myeloma, with protein criteria present, who have received exactly one prior regimen, and have shown, in the opinion of the investigator, to have disease progression are eligible for this study. All patients will receive topotecan 1.25 mg/m<sup>2</sup> q.d. IV over 30 minutes on days 1-5 repeated q 21 days. This schedule will continue as long as patients show complete remission, partial remission or stable disease and toxicity is acceptable. Topotecan dosage can be adjusted on nadir counts of the preceding cycle.

It is assumed that topotecan will be of interest if a true response rate of 20% or more is achieved in the treatment of patients with relapsed or refractory multiple myeloma.

**Progress:** One patient was entered in this study in FY93.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/109	<b>Status:</b> On-going
<b>Title:</b> SWOG 9240: A Phase II Trial of CVAD for Treatment of Non-Hodgkin's Lymphoma		
<b>Start Date:</b> 05/07/93	<b>Est. Completion Date:</b> May 94	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC		
<b>Associate Investigators:</b>		
LTC Howard Davidson, MC	MAJ Luke M. Stapleton, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Robert B. Ellis, MC	MAJ Timothy P. Rearden, MC	
CPT James S. D. Hu, MC	CPT Jennifer L. Cadiz, MC	
CPT Diana S. Willadsen, MC	MAJ Richard C. Tenglin, MC	
	LTC Robert D. Vallion, MC	
<b>Key Words:</b> Cancer:non-Hodgkin's lymphoma, cyclophosphamide, vincristine, doxorubicin, dexamethasone		

<b>Accumulative MEDCASE Cost:</b> \$0.00	<b>Est. Accumulative OMA Cost:</b> \$0.00	<b>Periodic Review:</b> / /
--	---	-----------------------------

**Study Objective:** 1) To evaluate the effectiveness, toxicities, and side effects of the CVAD chemotherapy regimen in previously untreated patients with intermediate and high-grade non-Hodgkin's lymphomas. 2) Secondary objectives are to further investigate the utility of the proliferative rate (determined by Ki-67 monoclonal antibody), the importance of cell-cell recognition molecules, the role of host response, and the value of detectable levels of p-glycoprotein as prognostic markers of outcome. These objectives will be addressed in a companion study to this protocol (SWOG 8819). 3) A further secondary objective will be to further utilize the central serum repository enabling clinicopathologic correlations with the results of studies on the material collected (see SWOG 8947).

**Technical Approach:** Treatment with CVAD chemotherapy will be administered every 21 days for 8 courses in the following doses: Cyclophosphamide 750 mg/m<sup>2</sup> IV on day 1, Vincristine 0.5 mg/day IV on day 1-4, Doxorubicin 12.5 mg/m<sup>2</sup>/day on day 1-4, and Dexamethasone 40 mg/day PO on day 1-4. Retreatment interval is 21 days for 8 courses. Patients who develop objective evidence of disease progression during treatment, patients who relapse following a complete remission, and patients who fail to achieve a complete remission after completing the specified protocol treatment may be treated according to the physician preference. Performance status will be graded according to the current Southwest Oncology Group grading scale.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 93/091	<b>Status:</b> Terminated
<b>Title:</b> SWOG 9244 (MSKCC-92-106, NCI-T92-0130): A Randomized Study of Cisplatin (CDDP) & Etoposide versus Carboplatin (CBDCA) + Etoposide in the Treatment of Good Risk Patients With Advanced Germ Cell Tumors		
<b>Start Date:</b> 04/02/93	<b>Est. Completion Date:</b> Apr 98	
<b>Department:</b> SWOG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC		
<b>Associate Investigators:</b>		
LTC Howard Davidson, MC	MAJ Luke M. Stapleton, MC	
MAJ Patrick L. Gomez, MC	MAJ Kenneth A. Bertram, MC	
MAJ Robert B. Ellis, MC	MAJ Mark E. Robson, MC	
MAJ Richard C. Tenglin, MC	CPT Jennifer L. Cadiz, MC	
LTC Robert D. Vallion, MC	CPT James S. D. Hu, MC	
	CPT Diana S. Willadsen, MC	
<b>Key Words:</b> Cancer:germ cell, etoposide carboplatin		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$0.00	/ /

**Study Objective:** 1. To determine, in a randomized trial, the differences in response, toxicity, time to relapse, and survival between two active chemotherapy regimens used in the treatment of good risk patients with disseminated germ cell tumors. 2. To validate prospectively the prognostic value of serum tumor marker decline in good risk patients treated with chemotherapy.

**Technical Approach:** Patients agreeing to participate in this study will be randomized to receive Cisplatin (CDDP) (20 mg/m<sup>2</sup>/day X 5 days) and etoposide (100 mg/m<sup>2</sup>/day X 5 days q 21 days X 4 cycles or Carboplatin (CBDCA) to be dosed for AUC (area under the curve) of 5.0 mg/ml-min (minimum dose of 400 mg/m<sup>2</sup> on Day 1 and Etoposide 100 mg/m<sup>2</sup> IV on Day 1-5. The treatment course is recycled at 21 days to a total of 4 cycles. Responding patients will be treated for all 4 cycles after which a complete assessment of all sites of disease should be performed. Following completion of four cycles of chemotherapy and radiographic and marker assessment, surgical resection of all residual masses should be considered. Retroperitoneal lymph node dissection, mediastinal node dissection, excision of pulmonary metastases, and/or resection of supraclavicular disease may need to be performed when residual disease is present. If residual malignant tumor is found but is completely excised, then two cycles of chemotherapy using Vinblastine .11 mg/kg/(day 1 and 2), Ifosfamide 1.2 gm/m<sup>2</sup> (days 1 - 5) and Cisplatin 20 mg/m<sup>2</sup>(days 1 - 5) should be administered. O'Brien/Fleming stopping rules are being used for the calculation of the overall sample size. As the data accumulate, five analyses will be undertaken after successive groups of 32 patients per arm. Each time the data are analyzed, two one-sided confidence intervals will be calculated. If the lower confidence limit (with one-sided error of 0.1) excludes a treatment difference of 10% then the trial will be stopped and the treatments will be declared equivalent. If the upper confidence limit (with one sided error of 0.2) excludes zero then the trial will be stopped and the carboplatin arm will be declared inferior. To make sure that one of these conditions occurs a sample size of 320 will be needed.

**Progress:** This study was closed to patient entry 15 May 93 due to poor patient accrual. No patients were enrolled at MAMC.



## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/092		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease					
<b>Start Date:</b> 04/02/93			<b>Est. Completion Date:</b> May 95		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>					
LTC Howard Davidson, MC			MAJ Luke M. Stapleton, MC		
MAJ Patrick L. Gomez, MC			MAJ Kenneth A. Bertram, MC		
MAJ Robert B. Ellis, MC			MAJ Timothy P. Rearden, MC		
MAJ Richard C. Tenglin, MC			CPT Jennifer L. Cadiz, MC		
CPT Diana S. Willadsen, MC			CPT James S. D. Hu, MC		
			LTC Robert D. Vallion, MC		
<b>Key Words:</b> cancer:lymphoma, tissue procurement					
<b>Accumulative MEDCASE Cost:</b>		<b>Est. Accumulative OMA Cost:</b>		<b>Periodic Review:</b>	
\$0.00		\$0.00		/ /	

**Study Objective:** 1. To acquire fresh snap-frozen lymphoma tissue from patients who relapse or have recurrent disease after being treated on Southwest Oncology Group treatment protocols. 2. To establish a standard set of procedures for routine acquisition, banking, and study of lymphoma tissues within the cooperative group. 3. To use the repository tissue to establish clinical correlations via presently activated phenotyping studies and future projected molecular studies assessing specimen DNA and RNA status. 4. To examine the biology of therapy failure in relationship to changes in pretreatment and post-therapy immunophenotypic data.

**Technical Approach:** Fresh frozen tissues will be acquired from relapsed patients for basic science protocols, both current and future, designed to better define the biology of relapsed non-Hodgkins's lymphoma. This is not a treatment protocol, nor will results be used to guide treatment decisions.

Fresh biopsies (from any organ site) will be snap-frozen and submitted with one stained (Hematoxylin and Eosin) histologic section with accompanying pathology report to The Department of Pathology at the University of Arizona in Tucson.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/110		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9246: A Phase II Evaluation of Taxol in Patients with Relapsed Non-Hodgkin's Lymphoma or Relapsed Hodgkin's Disease					
<b>Start Date:</b> 05/07/93			<b>Est. Completion Date:</b> Jun 94		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Mark E. Robson, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
LTC Howard Davidson, MC			MAJ Patrick L. Gomez, MC		
MAJ Kenneth A. Bertram, MC			MAJ Timothy P. Rearden, MC		
CPT Jennifer L. Cadiz, MC			MAJ Robert B. Ellis, MC		
CPT James S. D. Hu, MC			MAJ Richard C. Tenglin, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
<b>Key Words:</b> Cancer:Hodgkin's, Cancer:non-Hodgkin's, taxol					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>	\$0.00	<b>OMA Cost:</b>	\$0.00	/ /	

**Study Objective:** (1) To assess the response rate of relapsed low-grade non-Hodgkin's lymphoma, relapsed intermediate or high-grade non-Hodgkin's lymphoma, and relapsed Hodgkin's disease treated with taxol; (2) To assess the qualitative and quantitative toxicities of taxol administered in a phase II trial.

**Technical Approach:** All participants of this study must have a biopsy proven diagnosis of low, intermediate or high grade malignant non-Hodgkin's lymphoma or Hodgkin's disease and have received prior therapy. Participants will be stratified by type of disease: low grade lymphoma, intermediate or high grade lymphoma and Hodgkin's Disease. In an effort to avoid acute allergic reactions, all patients will be premedicated with Dexamethasone, Diphenhydramine, and Cimetidine prior to the administration of Taxol. The initial dose of Taxol will be 175 mg/m<sup>2</sup> for all patients except it will be 135 mg/m<sup>2</sup> for those who have received prior radiotherapy to 30% or more of marrow-bearing bone. Therapy will be administered only to inpatients and dosage may be modified for toxicities.

Estimates of response and toxicity will be made for each disease category separately. A response probability of 35% would be of interest, while further testing of this regimen would not be pursued if the response probability was 15% or lower.

**Progress:** No patients have entered this study at MAMC.

### Detail Summary Sheet

**Date:** 30 Sep 92      **Protocol No.:** 93/137      **Status:** On-going

**Title:** SWOG 9248: A Phase II Trial of Paclitaxel (Taxol) in Patients With Metastatic Refractory Carcinoma of the Breast

**Start Date:** 07/02/93      **Est. Completion Date:** Aug 98

**Department:** SWOG      **Facility:** MAMC

**Principal Investigator:** MAJ Robert B. Ellis, MC

<b>Associate Investigators:</b>	MAJ Luke M. Stapleton, MC
LTC Howard Davidson, MC	MAJ Kenneth A. Bertram, MC
MAJ Patrick L. Gomez, MC	MAJ Timothy P. Rearden, MC
MAJ Mark E. Robson, MC	CPT Jennifer L. Cadiz, MC
MAJ Richard C. Tenglin, MC	CPT James S. D. Hu, MC
LTC Robert D. Vallion, MC	CPT Diana S. Willadsen, MC

**Key Words:** cancer:breast, taxol

<b>Accumulative</b>	<b>Est. Accumulative</b>	<b>Periodic Review:</b>
<b>MEDCASE Cost:</b> \$0.00	<b>OMA Cost:</b> \$0.00	/ /

**Study Objective:** To evaluate: 1) the subjective improvement in patients with symptomatic refractory carcinoma of the female breast treated with paclitaxel; 2) the clinical response rate of paclitaxel in patients with refractory carcinoma of the female breast; and 3) the qualitative and quantitative toxicities of paclitaxel in a Phase II study.

**Technical Approach:** Women with breast cancer who have failed one chemotherapy program for metastatic disease will receive Paclitaxel 210 mg/m<sup>2</sup>/21 days IV over 3 hrs. Because of the high frequency of hypersensitivity reactions noted in previous clinical trials, patients will be premedicated with decadron, benedryl and tagamet. Objective responses will be assessed by standard criteria. Subjective response will be measured by use of a Patient Symptom Monitoring Questionnaire which will be completed by the patient and scored by the study coordinator.

Patients will be treated for a minimum of two cycles or until objective progression or unacceptable toxicity is noted. The primary endpoints are symptom response and objective tumor response.

**Progress:** No patients have entered this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 93/166		<b>Status:</b> On-going	
<b>Title:</b> SWOG 9303: Phase III Study of Radiation Therapy, Levamisole, and 5-Fluorouracil versus 5-Fluorouracil and Levamisole in Selected Patients With Completely Resected Colon Cancer					
<b>Start Date:</b> 09/03/93			<b>Est. Completion Date:</b> Oct 98		
<b>Department:</b> SWOG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> MAJ Timothy P. Rearden, MC					
<b>Associate Investigators:</b>			MAJ Luke M. Stapleton, MC		
MAJ Kenneth A. Bertram, MC			MAJ Patrick L. Gomez, MC		
MAJ Mark E. Robson, MC			MAJ Robert B. Ellis, MC		
MAJ Richard C. Tenglin, MC			CPT James S. D. Hu, MC		
LTC Robert D. Vallion, MC			CPT Diana S. Willadsen, MC		
MAJ Richard F. Williams, MC			CPT John R. Caton, MC		
<b>Key Words:</b> cancer:colon, irradiation, levamisole, 5-FU					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b>		\$0.00	<b>OMA Cost:</b>		\$0.00
					/ /

**Study Objective:** To determine whether 5-FU, levamisole and radiation therapy results in superior overall survival when compared to 5-FU and levamisole without radiation therapy in the management of patients with completely resected pathologic stage T<sub>4</sub>N<sub>0</sub>-2 colon cancer and selected patients with T<sub>3</sub>N<sub>1</sub>-2 colon cancer.

**Technical Approach:** This randomization clinical trial will compare radiation therapy, 5FU and levamisole with 5FU and levamisole in patients with completely resected colon cancer at high risk for local-regional recurrence and limited risk for system disease.

We will compare 5FU and levamisole, as delivered in the prior intergroup study, with one month of 5FU and levamisole followed by 5-5 1/2 weeks of 5FU, levamisole, and local-regional RT (45-50.4 Gy in 25-28 fractions), followed by 43 weeks of 5FU and levamisole.

**Progress:** No patients have entered this protocol at MAMC.

DETAIL SHEETS FOR PROTOCOLS

UNIVERSITY OF WASHINGTON NEURO-ONCOLOGY  
GROUP

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 88/073		<b>Status:</b> Completed	
<b>Title:</b> UWNG 86-01: Phase II Study of External Brain Irradiation and Hydroxyurea Followed by Procarbazine, CCNU, and Vincristine (PCV) for the Treatment of Primary Malignant Brain Tumors					
<b>Start Date:</b> 08/19/88			<b>Est. Completion Date:</b> Jul 91		
<b>Department:</b> UWNG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b> COL Irwin B. Dabe, MC CPT Denis Bouvier, MC			Robert Goodkin, M.D. MAJ Joseph H. Piatt, MC		
<b>Key Words:</b> tumor:brain,irradiation,PCV,procarbazine,CCNU,vincristine					
<b>Accumulative MEDCASE Cost:</b>		\$0.00	<b>Est. Accumulative OMA Cost:</b>		\$0.00
					<b>Periodic Review:</b> 12/04/92

**Study Objective:** To evaluate radiation therapy plus hydroxyurea and PCV in terms of the following parameters: time to progression from start of therapy, response rates and stabilization rate, survival time from start of therapy, and quality of life and activity level (Karnofsky).

**Technical Approach:** Patients must have a primary intracranial malignant glioma. Most patients will have had some form of surgery. Treatment will begin within four weeks of the operation at which the current diagnosis was made or within four weeks of clinical diagnosis. No prior cytotoxic, chemotherapy, or radiation therapy will be permitted. Local field radiotherapy will be employed. Only one course of radiotherapy will be given. The total dose to the tumor will be 5940 cGy delivered in a period of 6-7 weeks. The tumor volume will include at least the enhanced portion of tumor based on CT scan and a 2-3 cm margin of normal tissue in all directions. Every other day during radiotherapy, beginning day 1, patients will receive hydroxyurea, 300 mg/m<sup>2</sup> every six hours. PCV treatment will begin within two weeks after radiotherapy. CCNU, 110 mg/m<sup>2</sup> po, will be given on day one of each course. Procarbazine, 60 mg/m<sup>2</sup> po will be given days 8-14. Vincristine, 1.4 mg/m<sup>2</sup>, will be given IV push on days 8 and 29. Patients will be evaluated and courses given at six to eight week intervals in the absence of irreversible toxicity. Patients will remain on protocol until the completion of two full courses of PCV. If tumor progression is documented after the second course, the patient will be taken off protocol. If tumor progression is not demonstrated, PCV will be given for one year or a minimum of 6 courses (not to exceed 8 courses) and then stopped. All patients will be followed for survival. Patients who expire from tumor progression early in the course of therapy will be evaluable for analysis if one full course of PCV was administered.

**Progress:** No patients participated in this study at MAMC.

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92	<b>Protocol No.:</b> 88/017	<b>Status:</b> On-going
<b>Title:</b> UWNG 87-01: Phase II Study of TPDCFH for Recurrent Malignant Brain Tumor		
<b>Start Date:</b> 12/11/87	<b>Est. Completion Date:</b> Sep 90	
<b>Department:</b> UWNG	<b>Facility:</b> MAMC	
<b>Principal Investigator:</b> LTC Howard Davidson, MC		
<b>Associate Investigators:</b>		
COL Michael W. Potter, MC	Robert Goodkin, M.D.	
MAJ Joseph H. Piatt, MC	Frederick Helmer, M.D.	
LTC Lauren K. Colman, MC	COL Irwin B. Dabe, MC	
MAJ Ruben D. Sierra, MC	MAJ David M. Dunning, MC	
MAJ Thomas M. Baker, MC	CPT Denis Bouvier, MC	
<b>Key Words:</b> tumor:brain,chemotherapy,TPDCFH		
<b>Accumulative MEDCASE Cost:</b>	<b>Est. Accumulative OMA Cost:</b>	<b>Periodic Review:</b>
\$0.00	\$100.00	12/04/92

**Study Objective:** To determine whether TPDCFH chemotherapy for recurrent malignant glioma will increase time to progression and survival rate and to document the toxicity attendant on combined treatment.

**Technical Approach:** Patients will be eligible for this study if: they have received primary surgical treatment, radiotherapy, or adjuvant chemotherapy but no radiotherapy or chemotherapy for 8 weeks prior to entry; the tumor is a histopathologically confirmed recurrence of a malignant supratentorial glioma; liver and renal function are not seriously impaired (liver enzymes and serum creatinine within 1.5 x normal for laboratory; Karnofsky performance status is >60%. Recurrence will be signaled by worsening neurologic symptoms and signs measured by a neurologic examination. Enlargement of tumor volume as measured in contrast and noncontrast CT scans will serve as an additional criterion of recurrence. All patients will receive the following schedule: 0-66 hr: 6-thioguanine 30 mg/m<sup>2</sup> q 6 hr p.o. x 12 doses; 60-78 hrs:

## Detail Summary Sheet

<b>Date:</b> 30 Sep 92		<b>Protocol No.:</b> 89/013		<b>Status:</b> On-going	
<b>Title:</b> UWNG 88-01: Phase II Study of High Dose Methotrexate and Craniospinal Irradiation for the Treatment of Primary Lymphoma of the Central Nervous System					
<b>Start Date:</b> 01/20/89			<b>Est. Completion Date:</b> Nov 92		
<b>Department:</b> UWNG			<b>Facility:</b> MAMC		
<b>Principal Investigator:</b> LTC Howard Davidson, MC					
<b>Associate Investigators:</b>			Robert Goodkin, M.D.		
Edythe A. Albano, M.D.			MAJ Joseph H. Piatt, MC		
MAJ Frank A. Zimba, MC			COL Irwin B. Dabe, MC		
CPT Denis Bouvier, MC			MAJ Mark H. Kozakowski, MC		
MAJ Everardo E. Cobos Jr., MC			MAJ Kenneth A. Bertram, MC		
<b>Key Words:</b> lymphoma:central nervous system,chemoradiotherapy,methotrexate					
<b>Accumulative</b>		<b>Est. Accumulative</b>		<b>Periodic Review:</b>	
<b>MEDCASE Cost:</b> \$0.00		<b>OMA Cost:</b> \$328.00		12/04/92	

**Study Objective:** To evaluate this regimen; the endpoints of analysis will be time to progression of disease from beginning of therapy; response rates and disease stabilization rates; survival time measured from the beginning of therapy; quality of life and activity level measured by Karnofsky performance status.

**Technical Approach:** Patients must have a non-Hodgkin's lymphoma of the central nervous system with adequate renal, bone marrow, and liver functions and a performance status of >70%. HIV antibody titer must be negative. No prior chemotherapy or radiotherapy is permitted.

Methotrexate, 4 g/m<sup>2</sup>, will be administered over a four hour period. Calcium leucovorin, 25 mg, will be administered beginning 20 hours after completion of the methotrexate infusion and repeated for 8 doses parenterally on an every 6 hour basis following which an additional four doses will be administered every six hours by mouth. The methotrexate regimen will be administered every two weeks for three courses. Radiotherapy will begin two weeks after completion of methotrexate, and will consist of 5040 cGy to whole brain at 180 cGy/fraction (28 fractions) and 3060 cGy at 170 cGy/fraction (19 fractions) to spinal axis. Time to progression will be measured from the initiation of therapy until progression is documented. At that time the patient will be removed from the protocol and can be treated with other therapy as indicated. Patients will be followed until death.

**Progress:** This study is ongoing. One patient participated without any unusual adverse events.



# INDEX

## NAMES

Aaron GR 12, 74  
 Achilles J 231  
 Adams C 159  
 Adams J 254  
 Adams MM 15  
 Adler RA 13  
 Ahmed MA 201  
 Albano EA 497  
 Altemus D 20  
 Amling CL 25  
 Andersen CA 159, 290, 293, 310  
 Anderson DM 16, 25, 275, 280, 282, 315  
 Anderson EE 25  
 Anderson PL 285, 288  
 Andrade WP 83, 103  
 Aragonas 26  
 Arbuck SG 13  
 Archer KT 19  
 Argyros G 22  
 Arline AD 12  
 Armstrong AY 23, 200, 201, 204, 207  
 Ascjer DP 15  
 Asp AA 126, 129  
 Athya B 24  
 Avery RA 292  
 Babonis TR 61  
 Babu SS 25, 269  
 Bagg MD 26  
 Bagian JP 16  
 Bailey CA 189  
 Baker TM 403, 404, 405, 406, 407,  
 408, 409, 410, 411, 412,  
 496  
 Barja R 306  
 Barry MJ 16, 282, 293  
 Bass GT 12  
 Bass JW 15  
 Bauman JM 15, 24, 111, 112, 147, 148,  
 251, 252, 253  
 Bayliss PM 202, 203, 215, 216, 217,  
 222  
 Beachy JC 185, 191, 192, 194, 228,  
 229, 230, 243, 244, 245  
 Becker LR 16  
 Begus G 127  
 Bell BK 13, 119  
 Bell V 15  
 Belts RP 218  
 Belville WD 403, 408, 409

Bender GN 15, 25  
 Benson WL 15, 327, 328, 335, 337, 338,  
 339, 340, 341, 342, 343,  
 344, 345, 346, 347, 349,  
 350, 352, 353, 354, 355,  
 385, 398  
 Beresford SA 208  
 Bergin-Sperry MJ 72  
 Bernier RM 162  
 Bertoglio M 159  
 Bertram KA 62, 138, 139, 140, 141, 142,  
 143, 145, 147, 148, 150,  
 151, 387, 388, 413, 414,  
 415, 416, 418, 419, 420,  
 422, 423, 424, 425, 426,  
 427, 428, 429, 430, 431,  
 434, 435, 436, 437, 438,  
 439, 441, 446, 447, 448,  
 449, 451, 452, 454, 455,  
 456, 457, 462, 464, 465,  
 466, 467, 468, 469, 470,  
 471, 472, 473, 474, 475,  
 476, 477, 478, 479, 480,  
 481, 482, 483, 484, 486,  
 487, 488, 489, 490, 491,  
 492, 493, 497  
 Beveridge RA 13  
 Billingsley JL 16, 253  
 Binder RA 13  
 Birgenheier P 22  
 Birgenheier PS 14, 181  
 Blackburn S 191, 192  
 Blakeslee DB 303, 410  
 Blancke BW 315  
 Block K 17  
 Bloom DA 13  
 Blount BW 20, 91, 315  
 Boley TJ 202, 203, 213, 214, 215,  
 216, 217  
 Bourneman M 127  
 Bouvier DP 151, 408, 409, 413, 414,  
 415, 416, 417, 418, 419,  
 420, 421, 423, 424, 425,  
 426, 429, 431, 434, 435,  
 436, 437, 446, 495, 496,  
 497  
 Bower DJ 283  
 Boyd BD 12, 77  
 Bradley KL 221  
 Brady WK 15, 23, 245  
 Branch B 103  
 Brandt CA 15

# INDEX

Brandzel S	208	Carr MA	182
Brantner LM	79	Carter ER	24, 232, 233
Brantner RD	79, 80	Carter JR	268, 297
Bremner W	129	Carter PL	17, 26, 81, 116, 293
Brien JH	15	Caruso DR	20, 130
Briggs LM	15	Carver TD	234
Brilliant SE	149	Cassels JW	218
Brissette MD	15, 134, 141, 142, 146	Caton JR	169, 387, 388, 422, 472, 493
Broadhurst RB	231	Cavanaugh DG	16, 275, 277, 282, 293, 450
Brooks KL	236, 242	Cawthon MA	16, 25
Brown JS	13, 83, 103	Chamusco RF	111, 112
Brown SR	147	Chan AH	403, 404
Brunader REA	12	Chandler DW	16, 26
Bryson Dr	406, 407, 410, 411, 412	Chapin BL	20, 115, 116
Bubien RS	14	Charles JB	16, 17
Budd SE	24, 112, 147, 251, 252	Charney PJ	21, 188
Buertler AT	19	Chen JB	16
Buetow PC	24	Chen TY	17
Bullis WJ	204	Choi HS	15, 25
Bunner DL	20, 114, 123	Chuang HS	24
Burgess FW	16, 25, 72, 77, 274, 275, 276, 277, 278, 280, 282, 283	Chuang S	16
		Chuang SH	16, 255, 256
Burke TF	19, 81, 83	Clagett CL	109, 168
Burkle F	85	Clark J	24
Burri BJ	18, 323	Clayton WL	163, 164
Burroughs SL	325	Clifford AJ	323
Butcher JD	92	Clift SD	303
Butzin CA	15	Cobos E	150, 151, 399, 413, 414, 415, 416, 419, 420, 423, 424, 425, 426, 427, 428, 429, 431, 433, 434, 435, 436, 437, 438, 440, 441, 442, 443, 444, 445, 446, 450, 453, 458, 459, 460, 467, 497
Cadiz JL	20, 138, 139, 140, 141, 142, 145, 147, 148, 169, 399, 427, 428, 430, 433, 439, 440, 441, 442, 443, 444, 445, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 462, 464, 465, 466, 467, 468, 469, 471, 473, 474, 475, 476, 477, 478, 479, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492	Coleridge ST	85
		Colman LK	406, 407, 408, 409, 412, 496
Cambier PA	14, 20, 108, 109, 110, 111, 229	Colonna D	16, 25
Cameron SE	16	Colonna DM	280
Camp RA	303	Colvin KL	268
Campanaro J	22	Colvin R	186
Canonico DM	286	Congdon JE	404
Caputo M	17, 297	Conrad	P 316
Carlin KJ	118	Cook BA	391, 392, 393, 394, 395
Carlton MJ	134	Cooper RH	153, 154, 155
Carpenter CT	16, 26	Cosio MQ	17, 26, 303, 305
		Cotelingam JD	24
		Cox H	36
		Cragun WH	13, 14, 20, 21, 169, 170, 171, 268

# INDEX

Creel CA	52	Douglas DM	13, 83
Crenshaw SM	304	Downey GO	343, 347, 385, 398
Crothers BA	248	Dronen SC	85
Crouch DN	92	Dubravec VA	272
Culbertson G	24	Duffy LK	319
Cushner HM	160, 211	Dugger KA	93
Dabe IB	402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 417, 418, 421, 425, 437, 495, 496, 497	Duncan NO	14
Daizdos JE	12	Dunn T	13
Dalessandro LJ	177, 178	Dunning DM	407, 408, 409, 412, 496
Davidson H	14, 138, 139, 140, 141, 142, 143, 145, 147, 148, 150, 151, 387, 388, 399, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 462, 464, 465, 466, 467, 468, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 483, 484, 486, 487, 488, 489, 490, 491, 492, 495, 496, 497	Dupuy P	17
Davis RC	17, 415, 420	Dziados JE	12
Davis SM	308	Ebbeling WL	103
Deaconson TF	294	Ebersole D	16
Dearman RM	16, 275, 293	Edmond CV	26, 287
Decker MJ	282, 283, 295	Eggebroten WE	291, 293
DeFraites RF	15	Ellis DD	13, 19, 91
Degenhardt E	14	Ellis RB	20, 127, 138, 139, 140, 141, 142, 144, 145, 147, 148, 387, 388, 399, 422, 427, 428, 430, 433, 439, 440, 441, 442, 443, 444, 445, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 462, 464, 465, 466, 467, 468, 469, 470, 471, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493
Della-Giustina DA	79, 80	Engel CC Jr	204
Della-Giustina KL	285	Engibous PJ	12, 73
Dewan RN	167, 417, 449, 460	Enriquez J	240
Dhru RD	15	Enzenauer RW	18
Dixon ZR	18	Esplin VS	305
Dodai DD	15	Fallace J	16
Donatucci CF	17	Fannin LA	26, 300, 301
Donnelly J	25	Fariss BL	120
Dons RF	14	Fernicola PJ	304
Dorsay TA	263	Ficke RF	21
Dorsett CR	72, 308	Finder K	13
		Finney JL	303
		Fischer GW	15
		Fitz CR	16
		Fitzpatrick D	96
		Fleck SJ	12
		Foos CC	201, 205, 206
		Forred WA	12
		Fox	26
		French J	15
		Frey MAB	16
		Friedl KE	121

# INDEX

Fuery HA	222	Green NE	27
Gage TP	21	Greenfield NN	159
Gandara D	14	Grem JL	13
Garcia J	15	Gridley GD	277, 304
Gardner D	129	Griffin JM	12, 72, 77
Gatrell CB	85, 86	Griffith TG	303
Gee BT	26, 300, 301	Grover BS	13, 171, 172
Gendron BP	84	Guertler AT	12, 19, 21, 82
George C	14	Guevara JP	24, 239
George PI	14, 190	Gunzenhauser JD	223
Georgitis WJ	14, 20, 21	Guzman CM	12
Gerena L	12	Hall RA	17, 293
Gernon WJ	410	Hamilton JM	13
Geyer CA	14, 16	Handley JK	82
Gibbons RV	188	Hanel D	305
Gibson CA	20, 114, 123, 200, 297	Hannan CJ	118, 121, 129
Gibson CR	17	Hansberry KL	17, 26, 310, 311, 312
Gilbert BN	300	Hanscom DA	16
Gilliam LS	211, 212	Hansen CN	26
Gilman MD	160	Hansen CS	143, 149, 163, 169, 189, 301
Gingrich JR	26	Hansen J	59
Glaser	C 316	Harkless LB	16, 26
Glenn GM	237	Harlass FB	15
Glover WD	185	Harlass FE	15
Goerringer F	25	Harrington BC	92
Goho CD	12, 75	Harris SC	291, 293
Gomez PL	138, 139, 140, 141, 142, 145, 147, 148, 150, 151, 387, 388, 399, 415, 416, 419, 420, 422, 423, 424, 426, 427, 428, 429, 430, 431, 433, 434, 435, 436, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 462, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493	Harrison DH	201, 207
Gomez RR	20, 22, 108, 127, 130, 142, 144, 253, 308	Harwood SJ	22, 183, 186
Goodkin R	495, 496, 497	Haskell G	53
Grace TS	16, 26	Hatch KD	15
Grajcar MS	19	Haynor DR	25
Gram MC	15	Heironimus J	16
Grantham DW	16, 26	Heissser AH	15
Grathwohl KWA	22, 157	Hellman SL	15, 184
Grediagin A	23, 101	Helman JD	16, 25, 275, 278
		Helmer F	496
		Herd M	209
		Hermann KM	234
		Hicks S	186
		Hinson RM	15
		Hnatink O	13
		Ho VB	16, 24, 25, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 271
		Hobbs CJ	13
		Hodges GF	24, 141, 146, 474
		Hoeldtke NJ	200
		Holder K	315
		Holmes KD	88
		Homann JF	445, 450

# INDEX

Horan MP	168	Kelly PC	86, 231, 235, 237, 240
Howard J	127	Kemink JL	17
Hu JSD	138, 139, 140, 142, 145, 146, 148, 387, 388, 422, 428, 430, 439, 441, 447, 448, 449, 451, 452, 454, 455, 456, 457, 462, 464, 465, 466, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493	Kenevan RJ	303
Hubickey W	297	Keplar B	24
Hughes WA	279	Kern JD	13
Hunter N	17	Kiesling VJ	408
Hurley WT	79	Kileny PR	17
Hurst RL	277, 278, 279, 292	Kim GJ	21
Illions E	207	Kim Y	15, 25
Irvin TL	177, 178, 179	Kinney JB	15
Irvine TW	14, 22	Kirk LC	21
Jabbari B	14	Kiser WR	12, 13, 93, 94, 99
Jaeger M	24	Kittle PE	12, 74, 75, 76
Jeffers DJ	20, 158, 159	Knight JA	16, 293
Jensen HG	17, 27	Knight RW	26, 311
Jerant AF	12	Knodel DH	114, 116
Jhiang SM	20	Knotts SM	14
Jhiang SS	127	Kohl	S 316
Johnson	J 98	Koo B	16, 24
Johnson KR	89	Kopelman JN	15, 23, 202, 203, 205, 206, 208, 209, 210, 211, 213, 214, 215, 216, 217
Johnson NT	13	Kosoy AF	103
Jones DL	20, 158	Kowalski KR	22
Jones HL	12, 73, 74	Kozakowski MH	151, 413, 414, 415, 416, 418, 419, 420, 423, 424, 425, 426, 429, 431, 434, 435, 436, 437, 438, 446, 497
Jones RE	13, 16, 20, 91, 114, 115, 117, 118, 119, 120, 121, 122, 123, 126, 129, 164, 201	Kraemer WJ	12
Jones RO	18, 26, 27	Kraemer WU	12
Jordan E	13	Kransdorf MJ	16, 24
Jorgenson D	294, 295	Krause	P 316
JoynerRE	25	Krauss MR	15, 67, 221, 223, 224
Jullin JC	13	Kreder KJ	17
Kahn CA	235	Krivda s	13
Kannen KA	26	Krober MS	15, 236, 237, 239, 240, 241, 242, 243, 244, 245, 246, 249
Karren K	301	Kroenke K	21
Katakkar SB	401, 402	Kruse RW	12, 16
Katts N	24	Kugler JP	12, 13, 92, 94, 96, 315
Kaufmann CR	17, 276, 291	Kull DH	350, 355
Kawai N	17	Kushner JP	126, 172
Keeling J	20	Kyle DE	12
Keenan LM	20, 21, 169, 175, 188	Laird JR	14
Kelley JL	168	Lambie MG	55
		Lancaster A	101, 184
		Lance J	20
		Landry FJ	21, 158, 160
		Lane W	13
		Lang P	17

# INDEX

Larsen WI	23, 201	Markenson GR	23, 213, 214, 215, 216
Leander D	22	Martin M	103
Leander DJ	185, 234	Martin RK	12, 127, 130
Leathe JL	232	Martin RL	189
Leckie RG	25, 268	Mascette AM	110, 111
LeClair BM	93	Masi JD	241
Ledoux RA	103	Maslow AS	92, 203, 205, 206, 210, 213, 214, 215, 217
Lee CB	315	Matej LA	19, 62, 63, 70, 164
Lee RB	327, 328, 335, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 349, 350, 352, 353, 354, 355, 385, 398, 407	May EF	14
Lee SP	21	Mazzaferri EL	13, 20, 126, 127, 129, 130
Leininger M	163	McBurney JW	240, 285
LeMar H	14, 20	McCalmont T	20
LeMar HJ	21, 116, 123	McCarthy M	22
Lenhardt TM	24	McCarty JP	165, 237, 272
Lester EL	16	McDermott MT	20, 21
Lester PA	160	McKee K	221
Levine ME	319	McLaughlin S	14
Lewis EL	95, 315	McNeil JG	223
Lewis FM	198	McNeill KM	223
Liebenberg SP	85	Meadors LW	12
Liening DA	14	Meehan RT	16, 17
Lillegard WA	12, 13, 19, 20, 92	Merante F	16
Lin FL	103	Metcalf M	184
Ling GSF	14	Meyer CA	24, 25, 168, 175, 268, 269
Loan LA	14, 22, 186, 187	Michael RA	154
Lodato RJ	133	Michel TJ	248
Loop SM	17	Milhous WK	12
Lorenzen E	91	Minton TR	147
Lovins DE	96	Moe RD	83
Lucas C	21	Moffitt DR	232, 233, 242
Lynn MJ	17	Montigo H	306
Lyons MF	14, 17, 21, 133, 134, 135, 136, 177, 253	Moon M	20
Ma W	211	Mooney MJ	17
MacDonald D	93	Moore DC	19, 57, 58, 59, 60, 61, 248
Macedonia CR	23	Moore KH	19, 22, 59, 62, 63, 65, 70, 130, 141, 144, 164, 240
MacGregor D	16	Moriarty R	15
Mack SR	81	Mork TJ	12
MacKenzie MR	14	Morris JT	155
MacMillan JG	183, 193	Morris MR	17, 286, 303, 424, 434
Mader TH	16, 17, 18, 26, 297, 299, 300, 301	Moyer D	103
Magelssen DJ	206, 212, 218	Mueller JP	21
Mancuso JJ	26, 217	Muggelberg ML	103
Mangano D	278	Mukharjee D	159
Maniaci PA	181	Mullin JC	111
Marden LA COL	164	Mun SK	25
Marden LA CPT	162	Murphy FM	16
		Murray TR	80, 167
		Mygrant BI	188
		Neary MT	26
		Neidlinger TR	18

# INDEX

Neill GF	189	Phillips Y	22
Nekola MA	298, 299	Piatt JH	495, 496, 497
Nelson KM	206	Picano JJ	321
Neri AR	233	Pierce HI	401
Newman GE	25	Pike JD	13, 21, 22, 174, 175
Newman RA	60	Pina JS	168
Ng JD	26, 116, 297, 298, 299	Piratla V	303
Nold JM	82	Pitcher JD	304
Noonburg GE	83	Place RJ	17, 81, 279, 292
Norbeck JC	13	Plyman ML	16, 280
Nusbaum MR	13, 97	Plymate SR	13, 19, 70, 115, 118, 119, 120, 121, 129, 172
Nyreen MR	17	Polaner DM	17, 281
O'Reilly MJ	293	Polk AM	12
O'Rourke TJ	403, 404, 405, 410, 411	Pollock B	24
Oduola AMJ	12	Porter SB	20
Ohno AK	160	Potter ME	15, 218, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383
Olson J	201	Potter MW	496
Opheim GS	15	Powell DA	66
Ormseth EJ	160	Prewitt K	14, 109
Ostenson RC	17	Quinn KL	83, 173
Ow C	14	Rasband W	23
Pace SA	81	Rave MA	111, 112
Page MG	76	Rawlings JS	15, 24, 243, 244, 245
Panje WR	17	Ray G	14
Paris JA	111, 145	Raymond WR	300
Parker JES	25, 269, 270	Rea RE	190
Parmley VC	17, 18, 26, 27, 297, 299, 300, 301	Read JA	15, 23, 24, 202, 203, 210, 213, 214, 215, 216, 217, 219
Patience TH	12, 68	Rearden TP	138, 139, 141, 388, 422, 447, 451, 452, 457, 461, 462, 464, 466, 467, 469, 470, 472, 473, 476, 477, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493
Patrin GD	272	Reed HL	14, 20, 22, 114, 123
Pauulson DF	26	Reeder J	21
Paulson D	286	Reissman S	91
Paulson DF	26	Renaud M	22, 23
Payne LE	82		
Pearce WA	21, 135, 136, 177		
Peele ME	14, 20, 21, 22, 111, 124		
Peller PJ	16, 25, 257, 258, 259		
Peller TP	21, 177		
Perdue ST	190		
Perez LM	25, 26		
Perkins JA	17, 83, 286		
Perkins TA	243, 244, 245		
Perren RS	88		
Pestaner JC	25, 269		
Peterson MW	84		
Peterson NE	17		
Petra PH	63		
Phillip DF	221, 316		
Phillips RH	12, 19		
Phillips WA	399, 427, 440, 442, 443, 444, 445, 450, 453, 458, 459		

# INDEX

Renaud MT	191, 192	Savinske D	188
Reno JP	27	Sborov MJ	16, 25, 278, 280
Rhodes PH	15	Scaniffe JA	295
Ribera JE	53	Schiff S	14
Rice MM	85, 86, 230	Schirner WA	13, 91
Rich IM	325	Schlepp GE	21, 133, 134, 135, 136
Richardson MG	234, 299	Schmidt JA	226
Ricke RFWalsh ES	21	Schofield TD	15, 16
Rickman WJ	15	Schwartz BF	312, 313
Riordan KK	177, 178, 179	Scott JS	247
Ritchey MR	13	Seinberg SM	13
Robb ML	15	Self DJ	94
Roberts JD	17	Sheehan KM	105, 106
Robertson CA	98	Sheffler RL	140, 145, 150, 151, 399, 415, 416, 419, 420, 423, 424, 426, 427, 428, 429, 430, 431, 433, 434, 435, 436, 438, 439, 440, 441, 442, 443, 444, 445, 446, 448, 449, 450, 453, 454, 455, 458, 459, 460, 465, 467, 468, 471, 474, 475, 478
Robertson JE	26	Shields J	14
Robinson BH	16	Shimouchi A	17
Robinson MD	85	Sierra RD	407, 408, 409, 412, 496
Robson ME	13, 138, 139, 141, 147, 148, 149, 387, 388, 422, 447, 451, 452, 457, 462, 464, 466, 469, 470, 472, 473, 476, 477, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493	Silveira JL	288
Rogan KM	14	Simmang CL	253, 293, 294
Rohrer MK	160	Sisk LD	27
Romlein J	25	Sisk LE	18
Rone JK	14	Slieter SJ	20
Roots AE	242	Smirniotopoulos JG	16, 24, 265, 266
Rosen C	13	Smith CS	25
Rosey JJ	27	Smith D	22
Roth BJ	14, 22, 80, 157, 167, 169, 170, 171, 172, 173	Smith DS	306
Rovira MJ	24, 25, 173, 260, 261, 262, 263, 264, 271	Smith DV	15, 16, 25, 268
Rowe JL	249	Smith FR	15
Rowsey JJ	17	Smith JB	27
Rozanski TA	17	Smith SB	16, 17, 25, 293
Rubertone MV	15	Snodgrass G	25
Rucker KS	13	Snyder RH	21
Runkle GP	13, 99	Soong SJ	15
Rushing EJ	16	Sorensen G	13
Russell KM	88	Souliere CR	17, 26, 288
Sado AS	21, 22, 105, 157, 188, 279, 292	Sowray PC	140, 145, 150, 151, 399, 406, 412, 415, 416, 419, 420, 423, 424, 425, 426, 427, 428, 429, 430, 431, 433, 434, 435, 436, 438, 439, 440, 441, 442, 443, 444, 445, 446, 448, 450,
Sage MK	189		
Sakas L	127		
Saltiel D	106, 111, 112		
Sample SA	111		
Sarno AP	15		
Sauls F	16, 25		



# INDEX

	453, 454, 455, 458, 459, 460, 461, 465, 467, 468, 471, 474, 475, 478		
Spencer S	15	Taylor G	17
Spina JR	160	Teague GR	248
St Louis J	16	Tein I	16
St	Pierre P 27	Telepak RJ	16
Stafford EM	15, 248, 249	Tenglin RC	138, 139, 140, 141, 142, 145, 147, 148, 387, 388, 422, 428, 430, 439, 441, 447, 448, 449, 451, 452, 454, 455, 456, 457, 462, 464, 465, 466, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493
Staheli LT	27	Tenglin RC	14
Stajduhar DD	198	Thomas K	192
Stajduhar KC	14, 108, 110, 111, 229	Thomas KA	186, 191
Stanford	AN 272	Thompson IM	310
Stankus SJ	13	Thompson JW	22, 80, 157
Stapleton LM	138, 139, 140, 141, 142, 145, 146, 147, 148, 387, 388, 399, 422, 427, 428, 430, 439, 440, 441, 442, 443, 444, 445, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 462, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 486, 487, 488, 489, 490, 491, 492, 493	Thomsen-Archer KL	70
		Thrasher JB	17, 25, 26, 312, 313
Stecenko A	24	Tidwell M	306
Steele RW	15	Tier C	89
Stein	26	Timmons J	19
Stephan MJ	24	Timmons JH	61, 83, 126, 264, 270, 310
Stephenson S	235	Tobin LM	321
Stephenson SR	392, 393, 394, 395	Tollefson DFJ	290
Stevenson JG	15	Tony MO	16
Stewart D	15	Torrington K	13
Stewart RS	12, 19, 67, 68, 69, 248	Travis MT	17
StLouis JS	306	Tripp GC	209
Stoltzfus D	13	Truxal AR	26, 301
Stone MD	403, 405, 406, 410, 411	Tsuchida AM	14, 21, 133, 134, 135, 136, 177
Stonecipher KG	17, 27	Tuer WF	103
Stracener JC	61	Turner BS	14, 23, 183, 185, 187, 192, 193, 194, 195
Strand JA	411	Tuttle RM	20, 21, 22, 63, 114, 124, 126, 127, 129, 130, 144, 279, 292
Strohm PF	15		
Strong JS	188	Underhill SL	198
Stulting RD	17	Urich WM	101
Stutz FH	401, 402, 403, 404, 405, 410, 411	Uyemura MC	92
		Vaccaro JA	17, 415, 420, 435, 446
Styner MJ	19, 69, 70	Vahn CA	24
Sunshein K	16, 26	Vallion RD	138, 139, 142, 148, 387, 388, 422, 447, 451, 452, 457, 462, 464, 466, 469, 470, 472, 473, 476, 477, 479, 480, 481, 482, 483,
Sunshein KF	18, 26, 27		
Taillac PP	270		
Tapper D	18		

## INDEX

- |                |                              |                    |                    |
|----------------|------------------------------|--------------------|--------------------|
|                | 484, 486, 487, 488, 489,     | Wilson LA          | 17                 |
|                | 490, 491, 492, 493           | Wilson S           | 23                 |
| van Hamont JE  | 63, 122                      | Wilson SK          | 186                |
| Vance BJ       | 12                           | Wilson SS          | 167, 173, 417, 460 |
| Vanderlinde J  | 82                           | Winter MG          | 174                |
| Vanderlinde TM | 219                          | Wiren KM           | 65                 |
| VanManen JW    | 18, 27                       | Wiswell TE         | 183, 193           |
| VanManen W     | 26                           | Wittler RR         | 15                 |
| Varga JA       | 26                           | Wold H             | 14                 |
| Varga JH       | 17, 301                      | Wolf TC            | 17                 |
| Vaughan RE     | 267                          | Woods RJO          | 234                |
| Velanovich V   | 17, 18                       | Wortham D          | 14                 |
| Vu KK          | 317                          | Wortham DC         | 14                 |
| Waecker NJ     | 15                           | Wright JR          | 70, 164            |
| Wain J         | 17                           | Writer JV          | 226                |
| Wakeman G      | 91                           | Wygonski RJ        | 12, 77, 308        |
| Walker D       | 14                           | Yackel EE          | 23                 |
| Walker E       | 204                          | Yackovich FH       | 266                |
| Walladsen DS   | 479                          | Yancey MK          | 15                 |
| Walsh ES       | 21                           | Yanko CA           | 23                 |
| Walter MH      | 21                           | Yarborough LW      | 291                |
| Walz EJ        | 189, 282, 283                | Yeash J            | 13                 |
| Wang C         | 129                          | Yetter JF          | 13                 |
| Waring GO      | 17                           | Yoder CC           | 16                 |
| Waterhouse W   | 18                           | Young-McCaughan SB | 21, 23, 169,       |
| Weaver J       | 14                           |                    | 196, 198           |
| Webb SB        | 23, 194, 195                 | Youngberg R        | 26                 |
| Weber CR       | 12, 72                       | Youngberg RA       | 16                 |
| Weber RW       | 103                          | Yuan R             | 17                 |
| Weber SE       | 295                          | Zacher LL          | 175                |
| Wedmore IS     | 87                           | Zapol WM           | 17                 |
| Weir MR        | 237, 240, 241, 246, 247      | Zimba FA           | 173, 497           |
| Weiser J       | 25                           | Zwolan TA          | 17                 |
| Weisse ME      | 15                           |                    |                    |
| Wettlaufer JN  | 311, 313                     |                    |                    |
| Wheeler BR     | 303                          |                    |                    |
| White CB       | 239, 249                     |                    |                    |
| White DC       | 88, 89                       |                    |                    |
| White LJ       | 18, 297                      |                    |                    |
| Whittaker PE   | 13                           |                    |                    |
| Wilkinson SV   | 18, 27                       |                    |                    |
| Willadsen DS   | 83, 138, 139, 142, 148, 149, |                    |                    |
|                | 387, 388, 422, 447, 451,     |                    |                    |
|                | 452, 457, 462, 464, 466,     |                    |                    |
|                | 469, 470, 472, 473, 476,     |                    |                    |
|                | 477, 480, 481, 482, 483,     |                    |                    |
|                | 484, 486, 487, 488, 489,     |                    |                    |
|                | 490, 491, 492, 493           |                    |                    |
| Williams D     | 14, 23, 190                  |                    |                    |
| Williams RF    | 387, 472, 480, 493           |                    |                    |
| Williard WC    | 294                          |                    |                    |
| Willis CE      | 25                           |                    |                    |

## KEYWORDS

- 13-cis retinoic acid 486  
 4-aminobutyraldehyde 240  
 5-Fluorouracil 332, 360, 364, 398, 411, 424,  
 434, 438, 440, 443, 444,  
 460  
 5-FU 347, 371, 388, 464, 469, 493  
 5-FU-e TI 212  
 Augmentin 242  
 abdominal pain, morphine 81  
 abdominal trauma 219  
 ABV Hybrid 442  
 ABVD 442  
 actions 55  
 acute injuries 89  
 adenocarcinoma 343, 449

# INDEX

- ADHD 235
- adolescent
  - female 95
- adolescents 57, 61, 165
- adrenal 439
- Adriamycin 343, 399, 403, 484
- advance directives 98
- Aftacare 184
- age 228
- air flow obstruction 171
- airway obstruction 285
- albumin 170
- albuterol 84
- all trans-retinoic acid 480
- allogenic bone marrow 457
- alpha 2b interferon 453
- alpha interferon 373
- alpha-fetoprotein
  - low dose aspirin 214
- alpha-interferon 423, 469
- ambivalence 325
- aminothiadiazole 337
- amniotic fluid index 202
- amoniafide 329
- amphotericin B 140
- analgesia 278
- androgen 115
- anesthesia 77, 280
- animal model 84, 264, 301
- animal Study 65, 66, 84, 85, 86, 108, 122, 183, 193, 218, 229, 230, 237, 240, 241, 246, 247, 264, 291, 293, 301, 303, 306, 308
- antibody seroconversion 223
- antiemetics 143
- antigens 122
- Ara-C 412, 454, 457, 472, 477
- arachnoid granulations
  - MRI 261
- arctic 319
- ascorbic acid 151
- asthma 79
  - acute 88
  - heliox 232
- ATLS 291
- atrial natriuretic factor 285
- attitudes 55
- autologous bone marrow 457
- aviators 96
- azithromycin 154
- B-cell 465
- babesiosis 316
- back pain 96
- Barrett's 134
- barriers 97
- BCG 403, 408
- behavior 76
- BEP 349
- biliopancreatic bypass 116
- biological parameters 404, 474
- biology 392
- birthweight 228
- bismuth 136
- bladder 210
- bleomycin 169, 346, 349, 366, 409, 446
- blood clot formation
  - magnesium levels 274
- blood donors 226
- blood flow velocity 186
- body position 52
- bone 306
- bone marrow 146
- bone marrow transplantation 462
- bone protein 308
- bone scintigraphy 258
- bowel 218
- boys 60
- breast 144, 145, 196
- breast biopsy 68
- breast feeding
  - military 315
- bronchiolitis
  - helium-oxygen 233
- bronchoalveolar lavage 168
- bronchodilator 79
- bronchogenic 173
- bupivacaine 277, 283
- bursitis 179
- busulfan 457
- CA-125 357
- CAF 426
- calcium 84, 116
- calf 310
- cancer 53, 144, 145, 173, 184, 196, 430, 439, 449, 454, 455, 456, 468, 471, 474, 475, 478
  - bladder 403, 408, 415, 443
  - breast 141, 142, 198, 387, 402, 404, 405, 413, 414, 422, 426, 431, 432, 436, 440, 458, 462, 483, 492
  - cervical 347, 371
  - cervix 331, 344, 350, 360, 361, 364, 368, 370, 373, 374

## INDEX

### Cancer (Cont'd)

- CNS 394
- colon 411, 437, 493
- colorectal 438, 445, 461, 464
- desmoid tumor 476
- endometrial 348, 353, 357, 358, 369, 377, 379
- esophagus 134, 450
- germ cell 470, 479, 489
- head & neck 424, 433, 444
- hepatoma 480
- Hodgkin's 491
- leukemia 448, 457, 465, 472, 473
- lung 147, 167, 484
  - non-small cell 150, 418
  - small cell 425
- lymphoma 490
- myeloma 482, 487
- nasopharyngeal 434
- nervous system 466
- neuroblastoma 392
- non-Hodgkin's 491
- non-Hodgkin's lymphoma 488
- non-small cell lung 148, 452, 486
- ovarian 342, 343, 346, 351, 352, 362, 372, 375, 376, 380, 381, 385, 398, 407, 451, 477
  - epithelial 333
- ovarian carcinoma 356, 365
- ovarian epithelial carcinoma 336
- pain relief 138, 139
- papillary 378
- pediatric 391
- pelvic 328, 329, 330, 334, 335, 337, 338, 339, 340
- penis 409
- prostate 416, 420, 435, 459, 481
- rectum 388, 460
- renal cell 469
- small cell 477
- testicular 446
- thyroid 124, 129
- uterine 367
- vulva 355
- cancer, i. Key
  - alimentary tract 66
- carbohydrate composition 65
- carboplatin 150, 365, 419, 429
- carcinoma 347
- cardiac dimensions 110
- cardiac imaging 254
- cardiopulmonary disease 295
- carnitine 165
- CBDCA 419, 429
- CCNU 495
- cefexime 249
- cefoperazone 399
- cell
  - bone marrow 142
  - cytokine 142
  - growth 142
- cerebral venous system
  - MR angiography 271
- cerivcal mucus 207
- cervical dysplasia 207
- cesarean section 210
- chemo 346, 366, 423, 425
- chemoendocrine therapy 426
- chemohormonal therapy 413, 431
- chemoradiation 449
- chemoradiotherapy 355, 497
- chemotherapy 149, 361, 362, 394, 401, 402, 405, 407, 410, 417, 421, 431, 436, 437, 445, 446, 462, 468, 496
- chemotheray 450
- child separation 181
- children 73, 189, 242, 243, 256
  - 1-12 YO 300
  - 7-18 YO 231
- chloral hydrate 272
- chlorambucil 465
- CHOP 417
- chromic phosphate 351
- ciprofloxacin 300
- ciracadian timed doxorubicin 379
- circadian rhythm 319
- cis-diamminedichloroplatinum 409
- cisplatin 53, 143, 345, 346, 347, 349, 352, 356, 358, 359, 360, 361, 362, 364, 365, 366, 368, 370, 371, 372, 374, 375, 378, 379, 398, 418, 419, 434, 439, 443, 444, 446, 477, 484
- cisplatinum 328, 407, 424
- citrate 136
- Clarithromycin 242
- clinical info system 190
- clomiphene citrate 200
- collagen 212
- college cadets 248
- colonization 236
- Computed tomography
  - gadolinium enhanced 264
- Condylomata acuminata 212
- congestive heart failure 170
- conjunctivitis 300
- consolidation regimens 406
- conventional 268
- COPD 80
- corneal abrasion 82

## INDEX

- corneal perforations 299
- cotyledon 215
  - placental 213
- CPOD 172
- CPR 98
- critical care 182
- cromolyn sodium 234
- cryotreat 306
- CVAD 471
- cyclophosphamide 343, 349, 352, 362, 365, 378, 440, 457, 484, 488
- cyclosporin 372
- cyclosporine 472
- cyropreservation 201
- cyst
  - ovarian 317
- cystectomy 415
- cytogenetic studies 448
- cytometry 432, 433
- cytosine arabinoside 412
- D-alpha-tocopheryl acetate 163
- dactinomycin 349
- daunorubicin 412, 472
- delayed maturation and growth 60
- dental 74
- dentistry 73
- deslorelin 58
- dexamethasone 488
- DHAD 335
- diabetes 114, 184
- diagnosis 83
- diagnostic assays 243
- dihydroxyanthracenedione 335
- diarrhea 188
- dibromodulcitol 361
- didemnin B 330, 416
- digital 268
- discussion 97
- DNA 68, 382, 383, 424, 432, 433
- DNA flow cytometry 479
- dolasetron mesylate 143
- domestic violence 222
- doppler ultrasound 202
- doxorubicin 145, 358, 379, 440, 488
- doxycycline 154
- ductal patency 229
- duodenal ulcer 135
- duodenal ulcers 177
- echinomycin 339
- edatrexate 470
- ejection fractions 253
- emergency room 85, 405
- EMLA cream 189
- empathy 93
- endocrine resistance 416
- endocrine therapy 436
- endophthalmitis 301
- endotracheal suctioning 183, 187
- enuresis 285
- epidemiology 244, 245
- epididymis
  - normal flora 313
- epididymus 117
- epidural analgesia 217, 283
- epilepsy 163, 164, 165
- epinephrine 212
- epiphysis 306
- epithelium 183
- equine inhibin 65
- ER 414
- estrogen replacement 377
- estradiol 215
- etoposide 150, 334, 349, 366, 419, 484
- etoposide carboplatin 489
- exercise 92
- exercise capacity 167
- extravasation injuries 247
- familial factors 381
- family function 95
- family intervention 182
- fatty acid 120
- fazarabine 331
- female athletes 110
- fentanyl 283
- ferret 86
- fiberoptic bronchoscopy 175
- flow cytometry 382
- fluconazole 140
- fludarabine phosphate 465
- fluoroguinolones 312
- flutamide 435
- FNA 124
- free beta HCG 354
- from Christina Hrynio 224
- G-CSF 477
- gadoteridol 262
- gallbladder 253
- gallium nitrate 340
- gastric emptying
  - normal time 252
- gastric 449
- gastric ulcer 136
- gastric ulcers 177
- gastritis 178

## INDEX

- GCSF 149
- gentamicin 241
- gentamicin-Lasix 246
- glimepiride 114
- glucose intolerance
  - tocolytic agents 205
- glutamine 240
- glyburide 114
- GM-CSF 425
- gonads 129
- GR122311X 177
- GR88502X 177
- growth factor 70
- GYN surgery 206
- gynecologic surgery 218
- head & neck 286, 410
- head circumference 228
- headache 162
- heart disease 184
- heart rate 92
- helium 80
- helium-oxygen mixture 79
- hemolytic anemia 151
- hemoptysis
  - CT 175
- hepatitis C 221, 226
- hepatoma 478
- herniorrhaphies 276
- herpes simplex virus 209
- high resolution CT 168
- high risk infants 192
- histologic diagnosis 206
- HIV 153, 223, 243, 244, 245
- Hodgkin's disease 421, 442
  - Stages III & IV 401
- Holter monitoring 109
- home visitation 198
- hormonal therapy 420
- hormone receptors 68
- human sperm 119
- Huntington disease
  - CT and MR features 255
- hyaluronidase 247
- hydatidiform moles 354, 383
- hydorxyurea 477
- hydroxyurea 347, 364
- hydroxyurea 5-FU 368
- hyperactivation 201
- hyperkalemia 84
- hypogonadal 172
- hypotension 280
- hysterectomy 350, 370
- ICU patients 188
- idarubicin 457
- ifosfamide 338, 359, 416, 446
- ifosfamide cisplatin 367
- immunotherapy 408
- induction 77
- infant 187
- infants 233
- infection 236
- informed consent 74
- Intal 234
- intercourse 109
- interferon 356, 425
- interferon alpha 2 467
- interferon-A 427
- intermittent 310
- internship 93, 94
- interphalangeal joint 305
- intraocular pressure 87, 298
- intrauterine growth 228
- intubation 86
- iontophoresis 179
- IP 407
- irradiation 484, 493, 495
- isotope technique 323
- isotretinoin 373
- ITE 91
- IV cyclophosphamide 407
- Kapanol 138, 139
- keratoplasty 299
- keratotomy
  - altitude 297
- ketorolac 277
- lactobacillus 188
- lambs 229
- laparoscopy 133
  - colon 294
- laparotomy 351
- lateral recess 260, 263
- lead 235
- LEEP 207
- left bundle branch block
  - adenosine and exercise 112
- leg 310
- length 228
- leucovorin 388, 437, 438, 460, 464
  - high dose 332
- leukemia 454, 455, 456
  - lymphoblastic 406
  - myeloid 429
  - non-lymphocytic 412
- levamisole 411, 437, 460, 493
- LH 58

# INDEX

- isoforms 59
- lidocaine HCL 247
- Light reflection rheography 159
- lipid synthesis 119
- lipids 121
- liver 323, 445
- liver disease 133
- low birthweight 208
- low malignant potential 382
- lumpectomy 387
- lung 168, 451
- lymphadenectomy 350, 420
- lymphocytic 454
- lymphoid aggregates 146
- lymphoma 423
  - central nervous system 497
  - non-Hodgkin's 417
  - serum repository 441
  - tissue procurement 428
- M-VAC 415
- magnesium 106, 229
- malignancy
  - pelvic 327
- malnourished 172
- mammograms
  - nipple to lesion distance 269
- Megace 369
- megestrol acetate 369
- melanoma 467
- melatonin 319
- melphalan 345, 385
- merbarone 333
- Mesna 416
- mesodermal tumor 367
- mesothelioma 430
- metabolic disease 256
- metabolism 115, 116
- metacarpophalangeal joint 305
- methohexital-isoflurane-nitrous oxide
  - 77
- methotrexate 363, 409, 497
- metoclopramide 272
- microsurgery 303
- military parents 181
- minocycline 169
- misoprostol 178
- mitomycin-C 418
- mitotane 439
- mitoxantrone 454
- mivacurium neuromuscular blockade
  - 279
- modality RX 401
- modality therapy 402, 450
- modified NICU 191
- molar pregnancy 363
- molecular microbiology assay 69
- monoclonal antibodies 122
- monoclonal antibody 105, 147, 148, 301, 354
- MOPP 442
- moral reasoning 94
- morbidity 286
- morphology 121
- mountain sickness 87
- mouse 237
- MRI 173, 254, 262
- MS Contin 138, 139
- muscle efficiency 123
- Mycobacterium avium Complex Disease
  - 153
- mycosis fungoides 427
- myelogenous 456
- myeloid 455
- myeloma 453
- myocardial infarction 106, 109, 111
- myocardial ischemia 278
- myringotom
  - tube retention 288
- nasal mask 171
- nasogastric tissue sampling 66
- natural history 245
- needle aspiration 126
- neonatal 230
- neonatal emergency procedure 230
- Neonates 191
  - airway disease 234
- nephrotoxicity 241, 246
- neurodegenerative disease 256
- neuropathology 262
- neutropenia 140, 149, 151
- nictotine 213
- NICU environment 192
- nifedipine XL
  - pharmacy deletion 158
- non-Hodgkin's lymphoma 471
- nongonococcal urethritis 154
- noninsulin-dependent 114
- NSAID-induced 178
- nuclear blast 127
- nursing 190
- OCD 231
- ofloxacin 155
- omentum 308
- oncogene
  - papillary thyroid 130

# INDEX

- oncogene amplification 144
- ondansetron 72
- ongogene activation 127
- oral contraceptives 317
- orchiectomy 435
- osteoarthritis 177
- osteogenic sarcoma 475
- otoacoustic emissions 53
- overweight 200
- ovulation induction 200
- oxandrin 60
- oxygen 80
- oxyten utilization 123
- P32 352, 398
- PAD - review to see if need 224
- PALA 438, 464
- papillomavirus 248
- para-aortic lymph nodes 371
- parent 181
- parent participation 95
- parental preferences 89
- patching 82
- Patent ductus arteriosus 195
  - Newborn lamb model 108
- pathologic study 344
- pathology 260
- PCR 124
- PCV 495
- pediatric 244, 394
- pediatric cancer
  - Hodgkin's disease 393
- pediatric dentistry 76
- pediatric dentists 75
- pediatric pain 89
- pediatrics 86
- pelvic malignancy 332
- pelvic pain 204
- penicillin 239
- penicillin skin testing 103
- penile prosthesis 312
- pentoxifylline 374
- PgR positive 414
- PGTD 354
- pharyngitis 239
- phospholipid 117
- phospholipid synthesis 118
- photoperiod 319
- phrenic nerve 282
- physical examine 160
- physiologic and neurobehavioral effect
  - 192
- pig model 254
- pineal tumors 265
- piroxicam 336
- placental circulation 203
- Platinol 343
- pleural effusion 170
- pleural effusions 169
- pneumatic compression 310
- pneumonia 242
- pneumoperitoneum 295
- polymerase chain reaction 67
- positive pressure ventilation 171
- Postarthroscopy Analgesia
  - morphine and bupivacaine 304
- postmenopausal 413, 432
- postop patients 292
- postoperative complications 73
- postoperative nausea 72
- potassium 84
- power of attorney 98
- precocious puberty 58, 59
- preeclampsia 92
- pregnancy 162, 209, 219, 222
  - adolescent 95
  - attitudes 325
  - specialized fitness regime 101
- premature infants 185, 195
- premature neonates 186
- premenopausal 431
- prenatal care 208
- prevalence 97
- procarbazine 495
- progesterone 215
- prognostic factors 458
- ProMACE-Mopp 423
- promyelocytic 473
- prophylactic agents 280
- prophylaxis 237, 312
- propofol-nitrous oxide 77
- prostate carcinoma 70
- prostatectomy 311
- protein 70
- protein excretion 211
- protocol enrollment 380
- PTC oncogene 124
- pulmonary artery pressure 229
- pulmonary perfusion 251
- pulmonary surgery 275
- pyelonephritis 155
- pyridoxine 237, 241, 246
- quality of life 459, 461
- quinine 471, 482
- rabbit 230, 237, 246, 306



## INDEX

- racial differences 321
- radiation therapy 167, 368, 370, 371
- radiculopathy 260
- radioactive iodine = 129
- radiography
  - AMBER 268
- Radiotherapy 347
- radiotherapy 350, 353, 360, 385, 388, 394, 410, 417, 425, 434, 444
- randomized 169
- ranitidine 136, 177
- ranitidine bismuth citrate 135
- rectal 294
- recurrence 458
- referred shoulder pain 282
- refractive changes 297
- regeneration 183
- reproductive factors 381
- resection 437, 445
- residents 91
- respiratory mechanics package 174
- resuscitation bag 187
- retinoic acid 427
- retrievable coil occlusion system 108
- RheothRx 111
- rheumatoid arthritis 177
- risk factors 223
- ropivacaine 276
- Rorschach Inkblot Test 321
- routine surveillance 363
- sarcoma
  - uterine 341
- scintigraphic artifacts 257
- scintigraphy 259
- screening 231
- sedation 272
- seizures 237, 240
- self exam 422
- semen parameters 164
- sepsis 105
- sequence 65
- sequential 310
- sertraline 204
- serum marker 357
- serum repository 481
- severe 139
- sexual concerns 97
- sexual function 311
- sexual functioning 196
- Sexual Harassment 55
- sexual transmission 221
- SHBG
  - carbohydrate function, i.Key
  - SHBG
    - characterization, i.Key
    - Animal Study 63
  - SHBG, i.Key
    - breast cancer 62
  - shoulder pain 275
  - single void vs 24 hour urines 211
  - sinusitis 83
  - soft tissue 259
  - soft tissue sarcoma 468
  - soft tissue sarcomas 474
  - spermatozoa 117, 118, 120, 121, 201
  - spine 263
  - sports medicine 258
  - squamous cell 361
  - stapling 293
  - steroidal nondepolarizers 279
  - steroids
    - IV 88
    - oral 88
  - stomach 134
  - streptococcus 236, 239
  - suctioning 193
  - surfactant 185, 194, 195
  - surgery 286, 385, 404, 410, 450
  - surgical oophorectomy 414
  - surgical staging 342
  - survival 458
  - Swan Ganz catheters
    - replacement 157
  - swine 218, 247, 293
  - symptom checklist 231
  - symptom distress 325
  - tamoxifen 387, 426
  - taxol 362, 365, 375, 376, 491, 492
  - Tc-MDP uptake 259
  - temperature 186
  - tenderness 83
  - tendinitis 179
  - teratoma 346
  - testosterone 172
  - theophylline toxicity 240
  - thoracotomy 277
  - thrombocytopenia 151
  - thromboelastograph 106
  - thumb
    - carpal flexor retinaculum 305
  - thyroglobulin 124
  - thyroid 127
  - thyroid hormone 123
  - thyroid hormone suppression 126
  - thyroid nodules 126

## INDEX

- thyroid size 57
- thyroid volume 61
- tissue procurement 490
- TLC D-99 doxorubicin liposome 145
- TOBREX 300
- topotecan 478
- TPDCFH 496
- tracheal trauma 193
- training protocol 85, 86, 218, 230, 291, 293, 303
- transbronchial biopsy 168
- trephines 299
- trimethoprim-sulfamethoxazole 155
- trophoblastic neoplasia 383
- tube feeding 188
- tumor
  - brain 495, 496
  - germ cell 419
  - ovary 349
  - ovarian 345, 382
  - ovarian stroma 366
  - sinus 346
  - uterus 359
- Tumor necrosis factor
  - serum levels 292
- ultrasound 61, 202
- umbilical arteries 217
- umbilical circulation 203
- ureaplasma 122
- urethritis 67
- urinary tract 218
- urinary tract infections
  - female children 249
- urologic stones
  - conspicuity 267
- uroprotector mesna 338, 359
- VAC 349
- VAD 453
- VAD-P 482
- vaginal ultrasonography 206
- vagus nerve 275
- valproic acid 164
- varicella 236
- vasectomy
  - reversal 99
- velocimetry 217
- venous thrombosis 159
- ventricular arrhythmias 52
- verapamil 471
- videotaped education programs 184
- vincristine 349, 484, 488, 495
- vitamin A 323
- vitamin E 163
- VMCP 453
- volume status 160
- vomiting 72
- Von Hippel-Lindau Disease
  - radiologic pathology 266
- VP-16 439
- Waldenstrom's Macroglobulinemia 447
- waste anesthetic gas 75
- weightlifting 298
- Wilms' 391
- women 155
- Yale Brown Compulsive Scale 231
- zofran 143
- Zoladex 414

## ANNUAL REPORT DISTRIBUTION LIST

Defense Documentation Center	2 copies
Clinical Investigation Regulatory Office	2 copies
U.S. Army Medical Research and Development Command	1 copy
Each U.S. Army Medical Center (Department of Clinical Investigation)	1 copy

